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I. ABBREVIATIONS 
 
[3H]ACh, tritiated acetylcholine  
AC, adenylyl cyclase 
Acetyl-CoA, acetyl coenzyme-A 
ACG, anterior cingulate gyrus 
ACh, acetylcholine 
AD, adrenaline 
ADA, adenosine deaminase 
ADP, adenosine diphosphate 
AK, adenosine kinase 
AMP, adenosine monophosphate 
ATP, adenosine triphosphate 
BK, large-conductance (Ca2+)-activated K+ channel 
HBP, hiperplasia benigna da próstata 
BoNT, botulinum toxin 
BOO, bladder outlet obstruction 
BPH, benign prostatic hyperplasia 
BPS, bladder pain syndrome 
BR, bladder rat 
BSA, bovine serum albumin 
Ca2+, calcium ion 
cAMP, cyclic adenosine monophosphate 
ChAT, choline acetyltransferase 
CHO, chinese hamster ovary  
CHP, Centro Hospitalar do Porto 
CI, confidence interval 
CNS, central nervous system 
CoA, coenzyme A 
CREB, cyclic AMP response element-binding protein 
CTRL, control subjects 
DAG, diacylglycerol 
DIC, differential interference contrast 
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DWT, detrusor wall thickness 
EDTA, ethylenediamine tetraacetic acid 
EFS, electrical field stimulation 
EGF, epidermal growth factor  
EGFR, epidermal growth factor receptor 
ENT, equilibrative nucleoside transporter 
E-NTPDases, ecto-nucleoside triphosphate diphosphohydrolase 
ERK, extracelular signal regulated kinase 
EUS, external urethral sphincter 
GAPDH, glyceraldehyde 3-phosphate dehydrogenase 
Gi, inhibitory G protein 
GPCRs, G-protein coupled receptors 
Gs, stimulatory G protein 
HBP, hiperplasia benigna da próstata 
HPLC, high-performance liquid chromatography 
HR, hazard ratio 
HUT, higher urinary tract 
HX, hypoxanthine 
Hz, hertz 
IB, immunoblotting 
IC, interstitial cystitis 
ICBAS, Instituto de Ciências Biomédicas Abel Salazar 
ICC, interstitial cells of Cajal 
ICS, international continence society 
IHC, immunohistochemistry 
INO, inosine 
IP3, inositol triphosphate 
IUS, internal urethral sphincter 
K+, potassium ion 
KATP, ATP sensitive potassium channels  
kDa, kilodalton 
LP, lamina propria 
LUT, lower urinary tract 
LUTS, lower urinary tract symptoms 
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MAPK, mitogen-activated protein kinase 
MR, muscarinic receptors 
ms, millisecond 
MW, molecular weigh 
NA, noradrenaline 
Na+, sodium ion 
nAChR, nicotinic receptors 
NANC, non-adrenergic non-cholinergic 
NGF, nerve growth factor 
NK1, neurokinin 1 receptor 
NO, oxide nitric 
NPPS, nucleotide pyrophosphatase / phosphodiesterases 
NT5E, ecto-5’-nucleotidase 
OAB, overactive bladder 
OCTs, organic cation transporters 
OCT1, organic cation transporter type 1 
OCT3, organic cation transporter type 3 
OD, overactive detrusor 
PAC, pituitary adenylate cyclase 
PAC1, pituitary adenylate cyclase-activating polypeptide type 1 receptor 
PACAP, pituitary adenylate cyclase activating polypeptide 
PAG, periaqueductal gray 
PKA, protein kinase A 
PKC, protein kinase C 
PLC, phospholipase C 
PMC, pontine micturition centre 
PVDF, polyvenylidene difluoride 
RT-PCR, reverse transcriptase polymerase chain reaction 
S1, first stimulus 
S2, second stimulus 
SAH, s-adenosyl homocysteine 
SCI, spinal cord injury 
SDS, sodium dodecyl sulfate 
SMA, smooth muscle actin 
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T1/2, half degration time 
TRP, transient receptor potential 
TRPV1, transient potential vanilloid subtype 1 receptor 
TRPV4, transient potential vanilloid subtype 4 receptor 
TUI, trato urinário inferior 
U, urothelium 
UDP, uridine diphosphate 
UTP, uridine triphosphate 
UV, ultraviolet 
V, volts 
VDCAs, voltage-dependent anion channels 
VIP, vasoactive intestinal peptide 
VPAC2, vasoactive intestinal peptide receptor type 2 
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II. RESUMO 
O trato urinário inferior é essencial para receber a urina produzida pelo rim, 
proceder ao seu armazenamento e permitir o esvaziamento voluntário da bexiga 
mediante reflexos complexos coordenados pelo sistema nervoso central através da 
informação veiculada pelos nervos periféricos aferentes e eferentes. A bexiga tem 
duas funções principais, (1) receber e acondicionar a urina, funcionando como um 
reservatório, e (2) esvaziar voluntariamente quando se encontra preenchida. Estas 
funções podem ser vistas como tarefas simples. No entanto, a regulação do 
funcionamento da bexiga é complexa levando a que as suas disfunções sejam muito 
comuns e com uma elevada repercussão na qualidade de vida dos doentes e das 
suas famílias, bem como um grande impacto económico na sociedade. Apesar dos 
esforços crescentes na investigação científica das disfunções urinárias, ainda 
existem muitas lacunas no conhecimento relativo aos mecanismos envolvidos nas 
doenças do trato urinário inferior (TUI). Estas falhas determinam a necessidade de 
mais estudos para satisfazer as necessidades clinicas associadas às patologias do 
TUI.  
O conceito de “purinoma” foi recentemente introduzido na investigação 
científica e sabe-se, hoje, que a sinalização purinérgica tem enormes repercussões 
na fisiopatologia de diversas doenças, incluindo as disfunções do TUI. O “purinoma” 
engloba o conjunto de mecanismos que determinam a libertação celular de purinas 
(e/ou pirimidinas), a sua metabolização extracelular por enzimas específicas e os 
vários subtipos de recetores responsáveis pelas ações biológicas das purinas (e/ou 
pirimidinas) originais e dos seus metabolitos. Neste trabalho, estudou-se o 
envolvimento do sistema purinérgico e pirimidinérgico na fisiopatologia das 
disfunções da bexiga. Os resultados obtidos sugerem a existência de novos alvos 
terapêuticos relacionados com o “purinoma” como possíveis alternativas para o 
tratamento de doenças do TUI.  
As experiências foram realizadas em tiras do corpo da bexiga humana 
provenientes de doentes com obstrução infravesical por hiperplasia benigna da 
próstata (HBP) e de dadores de órgãos sem patologia conhecida do TUI (grupo 
controlo). A seleção dos doentes e, respetivos, controlos, bem como os 
procedimentos de colheita das amostras de bexiga humana, foram realizados por 
médicos especialistas do Serviço de Urologia do Centro Hospitalar do Porto (CHP). 
Foram, ainda, realizados ensaios “in vitro” com fragmentos de bexiga isolados de 
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ratazanas Wistar Han, bem como experiências de urodinâmica in vivo com cateter 
intravesical em ratazanas anestesiadas. Todos os procedimentos foram previamente 
aprovados pela comissão de ética do CHP e do Instituto de Ciências Biomédicas 
Abel Salazar (ICBAS). 
Os resultados obtidos nos ensaios in vitro mostram que a libertação urotelial 
de ATP normalizada pela acetilcolina (ACh) é cinco vezes maior no grupo de 
doentes obstruídos comparativamente com o grupo controlo. Estes resultados estão 
de acordo com a hipótese levantada pelo nosso grupo de investigação de que a 
medição dos níveis urinários de ATP pode ser considerada um biomarcador clínico 
de disfunção urotelial em doentes obstruídos (Silva-Ramos et al., 2016a). 
Apesar das evidências de que o ATP é uma peça chave na fisiopatologia das 
disfunções do TUI, pouco se sabe sobre o papel dos nucleótidos de uridina 
encontrados na urina humana neste contexto. Experiências anteriores do nosso 
grupo de investigação demonstraram que a ativação de recetores do subtipo P2Y6 
sensíveis ao UDP aumentava a frequência miccional em ratazanas anestesiadas e 
que este efeito era mediado indiretamente pelo aumento da libertação de ATP pelo 
urotélio vesical (Carneiro et al., 2014) através de hemicanais contendo pannexina-1 
(Timóteo et al., 2014). Não obstante, o papel dos recetores P2Y6 nunca tinha sido 
explorado na bexiga humana. Os resultados obtidos neste estudo mostram que a 
ativação de recetores do subtipo P2Y6 no urotélio humano promove a libertação não-
neuronal de ATP (e ACh) tanto em doentes com obstrução infravesical como nos 
indivíduos controlo, embora os níveis de ATP detetados sejam significativamente 
maiores no grupo dos doentes portadores de HBP. Os dados experimentais 
mostraram ainda o envolvimento de hemicanais contendo pannexina-1 na libertação 
de ATP induzida por estimulação de recetores P2Y6 no urotélio humano sugerindo a 
hipótese de que a manipulação destas vias pode constituir uma alternativa 
terapêutica eficaz para controlar a hiperatividade vesical em doentes obstruídos. 
Previamente demonstrou-se que os doentes com obstrução infravesical por 
HBP exibem défices na conversão extracelular dos nucleótidos de adenina pelas E-
NTPDases levando a uma acumulação exagerada de ATP no detrusor. Esta 
situação está normalmente associada à hiperatividade vesical por via da excessiva 
ativação de recetores ionotrópicos P2X sensíveis ao ATP localizados nos neurónios 
sensitivos suburoteliais (P2X2/3) e no detrusor (P2X1), mas também se pode dever 
indiretamente à redução dos níveis extracelulares de adenosina necessários à 
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ativação de recetores inibitórios do subtipo A1 nos nervos colinérgicos (Silva-Ramos 
et al., 2015a). Resultados apresentados nesta tese revelam pela primeira vez a 
existência de recetores excitatórios dos subtipos P2X3 e/ou P2X2/3 sensíveis ao 
ATP nas terminações nervosas colinérgicas do detrusor humano. A ação destes 
recetores não é contrariada pela ativação de recetores inibitórios sensíveis ao ADP 
devido a uma deficiência no catabolismo extracelular de ATP nos doentes obstruídos 
portadores de HBP. A redução dos níveis endógenos de ADP promove a 
sobreexpressão de recetores inibitórios do subtipo P2Y12, abrindo uma janela 
terapêutica aos agonistas destes recetores para o tratamento da hiperatividade 
colinérgica nos doentes com obstrução infravesical.  
Desde 2013, os agonistas dos adrenocetores-β3 (e.g. mirabegron) têm sido 
utilizados no tratamento dos sintomas da bexiga hiperativa em alternativa à perda de 
eficácia dos fármacos anti-colinérgicos. Apesar da sua aprovação e sucesso clinico 
existe alguma controvérsia relativamente ao mecanismo molecular subjacente ao 
efeito terapêutico desta classe de fármacos. O “ponto-chave” desta controvérsia 
reside no facto de se ter demonstrado que as concentrações plasmáticas atingidas 
com doses terapêuticas de mirabegron são insuficientes para causar relaxamento do 
detrusor humano in vitro. Recentemente, demonstrou-se que a ativação dos 
adrenocetores-β3 com doses baixas de mirabegron inibia a libertação de ACh em 
preparações de bexiga humana in vitro (D’Agostino et al., 2015). Porém, não existem 
evidências inequívocas da presença destes recetores nos terminais nervosos 
colinérgicos do detrusor humano (ver e.g. Coelho et al., 2017; discutido em Okeke et 
al., 2017; Andersson, 2017; Griffin et al., 2017). Esta controvérsia é sugestiva de que 
o efeito inibitório do mirabegron sobre a libertação de ACh se pode dever a um 
mecanismo indireto mediado pela libertação retrógrada de um mensageiro originado 
a partir do AMP cíclico intracelular capaz de inibir a libertação do neurotransmissor, 
tal como a adenosina. 
Os resultados mostram que a inibição da libertação de ACh causada por 
agonistas dos recetores β3 é de facto dependente da libertação de adenosina por 
intermédio do transportador equilibrativo de nucleósidos, ENT1, localizado nas fibras 
musculares lisas do detrusor humano e da ratazana. Foi, ainda, possível demonstrar 
experimentalmente que a adenosina formada a partir do catabolismo intracelular do 
AMP cíclico gerado pela activação do recetor β3 no detrusor atua como um 
mensageiro retrógrado por via da ativação de recetores pré-juncionais do subtipo A1 
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e que estes são os responsáveis pela inibição da atividade colinérgica produzida 
pelos agonistas β3. Apesar dos mecanismos moleculares responsáveis pela 
libertação de adenosina em resposta à estimulação dos recetores β3 ainda 
necessitar de elucidação, foi possível provar o envolvimento da via da EPAC nessa 
sinalização sem que a proteína cinase A (PKA) tenha um papel significativo.  
Os resultados mostram, ainda, que os doentes portadores de obstrução 
infravesical por HBP apresentam um aumento da densidade de recetores A1 e β3, e 
uma diminuição dos níveis de expressão do transportador equilibrativo de 
nucleósidos comparativamente com os indivíduos do grupo controlo. Apesar da 
limitação no transporte de adenosina para o meio extracelular, o controlo da 
libertação de ACh foi semelhante nos 2 grupos de indivíduos, porventura devido ao 
reforço da atividade β3 pelo mirabegron e/ou da sobreexpressão dos recetores 
inibitórios A1 localizados nas terminações nervosas colinérgicas. 
Em conclusão, este trabalho permitiu elucidar mecanismos moleculares e 
propor novos alvos terapêuticos para o tratamento das disfunções do TUI, em 
particular da hiperatividade da bexiga secundária à obstrução infravesival por HBP. 
Neste contexto, foi possível concluir que a manipulação da atividade do purinoma, 
em várias das suas vertentes, pode contribuir para o controlo medicamentoso da 
bexiga hiperativa. Propomos o uso de (1) antagonistas seletivos dos recetores P2Y6 
no tratamento da disfunção urotelial em doentes com obstrução infravesical, uma 
vez que o bloqueio destes recetores diminui os níveis de ATP libertados; (2) 
antagonistas seletivos para os recetores P2X3 e/ou P2X2/3 e/ou agonistas seletivos 
dos recetores P2Y12 para contrariar a excitabilidade nervosa colinérgica nos doentes 
obstruídos, e/ou (3) agonistas seletivos dos recetores A1 em conjunto com o 
mirabegron, ou outros agonistas β3, para aumentar a eficácia destes no tratamento 
da bexiga hiperativa. A utilização de uma abordagem molecular para aumentar o 
número e/ou função dos transportadores equilibrativos de nucleósidos (ENT1) na 
membrana plasmátiva dos doentes obstruídos poderá ser outra metodologia a ter 
em conta para melhorar a eficácia terapêutica dos agonistas β3 nos síndromes de 
bexiga hiperativa.  
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III. ABSTRACT 
The lower urinary tract (LUT) is essential to receive the urine produced by the 
kidney, to store it in the bladder and to allow voluntary emptying by complex reflexes 
coordinated by the central nervous system through the information conveyed by 
afferent and efferent peripheral nerves. The bladder has two main functions, (1) 
receiving and conditioning urine, functioning as a reservoir of urine, and (2) emptying 
voluntarily when it is full. These functions can be seen as simple tasks. However, 
bladder dysfunctions are very common and have a high impact on the quality of life 
of patients and their families; bladder dysfunctions are also a major economic burden 
for the society. Despite the increasing research efforts on this problem, there are still 
many gaps in our knowledge regarding the mechanisms involved in lower urinary 
tract symptoms (LUTS). These failures determine the requirement for further studies 
to meet the clinical needs inherent to LUTS. 
The concept of "purinome" has recently been introduced in scientific research 
and it is known today that purinergic signaling has enormous repercussions on the 
pathophysiology of various clinical situations, including LUTS. This designation 
encompasses the set of mechanisms that determine the cellular release of purines 
(and/or pyrimidines), their extracellular metabolism by specific enzymes, and the 
various receptor subtypes responsible for the biological actions of both purines 
(and/or pyrimidines) and their metabolites. In this study, the involvement of the 
purinergic and pyrimidinergic system in the pathophysiology of bladder dysfunctions 
was studied. The results obtained highlighted the existence of new therapeutic 
targets related to the “purinome” as putative alternatives for the treatment of diseases 
of the LUT. 
The experiments were performed on human bladder strips from patients with 
benign prostatic hyperplasia (BPH) and organ donors without known LUTS (control 
group). The selection of patients and their respective controls, as well as procedures 
for collecting human bladder samples, were performed by specialists from the 
Urology Service of the Porto Hospital Center (CHP). In vitro assays were also 
performed with bladder fragments isolated from Wistar Han rats. In addition, we 
perfomed in vivo urodynamic experiments after intravesical catheterism in 
anaesthetized rats. All procedures were previously approved by ethics committees of 
CHP and of the Abel Salazar Institute for Biomedical Sciences (ICBAS). 
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The results obtained in the in vitro assays show that the urothelial release of 
ATP normalized by acetylcholine (ACh) is five times greater in the group of 
obstructed patients compared to the control group. These results are in agreement 
with the hypothesis raised by our research group that the measurement of urinary 
ATP levels can be considered a clinical biomarker of urothelial dysfunction in 
obstructed human patients (Silva-Ramos et al., 2016a). 
Despite the evidence that ATP plays a key role in the pathophysiology of LUT 
dysfunctions, little is known about the role of uracyl nucleotides found in human urine 
in this context. Previous experiments from our research group have shown that the 
activation of UDP-sensitive P2Y6 receptor subtypes increased the voiding frequency 
in anaesthetized rats and that this effect was indirectly mediated by the increase in 
ATP release from the urothelium (Carneiro et al., 2014) through pannexin-1 
containing hemichannels (Timóteo et al., 2014). Nevertheless, the role of P2Y6 
receptors had never been explored in the human bladder. The results obtained in this 
study show that activation of the P2Y6 receptor subtype in the human urothelium 
favors the non-neuronal release of ATP (and ACh) both in obstructed patients and in 
control subjects. It is also worth noting that the P2Y6 receptor-induced ATP release 
was significantly higher in the group of patients with BPH than in controls. 
Experimental data further suggest the involvement of pannexin-1 containing 
hemichannels in the release of ATP induced by stimulation of the P2Y6 receptor in 
the human urothelium, thus raising the hypothesis that manipulation of these 
pathways may constitute an effective therapeutic alternative to control overactive 
bladder symptoms in obstructed patients. 
Patients with infravesical BPH obstruction have previously been shown to 
exhibit deficits in the extracellular conversion of adenine nucleotides by E-NTPDases 
leading to surplus ATP accumulation in the detrusor. This situation is usually 
associated with bladder overactivity due to an excessive activation of ATP-sensitive 
P2X ionotropic receptors located in suburotelial (P2X2/3) sensory neurons and in the 
detrusor (P2X1). Nevertheless, it might also be due indirectly to the reduction of 
extracellular adenosine generated from the extracellular catabolism of ATP, which is 
is required to activate inhibitory A1 receptors on cholinergic nerves terminals (Silva-
Ramos et al., 2015a). Results presented in this thesis show for the first time the 
existence of excitatory receptors of the ATP-sensitive P2X3 and/or P2X2/3 subtypes 
on cholinergic nerve varicosities of the human detrusor, whose action is left 
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unrestrained by deficient activation of ADP-sensitive inhibitory receptors due to the 
impairment of extracellular ATP breakdown in obstructed patients with BPH. The 
reduction of endogenous levels of ADP favours overexpression of inhibitory receptors 
of the P2Y12 subtype, opening a therapeutic window to agonists of this receptor 
subtype for the treatment of cholinergic hyperactivity in obstructed patients. 
Since 2013, 3-adrenoceptor agonists (like mirabegron) have been used in the 
treatment of overactive bladder symptoms as an alternative to the lack of efficacy of 
anti-cholinergic drugs. Despite the official approval and clinical success of these 
drugs there are still some controversies regarding the molecular mechanism 
underlying the therapeutic effects of this type of drugs. The major issue of this 
controversy is that the plasma concentrations achieved at therapeutic doses of 
mirabegron are not enough to cause relaxation of the human detrusor in vitro. 
Recently, activation of β3 adrenoceptors with low doses of mirabegron has been 
shown to inhibit ACh release in human bladder preparations in vitro (D'Agostino et 
al., 2015). However, there is no clear evidence for the presence of these receptors 
on cholinergic nerve terminals of the human detrusor (see eg Coelho et al., 2017, 
discussed in Okeke et al., 2017; Andersson, 2017; Griffin et al., 2017) leading to the 
hypothesis that the inhibitory effect of mirabegron on ACh release may be due to an 
indirect mechanism mediated by the retrograde release of a messenger originating 
from intracellular cyclic AMP that is capable of inhibiting the release of the 
neurotransmitter, such as adenosine. The results show that inhibition of ACh release 
caused by β3 receptor agonists is in fact dependent on adenosine release via the 
nucleoside equilibrating transporter, ENT1, located on smooth muscle fibers of the 
human and the rat detrusors. It was also possible to experimentally demonstrate that 
adenosine formed from the intracellular catabolism of cyclic AMP generated by 
activation of the β3 receptor in the detrusor acts as a retrograde messenger through 
the activation of pre-junctional A1 receptors, which are responsible for the inhibition of 
the cholinergic nerve activity caused by β3 receptor agonists. Although the molecular 
mechanisms responsible for the release of adenosine in response to stimulation of β3 
receptors is still lacking, it was possible to prove an involvement of the EPAC 
pathway in this signaling pathway without much participation of the protein kinase A 
(PKA).  
The results further suggest that A1 and β3 receptors are overexpressed in 
patients suffering from infravesical obstruction due to BPH, while the equilibrative 
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nucleoside transporter, ENT1, is downregulated, compared to control subjects. 
Despite these features leading to limitation of adenosine outflow to the extracellular 
medium, the control of ACh release was similar in both groups. This might be due to 
the relative increase in β3 receptors activity by mirabegron and/or to overexpression 
of the A1 inhibitory receptors located on the plasma membrane of cholinergic nerves 
of obstructed patients.  
In conclusion, this work elucidated the underlying molecular mechanisms and 
proposed novel therapeutic targets for the treatment of LUTS, in particular of bladder 
hyperactivity secondary to infravesal obstruction due to BPH. In this context, one 
may suggest that manipulation of the “purinome”, in several of its aspects, can 
contribute to drug ability to control of overactive bladder syndromes. We propose the 
use of (1) selective P2Y6 receptor antagonists for the treatment of urothelial 
dysfunction in patients with infravesical obstruction, since blockade of these 
receptors decrease the extracelular levels of ATP and, thus, its reactivity in the 
bladder; (2) selective antagonists of P2X3 and/or P2X2/3 receptors and/or selective 
agonists of the P2Y12 receptor in order to counteract cholinergic hyperexcitability in 
obstructed patients, and/or (3) selective A1 receptor agonists in conjunction with 
mirabegron, or other β3 agonists, which may be necessary to increase the 
therapeutic efficacy of the latter in patients with overactive bladder. The use of a 
molecular approach to increase the number and/or activity of equilibrative nucleoside 
transporters (ENT1) in the plasma membrane of obstructed patients may be another 
strategy deserving attention to improve the therapeutic efficacy of β3 agonists in 
overactive bladder syndromes. 
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IV. INTRODUCTION 
 
1. Urinary tract 
The urinary tract is composed by the kidneys, the ureters, the bladder and the 
urethra. The main function of this system is filtering the excess fluid and other 
substances from the bloodstream. In other words, it regulates the plasma 
composition through controlled secretion of salts, water and organic wastes (Vander 
et al., 2001; Provophys et al., 2006-2007). Urine is the final product of substances 
filtration from the blood, and is used to extract excess minerals or vitamins, as well as 
blood corpuscles from the body. The urinary system together with the other systems 
of the body contributes to maintain homeostasis (Provophys et al., 2006-2007; Drake 
et al., 2008). 
The urinary tract can be subdivided into two groups: the higher urinary tract 
(HUT) and the lower urinary tract (LUT). The HUT is constituted by the kidneys and 
the ureters, while the LUT is composed by the bladder and the urethra (Vander et al., 
2001; Provophys et al., 2006-2007; Drake et al., 2008). 
 
1.1. LOWER URINARY TRACT 
The LUT (Figure 1) has a complex physiology that includes both myogenic 
and neurologic aspects (Chapple, 2011). This system differs from other systems, 
because it dependents on the central nervous system (CNS) control, making a 
distinction from other structures that maintain a level of function even after the 
extrinsic neural input has been eliminated (Fowler et al., 2008).  
 
1.1.1. Urinary bladder 
The urinary bladder is a hollow organ with a muscular composition that allows 
it to be distensible or “elastic” during filling with urine. This organ is tetrahedral when 
empty and ovoid when filled (Macarak and Howard, 1999). As represented in Figure 
1 the bladder can also be divided into two main components, the bladder body, which 
is located above the ureteral orifices, and the base consisting of the trigone, the 
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urethrovesical junction, the deep detrusor, and the anterior bladder wall (Andersson 
and Arner, 2004). 
The bladder wall is formed by four layers of tissue, (1) the (innermost) mucosa 
(also denominated as urothelium), which separates the urine from the detrusor 
smooth muscle; (2) the submucosa; (3) the muscularis, a smooth muscle layer, also 
designated as detrusor muscle; and (4) the serosa, the continuation of the 
peritoneum (Van de Graaff and Ward Rhees, 2001). Towards the bladder base the 
ureters open into the lumen; the triangular region formed by orifices of both ureters 
and the bladder neck is called trigone (Figure 1) (Provophys et al., 2006-2007; Drake 
et al., 2008).  
  
 
 
 
 
 
 
 
 
 
 
The location of the urinary bladder in the human body depends on gender. In 
women the urinary bladder is located on the pelvic floor, while in men it is located on 
the superior pelvic floor due to the underlying prostate (Provophys et al., 2006-2007; 
Van de Graaff and Ward Rhees, 2001). The urinary bladder functions are urine 
storage and voiding. Urine storage of urine normally occurs under low filling 
pressure, which implies that the bladder relaxes during the filling phase. On the other 
hand, urine voiding requires a coordinated contraction of the bladder and relaxation 
of the urethra (Andersson and Arner, 2004). 
Various types of cells are present in the bladder wall: smooth muscle cells, 
efferent nerve fibers, fibroblast-like cells and interstitial cells of Cajal (ICCs), also 
known as interstitial cells. Based on their localization within the bladder wall, several 
subgroups of ICCs have been identified (McCloskey, 2010; McCloskey, 2013). These 
Ureters
Urothelium
Detrusor muscle
Ureteric orifice
Trigone
Internal sphinter
(bladder neck)
Urethra
External sphincter
Bladder
body
Bladder
base
Bladder
Figure 1. Parts of the lower urinary tract. The bladder is the main organ; it is lined by the 
urothelium and the detrusor smooth muscle to form a largest part of this organ.  
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cells acts as an amplification stage in the sensory response to the bladder-wall 
stretch, as occurs during the bladder filling (Fry et al., 2007).  
Both the detrusor and the mucosa are capable of independent spontaneous 
contractile activity (Kushida and Fry, 2016). If the two layers are in present the overall 
activity of the bladder is enhanced. Nevertheless, the contractile characteristics of 
both layers are not activated by similar stimuli, as judged by their responses to a 
wide spectrum of purinergic receptor agonists, capsaicin and extracellular pH 
changes (Kushida and Fry, 2016).  
 
1.1.1.1. Urothelium 
The urothelium, or uroepithelium, is a pseudostratified epithelium that covers 
the inner parts of the renal pelvis, the ureters, the urinary bladder, and the urethra. 
This epithelial cell layer grows on top of a basement membrane. It has a slow cellular 
turnover of approximately 6 months under normal circumstances (Walker, 1960; 
Lewis, 2000). Urothelial cells are specialized in the detection of both physical (e.g. 
distension, compression) and chemical (e.g. acids, inflammatory mediators) stimuli. 
The transducer role of the urothelium is enhanced by the close proximity of the 
urothelium to sensitive nerve afferents (Jen et al., 1995; Grol et al., 2008). 
  
The urothelium is formed by tree different cell layers, (1) a basal cell layer, (2) 
an intermediate cell layer and (3) an apical cell layer, which are represented in the 
Figure 2. The thickness of the urothelium reduces significantly during bladder filling 
mostly due to the fact that urothelial cells are highly deformable cells but also 
Figure 2. Scheme of the urothelium and suburothelium anatomy. The urothelium is 
composed of the umbrella, the intermediate, and the basal cells; while the suburothelium is 
constituted by the interstitial cells of Cajal, the myofibroblasts and the nerves. 
Interstitial cells of cajal
Umbrella cells
Intermediate cells
Basal cells
Urothelium
Suburothelium
(lamina propria)
Myofibroblasts
Blood vessels
Nervous innervation
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because urothelial cell layers have the ability to run over each other to increase 
several fold the bladder capacity. This structural adaptation allows the urothelium to 
play several roles, (i) as a barrier to infections and damaging molecules, (ii) in the 
release of signaling molecules (signaling role), and (iii) in relaying sensory stimuli 
after detecting physiological and chemical stimuli (transducer role) (Birder and de 
Groat, 2007). 
The cells of the innermost layer (apical layer) of the bladder urothelium are 
called umbrella cells and consist of large, flattened cells (Apodaca, 2004; Lewis, 
2000).  These cells are interconnected by tight junctions and are covered on their 
apical surface (nearly 70-80%) by crystalline proteins called uroplakins that assemble 
into hexagonal plaques (Hicks, 1975; Liang, 2001; Sun, 2006). The outermost layer 
of the urothelium consists of smaller basal cells that are separated from the 
suburothelial lamina propria (Birder, 2013). The small basal cells of the uroepithelium 
have properties typically seen in stem cells, such as, a slow turnover rate (Martin, 
1972). Between umbrella and basal cells are located the intermediate cells (Figure 2) 
(Wu et al., 2009; Lewis, 2000; Jost et al., 1989). In some species, umbrella cells and 
perhaps also the intermediate cells, have projections to the basement membrane 
(Apodaca, 2004). The layer of intermediate cells may be different among species. In 
the urinary bladder of rodents there is one intermediate cell layer, whereas in 
humans there are up to five intermediate layers present (Walker, 1960; Lewis, 2000).  
The lamina propria layer is composed of several types of cells including fibroblasts, 
sensory nerve ending, myofibroblasts and ICCs (see Figure 2) (Birder, 2013). 
During many years, it was believed that the urothelium had only one function: 
to act as a barrier against the bladder urine content. Increasing evidence 
demonstrate nowadays that the urothelium has many other roles which involve 
transport, regeneration, sensory functions, as well as the release of mediators (Guan 
et al., 2017). The urothelium is able to maintain high electrical resistance allowing 
only active ion transport between urine and blood (Lewis and Diamond, 1975). 
Urothelial cells exhibit “neuron-like” properties. Activation of urothelial cells by a 
variety of stimuli can trigger the release of various mediators (Table 1) which can 
impact on neural activity and, thereby, on bladder function (Birder, 2006). The 
mechanism underlying the release of these chemical mediators remains unclear and 
it is still not known whether different layers of the urothelium are responsible for 
secreting different mediators (Birder, 2011). On the other hand, there are a variety of 
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ion channels and receptors (see Table 1) which have been described throughout the 
urothelial layer from apical to basal cells (Guan et al., 2017; Wang et al., 2003; Lewis 
and Hanrahan, 1985). Afferent and efferent nerves are localized next to the 
urothelium, making the urothelium able to sense physical and chemical stimuli (Jen 
et al., 1995; Birder and de Groat, 2007).  
 
Table 1. Signaling molecules and receptors expression in the urothelium. 
Legend: ACH – acetylcholine; NA – noradrenaline; AD – adrenaline; ATP – adenosine 
triphosphate; NO – nitric oxide; NGF – nerve growth factor; VIP – vasoactive intestinal peptide; 
PACAP – pituitary adenylate cyclase activating polypeptide; PAC – pituitary adenylate cyclase; PAC1 
– pituitary adenylate cyclase-activating polypeptide type 1 receptor; VIP – vasoactive intestinal 
peptide; VPAC1 – vasoactive intestinal peptide receptor type 1; VPAC2 – vasoactive intestinal peptide 
receptor type 2; NK1 – neurokin-1 receptor; EGF – epidermal growth factor; EGFR – epidermal growth 
factor receptor; RT-PCR – reverse transcriptase polymerase chain reaction; IHC – 
immunohistochemistry; IB – immunoblotting. 
MOLECULE RECEPTOR SPECIE TECHNIQUE REFERENCES 
ACH 
Muscarinic 
(M1-M5); 
Nicotinic 
(α3,5,7,9,10; β3 e 
4) 
Rat; 
Human 
IHC; IB; RT-PCR 
Giglie et al., 2005; 
Tyagi et al., 2006; 
Kulman et al., 2008; 
Beckel et al., 2005; 
Bscheipfer et al., 2007. 
ADENOSINE 
Purinergic P1 
(A1, A2A, A2B, 
A3) 
Rat; 
Human 
WB; RT-PCR; IH 
Yu et al., 2006; Säve et 
al., 2009. 
ATP 
Purinergic P2 
(P2X1-7 and 
P2Y1,2,4,6) 
Rabbit; 
Rat; 
Human 
WB; IH; PCR; RT-
PCR 
Silva-Ramos et al., 
2013a; Timóteo et al., 
2014; Chopra et al., 
2008; Tempest et al., 
2014; Fergusson et al., 
1997. 
NA / AD 
Adrenergic 
receptors (α1A, 
1D; β1-3) 
Rat; 
Human 
WB; RT-PCR 
Ishihama et al., 2006; 
Michel and Vrgdar, 
2006. 
VIP/PACAP 
PAC1, VPAC1, 
VPAC2 
Rat RT-PCR Brass et al., 2005. 
EGF EGFR Human IHC RØtterud et al., 2004. 
SUBSTANCE P 
Tachykinin 
(NK1) 
Human RT-PCR/IB/IHC Freiro et al., 2010. 
BRADYKININ Bradykinin (B2) Rat RT-PCR / IC Chopra et al., 2005. 
NO - Rat Electrical recordings 
Cho et al., 2017; 
Yoshimura et al., 2001; 
Ozawa et al., 1999; 
Birder et al., 1998. 
NGF - Rat Elisa 
Suh et al., 2017; 
Yokokawa et al., 2016. 
CYTOKINES - Dog 
Fluorescence 
multiplex 
Kang et al., 2013; 
Wood et al., 2012; 
Kruse et al., 2012. 
PROSTAGLANDINS  - 
Rabbit; 
Human 
Radioimmunoassay; 
Elisa; functional 
studies 
Downie and Karmazyn, 
1984; Zhang and Bai, 
2014. 
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Table 1 represents the signaling molecules and receptors detected in the 
urothelium which can be involved in urinary bladder functioning in health and 
disease: it is however, worth to note that the underlying mechanism(s) and role(s) of 
some of these molecules are still unclear (reviewed in Winter et al., 2014). 
 
The urothelium can influences the contractile state of the detrusor smooth 
muscle through the release of mediators such as adenosine triphosphate (ATP) or 
nitric oxide (NO) (Santoso et al., 2010).  
 
 
 
2. The micturition reflex 
The urination or voiding, also known as micturition, is a process that begins in 
neonates as an involuntary process in which bladder emptying occurs without the 
conscious control of the individual (Beckel and Holstege, 2015). During voiding, the 
muscles of the urethra relax and the detrusor contracts, raising the intravesical 
pressure and causing the urine flow through the urethra. During urine storage the 
urethra is closed and the bladder smooth muscle is quiescent, allowing the bladder to 
distend and the intravesical pressure to remain low over a wide range of bladder 
volumes. The micturition reflex is coordinated by three sets of nerves 
(parasympathetic, sympathetic, and somatic) that emerge from the sacral and the 
thoracolumbar spinal cord (see Figure 3) (Fowler et al., 2008, Andersson, 1993; de 
Groat et al., 1993; Yoshimura and de Groat, 1997) involving pathways at many levels 
of the brain and multiple neurotransmitters (see Table 2) (Fowler et al., 2008).  
 
The storage and elimination of urine depend on the coordinated activity of 
smooth and striated muscles in the two functional units of the lower urinary tract, 
namely the urinary bladder and the bladder outlet consisting of the bladder neck, the 
urethra and the urethral sphincter (Morrison et al., 2005; Fry et al., 2005). The 
complexity of this mechanism is demonstrated by the number of reflexes present in 
voiding. A total of 12 reflexes are involved in the urine release (Mahony et al., 1977). 
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Table 2. Innervation in the urinary bladder. Nerve structures, molecules (neurotransmitters), 
receptors, micturition phase and functions involved in the bladder function. 
 
Legend: ACh – acetylcholine; ATP – adenosine triphosphate; NA – noradrenaline; α – 
adrenoceptor alpha subtype; β – adrenoceptor beta subtype.  
 
 
 
The micturition reflex consists of two phases. Firstly, there is the filling phase, 
when urine is released into the bladder from the ureters; secondly, there is the 
emptying phase when urine is conveyed from the bladder to the urethra. During the 
filling phase, the bladder acts as a reservoir for the urine, maintaining low intravesical 
pressures. This phenomenon happens due to the absence of parasympathetic nerve 
activity and to the distensible properties of the bladder wall that allow the bladder to 
stretch to accommodate a continuously growing volume of urine (Yoshimura and de 
Groat, 1997). In this phase, mechano-sensitive receptors present in the urinary wall 
activate bladder afferent nerves, resulting in increased neural activity in the 
hypogastric and pelvic nerves (Sengupta and Gebhart, 1994; Floyd et al., 1976; de 
Groat and Lalley, 1972).  
Activation of the sensitive system triggers a cascade of events: first-order 
afferent neurons convey sensory information, via pelvic nerves, to a cell group in the 
lateral dorsal horn and lateral part of the intermediate zone within the sacral spinal 
cord termed Gert’s Nucleus (Holstege, 2005; Holstege, 2010). 
 
NERVOUS SYSTEM 
NERVE 
STRUCTURES 
MOLECULE RECEPTORS 
MICTURITION 
PHASE 
FUNCTION 
AUTONOMIC 
Sympatic 
Preganglionic 
motoneurons  
hypogastric 
nerves 
NA α and β Filling 
Relaxation 
detrusor; 
Contraction 
internal 
sphincter 
Parasympatic 
Motoneurons  
pelvic nerve 
ACh and 
ATP 
Muscarinic 
and purinergic 
Emptying 
Contraction 
bladder; 
relaxation 
internal 
sphincter 
SOMATIC 
Motoneurons  
pudendal nerve 
ACh Nicotinic 
Filling and 
emptying 
Input into 
the reflex 
circuits that 
control 
bladder 
filling and 
emptying 
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Figure 3. Micturition control. Coordination between the bladder and the outlet 
(bladder neck, urethra and urethral sphincters) is mediated by hypogastric nerve 
(sympathetic system), pelvic nerve (parasympathetic system) and pudendal nerves (somatic 
system). Adapted from Kanai and Andersson, 2010. 
 
Together the complex interneuron circuitry within the spinal cord, 
parasympathetic innervation of the detrusor, is inhibited. The supraspinal input 
ensures that the voiding reflex remains under voluntary control as the decision to 
void is based on a combination of emotional, social and visceral sensation factors 
(Fowler et al., 2008). From the Gert’s Nucleus, second-order afferent fibers ascend 
within the fasciculus gracilis to relay sensory information pertaining to bladder filling 
to the midbrain periaqueductal gray (PAG) matter (Griffiths and Tadic, 2008; Kavia et 
al., 2005), where third-order neurons originate. Higher centers such as the insula, the 
thalamus, the anterior cingulate gyrus (ACG), and the prefrontal cortices have 
multiple connections with the PAG. Bladder afferents received by PAG are relayed 
onto the insula-often referred to as the sensory cortex of the autonomic nervous 
system (Drake et al., 2010). In turn, the PAG acts as an interface between the 
afferent and the efferent limbs of bladder control circuits. The main centre of control 
of the micturition is located in the M-region or Barrington’s nucleus, usually also 
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Parasympathetic
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muscle
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known as the pontine micturition centre (PMC). The PMC is located in the dorsal part 
of the caudal pontine tegmentum, adjacent to the locus coerulus (Fowler et al., 2008; 
Holstege, 2010). The PAG communicates with the PMC so that the higher centres 
ensure the maintenance of voluntary control of the voiding reflex. From the PMC, 
long fibres descend to the parasympathetic sacral bladder motoneurons and to the 
inhibitory interneurons to Onuf’s nucleus (Holstege, 2010). When the bladder is full 
and a higher level of bladder distension is reached, the maximal bladder afferent 
activity within the PAG results in the stimulation of the PMC. As a result of this 
spinobulbospinal reflex, voiding occurs. The PMC is, therefore, regarded as the final 
efferent nucleus on the micturition pathways that co-ordinates inhibition of the 
sphincters and ignition of detrusor contraction. Hence, the activity of the PMC needs 
to be inhibited during the bladder’s filling and storage phases (Shah et al., 2014).  
Sacral parasympathetic (pelvic) nerves provide excitatory inputs (cholinergic 
(e.g. ACh) and purinergic (e.g. ATP)) to the bladder and have an inhibitory (nitrergic 
(e.g. NO) effect on the urethra (de Groat et al., 1993; Ralevic and Burnstock, 1998). 
Thoracolumbar sympathetic pathways release noradrenaline (NA) and provide 
excitatory inputs to the bladder neck and the urethra, as well as both facilitatory and 
inhibitory inputs to parasympathetic ganglia, and, in some species, have an inhibitory 
effect on the detrusor (Andersson, 1993; de Groat et al., 1993). These sympathetic 
pathways mainly run through sympathetic nerve trunks (Sugaya et al., 1988a). The 
lumbosacral efferent pathways in the pudendal nerves provide cholinergic excitatory 
inputs to the striated muscle of the urethral sphincter. Afferent activity in the bladder 
and the urethra is conveyed to the central nervous system by three sets of nerves 
(Figure 3 and Table 2) (de Groat et al., 1993; Yoshimura and de Groat, 1997; 
Morrison, 1999).  
 
3. The cholinergic system   
Acetylcholine (ACh) is a major regulator of the urinary bladder function, acting 
in the whole structural component of the bladder including the detrusor muscle, nerve 
terminals and the urothelium (Chess-Williams, 2002; Andersson and Wein, 2004; 
Birder, 2005; Hedge, 2006). The sources of ACh can be neuronal (Rang et al., 2004) 
or non-neuronal (Wessler et al., 2003). In the bladder, cholinergic neurons provide 
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neuronal ACh, while the non-neuronal ACh is mainly originated from urothelial cells 
(de Groat et al., 2004; Lips et al., 2007).  
 
 
ACh is synthetized by the action of choline acetyltransferase (ChAT), which 
catalyses the reaction between acetyl coenzyme-A (acetyl-CoA) and choline. ACh 
and CoA are the reaction products. Acetyl-CoA is originated in the mitochondria from 
the complete oxidation of pyruvate. The formation of acetyl-CoA is catalyzed by an 
enzyme complex called pyruvate dehydrogenase complex. Choline that is need for 
the synthesis of ACh comes from various sources, including the circulating choline in 
the plasma, the hydrolysis of phospholipids from cell membranes and from the 
uptake of choline resulting from action of acetylcholinesterase (AChE) on ACh 
released into the synaptic cleft. High affinity choline uptake is mediated by a 
concentrative transporter, which exhibits high-affinity for choline and it is dependent 
on temperature and the transmembrane Na+ gradient. Synthesis of ACh is limited by 
the availability of choline (Rang et al., 2004). In neurons, synthesized ACh is 
transported into synaptic vesicles by an antiport mechanism. When an action 
potential reaches nerve terminals, it triggers Ca2+ influx from the extracellular milieu 
via voltage-sensitive channels, which promotes the fusion synaptic vesicles to the 
plasma membrane, and, consequently, the exocytosis of ACh to the synaptic cleft 
(Rang et al., 2004). Non-neuronal cells that produce ACh are not endowed with such 
effective vesicle storage. It is not even known whether the non-neuronal ACh is 
stored at all, but an equilibrium may exist between continuous synthesis, diffusion, 
release and hydrolysis (Wessler et al., 2003). The release mechanism of non-
neuronal ACh is not known. However, ACh is an organic cation and it may be 
transported by ubiquitously expressed organic cation transporters (OCTs). This 
hypothesis was corroborated using direct inhibitors (quinine, corticosterone) or 
 NEURONAL NON-NEURONAL 
SYNTHESIS Nerve terminal Whole cell 
STORAGE Vesicles Cytosol (?!) 
RELEASE Exocytosis synchronized demand Transporter mediator continuously 
RECEPTOR Hot spots Uniformly expressed 
ACTION Short lasting Continuously 
ELIMINATION Rapid Slow 
Table 3. Differences between neuronal and non-neuronal cholinergic system. 
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substrate inhibitors (amiloride, verapamil) of OCTs which reduced ACh release 
(Wessler et al., 2003). The urothelium expresses two types of organic cation 
transporters, the type 1 (OCT1) and type 3 (OCT3) (Lips et al., 2007). 
The ACh actions are conferred by two receptor families, G-protein-coupled 
muscarinic receptors (mAChR) and ionotropic nicotinic receptors (nAChR). 
 
3.1. MUSCARINIC RECEPTORS 
Muscarinic ACh receptors are responsible for bladder contractility (Andersson, 
1993). These receptors belong to the family of G-protein coupled receptors (GPCRs), 
which are the most abundant and pharmacologically targeted plasma membrane 
receptors (Lander et al., 2001; Fredriksson et al., 2003). A common structural feature 
of GPCRs are the extracellular N-terminus, seven membrane spanning domains, 
three extracellular and three intracellular loops and an intracellular C-terminus. 
Stimulation of various GPCRs leads to activation of particular G-proteins and their 
intracellular signaling pathways, which control many important physiological 
functions. The intracellular signaling pathways of GPCRs involve the activation an 
effector enzyme to generate an intracellular second messenger (e.g. cyclic 
adenosine monophosphate (cAMP), diacylglycerol (DAG)) (Lodish et al., 2000). In 
addition to these well-established pathways, it has also been demonstrated that 
receptors also transduce non-G-protein-mediated signaling via arrestins and G-
protein receptor kinases (Reiter and Lefkowitz, 2006; Lefkowitz and Shenoy, 2005; 
Lefkowitz, 1998). 
Five subtypes of muscarinic receptors denoted as M1-M5 and encoded by five 
different genes have been discovered and characterized pharmacologically (Bonner 
1989a, b; Bonner et al., 1987, 1988; Peralta et al., 1987; Kubo et al., 1986a). The M1, 
M3 and M5 receptor subtypes activate preferentially Gq/11 guanine nucleotide binding 
proteins. These receptors alter cellular activity by stimulating phospholipase C (PLC) 
and generating the second messenger inositol triphosphate (IP3) which induces the 
release of calcium from intracellular stores and DAG that causes activation of protein 
kinase C (Cauldfield and Birdsall, 1998; Jones et al., 1991). On the other hand, M2 
and M4 receptors couple to Gi/o proteins leading to inhibition of adenylate cyclase 
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(Peralta et al., 1988; Jones et al., 1991), decreases in cAMP levels and smooth 
muscle relaxation (Bolton and Zholos, 1997). 
 
Table 4. Characterization of muscarinic receptors in the bladder. 
G-PROTEIN 
COUPLED 
INTRACELLULAR 
EFFECTS 
MUSCARINIC 
RECEPTOR 
SUBTYPE 
EXPRESSION IN THE 
BLADDER 
FUNCTIONAL 
EVIDENCES 
Gq/11 ↑PLC  IP3  DAG 
M1 Urothelium; detrusor 
No functional 
evidences 
M3 
Urothelium; detrusor; 
ICCs; myofibroblasts 
Detrusor 
contraction 
M5 
Whole bladder?? But 
not in urothelium and 
detrusor isolated!! 
No functional 
evidences 
Gi/o ↓AC  ↓cAMP 
M2 
Urothelium; detrusor; 
ICCs; myofibroblasts 
Detrusor 
contraction 
M4 Urothelium; detrusor 
No functional 
evidences 
 
Legend: PLC – phospholipase C; IP3 – inositol triphosphate; DAG – diacylglycerol; AC 
– adenylyl cyclase; cAMP – cyclic AMP; M1 – muscarinic receptor type 1; M2 – muscarinic receptor 
type 2; M3 – muscarinic receptor type 3; M4 – muscarinic receptor type 4; M5 – muscarinic receptor 
type 5; ICC – interstitial cells of Cajal. 
 
Just like the majority of smooth muscle cells in many species, the smooth 
muscle of the urinary bladder, the detrusor, expresses a heterogeneous population of 
muscarinic receptors (see Table 4). With the exception of the muscarinic M5 
receptors, the other four subtypes of muscarinic receptors (M1-M4) were found in the 
uroepithelium and in the smooth muscle from human bladder (see Table 4; Tyagi et 
al., 2006). Notwithstanding this, the most relevant muscarinic receptors in urologic 
disorders seem to be of the M2 and M3 subtypes. The proportion of muscarinic M2 
and M3 receptors found in the detrusor muscle of humans, guinea pigs and rabbits 
vary between 70-80% and 30-20%, respectively (Mansfield et al., 2005; Chess-
Williams et al., 2001; Yamanishi et al., 2000). Despite the fact that the muscarinic M3 
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density is lower than muscarinic M2 receptors in the bladder of animals models 
(Yamanishi et al., 2000; Sellers et al., 2000) and humans (Yamanishi et al., 2015), 
the muscarinic M3 receptor is the main responsible for detrusor smooth muscle 
contraction (Yamanishi et al., 2015; Yamanishi et al., 2000; Sellers et al., 2000).  
Studies using M3 knock-out mice (Matsui et al., 2000) showed that these 
animals have severe deficits in smooth muscle function, with bladder contraction to 
the muscarinic agonist carbachol being reduced by about 95% (Matsui et al., 2000). 
The remaining response was antagonized by the selective muscarinic M2 antagonist, 
methoctramine, indicating a small M2 receptor component. Furthermore, severe 
urinary retention was observed in male M3 knock-out mice. These data suggest that 
smooth muscle contraction is predominantly mediated via muscarinic M3 receptors 
and that muscarinic M2 receptors play a minor role (Uchiyama et al., 2004). 
Experiments using M2 knock-out mice confirmed the assumption that the muscarinic 
M3 receptor is the predominant muscarinic receptor responsible for bladder 
contraction (Igawa et al., 2005). Interestingly, it was found that the muscarinic M2 
receptor subtype might play an important role in the local cholinergic modulation of 
the bladder afferent activity which contributes to bladder overactivity in healthy rats 
(Matsumoto et al., 2010).  
The pharmacological characteristics of muscarinic receptors in the urothelium 
and in the detrusor smooth muscle are very similar (Ogoda et al., 2016), yet the 
specific role of these receptors in the urothelium is still unclear. Imaging studies 
demonstrated that immunoreactivity against muscarinic M2 and M3 receptors was 
greater in the urothelium of rats with bladder outlet obstruction (BOO) than in their 
control littermates, but only the muscarinic M3 receptor was increased in the muscle 
layer of BOO animals (Kim et al., 2007). These results are compatible with the 
increased sensitivity to muscarinic agonists of the detrusor muscle of BOO animals 
(Speakman et al., 1987). The muscarinic M2 receptor is also overexpressed rats 
exhibiting detrusor overactivity after spinal cord injury (SCI) (Matsumoto et al., 2012). 
These evidences demonstrated that muscarinic receptors are implicated in the 
pathophysiology of bladder disorders (Mukerji et al., 2006; Wu et al., 2014) and, thus, 
changes in these receptors deserve to be elucidated.  
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3.2. NICOTINIC RECEPTORS 
The nicotinic receptors are heteromeric or homomeric cation channels, which 
exist as pentameric complexes of various combinations of α- and β-subunits 
(Sargent, 1993; Le Novére and Changeus, 1995; Lukas, 1995). The subtype 
composition determines essential channel characteristics such as ion preference, 
desensitization kinetics, and ligand specificity (Lukas et al., 1999; Elgoyhen et al., 
2001). In the mammalian nervous system eight ligand binding α (α2-α7, α9-α10) and 
three structural β (β2-β4) subunits were identified (Mao et al., 2006). Different subunit 
combinations result in specific nicotinic receptors subtypes, with α7 and α9 being the 
only subunits capable of forming functional homomeric receptors (Mao et al., 2006).  
In the bladder, activation of nicotinic receptors (i) facilitates the firing of 
mechano-sensitive afferents with terminals located near the bladder lumen, (ii) 
inhibits the firing of mechanosensitive afferents located near the serosal surface or in 
the muscle layers of the bladder, and (iii) excites unidentified-afferents (Yu et al., 
2016). Neuronal nicotinic acetylcholine receptors play a key role in the control of 
bladder function mediating fast synaptic transmission between preganglionic and 
post ganglionic bladder efferents. Wherever it has been examined autonomic ganglia 
express more than one nicotinic receptor subtype (Poth et al., 1997; Mandelzys et 
al., 1994; Listerud et al., 1991) and bladder ganglia likely express multiple nicotinic 
receptor subtypes (De Biasi et al., 2000). The nicotinic receptors containing the α3 
and β4 subunits are important for normal bladder function (Xu et al., 1999a,b). 
Neuronal nicotinic receptors expressed in pelvic neurons may contain combinations 
of α3β4, α3β2 and α3β2β4 subunits (De Biase et al., 2000). In the human bladder, α7-
homopentamers and α9/α10-heteropentamers (Beckel et al., 2006; Bschleipfer et al., 
2007) were also described. These are preferentially permeable to calcium, and in 
culture cells from rat epithelium showed a rise in intracellular Ca2+ in response to 
nicotine (Beckel et al., 2006). 
Nicotinic receptors present in the human bladder have an important role in the 
micturition control. It was also demonstrated that these receptors are involved in ATP 
release from bladder. Stimulation of different nicotinic receptors in the urothelium 
modulated ATP release in a reciprocal manner (Jenes et al., 2012; Beckel and 
Birder, 2012) with α7 stimulation inhibiting ATP release and α3 stimulation decreasing 
or increasing basal ATP release (Beckel and Birder, 2012). 
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4. The purinome 
The concept of purinome is recent, and comprise the protein machinery 
involved in the biological interplay of extracellular purine and pyrimidine ligands, with 
the purinergic receptors, enzymes, transporters/channels (Volonté and D’Ambrosi, 
2009). The novelty in the definition of purinome consists in grouping together known 
elements (ligand, receptors, transporters/channels and degrading enzymes) that 
contribute as a whole and not singularly, to the triggering maintenance and 
termination of purinergic signaling (Volonté and D’Ambrosi, 2009).  
In the humans, is described that approximately 3266 proteins use purines as 
cofactors. The human purinome encompass a wide-ranging functional repertoire and 
many of these proteins are attractive drug targets (Murray and Bussiere, 2009). On 
the other hand, purinergic signaling is not only regulated by the presence of ligands 
together with receptors, enzymes and transporters, but also by their broad-spectrum 
of direct/indirect interactions with a previously unrecognized cooperative network, 
defined as purinome (Volonté and D’Ambrosi, 2009). 
 
4.1. THE PURINERGIC SYSTEM 
Purinergic signaling is a primitive system (Burnstock, 1996) that is involved in 
many non-neuronal and neuronal mechanisms, in both short-term and long-term 
events (Abbracchio and Burnstock, 1998; Burnstock and Knight, 2004). These 
include exocrine and endocrine secretion, immune responses, inflammation, 
mechanosensory transduction, platelet aggregation and endothelial-mediated 
vasodilatation, and in cell proliferation, differentiation, migration and death in 
development and regeneration, respectively (Burnstock, 2006).  
The parasympathetic purinergic nerve-mediated component of contraction of 
the human bladder is small under normal situations, but it increases up to 40% in 
pathological conditions, such as interstitial cystitis (IC), outflow obstruction, idiopathic 
instability and some types of neurogenic bladder (Burnstock, 2001). These findings 
support the implications of the purinergic system in the pathophysiology of urinary 
bladder dysfunctions.  
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4.2. THE ROLE OF ATP  
Adenosine triphosphate (ATP) was discovery in 1970 as the transmitter 
responsible for the non-adrenergic non-cholinergic (NANC) neurotransmission in the 
gut and the urinary bladder (Burnstock et al., 1972). ATP is a multifunctional 
ubiquitous biological molecule that acts as the primary intracellular energy source for 
all living cells and also as an extracellular signaling molecule. In the urinary bladder, 
ATP is the main signaling molecule with a pivotal role in bladder fullness sensation 
and in various bladder disorders (Burnstock, 2003).  
Urothelium is the main source of ATP in the urinary bladder. Notwithstanding 
this, the extracellular amount of ATP significantly depends on the urothelium site, 
basal vs apical, as it largely depends on the expression and/or activity of co-localized 
ecto-nucleotidases (see below, section 4.4, Ecto-NTPDases). The larger purinergic 
tone may be partially related to the impairment of ecto-NTPDase1/CD39 activity, thus 
limiting the extracellular breakdown of ATP (Silva-Ramos et al., 2016b). Bidirectional 
release of ATP from in vitro rabbit urothelium demonstrated that stretching the tissue 
resulted in a transient fivefold increase in the rate of mucosal ATP release and a 
transient sixfold increase in serosal ATP release (Lewis and Lewis, 2006). These 
findings led to the conclusion that ATP may act as an important autocrine (Wang et 
al., 2005) and paracrine mediator (Cockayne et al., 2000) in the urinary bladder. 
The filling of the urinary bladder stretches the urothelium and thereby activates 
mechanotransduction pathways, which are likely initiated by increased tension at the 
apical surface of the umbrella cells. These external mechanical stimuli induce 
stretch-activated ATP release from urothelial cells (Fergusson et al., 1997; Cheng et 
al., 2011; Dunning-Davies et al., 2013). ATP starts the purinergic mechanosensory 
transduction mechanism by acting on P2X3 homomultimeric and P2X2/3 
heteromultimeric receptors on subepithelial sensory nerves, thus sending impulses to 
initiate the micturition reflex (Cockayne et al., 2005; Burnstock, 1999). Sensory 
information from the urinary bladder is conveyed by both lumbar splanchnic and 
sacral pelvis nerves to the spinal cord. Mechanosensitive properties of single afferent 
fibers in these two pathways showed that both low and high threshold stretch-
sensitive afferents are present in both pathways (Xu and Gebhart, 2008). Single unit 
analysis of sensory fibers in the mouse urinary bladder revealed both low-and high 
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threshold fibers sensitive to ATP contributing to physiological (non-nociceptive) and 
nociceptive mechanosensory transduction, respectively (Rong et al., 2002).  
Although ACh acting on smooth muscle muscarinic receptors is generally 
accepted as the primary effector controlling the bladder emptying, neural stimulation 
of the bladder is only partially inhibited by atropine, the anticholinergic drug (non-
selective muscarinic antagonist) (Cowan and Daniel, 1983). This fact may be 
explained by the dual effect of ATP in the bladder. Although this nucleotide is 
involved in bladder filling sensation of the micturition reflex, it may facilitate voiding of 
urine from the bladder. ATP is co-release with ACh from parasympathetic nerves 
supplying the bladder. ATP release from cholinergic nerves exerts its activity by 
activating ionotropic P2X1 receptors which prevails in the detrusor smooth muscle in 
order to favor contraction of the bladder (Kennedy et al., 2007). The molecular 
mechanisms underlying ATP effects under pathological conditions are partially 
unknown and deserve to be explore given that excessive purinergic signals are 
detected in overactive bladder syndromes. Notwithstanding, in patients with 
overactive detrusor (OD) (Chen et al., 2010) and overactive bladder (OAB) (Chen et 
al., 2013), ATP reveals to be an important factor for initial perception of need to 
voiding, indicated by first desire to void (Chen et al., 2013). These support the 
evidences that the ATP may mediate initial afferent sensation in patients with 
dysfunctions characterized by urgency (Chen et al., 2013). On the other hand, ATP 
concentrations remained unchanged after voiding, suggesting that voiding did not 
further induce ATP release into intraluminal fluid (Chen et al., 2014). However, in 
patients with OAB (Silva-Ramos et al., 2013) and bladder outlet obstruction (BOO) 
(Silva-Ramos et al., 2016a), the urinary levels of ATP were increased, similar was 
also observed in patients with neurogenic bladder syndromes (Munoz et al., 2012). 
These reports sustain the hypothesis that ATP may a urinary biomarker to lower 
urinary tract dysfunctions (Silva-Ramos et al., 2013; Silva-Ramos et al., 2016a; 
Cheng et al., 2010; Munoz et al., 2011). 
 
4.2.1. Mechanisms of ATP release  
The mechanisms that are involved in the release of ATP from the urinary 
bladder are still a matter of debate in the literature. Besides ATP exocytosis from 
bladder nerves (Novak, 2003), there are several additional mechanisms putatively 
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involved in ATP release from non-neuronal cells (e.g. urothelial cells); these include 
efflux via connexin or pannexin hemichannels (Shout et al., 2002; Timóteo et al., 
2014; Negoro et al., 2013), maxi-ion channels, ATP-binding cassette transporters, 
and P2X7 receptor channels (Burnstock, 2007). 
As described above (section 4.2) ATP can be released both to the serosal and 
mucosal sites of the urothelium (Lewis and Lewis, 2006; Fergusson et al., 1997). 
ATP release from apical and basolateral membranes of the epithelial cells may 
involve the following mechanisms: (i) ATP-permeable release channels that may be 
present in each membrane domain and that are likely anion-permeable channels; (ii) 
plasma membrane forms of the mitochondrial porins or voltage-dependent anion 
channels (VDCAs); (iii) adenine nucleotide transporters; (iv) adenine 
nucleotide/nucleoside exchangers that are located in the mitochondrial membrane 
and may also be expressed in the plasma membrane and the ATP-filled vesicles 
(Schwiebert and Zsembery, 2003); (v) transient receptor potential (TRP) vanilloid 
receptor subtype 1 (TRPV1, Charrua et al., 2009) or TRPV4 channels (Mochizuki et 
al., 2009); (vi) ABC transporters (Wang et al., 2005) and (vii) mechanosensitive 
channels (Dunning-Davies et al., 2013; Birder et al., 2003).  
 
4.3.  PURINERGIC RECEPTORS 
Purinergic signals in the urinary bladder are complex and depend on the 
activation of specific purinoceptor subtypes. These belong to two main families, 
identified as P1 and P2 for adenosine and adenine and/or uracil nucleotides, 
respectively (Burnstock, 1978). P2 purinoceptors are subdivided in ionotropic ligand-
gated P2X channels and metabotropic G-protein-coupled P2Y receptors (Abbracchio 
and Burnstock, 1994). Regarding the P1 receptors four G-protein-coupled receptor 
subtypes (A1, A2A, A2B, and A3) have been cloned and pharmacologically 
characterized (Fredholm et al., 2001). 
In the urinary bladder several cell types participate in the purinergic signaling 
cascade controlling bladder activity. These include urothelial cells (Schwiebert et al., 
2003; Dunning-Davies et al., 2013), ICCs (Li et al., 2013), smooth muscle fibers (Yu 
et al., 2006; Gopalakrishnan et al., 2002) and suburothelial nerve fibers (Birder and 
Andersson, 2013; Gonzalez et al., 2014). 
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4.3.1. P2X receptors 
P2X receptors are ATP-gated ion channels which mediate rapid (within 10 ms) 
and selective permeability to cations (Na+, K+ and Ca2+) (North, 2002). They are 
distributed essentially on excitable cells (smooth muscle cells, neurons and glial 
cells) and their role is to mediate fast excitatory neurotransmission in response to 
ATP in both the central and the peripheral nervous systems. This contrasts with the 
slower onset of response (less than 100 ms) to ATP acting at metabotropic P2Y 
receptors.  
The first cDNA encoding a P2X receptor (P2X1) was isolated in 1994 (Brake 
et al., 1994; Valera et al., 1994) and since then, seven different P2X receptor 
subunits have been identified (P2X1-7) (Abbracchio et al., 2009; Surprenant and 
North, 2009; North, 2002; Ravelic and Burnstock, 1998). The members of this 
receptor family show conserved subunit topology. They comprise two 
transmembrane spanning regions and possess intracellular amino- and carboxy-
terminus which contain consensus binding motifs for protein kinases. A large 
extracellular loop exits which contains 10 conserved cysteine residues and is capable 
of forming a series of disulfide bridges. The first transmembrane is involved in 
channel gating while the second lines the ion pore in the membrane (North, 2002; 
Roberts et al., 2006). P2X receptor subunits are capable of forming functional 
homomeric and heteromeric trimers (North, 2002; Roberts et al., 2006).  
Despite the presence of all types of P2X receptors in the urinary bladder (see 
Table 5), only the P2X1, P2X2, and P2X3 homomers and the P2X2/P2X3 heteromer 
have been primarily associated with bladder function (Ford et al., 2006; Cockayne et 
al., 2005). In general terms, the P2X1 receptor has been associated with the detrusor 
motor response (O’Reilly et al., 2001; Hoyle et al., 1989; Husted et al., 1983; Palea et 
al., 1994), whereas P2X2 and P2X3 subtypes are linked to bladder sensation (Smith, 
2011). Both P2X1 and P2X3 receptors close quickly (hundreds of milliseconds) in the 
continued presence of ATP, whereas the P2X2 receptor remains open for the 
duration of ATP binding (Burnstock, 2000).  
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Table 5. Localization of P2X receptor subtypes in the urinary bladder. 
 
Due to the role of P2X2 and P2X3 receptors in bladder sensation and pain, 
various studies have been developed to understand their function in bladder 
diseases. In a systematic study of purinergic mechanosensory transduction in the 
mouse urinary bladder, it was shown that the activity initiated in pelvic sensory 
nerves through ATP release from the urothelium was mimicked by α,β-methylene 
ATP (α,β-meATP) and attenuated by P2X3 receptor antagonists, as well as in P2X3 
knockout mice; the P2X3 receptors were localized on suburothelial sensory nerve 
fibers (Vlaskovska et al., 2001; Carneiro et al., 2014). Prolonged exposure to a 
desensitizing concentration of α,β-meATP significantly reduced the 
mechanosensitive activity of the pelvic nerve (Namasivayam et al., 1999). P2X3 
knockout mice exhibit reduction of inflammatory pain and marked urinary bladder 
hyporeflexia with reduced voiding frequency and increased voiding volume, thus 
suggesting that the P2X3 receptor is involved in mechanosensory transduction 
underlying both inflammatory pain and physiological voiding reflexes (Cockayne et 
al., 2000). Subsequently, using P2X2 knockout mice and P2X2/P2X3 double 
knockout mice, the same group showed that the P2X2 receptor subtype may also be 
involved in mediating the sensory effect of ATP in the bladder (Cockayne et al., 
2005).  
The urinary levels of ATP are increased in the patients with neurogenic 
(Munoz et al., 2012) and non-neurogenic overactive bladders (Silva-Ramos et al., 
P2X 
RECEPTOR 
SUBTYPES 
LOCALIZATION IN 
THE BLADDER 
SPECIES REFERENCES 
P2X1 Detrusor 
Rat; 
human 
O’Reilly et al., 2001; Lee et al., 2000; 
Carneiro et al., 2014; Silva-Ramos et al., 
2015b; Moore et al., 2001; O’Reilly et al., 
2002; Elneil et al., 2001. 
P2X2 
Detrusor intracellular; 
suburothelium; 
urothelium 
Rat; 
human 
Lee et al., 2000; Tempest et al., 2004; 
Svennersten et al., 2015. 
P2X3 
Detrusor; suburothelial 
nerves; urothelium 
Rat; 
human 
Lee et al., 2000; Vlaskovska et al., 2001; 
Elneil et al., 2001; Carneiro et al., 2014; 
Svennersten et al., 2015. 
P2X4 
Detrusor; nerve 
varicosities; capillary 
membranes 
Rat; 
human 
Lee et al., 2000; Moore et al., 2001; O’Reilly 
et al., 2002. 
P2X5 Detrusor; epithelial cells Rat Lee et al., 2000. 
P2X6 
Detrusor; urothelial 
nucleic 
Rat Lee et al., 2000. 
P2X7 Detrusor; urothelium Human Svennersten et al., 2015. 
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2013), bladder outlet obstruction (BOO, Silva-Ramos et al., 2016a), and other lower 
urinary tract syndromes (Birder et al., 2011). Alterations in urinary ATP are usually 
accompanied by changes in the density of P2X receptors in the bladder, implying that 
a concerted action of these changes might have impact in the pathophysiology of 
lower urinary tract diseases. For instance, patients with BOO exhibit increased 
urinary ATP (Silva-Ramos et al., 2016a) and overexpress the P2X3 receptor in the 
bladder urothelium as detected by western blot analysis (Kim et al., 2007). Increased 
levels of ATP in the bladder are also associated with neurogenic bladder overactivity 
mediated by activation of P2X3 and P2X2/3 receptors. The same occurred in a rat 
model of neurogenic detrusor overactivity (Munoz et al., 2012); these authors 
showed that increased ATP levels strengthened P2X3 and P2X2/3 receptors 
activation leading to intensification of sensory bladder signals and generation of non-
voiding contractions, which might contribute to LUTS.  
Disorders of the central nervous system, such as hyperactivity of the spinal 
cord, which are common in chronic pain states (D’Mello and Dickenson, 2008) may 
promote a multiple pain mediators release. These mediators (e.g. ATP) can sensitize 
and affect the expression of P2X3 receptors located in the peripherally and centrally 
(Paukert et al., 2001; Ramer et al., 2001). In recent years it has been demonstrated 
that tonic activation of presynaptic P2X3 and P2X2/3 receptors in the spinal cord 
facilitates the sensory input of the micturition reflex. This has been demonstrated in 
vivo using a novel selective antagonist of these receptors and through activation of 
the extracellular-signal-regulated kinase (ERK) signaling pathway following a 
peripheral noxious stimulation (Kaan et al., 2010). These data open avenues for 
therapeutic approaches to treat various sensory dysfunctions including chronic pain 
states and potentially, the OAB syndrome, by focusing on targeting the inhibition of 
sensory purinergic signals (Munoz et al., 2012; Kaan et al., 2010). 
 
4.3.2. P2Y receptors 
P2Y receptors are G-protein coupled (metabotropic) receptors, which are 
categorized into several subfamilies that predominantly couple to (1) Gq (P2Y1, P2Y2, 
P2Y4, P2Y6 and P2Y11) and, therefore, activate phospholipase C (PLC), and (2) Gi 
(P2Y11, P2Y12, P2Y13 and P2Y14) that inhibit adenylyl cyclase (AC) (Abbracchio et al., 
2006) and regulate voltage-gated ion channels activity (Abbracchio et al., 2006; 
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Burnstock, 2006). The P2Y11 receptor is dually coupled to PLC and AC stimulation 
(Abbracchio et al., 2006). 
Pharmacologically, P2Y receptors can be subdivided into (1) adenine 
nucleotide-preferring receptors mainly responding to ATP and ADP (human and 
rodent P2Y1, P2Y12 and P2Y13 and human P2Y11), (2) uracil nucleotide-preferring 
receptors (human P2Y4 and P2Y6) responding to either UTP and UDP, respectively, 
(3) receptors of mixed selectivity (human and rodent P2Y2 and rodent P2Y4), and (4) 
nucleotide sugar-preferring human P2Y14 receptor responding to UDP-glucose and 
UDP-galactose (Abbracchio et al., 2006; Lazarowski et al., 2003). In summary, the 
uracil nucleotide, UTP, activates two subtypes of receptors (P2Y2 and P2Y4 
receptors), while UDP, previously thought to activate only a single subtype (P2Y6 
receptors), is actually known to also activate P2Y14 receptors along with the originally 
designated native agonist UDP-glucose (Carter et al., 2009). Six of the eight known 
P2Y subtype receptors have been found in the urinary bladder (Table 6). 
 
Table 6. Localization of P2Y receptor subtypes in the urinary bladder. 
 
Despite the different subtypes of P2Y receptors described, the P2Y1 receptor 
subtype has been better characterized because it is associated to inhibition of 
cholinergic neurotransmission in the human bladder (Silva et al., 2011). In addition, 
cystometry studies demonstrate that activation of the P2Y1 receptor inhibits the tone 
of the rat detrusor (King et al., 2004; Carneiro et al., 2014).  
P2Y 
RECEPTOR 
SUBTYPES 
LOCALIZATION IN THE BLADDER SPECIES REFERENCES 
P2Y1 
Detrusor; urothelium; suburothelium; 
epithelial cells 
Cat; rat; human 
Birder et al., 2003; 
Carneiro et al., 
2014; Säve and 
Persson, 2010. 
P2Y2 Detrusor; epithelial cells Cat; rat; human 
Birder et al., 2003; 
Chopra et al., 2008; 
Säve and Persson, 
2010. 
P2Y4 Urothelium Cat Birder et al., 2003. 
P2Y6 Detrusor; urothelium 
Rat; guinea-pig; 
mouse 
Carneiro et al., 
2014; Timóteo et al., 
2014; Sin et al., 
2006; Yu et al., 
2013. 
P2Y11 Epithelial cells Human 
Säve and Persson, 
2010. 
P2Y12 Detrusor Mouse Yu et al., 2013. 
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Interactions between P2Y and P2X receptors have been reported, 
demonstrating the complexity of the purinergic signaling pathways in the urinary 
bladder. Yu et al. (2013) showed that activation of the P2Y6 receptor by UDP in 
detrusor smooth muscle strips from mice modulates P2X1-receptor-mediated 
contractile responses. These authors hypothesized that synergism between P2Y6 
and P2X1 may be relevant under pathological conditions, but this theory was never 
confirmed or dismissed.  
Our group demonstrated that activation of urothelial expressed UDP-sensitive 
P2Y6 receptors increases the voiding frequency in the anaesthetized rat (Timóteo et 
al., 2014). This effect is indirectly mediated by ATP released from the urothelium via 
pannexin-1 hemichannels, which leads to the subsequent activation of P2X3 
receptors on sub-urothelial sensory nerve fibers. Interestingly, ATP mediated 
detrusor contractions, via activation of excitatory P2X1 receptors, may be 
counteracted by its metabolite, ADP, resulting from its catabolism by ecto-
nucleotidases. Formation of ADP in the detrusor layer favors activation of 
prejunctional inhibitory P2Y1 receptors controlling ACh release from cholinergic nerve 
endings (Silva et al., 2011). 
 
4.4. ECTO-NTPDASES 
As a matter of fact, ATP may have direct effects via activation of P2X 
purinoceptors, and indirect effects after its enzymatic conversion into ADP and 
adenosine, which are able to activate P2Y and P1 receptors, respectively. The 
extracellular hydrolysis of ATP is catalyzed by membrane-bound ecto-nucleotidases, 
the NTPDases presenting the highest affinity of ATP. These enzymes play very 
important physiological roles because rapid ATP catabolism results in transient 
responses of target tissues to ATP and formation of biologically active ATP 
metabolites (e.g. ADP and adenosine) shifts fast ATP responses to more durable 
effects operated by metabotropic P2Y and P1 receptors. 
Once released into the extracellular space, ATP is hydrolyzed into adenosine 
diphosphate (ADP) and adenosine monophosphate (AMP) by ecto-nucleoside 
triphosphate diphosphohydrolases (also known as ecto-nucleotidases, E-NTPDases, 
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NTPDases), which are then metabolized into adenosine by ecto-5’-nucleotidase 
(Zimmermann, 2000; Zimmermann et al., 1998).  
Four main families of ecto-nucleotidases are characterized: E-
NTPDases/Ecto-NTPDases (ectonucleoside triphosphate diphosphohydrolases), 
nucleotide pyrophosphatase/phosphodiesterases (NPPs), alkaline phosphatases and 
ecto-5’-nucleotidase (NT5E/ecto-5’-NTPdase). These families differ primarily on their 
substrate specificities, with E-NTPDases being highly specific for 
ATP/UTP/ADP/UDP (Robson et al., 2006), while NPPs (Sakagami et al., 2005; 
Gijsbers et al., 2003) catalyze phosphohydrolysis on a broader range of substrates 
including lysophospholipids and choline phosphate esters (Robson et al., 2006; 
Vorhoff et al., 2005; Stefan et al., 2005; Stefan et al., 2006).  
The NTPDase family is composed by eight different proteins. Individual 
NTPDases subtypes differ in functional properties and cellular location. Four of the 
NTPDases are typically cell surface-located enzymes with an extracellular facing 
catalytic site (E-NTPDase1, 2, 3, 8). NTPDases 5 and 6 exhibit intracellular 
localization and undergo secretion after heterologous expression. NTPDases 4 and 7 
are entirely intracellularly located, facing the lumen of cytoplasmic organelles 
(Robson et al., 2006). Plasma membrane bound E-NTPDases can be differentiated 
according to substrate preference, divalent cation usage and product formation. All 
E-NTPDases require Ca2+ or Mg2+ ions in the millimolar range for maximal activity 
and are inactive in their absence (Zimmermann, 2001; Kukulski et al., 2005). All 
these enzymes hydrolyse nucleoside triphosphates, including the physiologically 
active ATP and UTP (Robson et al., 2006). The ATP metabolism and the role of 
NTPdases are shown in the Figure 4.  
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Figure 4. ATP metabolism and role of E-NTPDases.  NTPDase1 (CD39 or apyrase) 
dephosphorylates ATP directly into AMP, with minimal accumulation of ADP. NTPDase2 (ATPase) is 
a preferential nucleoside triphosphatase hydrolyzing ADP 10 to 15 times less efficiently than ATP, 
leading to minimal AMP accumulation. NTPDase3 is a functional intermediate between NTPDase1 
and NTPDase2. The E-NTPDases cascade can be terminated by ecto-5’-nucleotidase (CD73) with 
hydrolysis of adenine monophosphate into adenosine. 
 
Using molecular biology techniques it was demonstrated that all the eight 
members of NTPDases, as well as ecto-5’-nucleotidase, are expressed in the mouse 
bladder. However, of the distribution of NTPDases in the mouse bladder is 
heterogeneous; E-NTPDase1 is present in the endothelium of blood vessels in the 
lamina propria and in the detrusor smooth muscle, while E-NTPDase2 is expressed 
in cells localized to the region of the lamina propria adjacent to the detrusor and 
surrounding the detrusor muscle bundles (Yu et al., 2011). The same pattern was 
observed in the rat bladder (Carneiro et al., 2014). E-NTPDase3 is present in the 
urothelium, occurring on membranes of intermediate and basal epithelial cells, but is 
absent from the umbrella cells (Yu et al., 2011). The expression and localization of E-
NTPDase8 protein in the urothelium was confirmed by immunoblotting and 
immunofluorescence, respectively. Like the E-NTPDase1 also ecto-5’-nucleotidase 
was present in the detrusor smooth muscle. Co-localization of these enzymes 
suggest that ATP-mediated effects may be balanced by fairly rapid adenosine 
formation, which may fine-tuning control bladder muscle activity during the micturition 
cycle in the mouse (Yu et al., 2011).  
Studies using immunofluorescence confocal microscopy showed that the 
human urothelium exhibits NTPDase1, NTPDase2 and NTPDase3 in the apical 
plasma membrane of umbrella cells, whereas the intermediate layer stained 
positively against E-NTPDase1 and NTPDase2, but no NTPDase3 immunoreactivity 
was found (Correia-de-Sá, 2010; Silva-Ramos et al., 2015b). The most expressed E-
NTPDase2 is the main contributor to the extracellular catabolism of ATP leading to a 
preferential ADP accumulation with low adenosine formation at the luminal surface of 
the isolated human urothelium. Despite this, a role for ADP in the urothelium is still 
missing. Interestingly, tissue elements at or below the basal layer of the urothelium 
(e.g., blood vessels, myofibroblasts and nerve fibers) and the detrusor smooth 
muscle layer, were positively stained with NTPDase1, NTPDase2 and ecto-5´-
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nucleotidase, which indicates that biosynthesis of adenosine from adenine 
nucleotides is positioned to favor a more important role of the nucleoside in the 
suburothelium and the detrusor smooth muscle, namely regulating cholinergic nerve 
activity (Silva-Ramos et al., 2016b).  
Beyond the role of E-NTPDases in the ATP/UTP metabolism and, 
consequently, the effects through purinergic receptors activation, the function and 
expression of these enzymes have been implicated in the bladder dysfunctions. In 
the patients with bladder outlet obstruction (BOO) due to benign prostatic hyperplasia 
(BPH) it was demonstrated that there is an impairment of E-NTPDase1/CD39 activity 
in the detrusor smooth muscle leading to the unbalance of extracellular ATP 
accumulation and endogenous adenosine formation, which might explain the 
increased neuronal excitation in mucosal-denuded detrusor strips from these patients 
(Silva-Ramos et al., 2015a). Alterations in the expression of E-NTPDase3 and ecto-
5’-nucleotidase/CD73 have also been associated in bladder tumorigenesis in animal 
models (Rochenbach et al., 2014). The same was observed in human urinary 
bladder samples from patients with bladder cancer in which an increase of CD73 
expression was detected (Wettstein et al., 2015). Ecto-5’-nucleotidase has been 
proposed as a putative biomarker and/or pharmacological target for bladder cancer 
(Rochenbach et al., 2014; Wettstein et al., 2015). 
 
4.5. ADENOSINE 
As mentioned above, alterations in the activity of E-NTPDases might have 
implications in endogenous adenosine formation and P1 purinoceptors activation. 
Extracellular adenosine may originate from the catabolism of released adenine 
nucleotides (e.g. ATP, cyclic AMP) by E-NTPDases or alkaline phosphatases (Latini 
and Pedata, 2001; Parkasam et al., 2012). In addition, adenosine may be released 
as such from cells via equilibrative nucleoside transporters (Hirsh et al., 2007). 
Inactivation of extracellular adenosine is mainly mediated by cellular uptake and 
extracellular deamination by adenosine deaminase (ADA). The driving force for 
adenosine uptake into the cells is its rapid intracellular phosphorylation to AMP by 
adenosine kinase (AK), which contributes to keep low the cytosolic concentrations of 
adenosine (Latini and Pedata, 2001).  
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Distinct mechanisms of adenosine turnover operating at each surface of the 
uroepithelium have been reported in the urinary bladder; these mechanisms 
contribute to keep within certain limits the amount of extracellular adenosine 
(Parkasam et al., 2012). Notwithstanding this, the urothelium can be a site of 
adenosine biosynthesis and release (Yu et al., 2006). In the rat uroepithelium, 
adenosine modulates the traffic of vesicles within the cell, which contributes to 
increase the membrane cell area during bladder filling and to release vesicle-
containing signaling mediators. It is highly likely that adenosine might regulate other 
functions of the bladder mucosa, including ion transport, uroepithelial-afferent nerve 
signaling, and bladder contraction (Yu et al., 2006). Besides this, adenosine has 
been shown to negatively modulate stretch-induced ATP release from apical 
umbrella cells through the activation of A1 receptor (Dunning-Daves et al., 2013). 
Taking into consideration that adenosine levels at the luminal site of the urothelium 
are 10-fold below those found beneath the basal layer, one may hypothesize that 
adenosine A1 receptor-mediated facilitation of ATP release plays a minor role in 
physiological conditions, yet it may contribute to bladder overactivity in disease states 
once its concentration becomes elevated, like in bladder ischemia-reperfusion and 
inflammatory cystitis (Silva-Ramos et al., 2016a). Differences in the kinetics of ATP 
metabolism by ecto-nucleotidases and adenosine biosynthesis between luminal and 
serosal sides of the urothelium was demonstrated by Silva-Ramos and colleagues, 
which may explain the dominant role of adenosine in the suburothelium and detrusor 
smooth muscle layers (Silva-Ramos et al., 2015b). In the urinary bladder, it has also 
been reported that adenosine partially relaxes pre-contracted urinary bladder 
detrusor strips exposed to carbachol, ACh, or potassium depolarization in rats, 
guinea-pigs (Acevedo et al., 1992; Brown et al., 1979; Nicholls et al., 1992; King et 
al., 1997; Burnstock et al., 1978) and humans (Rubinstein et al., 1998). 
 
4.5.1. P1 receptors 
Four types of adenosine receptors have been cloned, A1, A2A, A2B and A3; 
these receptors were initially characterized by their differential coupling to the 
adenylyl cyclase (AC) / cAMP pathway (Fredholm et al., 2011). All of these receptors 
are G protein-coupled exhibiting seven transmembrane domains. Adenosine A1 and 
A3 receptors interact with members of the Gi/o family and inactive AC to decrease the 
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production of cAMP, whereas A2A and A2B receptors are coupled to Gs/olf and 
stimulate cAMP production (Klinger et al., 2002; Schulte et al., 2003; Fredholm et al., 
2011), resulting in the activation of protein kinase A (PKA) and phosphorylation of the 
cAMP response element binding protein (CREB) (Fredholm et al., 2011; Cunha, 
2001; Paes-de-Carvalho, 2002). In addition, the adenosine A1 receptor increases 
phospholipase C (PLC) activity through a pertussis toxin-sensitive G protein. These 
receptors can couple directly to and inhibit cardiac K+ channels and types Q, N and P 
voltage sensitive Ca2+ channels (Ali et al., 1991). The A1 receptor activation can also 
increase mitogen-activated protein kinase (MAPK) pathway (Shulte and Fredholm, 
2000; Dickenson et al., 1998). Activation of the A2A receptor can promote activation 
of PKC in cAMP-dependent and independent mechanisms (Fredholm et al., 2011; 
Socodato et al., 2011), contrary to the activation of A2B receptors that can stimulate 
PKC activity by direct coupling to Gq proteins (Fredholm et al., 2011). The adenosine 
A1 and A2A receptors have high affinity for adenosine while the A2B and A3 receptors 
show relatively lower affinity for adenosine in rodents (Fredholm et al., 2011). 
All these subtypes of adenosine receptors have been shown to exist in the 
bladder of experimental animals and human beings. RT-PCR analysis showed that 
that A2A and A2B receptors are more expressed than the A1 receptor, with the A3 
receptor being the least expressed receptor (Dixon et al., 1996; Owen et al., 2012). 
Discrepancy between the relative abundance of A1 and A2 receptor subtypes in the 
detrusor (Dixon et al., 1996) may be attributed to their preferential localization on tiny 
nerve terminals and smooth muscle fibers, respectively (Nicholls et al., 1992; 
Acevedo et al., 1992). 
All four adenosine receptors are expressed in the rat uroepithelium, with the A1 
receptors preferentially located in the apical membrane of the umbrella cells layer, 
whereas the A2A, A2B and A3 receptors are localized intracellularly or on the 
underlying cell layers (Yu et al., 2006). These authors showed that adenosine 
receptors modulate exocytosis of different molecules in umbrella cells (Yu et al., 
2006).  
The role of adenosine receptors was also detected in the central control of 
micturition in rats. Results showed that the inhibitory effect of an A2A receptor 
antagonist in the spinal cord was enhanced after infusion of acid acetic into the 
bladder, thus indicating that adenosine exerts an excitatory action via A2A receptor 
activation in the spinal cord when C-fiber bladder afferents are stimulated by 
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chemical irritants (Kitta et al., 2014). These findings were corroborated using a rat 
model of Parkinson’s disease showing that the excitatory drive mediated by 
adenosine A2A receptors on bladder overactivity was operated at a supraspinal site 
(Kitta et al., 2014); bladder overactivity in these animals were also suppressed by A2A 
receptors blockage. The involvement of A1 receptors in the central control of 
micturition has also been observed. Data showed that activation of inhibitory 
adenosine A1 receptors in the brain may counteract nociceptive inputs from the 
bladder. Moreover, activation of the A1 receptor also exerts a peripheral inhibitory 
effect on micturition (Kitta et al., 2014). These findings suggest that adenosine A1 
receptor agonists and A2A receptor antagonists might be effective for the treatment of 
overactive bladder (Kitta et al., 2014; Kitta et al., 2012). 
Previous studies showed that A1 and A2A receptors are present in the human 
detrusor, while immunoreactivity against A2B and A3 receptors was vestigial. Our 
group demonstrated that the adenosine A1 receptor is predominantly localized in 
cholinergic nerve terminals and that this receptor subtype is overexpressed in 
bladder strips from patients with BOO due to benign prostatic hyperplasia (BPH) 
(Silva-Ramos et al., 2015a). Functional data show that adenosine significantly 
decreases [3H]ACh release from bladder strips of BOO patients and this effect 
depends on A1 receptors activation (Silva-Ramos et al., 2015a). Interestingly, the 
adenosine inhibitory effect on [3H]ACh release was significantly higher in BPH 
patients than in control individuals (Silva-Ramos et al., 2015a). The 
immunolocalization studies showed that A1 and A2A receptors are the most 
expressed receptors in the human detrusor, whereas immunoreactivity of A2B and A3 
receptors is less evident. Co-localization studies showed a differential distribution of 
the A1 receptor, which is localized preferentially on VAChT positive cholinergic 
nerves, whereas the A2A receptor is diffusely expressed on smooth muscle fibers of 
the human detrusor (Silva-Ramos et al., 2015a). On the other hand, the activation of 
A2A receptors with a selective agonist, CGS21680C, didn´t have a significantly effect 
in the evoked-[3H]ACh release. Thus suggesting that adenosine via A1 receptors 
activation might have a dominant effect in to reducing detrusor hyperactivity in the 
human bladder (Silva-Ramos et al., 2015a). Data obtained in the human bladder 
agree with the hypothesis raised in rodents (e.g. bladder overactivity due to acetic 
acid irritation) concerning the therapeutic potential of adenosine A1 receptor 
activation to reduce bladder overactivity (Kitta et al., 2014). In patients with BOO due 
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BPH, was observed an impairment of ecto-NTPDase1 activity that unbalances 
extracellular ATP accumulation and endogenous adenosine formation leading to 
increased neuronal excitation in detrusor from these patients (Silva-Ramos et al., 
2015a). While extracellular ATP accumulation may contribute to hyperexcitation of 
suburothelial nerve afferents via P2X3 receptors and to detrusor reactivity via P2X1 
subunit-containing receptors. Deficits in adenosine formation may also play a role in 
generating symptoms of bladder dysfunction in BPH patients (Silva-Ramos et al., 
2015a). Thus, the loss of the inhibitory tone exerted by prejunctional A1 receptors on 
ACh release from stimulated cholinergic nerves in the detrusor may be a target for 
therapeutic intervention of bladder dysfunctions associated with outflow obstruction 
(Silva-Ramos et al., 2015a).  
Recent evidences based on electrophysiologic and myographic recordings 
corroborate the theory that activation of prejunctional A1 adenosine receptors may 
provide a mean to dampen aberrant neurotransmission to the detrusor in human and 
murine bladders (Searl et al., 2016), supporting a putative role for A1 receptor 
agonists in the treatment of LUTS. 
 
 
5. Adrenergic system 
 
The bladder filling is primarily controlled by sympathetic inputs, whereas 
voiding is under parasympathetic influence. During the filling, distension of the 
detrusor muscle in the body of the bladder is achieved by suppression of the 
excitatory efferent parasympathetic influence through neural reflex and the 
concomitant closure of the bladder outlet through sympathetic-mediated tonic 
contraction of the base of the bladder and the urethra (Applebaum et al., 1980; Maggi 
et al., 1987, 1988; Elbadawi, 1988). Postganglionic sympathetic neurons innervating 
the bladder release norepinephrine (also denominated as noradrenaline, NA) which 
binds to both α- and β-adrenoceptors (de Groat and Booth, 1980; Maggi and Meli, 
1982). Sympathetic stimulation of the LUT can lead to both excitatory and inhibitory 
effects. The highest density of adrenergic nerves is present in the urethra, the 
bladder neck and the bladder body (de Groat and Yoshimura, 2001). In the urethra 
and the bladder neck, the smooth muscle cells express predominantly α1-receptors 
which are responsible for generating muscle tone and occluding the urethral orifice 
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during the storage phase of the micturition cycle (de Groat and Yoshimura, 2001). In 
the bladder body, adrenergic fibers are found manly in the smooth muscle bundles. 
Relaxation of the smooth muscle is mediated by β-adrenergic receptors (Andersson, 
1993). NA has revealed to be an effective inhibitor of bladder muscle strip 
contractions (Âmark et al., 1986).  
The adrenergic receptors were differentiated pharmacologically into α- and β-
adrenergic receptors for the first time in 1948 by Ahlquist (Ahlquist, 1948). Several 
years later the adrenoceptors were distinguished into four subtypes using adrenergic 
agonists and antagonists. These types are: α1, α2, β1 and β2 adrenergic receptors 
(Lands et al., 1967; Ablad et al., 1974). Later on, a new subtype of β-adrenergic 
receptor was characterized, the β3-adrenoceptor.  
Actually three different β-adrenoceptors subtypes have been cloned and 
characterized using pharmacological methods (Bylund et al., 1994). The β3-
adrenoceptor was cloned in 1989 and has been intensively studied because of their 
involvement in glucidic and lipidic metabolism. β-adrenoceptors are G protein-
coupled receptors (Strosberg, 1993) exhibiting seven transmembrane domains 
(Coman et al., 2009) spanning the lipid bilayer. 
The mRNA of all three β-adrenoceptor isoforms (β1, β2, β3) has been identified 
in the detrusor (Fujimura et al., 1999; Seguchi et al., 1998); 97% of the β-
adrenoceptor mRNA found in the detrusor is for the β3-adrenergic receptor subtype, 
while only 1.5% and 1.4% refers to β1- and β2-adrenoceptors mRNAs, respectively 
(Nomiya and Yamaguchi, 2003; Michel and Vrydag, 2006). Immunolocalization 
studies demonstrate that β-adrenoceptors are present throughout the bladder. The 
β1-adrenoceptor is present in the urothelium and though in lesser amounts in ICCs 
and detrusor smooth muscle fibers. The β2-adrenoceptor is located in the urothelium, 
ICCs and detrusor muscle fibers, but its distribution is heterogeneous being the 
urothelium the most enriched region and the detrusor muscle the less labeled region. 
The β3-adrenoceptor is expressed in higher amounts in interstitial cells, whereas 
lesser amounts are found in the urothelium (Limberg et al., 2010; Otsuka et al., 
2013), detrusor smooth muscle fibers (Otsuka et al., 2013), and cholinergic nerve 
terminals innervating the detrusor (Coelho et al., 2017). Receptor expression studies 
do not perfectly match functional data using selective β-adrenoceptors agonists; the 
β3-adrenoceptor seems to be the most relevant receptor subtype causing human 
detrusor relaxation (Igawa et al., 1998; Svalo et al., 2013). The noradrenaline effect 
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observed in the bladder body is mainly attributed to the β3-adrenoceptor, while the 
α1-adrenoceptor seems to be less important (Chou et al., 2003). Unlike other 
receptor subtypes, like purinergic receptors, β3-adrenoceptors expression is not 
affected by age of the individuals (Limberg et al., 2010). 
Regarding ICCs present in the bladder wall, it was demonstrated that a 
population of these cells have the machinery to store, release and respond to 
catecholamines. Thus, it is highly possible that these cells are part of a β-adrenergic 
system operating in the bladder wall beyond noradrenergic nerves and the receptors 
present in the detrusor smooth muscle. The ICC-related β-adrenergic system is 
possibly linked to the generation of non-voiding spontaneous microcontractions and 
may be involved in mechanisms underpinning bladder sensation (Persyn et al., 
2016). β3-adrenergic receptor agonists may increase bladder capacity and inhibit the 
bladder instability associated with hyperreflexia and detrusor hypertrophy (Woods et 
al., 2001). These receptors are coupled to the stimulatory G protein (Gs) and its 
agonists have the ability to activate AC leading to increases in intracellular cAMP 
and, thereby, protein kinase A activation causing relaxation of the bladder smooth 
muscle (Tyagi et al., 2009; Wallukat, 2002; Jóźwiak-Bębenista et al., 2016). On the 
other hand, is questioned the role of cAMP in β-adrenoceptors mediates relaxation 
because inhibitors of AC or PKA had limited effect on rat detrusor relaxation, 
suggesting that other unknown pathways are involved (Frazier et al., 2005). 
Interestingly, the AC/cAMP intracellular pathway is affected by hypoxic 
conditions (Jóźwiak-Bębenista et al., 2016), which have been implicated in LUTS, 
thus affecting the therapeutic success of β3-adrenergic receptor agonists. 
 
 
6. Lower urinary tract symptoms 
 
The term “lower urinary tract symptoms (LUTS)” was introduced 13 years ago 
by Abrams (Abrams, 1994). LUTS designate a number of symptoms regarding 
storage (irritative), voiding (obstructive), and postmicturition symptoms (Abrams et 
al., 2002). According with the International Continence Society (ICS), voiding 
symptoms include slow stream, splitting / spraying, hesitancy, intermittency, straining 
and terminal dribble (Abbrams et al., 2002), while storage symptoms are primarily 
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related to overactive bladder (OAB), like urgency with or without urgency 
incontinence, usually with frequency and nocturia (Abrams et al., 2002).  
In a large population-based survey known as the EPIC study, the prevalence 
of any voiding symptom was 26% among men and 20% among women. However, 
this percentage was higher when looking for the prevalence of any storage 
symptoms, 51% and 60% among men and women, respectively (Irwin et al., 2006). 
The prevalence of LUTS suggestive of OAB was 10.8% in men and 12.8% in women 
(Irwin et al., 2006). In Portugal, the prevalence of OAB in people with 40 years of age 
or older was reported to be of 29.4% in women and of 35.1% in men (Correia et al., 
2009). 
It is clearly recognized that OAB symptoms have a negative impact in the 
quality of life of both men and women, reducing emotional wellbeing and productivity 
(Currie et al., 2006; Irwin et al., 2006a; Stewart et al., 2003). OAB without urge 
incontinence is more common in men, whereas association with incontinence has a 
female predominance. The frequency of associated female incontinence increases 
with age but it significantly increases after approximately 45 years of age. In contrast, 
male-associated incontinence increases with age but rises sharply after 
approximately 65 years of age (Helfand et al., 2009). 
Men with 50 years of age or older who complaint predominantly of voiding 
symptoms are typically considered to have LUTS, which is suggestive of bladder 
outlet obstruction (BOO). Benign prostatic hyperplasia (BPH) is a strictly histological 
diagnosis and may result in BOO with postmicturition symptoms that include the 
feeling of incomplete emptying and post-micturition dribble (Abbrams et al., 2002). 
Histological BPH was never observed in men under the age of 30 years. 
Approximately half of the men in their sixth decade of life exhibit histological evidence 
of BPH. Almost 90% of men develop histologic BPH by the ninth decade of life 
(Lepor, 2004).  
OAB and BPH, contribute substantially to societal burden. A health economic 
model estimated that 20 million people aged older than 40 years of age experienced 
symptoms of OAB in 2000 (Irwin et al., 2006); at the moment, it is estimated that an 
excess of 100 million men and women are afflicted with bothersome LUTS due to 
BPH and OAB, respectively. The prevision for the year 2020 is that more than 25% of 
the population worldwide will be affected with by LUTS (Irwin et al., 2006). 
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7. Current treatments of LUTS 
 
The difficulty in treating LUTS begins in the suboptimal knowledge about the 
pathophysiology of these conditions. Interestingly, all these disease conditions have 
a common feature as they are associated with increased release of ATP from 
bladder urothelial cells above the levels released normally in response to bladder 
distension during urine storage (Fergunson et al., 1997; Vlaskovska et al., 2001). 
Augmentation of urinary ATP levels was verified in patients with interstitial cystitis / 
bladder pain syndrome (IC/BPS) (Sun et al., 2001; Fry et al., 2014), but also in 
women with idiopathic OAB (Silva-Ramos et al., 2013) and men with LUTS due to 
BPH (Silva-Ramos et al., 2016a). This led to the conclusion that urinary ATP 
measurements may function as a highly-sensitive biomarker of bladder overactivity 
(Silva-Ramos et al., 2013; 2016a). On the other hand, the increase in the expression 
of P2X3/P2X2/3 receptors in the detrusor smooth muscle, urothelium and afferent 
terminals from animal models and patients with LUTS, prompted for studies to 
investigate these receptors as putative therapeutic targets (Burnstock, 2017). AF-
219, a P2X3/P2X2/3 antagonist that is metabolically stable and orally bioavailable, is 
being investigated as a treatment for urinary tract dysfunctions (Ford and Cockayne, 
2011). Manipulation of other purinergic receptors, such as P2X1 and P2X7, that are 
impaired in LUTS has also been investigated as putative new drugs targets to 
improvement the LUTS (Burnstock et al., 2017).  
Anticholinergic therapy is more common and anti-muscarinic drugs are first 
line treatment of LUTS, predominantly of the OAB type. More recently, it has been 
approved the clinical use of β3-adrenoceptors agonists (mirabegron) to treat OAB 
syndromes (Andersson, 2013; Andersson et al., 2013). Other drugs, such as the 
phosphodiesterase 5 inhibitor (tadalafil) (Lythgoe et al., 2013), and the blocking of 
afferent and efferent nerves with botulinum toxin (Magera et al., 2014; Andersson, 
2013; Laerence et al., 2010; Smith et al., 2005; Chancellor et al., 2008), were also 
introduced. There are LUTS treatment options not involving drugs; these are 
intermittent catheterization, sacral neuromodulation and posterior tibial nerve 
stimulation (Chua et al., 2015).  
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7.1. ANTICHOLINERGIC DRUGS 
The mainstay of treatment of OAB is the use of anticholinergics, which exert 
their action by blocking the muscarinic receptors located in the bladder smooth 
muscle (Abrams et al., 2006b). Although muscarinic M2 receptors dominate M3 
receptors in the bladder in a 3:1 ratio, the muscarinic M3 receptors seem to be the 
most important muscarinic receptor for the detrusor contraction (Abrams et al., 
2006b; Chess-Williams et al., 2001). The muscarinic M2 receptors located in the 
bladder may play a role in the detrusor contraction by reversing β-adrenoceptor-
mediated smooth muscle relaxation, indirectly enhancing M3 receptor mediated 
contractions, or increasing urgency sensations (Skaskin et al., 2011; Hegde et al., 
1997; Yamanishi et al., 2000; Daly et al., 2010). Muscarinic M2 receptors are also 
located in the heart and modulate the heart pacemaker activity and atrioventricular 
conduction. Blockage of the M2 receptors, in addition to the inhibitory effect on the 
detrusor contractions through M3 pathways, also results in an increase in heart rate 
(Harvey and Belevych, 2003). Antimuscarinic drugs differ in their pharmacological 
profile at the five distinct human muscarinic receptors (Andersson et al., 2011). 
Essentially, tolterodine, fesoterodine, propiverine and trospium, do not discriminate 
among the five muscarinic receptor subtypes. Oxybutynin and solifenacin possess a 
marginal selectivity for M3 receptors over the muscarinic M2/M3 subtypes receptors, 
whereas darifenacin has a high degree of selectivity for muscarinic M3 receptors over 
the muscarinic M2/M4 receptors subtypes. Theoretically, in terms of the increase in 
heart rate, OAB antimuscarinics having selectivity for muscarinic M3 over M2 
receptors must be advantageous compared to non-selectivity drugs (Andersson et 
al., 2011). The M3 receptor subtype mediating bladder contractions is also located in 
the salivary glands, gastrointestinal smooth muscle, and ciliary and iris sphincter 
muscles. Therefore, blockade of this receptor results in side effects common to most 
anti-muscarinic drugs, such as dry mouth, constipation, and blurred vision (Chapple 
et al., 2008; Novara et al., 2008; Kessler et al., 2011; Meek et al., 2011).  
Despite the high intake of medications with anticholinergic properties by the 
community-dwelling elderly population, the effects on cognitive decline and dementia 
have rarely been evaluated. The risk of incident dementia over a 4-years follow-up 
period was also increased in continuous users (hazard ratio (HR), 1.65; 95% CI, 
1.00-2.73) but not in those who discontinued the use of anticholinergic drugs (HR, 
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1.28; 95% CI, 0.59-2.76). Elderly people taking anticholinergic drugs were at an 
increased risk of cognitive decline and dementia. Discontinuing anticholinergic 
treatment was associated with a decreased risk (Carrière et al., 2009). Adherence to 
anticholinergic therapy in OAB has been shown to be as low as 20% after 6 months 
of follow-up in real-life practice (Kelleher et al., 1997). 
 
7.2. β3-ADRENOCEPTOR AGONISTS  
Whereas anti-muscarinics bind to muscarinic receptors of the urinary bladder 
and inhibit involuntary bladder contractions, stimulation of β3-adrenoceptors in the 
detrusor muscle involves bladder relaxation during the filling phase, thus improving 
the bladder storage capacity (Igawa et al., 1999; Fujimura et al., 1999). Herein lays 
the potential of the drugs that act as β3-adrenoceptor agonists to treat the OAB 
symptoms (Kumar et al., 2003).  
In June of 2012, mirabegron, a selective β3-adrenergic receptor agonist was 
approved for the treatment of OAB with symptoms of urge urinary incontinence in the 
United States (US) under the branded name Myrbetriq® (Astellas Pharma US Inc.). 
In July 2011, the same drug received approval for its use in Japan (under the name 
of Betanis®) and by 2013 the European Commission approved its use in Europe 
(under the name of Betmiga®). 
Mirabegron is a first-in-class therapeutic agent with a novel mechanism of 
action for the treatment of OAB. Mirabegron improves the storage capacity of the 
bladder, extending the duration of the storage phase, with potentially greater 
tolerability compared to the anti-muscarinic agents (Package, 2012). In clinical 
studies, the most frequently reported adverse effects occurring in patients receiving 
treatment with mirabegron include hypertension, nasopharyngitis, urinary tract 
infection, headache, constipation, upper respiratory tract infection, arthralgia, and 
tachycardia (Package, 2012). The potential for mirabegron to non-selectively 
stimulate β3-receptors in other types of smooth muscle may lead to both increased 
blood pressure and heart rate. As a result, mirabegron may not be suitable for 
patients with severe uncontrolled hypertension or tachycardia prior to use, orthostatic 
hypotension, or any other significant cardiac condition that may predispose to 
arrhythmias (Bridgeman et al., 2013). However, more than 50% of the patients had 
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previously discontinued anti-cholinergics medication for OAB, thus allowing us to 
obtain data on the effectiveness of mirabegron in patients already treated with 
anticholinergics (Angulo et al., 2013), once time, that the action mechanism of 
mirabegron is unknown.  
 
7.3. BOTULINUM TOXIN 
In addition to the therapies mentioned above, botulinum toxin (BoNT) is also 
being used for the treatment of OAB. This therapeutic alternative is used for patients 
whose symptoms are refractory to conventional therapy (e.g. anti-cholinergic drugs) 
(Harris and Rissolo, 2016; Jhang and Kuo, 2016). The BoNT has two different sites 
of action: it reduces the release of both ACh and ATP from parasympathetic nerves 
(Lawrence et al., 2010), and, on the other hand, it reduces the release of ACh and 
ATP from urothelial cells, reducing, consequently, the stimulatory drive of the voiding 
reflex (Smith et al., 2005; Chancellor et al., 2008).  The BoNT treatment also alter the 
expression of P2 and other receptors. Four weeks after BoNT injections was 
demonstrated the decreased expression of P2X3 and TRPV1 receptors in the 
bladder mucosa and suburothelial nerves fibers, respectively from patients with 
overactivity detrusor (Apostolidis et al., 2005). Additionally, the decline in P2X3 
receptors was significantly correlated with the reduction of urgency episodes four and 
sixteen weeks after botulin toxin injection (Apostolidis et al., 2005). Therefore, it 
appears that the clinical efficacy of BoNT relies not only on the blockade of 
transmitter release from efferent nerves, but also on its action on urothelial sensory 
mechanisms. The BoNT, in particulary the onabotulinumtoxin-A type, provided 
greater relief of OAB symptoms compared with most other licensed doses of 
anticholinergics and mirabegron in the network (Drake et al., 2017).  
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V.  AIMS 
 
The main objective of this thesis was to investigate the role of the purinome 
(purines releasing sites, enzymatic breakdown and purinoceptors activation) to 
control hyperactivity of the human urinary bladder prompting for new pharmacological 
targets to treat overactive bladder (OAB) syndromes.  
 
Our specific objectives were: 
(1) To evaluate in parallel changes in the release of ATP and ACh from the 
urothelium of patients with bladder outlet obstruction (BOO) compared to 
control individuals; 
(2) To study the role of UDP-sensitive P2Y6 receptors in the human urothelium 
from patients with BOO due benign prostatic hyperplasia (BPH) compared to 
control men; 
(3) To investigate the role of ADP-sensitive receptors in the control of excitability 
produced by P2X2/3 receptors activation on evoked [3H]ACh release from 
cholinergic nerves in the bladder of control individuals and obstructed patients 
due to BPH.  
(4) To explore the participation of purines in the therapeutic effect of β3-
adrenoceptor agonists in human and rat urinary bladders; 
(5) To investigate the intracellular signaling pathways linking β3-adrenoceptors 
activation and adenosine overflow from human and rat detrusor smooth 
muscle fibers. 
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ABSTRACT 
Purpose: Deregulation of purinergic bladder signaling may contribute to 
persistent detrusor overactivity in patients with bladder outlet obstruction. Activation 
of uridine diphosphate sensitive P2Y6 receptors increases voiding frequency in rats 
indirectly by releasing adenosine triphosphate from the urothelium. To our knowledge 
this mechanism has never been tested in the human bladder. 
Materials and Methods: We examined the role of the uridine diphosphate 
sensitive P2Y6 receptor on tetrodotoxin insensitive nonneuronal adenosine 
triphosphate and [3H]acetylcholine release from the human urothelium with the 
lamina propria of control organ donors and patients with benign prostatic hyperplasia. 
Results: The adenosine triphosphate-to-[3H]acetylcholine ratio was fivefold 
higher in mucosal urothelium/lamina propria strips from benign prostatic hyperplasia 
patients than control men. The selective P2Y6 receptor agonist PSB0474 (100 nM) 
augmented by a similar amount adenosine triphosphate and [3H]acetylcholine 
release from mucosal urothelium/lamina propria strips from both groups of 
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individuals. The facilitatory effect of PSB0474 was prevented by MRS2578 (50 nM) 
and by carbenoxolone (10 µM), which block P2Y6 receptor and pannexin-1 
hemichannels, respectively. Blockade of P2X3 (and/or P2X2/3) receptors with 
A317491 (100 nM) also attenuated release facilitation by PSB0474 in control men but 
not in patients with benign prostatic hyperplasia. Immunolocalization studies showed 
that P2Y6, P2X2 and P2X3 receptors were present in choline acetyltransferase 
positive urothelial cells. In contrast to P2Y6 staining, choline acetyltransferase, P2X2 
and P2X3 immunoreactivity decreased in the urothelium of benign prostatic 
hyperplasia patients. 
Conclusions: Activation of P2Y6 receptor amplifies mucosal adenosine 
triphosphate release underlying bladder overactivity in patients with benign prostatic 
hyperplasia. Therefore, we propose selective P2Y6 receptor blockade as a novel 
therapeutic strategy to control persistent storage symptoms in obstructed patients. 
 
Key Words: urinary bladder neck obstruction, urothelium, acetylcholine, 
adenosine triphosphate, purinoceptor P2Y6. 
 
INTRODUCTION 
Changes in the bladder sensory system during urine storage may contribute to 
detrusor overactivity in patients with BOO. The urothelium has a key sensory role 
during bladder filling by releasing chemical mediators, including ACh and ATP, from 
nonneuronal stores (Yoshida et al., 2010). Targeting sensory nerve afferents by 
signaling molecules released from the urothelium may be exaggerated under 
pathological conditions, leading to increased bladder sensation and detrusor 
overactivity. Thus, we hypothesized that the urothelium may be a key factor in the 
mechanism through which BOO associated with BPH causes lower urinary tract 
symptoms (Mirone et al., 2017). Long-term changes in nonneuronal ACh and ATP 
release from the urothelium may explain why many patients undergoing obstruction 
relief procedures such as prostatectomy still report persistent storage symptoms. 
While neuronal release of ACh acting mainly on detrusor smooth muscle 
muscarinic M3 receptors promotes bladder emptying (Chess-Williams et al., 2001), 
nonneuronal ACh synthesis and release from the urothelium may occur during the 
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storage phase (Winder et al., 2014). Exposure of urothelium, afferent nerves and 
detrusor smooth muscle simultaneously to ACh and ATP may change under 
pathological conditions (Ochodnicky et al., 2013). Therefore, the precise mechanisms 
and sites of action of muscarinic receptor antagonists used to treat overactive 
bladder symptoms remain elusive (Sellers and Chess-Williams, 2012). Moreover, an 
increase in atropine resistant purinergic tone through the abnormal production, 
release and metabolism of ATP or altered expression of various P2 purinoceptors is 
a common feature of many urological diseases (Ruggieri, 2006; Sjöogren et al., 
1982; Palea et al., 1993; Yoshida et al., 2004). Mounting evidence suggests that ATP 
is released predominantly from the bladder urothelium in response to mechanical 
(distension) and chemical (capsaicin, ACh and, bradykinin) stimulation (Khera et al., 
2004; Wang et al., 2005). Urothelial ATP release is augmented in patients with 
increased bladder sensation and voiding frequency (Sun and Chai, 2006; Silva-
Ramos et al., 2013; Sun et al., 2002). 
In contrast to the compelling evidence of the extracellular signaling role of 
ATP, the hypothesis that uracil nucleotides also have autocrine/paracrine actions has 
only recently gained experimental support. Our group reported that activation of the 
UDP sensitive P2Y6 receptor increased voiding frequency in anesthetized rats 
indirectly by releasing ATP from the urothelium via pannexin-1 hemichannels 
(Timóteo et al., 2014) and subsequent activation of P2X3 receptors on suburothelial 
nerve afferents (Carneiro et al., 2014). In the bladder ionotropic P2X3 receptors can 
function as homomultimeric P2X3 and heteromultimeric P2X2/3 channels (Cockayne 
et al., 2005). Involvement of pannexin-1 hemichannels provides a direct pathway for 
mechanically induced ATP release and for ATP induced ATP release through 
interaction with P2 purinoceptors (Negoro et al., 2014). The precise transport 
mechanisms involved in ATP release are still under active debate. There is evidence 
for exocytotic vesicular release of ATP from urothelial cells while nonvesicular ATP 
release may also be mediated by the activation of stretch, voltage and/or ligand 
gated ion channels and receptors, mitochondrial porins and ATP binding cassette 
transporters (Winder et al., 2014). We examined the role of P2Y6 receptor on 
nonneuronal ATP and [3H]ACh release from mucosal U/LP strips from control organ 
donors and patients with BPH using highly selective agonists and antagonists to 
understand the storage symptoms remaining in patients after obstruction relief 
procedures. Given that morphological and functional abnormalities in the epithelium, 
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smooth muscle fibers, extracellular matrix and neuronal network are common in the 
bladder of patients with BPH (Mirone et al., 2007), we also evaluated changes in the 
presence of ChAT (the enzyme responsible for ACh synthesis) and the P2 receptor 
subtypes metabotropic P2Y6, and ionotropic P2X2 and P2X3 in the human bladder 
mucosa by confocal microscopy. 
 
MATERIAL AND METHODS 
Human Bladder Samples 
Samples were collected from the anterior wall of the bladder dome of 50 
consecutive patients with a mean ± SEM age of 70 ± 2 years with BPH who 
underwent transvesical prostatectomy and 26 male organ donors with a mean age 55 
± 3 years at the time of organ harvest for transplantation. Samples were immediately 
placed at 4ºC to 6ºC in mannitol transplantation solution at 400 mOsm/kg (M-400) not 
supplemented with ATP or adenosine (4.190 gm 100 ml-1 mannitol, 0.205 gm 100 ml-
1 KH2PO4, 0.970 gm 100 ml-1 K2HPO4.3H2O, 0.112 gm 100 ml-1 KCl and 0.084 gm 
100 ml-1 NaHCO3, pH 7.4) and transported to the laboratory. Experiments were 
performed within the first 24 hours after collection, which corresponds to the tissue 
viability window. This study and all its procedures were approved by the ethics 
committees of Centro Hospitalar do Porto and Instituto de Ciências Biomédicas de 
Abel Salazar, Universidade do Porto. All patients with BPH provided signed informed 
consent to use the biological material. The investigation conformed to the principles 
outlined in the Declaration of Helsinki. 
 
ATP and [3H]ACh Release Quantification 
Human mucosal U/LP strips can be easily separated from the underlying 
smooth muscle layer by blunt dissection (Kumar et al., 2004). Absence of the 
detrusor smooth muscle layer was confirmed by confocal microscopy (Figure 5). 
Mucosal strips were mounted in 3 ml perfusion chambers heated to 37ºC and 
superfused with gassed (95% O2 and 5% CO2) Tyrode’s solution (pH 7.4) containing 
(mM): NaCl 137, KCl 2.7, CaCl2 1.8, MgCl2 1, NaH2PO4 0.4, NaHCO3 11.9, glucose 
11.2 and choline 0.001.  
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Figure 5. (A) Relative abundance of contractile elements, such as α-smooth muscle actin 
(SMA), in transverse sections of the human urothelium (U) with lamina propria (LP) attached 
compared to the detrusor (D) smooth muscle layer. Differential interference contrast (DIC) is show to 
facilitate delimitation of tissue boundaries. Scale bars = 50 µm. Myographic recordings shown in (B) 
were obtained in parallel using mucosal and detrusor strips from a 59-years old HBP patient, which 
were mounted in organ baths continuously superfused with gassed (95% O2 and 5% CO2) Tyrode’s 
solution (pH 7.4); please note that tension scale bars in the two graphs are different. Despite mucosal 
SMA-immunoreactivity is scarce, the isolated strips from the human mucosa contract in response to 
electrical field stimulation (EFS, 40 V square pulses of 1 ms duration, delivered at 1-50 Hz frequency). 
 
After a 30-min equilibration period, the preparation were loaded with 1 µM 
[3H]choline (specific activity 2.5 µCi nmol-1) during 40 min. [3H]ACh release was 
elicited twice (S1 and S2) by electrical field stimulation using 200 pulses (1 ms 
duration, 40 V) delivered at 10 Hz frequency. Tritium content was measured by liquid 
scintillation spectrometry (TriCarb2900TR, Perkin Elmer, Boston, USA) (% counting 
efficiency: 58±2%) using 400 µL aliquots of superfusate samples collected 
automatically every 3 min using a fraction collector (Gilson, FC203B, France). 
Aliquots of these samples were immediately freeze-dried in liquid nitrogen and 
preserved at -80ºC for subsequent ATP quantification by bioluminescence using the 
luciferin-luciferase ATP kit HS II (Roche Applied Science, Indianapolis, USA) 
according to manufacturer’s instructions (see e.g. Silva-Ramos et al., 2013; Timóteo 
et al., 2014; Carneiro et al., 2014). Stimulation-evoked [3H]ACh and ATP release was 
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calculated by subtracting the basal outflow from the total outflow in the three samples 
collected following the stimulation period. In control conditions, transmitters release in 
S2 decayed 15-20% as compared to S1 (Figure 8, cf. Carneiro et al., 2014).  Cell 
integrity was assessed by measuring lactate dehydrogenase (EC 1.1.1.27, 
intracellular enzyme) activity in superfusates.  
 
Kinetic analysis of the extracellular ATP catabolism by HPLC 
Mucosal U/LP strips were mounted in 2-mL perfusion chambers heated at 
37ºC. After a 30-min equilibrium with gassed (95% O2 and 5% CO2) Tyrode’s 
solution, the preparations were incubated with ATP (30 µM) (zero time). Samples of 
75 µl were collected from the organ bath at different times up to 45 min for HPLC 
(with UV) detection) analysis (LaChrome Elite, Merck, Germany) of the variation of 
substrate disappearance and products formation (see e.g. Kumar et al., 2004). 
 
Chemicals and Solutions 
A317491 (5-[[[(3-phenoxyphenyl)methyl][(1S)-1,2,3,4-tetrahydro-1-
naphthalenyl]amino]carbonyl]-1,2,4-benzenetricarboxylic acid sodium salt hydrate), 
BAPTA-AM (1,2-Bis(2-aminophenoxy)ethane-N,N,N′,N′-tetraacetic acid tetrakis 
acetoxymethyl ester), carbenoxolone, MRS2578 (N,N''-1,4-butanediylbis[N'-(3-
isothiocyanatophenyl)thiourea), PSB0474 (3-(2-oxo-2-phenylethyl)-uridine-5'-
diphosphate disodium salt), tetrodotoxin citrate (TTX) were from Tocris Bioscience 
(Bristol, UK); Choline chloride and foetal bovine serum were from Sigma (St. Louis, 
MO, USA); [methyl3H]choline chloride (in ethanol, 85.5 Ci.mmol-1) was from Perkin 
Elmer (Boston, USA). MRS2578 and A317491 were dissolved in dimethylsulphoxide 
(DMSO) stock solution. Other drugs were prepared in Tyrode’s solution. No statistical 
differences between control experiments, made in the absence or in the presence of 
DMSO at the maximal concentrations used (0.5% v.v-1), were observed. 
 
Immunofluorescence Staining and Confocal 
Microscopy Observation 
Mucosal U/LP strips isolated from human bladder samples as described were 
stretched and fixed in periodate-lysine-paraformaldehyde solution for 16 hours at 
4ºC. Sections (16 µM) were incubated with selected primary antibodies (see Table 
7).  
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Table 7. Primary and secondary antibodies used in immunohistochemistry experiments. 
Antigen Code Host Dilution Supplier 
Primary antibodies: 
P2Y6 APR-011 Rabbit 1:100 
Alomone Labs, 
Jerusalem, Israel 
P2X2 (H-116) SC-25693 Rabbit 1:50 
Santa Cruz 
Biotechnology, 
Dallas, TX 
P2X3 (R-19) SC-31492 Goat 1:25 
Santa Cruz 
Biotechnology 
ChAT AB144P Goat 1:750 Chemicon® 
CK17 MAB1677 Mouse 1:150 Chemicon 
Vimentin M0725 Mouse 1:150 
Dako, Glostrup, 
Denmark 
PGP 9.5 7863-1004 Mouse 1:500 Serotec® 
α-Smooth muscle actin-fluorescein 
isothiocyanate 
F3777 Mouse 1:300 Sigma® 
Secondary antibodies: Donkey 1:1000 Molecular Probes® 
Alexa Fluor® 488 anti-mouse A-2120    
Alexa Fluor 488 anti-rabbit A-21206    
Alexa Fluor 633 anti-goat A-21082    
Alexa Fluor 680 anti-rabbit A-10043    
 
Antibodies were diluted in incubation buffer (fetal bovine serum 5%, serum 
albumin 1% and Triton X-100 0.3% in phosphate buffered saline) ate 4ºC for 16 
hours. After washout, incubation with secondary antibodies was performed in the 
dark for 2 hours at room temperature (see Table 7) (Timóteo et al., 2014; Carneiro et 
al., 2014). Observation were made and analyzed with a FluoViewTM FV1000 laser 
scanning confocal microscope. Collagen autofluorescence in the lamina propria was 
subtracted from specific immunofluorescence signals in all confocal micrographs 
(Figure 6). 
Pre-adsorption tests with an excess of corresponding antigen peptide 
sequences were performed to validate the specificity of P2X2, P2X3 and P2Y6 
antibodies (Figure 7). 
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Figure 6. Method used to reduce interference of collagen autofluorescence in confocal 
microscopy images of mucosal slices of the human bladder. In panel (A), shown are the results of 
lambda scan performed using 488, 543 and 633 nm excitation laser lines. Spectral emission of 
collagen autofluorescence was maximal in the lamina propria within the 550-625 nm range when the 
543 nm excitation laser was used. The example in panel (B), shows the procedure used to subtract 
collagen autofluorescence (emission in the 543 nm laser channel) from specific  immunofluorescence 
signals obtained with 488 and 633 nm excitation lasers; this negative control, containing only anti-
rabbit Alexa Fluor 488 and anti-goat Alexa Fluor 633 secondary antibodies (see Table 7), was 
counterstained with DAPI (405) to facilitate microscopic observations. The methodology exemplified 
here for a control human mucosal U/LP sample was applied to all confocal micrographs in this study, 
including those from BPH patients. 
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Figure 7. To test for the specificity of P2X2, P2X3 and P2Y6 receptor antibodies some 
sections were processed with primary antibodies pre-adsorbed with 10-fold molar excess of the 
corresponding antigen peptide sequences, overnight at 4ºC. Sections were then processed as 
described in Methods with the pre-absorbed antiserum and with the normal antiserum, in parallel. 
During documentation of purinoceptor pre-absorption controls, settings on the confocal microscope 
were adjusted appropriately to show immunoreactivity for sections that were processed normally (no 
pre-absorption) (see e.g. figure 12) and these settings were maintained when documenting pre-
absorption controls to minimize biases during capture and printing of digital images. Note that antigen 
pre-adsorption with the specific peptide sequences totally prevented immunofluorescence signals 
detection. Scale bars = 100 µm. 
 
 
Data Presentation and Statistical Analysis 
Results are expressed as the mean ± SEM in the number of individuals used 
for a particular set of experiments. Statistical data analysis was performed with 
GraphPad Prism®, version 6.04 for Windows®. The impaired Student t-test with the 
Welch correction was used for statistical analysis with 2-tailed P<0.05 considered 
significantly different. 
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RESULTS 
 
P2Y6 and P2X3 (and/or P2X2/3) Receptors Cooperated to Increase 
Nonneuronal ATP and [3H]ACh Release from Control Mucosal U/LP Strips 
Electrical stimulation of mucosal U/LP strips increased ATP and [3H]ACh 
outflow (Figure 8). Stimulation induced release was not affected by blocking nerve 
action potentials with TTX (1 µM), suggesting that ATP and [3H]ACh are mostly 
release from nonneuronal stores (Yoshida et al., 2010; Sadananda et al., 2009). The 
negligible (less than 8.0 mU/ml) activity of lactate dehydrogenase in bath samples 
collected before and after electrical field stimulation of the bladder mucosa in an 
indicator of cell integrity. Electrical stimulation of mucosal strips of the human bladder 
increased tissue tension above that of spontaneous phasic activity in a frequency 
dependent manner (Figure 5) (Moro and Chess-Williams, 2012). The UDP analogue 
and selective P2Y6 receptor agonist PSB0474 (100 nM with 15-minute incubation) 
significantly increased ATP and [3H]ACh release from the stimulated mucosa of 
control bladder samples (P< 0.05, Figure 8, A and B). Pretreatment with the selective 
and irreversible P2Y6 receptor antagonist MRS2578 (50 nM in S1 and S2), prevented 
the facilitatory effect of PS0474 (100 nM) (Figure 8, C). Urinary ATP can cause more 
ATP to be released by urothelial cells and this vicious cycle may occur through the 
activation of P2X3 and/or P2X2/3 receptors (Sun and Chai, 2006). Blockade of 
positive feedback operated via P2X3 and/or P2X2/3 receptors with A317491 (100 nM 
in S1 and S2) attenuated PSB0474 (100 nM) induced mucosal release of ATP and 
[3H]ACh (Figure 8, C). 
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Figure 8. Facilitatory effect of selective P2Y6 receptor agonist PSB0474 on ATP and [3H]ACh 
release from stimulated mucosal strips of control human bladders. PSB0474 (100 nM) was added 15 
minutes before S2 (arrow). P2Y6 antagonist MRS2578 (50 nM) and P2X3 and/or P2X2/3 antagonist 
A317491 (100 nM) were added to incubation medium ate beginning of release period (time zero) and 
were present throughout assay, including S1 and S2. Graphs show outflow of ATP (A) and [3H]ACh (B) 
from human mucosal U/LP strips in typical experiments. Change in ratio between evoked ATP and 
[3H]ACh release during two stimulation periods (S2/S1) relative to that in control conditions in absence 
of test drugs (dashed horizontal line) was considered measure of effect of PSB0474 (C). In control 
conditions S2/S1 was 0.83 ± 0.05 and 0.83 ± 0.06, respectively. Bars represent SEM of 4 to 6 
individuals. Dashed horizontal line indicates S2/S1. Asterisk indicates significantly different vs control 
S2/S1 (unpaired Student t test with Welch correction P< 0.05). Pound sign indicates significantly 
different vs PSB0474 alone (unpaired Student t test with Welch correction P< 0.05). 
 
 
BPH Patients 
 
Mucosa Released Higher Amounts of ATP via Pannexin-1 Hemichannels 
with Tonic Control by P2Y6 Receptor 
Figure 9 shows that in vitro mucosal U/LP strips from BPH patients release 
more ATP than strips from the control group (P< 0.05). The relative proportion of ATP 
compared to [3H]ACh release per mg wet tissue in matched samples of 6 patients 
with BPH (mean 35.63 ± 7.91) and 5 control men (mean 6.81 ± 1.47) indicates that 
this ration was fivefold higher in the mucosa of obstructed bladders (Kumar et al., 
2004). HPLC experiments to study the kinetics of extracellular ATP catabolism 
showed that the half degradation time of ATP (30 µM) by ectonucleotidases 
increased from a mean of 35 ± 3 minutes in 4 control men to a mean of 61 ± 16 
minutes in 4 patients with BPH (P< 0.05). This may also contribute to keep high 
nucleotide levels in the bladder mucosa. The increase in the purinergic component 
originating from the mucosa of BPH patients is under tonic control of the UDP 
sensitive P2Y6 receptor because it was down-regulated by MRS2578 (50 nM in S1 
and S2). On its own the P2Y6 receptor antagonist decrease (P< 0.05) evoked a ATP 
release per mg wet tissue from a mean of 392 ± 179 fmol/mg in 6 in BPH patients to 
48 ± 6 fmol/mg in 4 and from 109 ± 25 fmol/mg in 5 controls to 62 ± 11 fmol/mg in 4 
without much affecting the outflow of [3H]ACh (P > 0.05).  
 
 
___________________________________________________ORIGINAL RESEARCH ARTICLES 
PhD Thesis: Isabel Sofia Dias da Silva________________________________________74 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9. Amount of ATP and [3H]ACh release from stimulated mucosal U/LP strips of patients 
means of 69 ± 4 years old with outflow obstruction due to BPH and control organ donors mean of 59 ± 
4 years old. DPM, disintegrations per minute. X axis represents ATP and [3H]ACh content in samples 
collected during S1 in absence of test drugs. Bars represent SEM of matched mucosal bladder from 5 
controls and 6 BPH patients. Asterisk indicates significantly different vs control (unpaired Student t test 
with Welch correction P < 0.05). 
 
 
The PSB0474 (100 nM) induced surplus ATP release from TTX insensitive 
nonneuronal mucosal stores was not modified by removing Ca2+ and supplementing 
incubation medium with the fast intracellular Ca2+ chelator BAPTA-AM (5 µM in S1 
and S2). Mean S2/S1 ratios were 1.24 ± 0.07 in 6 preparations and 1.17 ± 0.06 in 5, 
respectively. Conversely carbenoxolone applied in S1 and S2 at a concentration (10 
µM) that inhibited pannexin-1 containing hemichannels in the rat bladder (Timóteo et 
al., 2014) virtually abolished stimulation induced ATP outflow from human mucosal  
strips without modifying the release of [3H]ACh in 4 preparations (data not shown). 
 
Loss of Cooperation between P2Y6 and P2X3 or P2X2/3 Receptors in 
Bladder Mucosa 
Activation of P2Y6 receptor with PSB0474 (100 nM with 15- minute incubation) 
increased the evoked release of ATP and [3H]ACh to a similar extent from the 
bladder mucosa of controls and BPH patients (Figure 10). As in control men, 
selective blockade of P2Y6 receptor with MRS2578 (50 nM in S1 and S2) also 
prevented PSB0474 (100 nM) induced facilitation of ATP and [3H]ACh release from 
mucosal strips of BPH patients (Figure 10). This was not verified regarding 
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cooperation between P2Y6 and P2X3 (or P2X2/3) receptors, given that the P2X3 
(and/or P2X2/3) receptor antagonist A317491 (100 nM in S1 and S2) did not 
attenuate PSB0474 (100 nM) facilitation of evoked [3H]ACh release (Figure 11).  
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 10. Activation of P2Y6 receptor with PSB0474 facilitated similar ATP and [3H]ACh 
outflow in mucosal U/LP strips from patients mean of  70 ± 4 years old. PSB0474 (100 nM) was added 
15 minutes before S2 and selective P2Y6 receptor antagonist MRS2578 (50 nM) was present 
throughout assay, including S1 and S2. Ordinates indicate changes in S2/S1 in presence of PSB0474 
(100 nM) vs corresponding S2/S1 in control conditions (dashed horizontal line). In absence of added 
drugs S2/S1 was 0.83 ± 0.05 and 0.83 ± 0.06 for [3H]ACh and ATP release in controls, and 0.84 ± 0.04 
and 0.86 ± 0.04, respectively, in BPH patients. Data are shown as mean ± SEM of 4 to 8 individuals. 
Single asterisk indicates significantly different vs control (unpaired Student t test with Welch correction 
P < 0.05). Double asterisks indicate significantly different vs PSB0474 alone (unpaired Student t test 
with Welch correction P <0.05). 
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Figure 11. Blockade of P2X3 and/or P2X2/3 receptors with A317491 attenuated facilitation of 
[3H]ACh release from stimulated U/L strips induced by PSB0474 in control organ donors mean of 59 ± 
8 years old but not in patients with BHP mean of 71 ± 4 years old. PSB0474 (100 nM) was added 15 
minutes before S2 and P2X3 and/or P2X2/3 antagonist A317491 (100 nM) was present throughout 
assay, including S1 and S2. Ordinates indicate changes in S2/S1 in presence of PSB0474 (100 nM) 
compared to corresponding S2/S1 in control conditions (dashed horizontal line). In absence of added 
drugs S2/S1 was 0.83 ± 0.05 and 0.83 ± 0.06 for [3H]ACh and ATP release in controls, and 0.84 ± 0.04 
and 0.86 ± 0.04, respectively, in BPH patients. Data are shown as mean ± SEM of 5 to 8 individuals. 
Asterisk indicates significantly different vs PSB0474 alone (unpaired Student t test with Welch 
correction P < 0.05). 
 
 
Changes in P2 Purinoceptor and ChAT Immunostaining Patterns in 
Mucosal U/LP Strips 
The presence of P2Y6, P2X2, P2X3 receptors and ChAT (the enzyme that 
syntheses ACh) in human urothelium was demonstrated by immunofluorescence 
confocal microscopy (Figure 12). P2X2, P2X3 and P2Y6 receptors were also 
observed in the suburothelial layer.  The presence of ChAT and, thus, the ability to 
synthesize and release ACh decreased significantly in the urothelium of BPH patients 
compared to healthy controls (Figure 9). Figure 12 shows that immunoreactivity 
against P2X2 and P2X3 receptors almost disappeared from the urothelium of BHP 
patients. In the suburothelial layer P2X2 receptor is predominantly localized in blood 
vessels and vimentin positive (myo)fibroblasts while P2X3 receptors stained PGP 9.5 
positive suburothelial nerve fibers (Figures 12 and 13, A and B). In contrast to the 
partial loss of ionotropic P2X receptor staining, immunoreactivity against P2Y6 
receptor remained almost unaltered in the urothelium of BHP patients compared to 
control men (Figure 12). However, labeled cells were more sparse, denoting 
increased urothelial permeability (Mirone et al., 2007). P2Y6 receptor was localized 
throughout the urothelial layer, including the more superficial umbrella cells stained 
with CK17 (Figure 13, C). Suburothelial P2Y6 receptors stained more intensely in 
BHP patients (Figure 12). 
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Figure 12. Color confocal micrographs show immunoreactivity against ChAT and P2 
purinoceptors (green areas), namely P2Y6, P2X2 and P2X3, in transverse U/L sections from control 
organ donors and patients with outflow obstruction due to BPH. Black and white images are 
differential interference contrast images. Data represent 5 individuals per group, including organ 
donors (ChAT and P2Y6 section H79OD, and P2X2 and P2X3 section H75OD) and BPH patients 
(ChAT and P2X2 section H24BPH, and P2Y6 and P2X3 section H77BPH). V. blood vessel. Scale bars 
indicate 100 µm. 
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Figure 13. Co-localization experiments of P2X2, P2X3 and P2Y6 receptors with type specific 
cell markers in human bladder mucosal urothelium (U) attached to lamina propria (LP). Urothelial 
cells, fibroblasts and suburothelial nerve fibers (red areas) were stained with CK17, vimentin (Vim) 
and PGP 9.5, respectively. To facilitate visualization of small nerve fibers stained with PGP 9.5 images 
correspond to higher magnification intensity projections over Z axis of 6 confocal stacks. P2X2 
receptors (green areas) co-localized with vimentin positive fibroblast cells (open triangles) while PGP 
9.5 stained suburothelial nerve fibers expressed P2X3 receptors (solid triangles). Co-localization 
(yellow areas) of P2Y6 receptor (green areas) and CK17 (red areas) was observed throughout 
urothelium, including most superficial umbrella cells (arrows). Differential interference contrast (DIC) 
images are shown to facilitate delimitation of tissue boundaries. Scale bars indicate 30 or 50 µm. 
 
DISCUSSION 
To our knowledge immunofluorescence confocal microscopy data showed for 
the first time that the UDP sensitive P2Y6 receptor is abundantly expressed in human 
urothelium, including the highly differentiated superficial umbrella cells. Besides its 
presence in the urothelial layer, the expression of P2Y6 receptors in suburothelial 
myofibroblasts and detrusor smooth muscle fibers has also been reported (Timóteo 
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et al., 2014; Carneiro et al., 2014; Yu et al., 2013; Sui et al., 2006). More importantly 
we found that activation of P2Y6 receptor facilitated the release of ATP and ACh from 
nonneuronal urothelial sources, thus, contributing to initiation and local propagation 
of signals from the human urothelium to underlying bladder layers, namely 
suburothelial nerve fibers, myofibroblasts and detrusor smooth muscle, which are 
endowed with P2 and cholinergic receptors (Winder et al., 2014; Fry et al., 2012). 
Cooperation between metabotropic P2Y6, and ionotropic P2X3 and/or P2X2/3 
receptors in the human urothelium with lamina propria contributes to enhance ATP 
and ACh release. These findings fully agree with data from our group demonstrating 
that urothelial P2Y6 receptors act synergistically with P2X3 receptors and both have 
important roles in the mechanosensory purinergic pathway commanding the 
micturition reflex in anesthetized rat without much affecting the motor drive during 
bladder voiding (Carneiro et al., 2014). The expression and function of P2Y6 receptor 
was conserved in the urothelial layer of BPH patients while we noted a relative 
intensification of P2Y6 receptor staining in suburothelial myofibroblasts compared to 
that in control men. This pattern contrasted with the loss of P2X2 and P2X3 
immunoreactivity from the urothelium of BPH patients, comparable to that observed 
in other pathological conditions of the human bladder (Ruggieri, 2006). These 
findings may explain why the potent and selective P2X3 and P2X2/3 receptor 
antagonist A317491 became inactive upon transmitter release induced by P2Y6 
receptors activation in BPH patients. P2X3 and the heterodimer P2X2/3 are fast 
desensitizing ionotropic receptors that are activated almost exclusively by ATP. 
Decreased activity of ectonucleotidases has been shown in overactive bladders, 
leading to increased smooth muscle responses to ATP (Harvey et al., 2002). Thus, it 
seems possible that extracellular ATP accumulation as in this study might contribute 
to the loss of P2X2 and P2X3 receptor staining in these patients. 
Bladder wall thickness due to smooth muscle hypertrophy and connective 
tissue infiltration, accompanied by autonomic denervation of the detrusor, has been 
found in decompensated bladders secondary to BPH (Levin et al., 2000). However, 
less is known regarding morphological changes operating in the mucosa of these 
patients, which may be important to explain the pathophysiology of obstructed 
bladders. This study shows that gross morphological alterations hardly sustained 
immunohistochemical differences in the bladder mucosa of controls and BPH 
patients, prompting more relevant modifications in gene expression and transcription 
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to explain mechanically induced deregulation of the synthesis of many proteins such 
as receptors, ionic channels and enzymes (Mirone et al., 2007).  
Notwithstanding the lack of the positive feedback mechanism operated by 
released ATP via urothelial P2X3 and/or P2X2/3 receptors in BPH patients, the 
magnitude of the P2Y6 mediated facilitation of ATP and [3H]ACh release from 
mucosal U/LP strips was essentially conserved. This paradox can be explained by 
considering 1) up-regulating of P2Y6 receptors in the suburothelial layer, probably in 
myofibroblasts, and 2) prolongation of ATP half-life in obstructed bladders. Thus, the 
significant increase in the ATP/ [3H]ACh release ratio verified in the mucosa of BPH 
patients can be partially attributable to deficits in the expression and/or activity of 
ATP metabolizing enzymes, namely NTPDases, along with partial loss of ChAT, 
which together with the mitochondrial enzyme carnitine acetyltransferase are 
responsible for ACh synthesis in the urothelium (Lips et al., 2007). Our data suggest 
that bladder outlet obstruction counteracted age related increases in nonneuronal 
ACh release (Yoshida et al., 2004) while favoring mucosal ATP accumulation (Figure 
9) because no significant changes were observed in the ACh content of mucosal 
strips from BPH patients compared to the younger control group. Whether this 
impacts antimuscarinic drug resistance to treat bladder overactivity in BPH patients 
remains to be elucidated. 
While huge amounts of extracellular ATP may leak from injured cells, the 
mechanism of ATP release from intact urothelial cells is still a matter of debate. In 
this study ATP release from mucosal U/LP strips was not due to cell damage 
because we detected no significant changes in the activity of the intracellular enzyme 
lactate dehydrogenase in incubation fluid. We also found that the stimulation evoked 
ATP and [3H]ACh release from human mucosal strips originated from TTX insensitive 
nonneuronal stores and was Ca2+ independent, thus, excluding a major contribution 
of vesicular exocytosis. Nonvesicular release of ACh from urothelial cells has been 
shown to occur via the organic cation transporters OCT1 and OCT3 (Winder et al., 
2014; Lips et al., 2007). Stretch induced ATP release from the urothelium is mainly 
attributable to vesicular membrane traffic in umbrella cells (Wang et al., 2005) but 
nonvesicular mechanism of ATP outflow may also exist under various 
pathophysiological conditions. A significant role of pannexin-1 containing 
hemichannels on P2Y6 receptor mediated ATP release to control bladder 
urodynamics has been demonstrated in the anaesthetized rat (Timóteo et al., 2014).  
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Likewise we report that the pannexin-1 inhibitor carbenoxolone significantly 
attenuated stimulation evoked and PSB0474 induced ATP release facilitation. 
Although carbenoxolone may also block connexin containing hemichannels, their 
involvement in ATP release under the current conditions is less plausible. This is 
because, unlike pannexin-1, connexin hemichannels close at normal millimolar Ca2+ 
(eg 1.8 mM CaCl2 in Tyrode solution) and open under Ca2+ depletion conditions 
(Fasciani et al., 2013). This supports our hypothesis that pannexin-1 containing 
hemichannels may have a relevant role in the outflow of ATP from the human 
bladder mucosa. 
The observation that selective blockade of the UDP sensitive P2Y6 receptor 
with MRS2578 decreased ATP outflow from mucosal strips suggests that UTP or 
UDP is endogenously released. Considerable amounts of UTP and UDP were 
detected along with ATP and ADP in urine specimens of asymptomatic controls and 
patients with overactive bladder with a trend toward higher urinary levels of ATP and 
UDP in the patient group (Contreras-Sanz et al., 2012). Inhibition of ATP release by 
MRS2578 was more pronounced in mucosal strips from BPH patients than from 
control men while no changes were found regarding [3H]ACh outflow in both groups. 
Therefore, one may assume that uracil nucleotides, in particular UDP, are most likely 
to affect (via the P2Y6 receptor) ATP outflow from stimulated mucosal strips of BPH 
patients. 
 
CONCLUSIONS 
Data suggest that down modulation of transmitters release from the bladder 
sensory system with selective P2Y6 receptor antagonists may be a novel therapeutic 
strategy to control persistent storage symptoms in patients with BOO. Further studies 
interplay between various P2 purinoceptors to control nonneuronal reflexes in the 
human bladder mucosa. 
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ABSTRACT 
Purines have important roles in the regulation of human bladder function. 
Purinergic signaling increases significantly in patients with lower urinary tract 
symptoms (LUTS), such as overactive bladder (OAB) and bladder outflow obstruction 
(BOO) due benign prostatic hyperplasia (BPH). Our group demonstrated that 
uroepithelial cells and cholinergic nerves from men with BOO due to BPH release 3-5 
fold more ATP than control individuals. It is, therefore, tempting to admit that the 
purinergic signaling cascade may be a novel therapeutic target to control bladder 
overactivity when anticholinergic drugs and 3-adrenoceptor agonists fail or are 
contraindicated. ATP released from the urothelium during bladder filling is 
responsible for the sensory input to the central nervous system by activating 
ionotropic P2X3 and/or P2X2/3 receptors on suburothelial nerve afferents. ATP is 
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also involved in pathological bladder contractions through the activation of P2X1 
receptors on smooth muscle fibers, but so far no attempts have been made to show 
a neuromodulatory role of the nucleotide in the human bladder. ATP-induced bladder 
excitability may be cut-short by membrane-bound NTPDases, which sequentially 
hydrolyze ATP into ADP, AMP and adenosine. Like adenosine, ADP also restrains 
cholinergic neuromuscular transmission in the bladder via inhibitory P2Y receptors, 
which subtype has not yet been identified. In this study, we aimed at investigating the 
extracellular catabolism of ATP by subtype-selective NTPDases in the detrusor of 
men with BOO due to BPH, as well as the interplay between ATP-sensitive ionotropic 
P2X and ADP-activated metabotropic P2Y receptor subtypes to control hyperactivity 
of cholinergic nerves in the pathological human bladder. The kinetics of the 
extracellular catabolism of ATP and ADP is 1.4 and 1.9 times slower in the detrusor 
of BPH patients than in control individuals. This difference was mainly attributed to 
decreases in NTPDase1/CD39 (ATP diphosphohydrolase) activity converting both 
ATP and ADP directly into AMP, with subsequent dephosphorylation to adenosine by 
ecto-5’-nucleotidase/CD73 on smooth muscle fibres. Only minor changes were 
detected in the expression of NTPDase2 (ATPase) bound to cholinergic nerve fibres, 
which might favour transient ADP accumulation at the neuromuscular synapse. 
Differential inhibition of NTPDase1 and 2 respectively with ARL67156 (100 µM) and 
POM-1 (100 µM) decreased evoked [3H]ACh release by 13±8% (n=5) and 24±6% 
(n=5) in BOO patients, but the two compounds were about equipotent (~30%) on 
evoked transmitter release in control individuals. While the P2X3 receptor antagonist, 
A317491 (100 nM), decreased [3H]ACh release by 20±2% (n=4) and 24±6% (n=5) in 
control and BOO patients, respectively, the P2X2/3 receptor blocker, TNP-ATP (10 
nM), was more effective in BOO patients (43±16%, n=4) than in controls (27±9%, 
n=4). Selective antagonism of the ADP-sensitive P2Y12 receptor with AR-C66096 
(100 nM), but not of P2Y1 and P2Y13 receptors with MRS2179 (300 nM) and 
MRS2211 (10 µM), increased [3H]ACh release by 23±9% (n=5). Data suggest that 
transient accumulation of ADP leading to inhibition of cholinergic neurotransmission 
via P2Y12 receptors may partially counteract hyperactivity of cholinergic nerves 
operated by surplus ATP through ionotropic P2X2/3 receptors activation in men with 
BPH.  
 
___________________________________________________ORIGINAL RESEARCH ARTICLES 
PhD Thesis: Isabel Sofia Dias da Silva________________________________________86 
 
Keywords: human detrusor bladder, ecto-NTPDases, ADP-sensitive 
receptors, P2X3 receptors, P2X2/3 receptors. 
 
INTRODUCTION 
ATP is involved in the mechanosensory function of most hollow organs 
(Burnstock, 2007). In the urinary bladder, ATP released upon distension of the 
urothelium during bladder filling activates the P2X3 receptor on suburothelial sensory 
nerve fibers to initiate the micturition reflex (Calvert et al., 2008). Activation of 
heteromeric P2X2/3 receptors localized on lumbosacral and splanchnic nerves may 
also participate in bladder sensation to stretch, pressure and irritation (Ford, 2012). 
Mice lacking P2X2, P2X3, or both receptors have reduced bladder reflexes and 
increased bladder volume threshold (Ford, 2012). Selective P2X3 receptor 
antagonists, including A317491, reduce bladder hyperactivity in experimental models 
(Lu et al., 2007; Brederson and Jarvis, 2008), thus supporting the theory that 
blockade of P2X3 receptors may be therapeutically useful to control overactive 
bladder (OAB), interstitial cystitis and bladder hyperactivity due to bladder outlet 
obstruction (BOO) (Burnstock, 2007; Ford, 2012).  
Localization of ATP-sensitive P2 receptors subtypes in the human urinary 
bladder is not fully resolved. The P2X2 receptor is expressed predominantly in 
vimentin-positive cells located in the suburothelium, with lower levels of expression in 
actin-positive smooth muscle fibers. The P2X3 receptor is also expressed in 
vimentin-positive cells in the suburothelium and in those surrounding smooth muscle 
fibers (Svennersten et al., 2015). Both P2X2 and P2X3 receptors are also present in 
choline acetyltransferase-positive urothelial cells, but the P2X2 and P2X3 
immunoreactivity decreases in the urothelium of patients with BOO due BPH; this 
situation is contrary to the increase in UDP-sensitive P2Y6 receptor staining in the 
same cells (Silva et al., 2015). Coincidently or not, activation of the P2Y6 receptor, 
but not P2X2 and P2X3 receptors facilitates the release of ATP and ACh from the 
human urothelium and this effect is particularly evident in patients with BOO due to 
BPH (Silva et al., 2015).  
Our group demonstrated that women with overactive bladder (Silva-Ramos et 
al., 2013) and men with BOO due to BPH (Silva-Ramos et al., 2016a) have increased 
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levels of urinary ATP. These findings led us to hypothesize that the urinary ATP may 
be a valuable biomarker of detrusor competence, which may be useful to distinguish 
low urinary flow rates due to BOO from detrusor underactivity (Silva-Ramos et al., 
2016a). Patients with BOO also exhibit impaired NTPDase1/CD39 activity, the 
enzyme responsible for the extracellular hydrolysis of ATP directly into AMP (Silva-
Ramos et al., 2015a). Reduced ATP hydrolysis due to deficient NTPDase1/CD39 
activity might explain (1) urinary ATP accumulation, and (2) shortage of adenosine 
leading to A1 receptor-mediated inhibition of cholinergic nerve activity in the bladder 
of obstructed human patients (Silva-Ramos et al., 2015a). Thus, cholinergic 
hyperactivity due to adenosine deficiency together with increased activation of 
ionotropic P2X1 receptors in detrusor smooth muscle fibers by accumulating ATP 
contribute to detrusor overactivity (Kennedy et al., 2007; Silva-Ramos et al., 2016b).  
Despite our knowledge about the pathophysiological role of ATP and 
adenosine in the urinary bladder, no attempts have been made so far to investigate 
the role of the ATP intermediate metabolite, ADP, in the human detrusor. ADP 
signals are mediated preferentially by metabotropic P2Y1, P2Y12 and P2Y13 receptors 
(Communi et al., 2001; Marteau et al., 2003). Activation of the P2Y1 receptor inhibits 
ACh release from cholinergic nerves of the rat urinary bladder (Carneiro et al., 2014). 
Using myographic recordings, Yu et al. (2014) showed that ADP causes smooth 
muscle contraction in the mouse bladder through the activation of the P2Y12 receptor, 
without the participation of P2Y1 and P2Y13 receptors. The identification of the P2Y12 
receptor in smooth muscle fibers offers potentially novel treatment strategies for 
bladder contractility disorders using clinically available P2Y12 receptor antagonists, 
such as the antithrombotic drug clopidogrel.  
In this study, we aimed at investigating the extracellular catabolism of ATP and 
ADP by subtype-selective NTPDases in the detrusor of men with BOO due to BPH, 
as well as the interplay between ATP-sensitive ionotropic P2X and ADP-activated 
metabotropic P2Y receptor subtypes to control cholinergic neurotransmission in 
obstructed human bladders.    
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MATERIAL AND METHODS 
Human Bladder Samples 
 
Human bladder samples were collected as described by previous studies from 
our group (Silva-Ramos et al., 2015a; Silva et al., 2015). Urinary bladder samples 
were removed from the anterior wall of the bladder dome of 46 consecutive patients 
(mean ± SEM age of 69.87 ± 1.20 years) with bladder outlet obstruction (BOO) due 
benign prostate hyperplasia (BPH) who underwent transvesical prostectomy and 21 
male organ donors (mean age of 49.43 ± 3.25 years) at the time of organ harvest for 
transplantation. Samples were immediately placed in cold (4-6ºC) mannitol 
transplantation solution at 400 mOsm/kg (M-400) not supplemented with ATP or 
adenosine (4.190 gm 100 ml -1 mannitol, 0.205 gm 100-1 KH2PO4, 0.970 gm 100-1 
K2HPO4.3H2O, 0.122 gm 100 ml-1 KCl and 0.084 gm 100 ml-1 NaHCO3, pH 7.4), and 
transported to the laboratory. Experiments were performed within the first 24 hours 
after collection, which corresponds to the tissue viability window. This study and all 
its procedures were approved by the ethics committees of Centro Hospitalar do Porto 
and Instituto de Ciências Biomédicas Abel Salazar, medical school. All patients with 
BPH provided signed informed consent to use the biological material. The 
investigation conformed to the principles outline in The Code of Ethics of the World 
Medical Association (Declaration of Helsinki). 
 
 
 
[3H]ACh release experiments 
 
After dissecting out the mucosa through cleavage at the lamina propria, 
detrusor muscle strips (~1.5x5 mm) were mounted in 3 ml capacity vertical perfusion 
chambers heated at 37ºC. The procedures used for labeling the preparations and 
measuring evoked [3H]ACh release were described previously (Silva-Ramos et al., 
2015a; Silva et al., 2015). Briefly, the preparations were superfused with gassed 
(95% O2 and 5% CO2) Tyrode’s solution (pH 7.4) containing (mM) NaCl 137, KCl 2.7, 
CaCl2 1.8, MgCl2 1, NaH2PO4 0.4, NaHCO3 11.9, glucose 11.2 and choline 0.001. 
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After a 30-min equilibration period, cholinergic neurons were loaded with 1 µM 
[3H]choline (specific activity 2.5 µCi nmol-1) under electrical field stimulation (EFS, 1 
Hz frequency, 0.5 ms pulse width, 40 V) during 40 min. Washout of the preparations 
was performed for 60 min by superfusion (15 mL min-1) with Tyrode’s solution 
supplemented with the choline uptake inhibitor, hemicholinium-3 (10 µM). Tritium 
content was measured by liquid scintillation spectrometry (TriCarb2900TR; Perkin 
Elmer, Boston, USA) (% counting efficiency = 58±2 %) after appropriate background 
subtraction, using 400 µL bath samples collected automatically every 3 min with a 
fraction collector (Gilson, FC203B, France). [3H]ACh release was evoked by two 
periods of electrical field stimulation (S1 and S2, 200 pulses of 0.5 ms duration 
delivered at 10 Hz frequency). Therefore, the evoked [3H]ACh release was calculated 
by subtracting the basal tritium outflow from the total tritium outflow during the 
stimulation period (see, e.g. Silva-Ramos et al., 2015a; Silva et al., 2015).  
 
 
Kinetic of the extracellular catabolism of ADP by HPLC 
 
For the kinetic experiments of the extracellular catabolism of ADP, detrusor 
strips without the mucosa were mounted in a 2 mL organ bath. All experiments were 
performed at 37ºC. Preparations were superfused with gassed (95% O2 and 5% 
CO2) Tyrode’s solution. After equilibrium, the preparations were incubated with 30 
µM of ADP (zero time). Samples of 75 µL were collected from the organ bath at 
different times up to 45 min for HPLC (with UV detection) analysis (LaChrome Elite; 
Merck, Germany) of the variation of substrate disappearance and product formation 
(Duarte-Araújo et al., 2004; Correia-de-Sá et al., 2006; Vieira et al., 2014; Silva-
Ramos et al., 2015a). The stoichiometry of ADP conversion into their metabolites 
was kept unaltered (30 µM). Considering that the curvilinear decrease of the initial 
substrate with time is characteristic of first-order kinetics, the half-degradation time 
was estimated from polynomial fitting of linear semilogarithmic progress curves of the 
catabolism of adenine nucleotides for each separate experiment (see, e.g. Duarte-
Araújo et al., 2004; Silva-Ramos et al., 2015a). 
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Immunofluorescence Staining and Confocal Microscopy Observation 
 
Detrusor strips from human bladder samples as described were stretched and 
fixed in periodate-lysine-paraformaldehyde solution for 16 hours at 4ºC. Sections (16 
µm) were incubated with select primary antibodies (see table 8). Antibodies were 
diluted in incubation buffer (fetal bovine serum 5%, serum albumin 1% and Triton X-
100 0.3% in phosphate buffered saline ate 4ºC for 16 hours. After washout, 
incubation with secondary antibodies was performed in the dark for 2 hours at room 
temperature (see table 8) (Silva-Ramos et al., 2015a). Observations were made and 
analyzed with a FluoViewTM FV1000 laser scanning confocal microscope. During 
documentation of detrusor sections from control and BOO patients, settings on the 
confocal microscope were kept unaltered to minimize bias. 
 
 
Table 8. Primary and secondary antibodies used in immunohistochemistry experiments. 
Antigen Code Host Dilution Supplier 
Primary antibodies: 
NTPDase1 hN1-9L(I4) Rabbit  1:200 J Sévigny 
NTPDase2 hN2-2L Rabbit 1:200 J Sévigny 
NTPDase3 nH3-1c(I4) Guinea-pig 1:200 J Sévigny 
Ecto-5’-nucleotidase h5’NT-2c(I4) Guinea-pig 1:200 J Sévigny 
P2Y1 APR-009 Rabbit 1:75 Alomone 
P2Y12 APR-020 Rabbit 1:50 Alomone 
P2Y13 APR-017 Rabbit 1:50 Alomone 
VAChT SAB5200240 Mouse 1:50 Sigma 
Secondary antibodies:    
Alexa Fluor 488 anti-rb A-21206 Donkey 1:1500 Mol. Probes 
Alexa Fluor 568 anti-ms A-10037 Donkey 1:1500 Mol. Probes 
Dylight 649 anti-gp 706-495-148 Donkey 1:150 Jackson ImmunoR. 
 
 
Drugs and solutions 
 
Adenosine 5’-[β-thio]diphosphate tritithium salt (ADPβS), pyridoxal phosphate-
6-azo(benzene-2,4-disulfonic acid) tetrasodium salt hydrate (PPADS tetrasodium salt 
hydrate), anhydrous glycerol, choline chloride, fetal bovine, hemicholinium-3, 
paraformaldehyde (prills), lysine and sodium periodate were obtained from Sigma 
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(St. Louis, MO, USA); ADP, 5-[[[(3-Phenoxyphenye)methy][[(1s)-1,2,3,-4-tetrahydro-
1-aphthalenyl]amino]carbonyl]-1,2,4-benzenetricarboxylic acid sodium salt hydrate 
(A317491 sodium salt hydrate), 6-N,N-Diethyl-D-β,γ- dibromomethylene ATP 
trisodium salt (ARL67156 trisodium salt), sodium metatungstate (POM-1), 2-
(Propylthio)adenosine-5’-O-(β,γ, difluoromethylene)(triphosphate tetrasodium salt 
(AR-C66096 tetrasodium salt), 2’,3’-0-(2,4,6-Trinitrophenyl)adenosine-5’-triphosphate 
tetra(triethylammonium) salt (TNP-ATP triethylammonium salt), 2-[(2-Chloro-5-
nitrophenyl)azo]-5-hydroxy-6-methyl-3-[(phosphonooxy)-4-pyridinecarboxaldehyde 
disodium salt (MRS2211) were obtained from Tocris Bioscience (Bristol, UK); 2’-
deoxy-N6-methyladenosine 3’, 5’-biphosphate tetrasodium salt (MRS2179) was 
obtained from ABCAM (Cambridge, UK);  [methyl-3H] choline chloride (ethanol 
solution, 80.6 Cinmol-1) was obtained from Perkin Elmer (Boston, USA); serum 
albumin, Triton X-100 were obtained from Merck (Darmstadt, Germany); The 
antibodies against ecto-NTPDases and ecto-5’-nucleotidase were a kind gift from J. 
Sévigny (Univ. Lavel, Québec, QC, Canada). PPADS was made up as 3 mmol.L-1, 
while TNP-ATP was made up as 10 mmol.L-1 stock solution in distilled water. 
A317491 was prepared in DMSO. All the other compounds were dissolved in 
Tyrode’s solution. PPADS was kept protected from light to prevent 
photodecomposition. All stock solutions were stored as frozen aliquots at -20 ºC. 
Dilutions of these stock solutions were made daily and appropriate solvent controls 
were done. No statistical differences between control experiments, made in the 
absence or in the presence of the solvents at the maxima concentration used (0.5% 
v/v), were observed. 
 
 
Data Presentation and Statistical Analysis 
 
Results are expressed as the mean ± SEM in the number of individuals used 
for a particular set of experiments. Statistical data analysis was performed with 
GraphPad Prism®, version 6.04 for Windows®. The unpaired Student t-test with the 
Welch correction was used for statistical analysis with 2-tailed p<0.05 considered 
significantly different. 
 
 
___________________________________________________ORIGINAL RESEARCH ARTICLES 
PhD Thesis: Isabel Sofia Dias da Silva________________________________________92 
 
 
RESULTS 
Expression and activity of ecto-NTPDases in the urinary bladder of 
control individuals and BPH patients 
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Figure 14. (A) Confocal micrographs showing the immunoreactivity against NTPDase1, 2, 3 
and ecto5’-nucleotidase in transverse sections of the detrusor from organ donors (control) and BOO 
patients. NTPDase1, 2, 3 and ecto5’-nucleotidase immunoreactivity is shown in green. Images are 
representative of five individuals per group, control and BOO patients. NTPDase1, 2 (panels A-H) and 
ecto5’-nucleotidase (panels M-P) are the most expressed ecto-nucleotidases in the human detrusor, 
while immunoreactivity against NTPDase3 is not observed (panels I-L). NTPDases 1 and 2 are more 
evident in the detrusor of control subjects (panels B, F and N) than in BOO patients (panels D, H and 
P). Scale bars = 50 µm. (B) The kinetics of the extracellular catabolism of ADP is shower in mucosal-
denuded detrusor strips from patients with outflow obstruction due to benign prostatic hyperplasia 
(BPH) as compared to control organ donors (control). ADP (30 µM) was added at zero time to the 
incubation medium. Samples were collected from the incubation fluid at the indicated times on the 
abscissa and analyzed by HPLC with UV detection to quantify ADP (filled circles) and its metabolites, 
AMP (filled triangles), adenosine (ADO, open squares), inosine (INO, filled squares) and hypoxanthine 
(HX, filled lozenges). Average results obtained from three to four individuals of BOO patients and 
control individuals, respectively; the vertical bars represent SD and are shown when they exceed the 
symbols in size. 
 
 
Figure 14A shows the immunolocalization of ecto-NTPdases 1, 2 and 3 and 
ecto-5’nucleotidase/CD73 in the human detrusor from control individuals (panels B, 
F, J, N) and patients with bladder outlet obstruction (BOO) (panels D, H, L, P). The 
expression of ecto-NTPDase1 and 2 enzymes decreases in the detrusor of BOO 
patients compared to control individuals. Ecto-NTPDase3 was absent from detrusor 
samples of both groups of individuals, controls and BOO patients. No changes in 
ecto-5’nucleotidase/CD73 immunoreactivity seem to occur between the control group 
and patients with BOO.   
Figure 14B shows the time course of the extracellular catabolism of ADP in 
urothelium-denuded detrusor strips from control organ donors and BOO patients. 
Detrusor strips from control subjects hydrolyze extracellular ADP (30 µM) with a half-
degradation time (t1/2) of 19±3 min (n=4), but this time increases (P<0.05) to 34±9 
min (n=3) in patients with BOO due to BPH. Deficient extracellular ADP catabolism is 
compatible with the reduced amounts of ecto-NTPDases 1 and 2 in the detrusor of 
BPH patients compared to control individuals. The ADP metabolites detected in the 
bath were AMP, adenosine, inosine and hypoxanthine, whose concentrations 
increased with time. The concentration of ADP metabolites rose faster in control 
samples than in the detrusor from BOO patients. Interestingly, AMP concentrations in 
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the bathing fluid were higher than adenosine during the first 15 min following ADP 
(30 µM) applications (Figure 14B). This pattern indicates that (1) ecto-
5’nucleotidase/CD73 (EC 3.1.3.5) is the rate limiting step of adenosine formation 
from the extracellular catabolism of adenine nucleotides in the human detrusor and 
that (2) this enzyme may be feed-forwardly inhibited by high levels of ADP in the 
extracellular milieu, as verified in many other tissues (e.g. neuromuscular junction, 
myenteric plexus, hippocampus) (Magalhães-Cardoso et al., 2003; Vieira et al., 
2014; Cunha et al., 1992).  
 
 
Role of the ecto-NTPDase2 localized on cholinergic nerves of the bladder 
of BOO patients 
Inhibition of ecto-NTPDases with ARL67156 (100 µM) and POM-1 (100 µM) 
decreased [3H]ACh from stimulated cholinergic nerve terminals innervating the 
human detrusor (Figure 15A). ARL67156 (100 µM) is a preferential inhibitor of ecto-
NTPdase1, without any effect on ecto-NTPDase2 (Lévesque et al., 2007). To prevent 
ecto-NTPdase2 activity we used POM-1, a sodium polyoxotungstate exhibiting high 
affinity for ecto-NTPDases 1, 2 and 3 in recombinant cells (Wall et al., 2008). While 
both drugs exhibited a similar potency in bladder samples from control individuals, 
i.e. when ARL67156 (100 µM) and POM-1 (100 µM) were applied 15 min before S2 
(second stimulus) the amount of evoked [3H]ACh release decreased by 34±5% (n=5) 
and 29±4% (n=4), respectively, the magnitude of the inhibitory effect of ARL67156 
(100 µM) decreased to 13±8% (n=5) in the detrusor of BOO patients but the same 
did not occur with POM-1 (100 µM, 24±6%, n=5).  
Taken together, these results suggest that inhibition of ecto-NTPDase1 (ATP 
diphosphohydrolase or apyrase) becomes functionally irrelevant accompanying the 
drop in NTPDase1 immunoreactivity in the detrusor of BOO patients (see Figure 
14A). Despite we also observed a decline in ecto-NTPDase2 immunoreactivity in 
detrusor smooth muscle fibers of BOO patients, inhibition of this enzyme may still 
control evoked [3H]ACh release because a subset of ecto-NTPDase2 co-localizes 
with the vesicular ACh transporter (VAChT) in cholinergic nerve fibers innervating the 
detrusor (Figure 15B), where it can mediate ADP accumulation from the hydrolysis of 
released ATP.       
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Figure 15. (A) Inhibition of NTPDases activity with ARL67156 and POM-1 decreases 
electrically evoked [3H]ACh release from detrusor strips of cadaveric organ donors (control) and BOO 
patients. ARL67159 (100 µM) and POM-1 (100 µM) were applied 15 minutes before S2. The ordinates 
are changes in S2/S1 ratios compared to the S2/S1 ratio obtained without addition of any drug. Data are 
means ± SD of four to five individuals. *P<0.05 (unpaired Student’s t test with Welch’s correction) 
represents significant differences when compared with zero percent of change or with the effect of the 
same drug in control individuals, respectively. (B) Co-localization of NTPDase2 with vesicular 
acetylcholine transporter (VAChT) in the human detrusor from control subject; to facilitate visualization 
of small cholinergic nerve terminals staining for VAChT (red) images correspond to the intensity 
projections over Z axis of five to six confocal microscopy stacks taken at the smooth muscle layer. 
VAChT-positive cholinergic nerve terminals (red) stained positively with antibody against the 
NTPDase2 (green); yellow staining denotes co-localization. Scale bars = 100 µm.  
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 ADP accumulation in the detrusor of men with BOO due BPH 
contributes to attenuate cholinergic hyperactivity via P2Y12 receptors 
activation 
To investigate the activity of ADP-sensitive receptors on [3H]ACh release from 
stimulated human detrusor samples, we used the enzymatically-stable ADP 
analogue, ADPβS (100 µM), which activates P2Y1 (Shachter and Harden, 1997; 
Waldo et al., 2002), P2Y12 (Herbert and Savi, 2003) and P2Y13 receptors (Marteau et 
al., 2003). ADPβS (100 µM, applied 15 min before S2) was devoid of effect on 
evoked [3H]ACh release from the detrusor of control individuals, but it significantly 
(P<0.05) decreased transmitter release by 23±4% (n=7) in detrusor samples from 
men with BOO due to BPH (Figure 16A). The inhibitory effect of ADPβS (100 µM) 
was fully reversed by selectively blocking the P2Y12 receptor with AR-C66096 (100 
nM), when the antagonist was present throughout the experimental period (i.e. both 
in S1 and S2).  
To evaluate the endogenous role of ADP-sensitive receptors on [3H]ACh 
release from detrusor strips isolated from BPH patients, we used MRS2179 (300 
nM), AR-C66096 (100 nM) and MRS2211 (10 µM) which selectively antagonize 
P2Y1, P2Y12 and P2Y13 receptors, respectively. Blockade of P2Y1 and P2Y13 
receptors with MRS2179 (300 nM) and MRS2211 (10 µM) did not significantly 
change the evoked transmitter release from detrusor samples of obstructed patients 
(Figure 16B). This contrasts with the signiticant (P<0.05) facilitatory effect observed 
upon blocking the P2Y12 receptor with the AR-C66096 (100 nM).  
Overall, these results indicate that endogenous ADP accumulation at the 
neuromuscular synapse of the obstructed human detrusor contributes to attenuate 
cholinergic hyperactivity through the activation of P2Y12 receptors.    
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Figure 16. (A) Activation of ADP-sensitive receptors with ADPβS, an enzymatically-stable 
ADP analogue, inhibits [3H]ACh release from electrical stimulated detrusor strips of control individuals 
and patients with BOO due to BPH. ADPβS (100 µM) was added 15 minutes before S2 and the P2Y12 
receptor antagonist, AR-C66096 (100 nM), was present throughout assay, including S1 and S2. 
Ordinates indicate changes in S2/S1 in presence of ADPβS (100 µM) compared to corresponding S2/S1 
in control conditions (dashed horizontal line). In the absence of added drugs the S2/S1 ratio was 0.83 ± 
0.05 in controls and 0.84 ± 0.04 in patients with BOO. Data are means ± SD of four to seven 
individuals. *,** P<0.05 (unpaired Student’s t test with Welch’s correction) represents significant 
differences when compared with zero percent of change or with the effect of the same drug in control 
individuals, respectively.  (B) Effects of the blockade of P2Y1, P2Y12 and P2Y13 receptors with 
MRS2179 (300 nM), AR-C66096 (100 nM) and MRS2211 (10 µM) on evoked [3H]ACh release from 
detrusor samples from patients with BOO due to BPH. AR-C66096, MRS2179 and MRS2211 were 
added to the incubation media 15 minutes before S2. The ordinates are changes in S2/S1 ratio 
compared to the S2/S1 ratio obtained without addition of any drug. Data are means ± SD of three to 
four individuals.  
 
 
Localization of ADP-sensitive receptors in the human urinary bladder 
from control subjects and patients with bladder outlet obstruction 
 Figure 17A shows confocal microscopy images of human detrusor samples 
isolated  from control individuals (panels B, F, J) and from patients with BOO due 
BPH (panels D, H, L) stained against ADP-sensitive receptors, P2Y1, P2Y12 and 
P2Y13. The smooth muscle fibers of the human detrusor are endowed with P2Y1 and 
P2Y12 receptors, but we did not find P2Y13 receptor immunoreactivity. While no 
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significant changes were detected concerning the P2Y1 immunoreactivity between 
control individuals (Figure 17A(B)) and patients with BOO due to BPH (Figure 
17A(D)), the P2Y12 immunofluorescence staininig increased substantially in samples 
from obstructed patients (compare Figures 17A(F) and 17A(H)).  
In addition to the presence of P2Y12 immunoreactivity in detrusor smooth 
muscle fibers (green staining), Figure 17B shows that this receptor is also present on 
VAChT-positive cholinergic nerve fibers (red stainig) denoted by the yellow staining 
resulting from merging the two channels in the confocal microscope. This finding 
supports the predominant neuromodulatory role of the P2Y12 compared to the other 
ADP-sensitive receptors in obstructed human detrusor samples.        
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Figure 17. (A) Tissue distribution of ADP-sensitive receptors (green staining), P2Y1, P2Y12 
and P2Y13 receptors, in transverse sections of the detrusor of control organ donors (panels B, F, J) 
and of patients with bladder outlet obstruction (BOO) due to benign prostate hyperplasia (BPH) (D, H, 
L). Black and white images are differential interference contrast (DIC) images. Data represent four 
individuals per group, including organ donors and men with BOO. Scale bars: 100 µm.  (B) Co-
localization experiments of the P2Y12 receptor and vesicular acetylcholine transporter (VAChT) 
immunoreactivity in human detrusor samples from control subjects bladder. A subset of P2Y12 
receptors (green staining) co-localizes with VAChT (red staining) on cholinergic nerve fibers. To 
facilitate visualization of small nerve fibers stained with VAChT images correspond to higher 
magnification intensity projections over Z axis of six confocal microscopy stacks. Scale bars: 50 µm. 
 
 
ATP acting via P2X2/3 heterodimers favours cholinergic hyperactivity in 
obstructed human detrusor strips    
As a consequence of deficits in the expression and activity of ecto-NTPDase 1 
and 2 ATP may accumulate in the detrusor of patients with BOO due to BPH 
compared to control individuals (Silva-Ramos et al., 2015a; see also Figure 14A this 
chapter). Using myographic recordings, it was demonstrated that ATP accumulated 
in the bladder contributes to increase detrusor responsiveness via the activation of 
overexpressed P2X1 receptors on smooth muscle fibers (Silva-Ramos et al., 2016b), 
but no studies were performed so far to investigate the role of ionotropic P2X 
receptors in the control of cholinergic neurotransmission and whether they interfere 
with the inhibitory control mediated by ADP (via P2Y12 receptor activation) on evoked 
[3H]ACh release from obstructed detrusor samples. 
The non-selective P2 receptors antagonist, PPADS (10 µM), decreased by 
43±6% (n=4, P<0.05) the evoked release of [3H]ACh in the detrusor of men with BOO 
due BPH, without affecting the transmitter release (6±8%, n=4) in control individuals 
(Figure 18). A similar trend was observed by blocking selectively P2X2/3 receptor 
heterodimers with TNP-ATP (10 nM). This drug was more effective in decreasing 
evoked [3H]ACh release in the detrusor of obstructed patients (43±16%, n=4) than in 
control organ donors (Figure 18). The selective P2X3 antagonist, A317491 (100 nM), 
attenuated the release of [3H]ACh from the detrusor by 20±2% (n=4) and 24±4% 
(n=5) in control individuals and in BOO patients, respectively (Figure 18). Results 
indicate that surplus ATP acting via P2X2/3 heterodimers favours cholinergic 
hyperactivity in obstructed human bladders.   
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Figure 18. Effects of PPADS (10 µM), A317491 (100 nM) and TNP-ATP (10 nM) on 
electrically evoked [3H]ACh release from urothelium-denuded detrusor strips from cadaveric organ 
donors (control) and men with bladder outflow obstruction (BOO) due benign prostatic hyperplasia 
(BPH). Drugs were applied 15 minutes before S2. The ordinates are changes in S2/S1 ratio compared 
to the S2/S1 ratio obtained without addition of any drug. *,**P<0.05 (unpaired Student’s t test with 
Welch’s correction) represents significant differences when compared with zero percent of change or 
with the effect of the same drug in control individuals, respectively. 
 
Tonic activation of ADP-sensitive inhibitory P2Y12 receptors restrains 
P2X2/3-mediated excitation of cholinergic nerves in obstructed detrusor 
samples 
Taking into consideration that the inhibitory P2Y12 receptor-mediated tonus 
increases in the detrusor of men with BOO due to BPH along with cholinergic 
hyperexcitation operated by surplus ATP accumulation via P2X2/3 heterodimers, we 
thought it was important to investigate the interplay between these two purinoceptors 
in the control of [3H]ACh release in the obstructed human bladder. Figure 19 shows 
that selective blockade of the P2Y12 receptor with AR-C66096 (100 nM) fully 
prevented (7±13%, n=4) the inhibitory effect of the P2X2/3 antagonist, TNP-ATP (10 
nM, -43±16 %, n=4) on evoked [3H]ACh release from detrusor strips of BOO patients. 
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Figure 19. Blockade of the P2Y12 receptor with AR-C66096 (100 nM) prevented the inhibitory 
effect of TNP-ATP (10 nM, a P2X2/3 receptor antagonist) on [3H]ACh release from stimulated detrusor 
strips of BOO patients. TNP-ATP (10 nM) was added 15 min before S2 and AR-C66096 (100 nM) was 
present throughout assay, including S1 and S2. The ordinates are changes in S2/S1 ratio compared to 
the S2/S1 ratio obtained without addition of any drug. Data are mean ± SD of four to six individuals. 
*,**P<0.05 (unpaired Student’s t test with Welch’s correction) represents significant differences when 
compared to the situation where no drugs were added to the incubation solution or to the effect of 
TNP-ATP in the absence of AR-C66096. 
 
DISCUSSION 
Mounting evidence indicate that deregulation of the purinergic signaling 
pathway is involved in urinary bladder disorders (review by Burnstock, 2014; Rapp et 
al., 2005), both in humans (Palea et al., 1993; Silva-Ramos et al., 2015a; Silva et al., 
2015) and in experimental animal models (Timóteo et al., 2014; Banks et al., 2006; 
Birder et al., 2006; Calvert et al., 2001). There is however gaps in our knowledge 
concerning the key purinergic players underlying urinary bladder disorders and how 
the information made available might contribute to the rehabilitation of the normal 
bladder function using drugs targeting the purinergic signaling pathway.  
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In a previous study, our group showed that impairment of ecto-NTPDases 
activity in detrusor strips from patients with BOO due BPH contributes to increase 
extracellular ATP content in the bladder leading to cholinergic hyperactivity, also 
because adenosine formation from released adenine nucleotides by ecto-
5’nucleotidase/CD73 and, subsequent, activation of prejunctional inhibitory A1 
receptors is deficient (Silva-Ramos et al., 2015a). Here, we add some information 
indicating that along with the dominant extracellular ATP catabolism by ecto-
NTPDase1/CD39 (also called ATP diphosphohydrolase or ecto-apyrase, EC 3.6.1.5) 
converting the nucleotide directly into AMP (Silva-Ramos et al., 2015a), ATP 
dephosphorylation into ADP by ecto-NTPDase2 (CD39L1, ATPase, EC 3.6.1.3) may 
also play a role when ecto-NTPDase1/CD39 is deficient or inhibited, as verified in the 
obstructed human detrusor. Localization of ecto-NTPDase2 on VAChT-positive 
cholinergic nerve terminals in the human detrusor indicates that ADP formation from 
released / accumulated ATP (Silva et al., 2015) may reach high enough levels to 
modulate cholinergic neurotransmission in obstructed human bladders. As a matter 
of fact, our results show here for the first time that endogenous ADP (and its 
enzymatically-stable analogue, ADPβS) downregulates [3H]ACh release from 
stimulated cholinergic nerves through the activation of prejunctional inhibitory P2Y12 
receptors in obstructed human bladders. Interestingly, these receptors co-localize 
with the P2Y1 receptor (another ADP-sensitive receptor) on smooth muscle fibers of 
the human detrusor, but only the P2Y12 receptor is upregulated in the detrusor of 
men with BOO due BPH.  
The kinetics of the extracellular ATP and ADP catabolism is 1.4 and 1.9 times 
slower in the detrusor of BOO patients than controls, respectively (Silva-Ramos et 
al., 2015a; this study). This difference is mainly attributed to decreases in ecto-
NTPDase1/CD39 expression and activity converting ATP and ADP directly into AMP, 
with the subsequent dephosphorylation of AMP to adenosine by ecto-
5’nucleotidase/CD73 in smooth muscle fibres. Minor changes were detected in the 
expression of ecto-NTPDase2 bound to VAChT-positive cholinergic nerve terminals, 
which might favour transient ADP accumulation at the detrusor cholinergic 
neuromuscular synapse of patients with BOO due BPH. This was hypothesized 
because ecto-NTPDase2 is a nucleoside triphosphatase hydrolyzing ATP 10-15 
times more efficiently than ADP (Matsuoka and Ohkubo, 2004). Conversely, 
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NTPDase3 seems to be absent from the human detrusor as demonstrated by the 
lack of immunoreactivity detected by confocal microscopy using a highly specific 
NTPDase3 antibody. A similar distribution pattern of ecto-NTPDases was found in 
the mouse bladder, where immunolocalization studies showed that ecto-
5nucleotidase/CD73 is present in detrusor smooth muscle fibers together with the 
ecto-NTPDase1/CD39 (Yu et al., 2011). The presence of ecto-NTPDase2 on VAChT-
positive cholinergic nerve terminals was also observed in the rat detrusor (Carneiro 
et al., 2014).  
The functional role of NTPDases 1 and 2 on evoked [3H]ACh release from the 
human bladder was evaluated using subtype-specific inhibitors. ARL67159 (100 µM) 
is a weak competitive inhibitor of NTPDase1, NTPDase3 and NPP1, without any 
effect on NTPDase2 and ecto-5’nucleotidase (Lévesque et al., 2007). ARL67159-
induced inhibition of [3H]ACh release from the human detrusor was much more 
evident in control individuals than in patients with BOO due to BPH. On the other 
hand, POM-1 (100 µM), a potent inhibitor of all NTPDases including NTPDase2 (Wall 
et al., 2008), had a similar inhibitory effect on transmitter release from both groups of 
individuals. The lack of the inhibitory effect of ARL67156 on evoked [3H]ACh release 
from obstructed human detrusor samples suggests that it might depend on transient 
ADP accumulation and activation of ADP-sensitive P2Y receptors on cholinergic 
nerve terminals.  
ADP is the endogenous agonist of P2Y1, P2Y12 and P2Y13 receptors, as it 
binds to these receptors with greater affinity than ATP (Palmer et al., 1998; 
Boeynaems et al., 2003; Marteau et al., 2003). At the P2Y1 receptor, ADP and its 
analogues tend to be full agonists (the EC50 of ADP is ~100 nM), whereas ATP may 
act as a partial agonist (Abbracchio et al., 2006). At the P2Y12 receptor, ADP and its 
analogues activate (the EC50 of ADP is ~100 nM) and 5’-triphosphate derivatives 
antagonize the receptor (Gachet and Hechler, 2005). At the P2Y13 receptor, both 
ADP and ATP might act as full agonists, with EC50 values of ~100 nM (Abbracchio et 
al., 2006). ADPβS is an enzymatically-stable ADP analogue and a potent agonist of 
P2Y1 (EC50 = 96 nM), P2Y12 (EC50 = 82 nM) (Jacobson et al., 2002) and P2Y13 (EC50 
= 42 nM) (Communi et al., 2001) receptor subtypes. In this study, we used ADPβS at 
a higher concentration (100 µM) in order to activate all ADP-sensitive receptors. 
ADPβS decreased [3H]ACh release from stimulated detrusor strips isolated from 
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BOO patients, but it was without effect in preparations from control individuals. The 
inhibitory effect of ADPβS was fully reverserd upon blocking the P2Y12 receptor with 
AR-C66096. On its own, blockage of the P2Y12 receptor facilitated [3H]ACh outflow 
from obstructed human detrusor samples, but the same did not occur when P2Y1 
(MRS2179) and P2Y13 (MRS2211) receptor antagonists were used instead of AR-
C66096. The presence of P2Y12 immunoreactivity on VAChT-positive cholinergic 
nerve fibers and the overexpression of this receptor in detrusor samples from BPH 
patients strengthen our theory that transient endogenous ADP accumulation in the 
bladder of BPH patients may partially control cholinergic hyperactivity through tonic 
activation of inhibitory P2Y12 receptors.  
The role of P2Y1 and P2Y12 receptors localized on smooth muscle fibers of the 
human detrusor remains to be determined. Activation of P2Y12 receptors in smooth 
muscle fibers induces bladder contractions in mice (Yu et al., 2014). The presence of 
P2Y1 receptors was also demonstrated by RT-PCR analysis in smooth muscle cells 
of the rat detrusor (Obara et al., 1998). Our group showed that P2Y1 receptors are 
localized in VAChT-positive cholinergic nerves of the rat urinary bladder, where they 
may counteract bladder overacitivty caused by activation of UDP-sensitive P2Y6 
receptors (Carneiro et al., 2014). We found no significant immunoreactivity against 
the P2Y13 receptor in the detrusor of both control individuals and BPH patients. The 
absence of P2Y13 receptors in the human bladder was confirmed by RT-PCR 
analysis (Communi et al., 2001). These findings indicate that the P2Y13 receptor is 
not involved in the control of cholinergic neurotransmission in the human detrusor, 
notwithstanding the fact that it has been involved in the presynaptic control of ACh 
release at the mouse motor endplate (Guarracino et al., 2016).     
In 1972, Burnstock showed for the first time that ATP contributes along with 
ACh to the contractile responses produced by parasympathetic nerve stimulation in 
the urinary bladder (Burnstock, 1972). Later on, it was demonstrated that ionotropic 
P2X receptors, namely P2X3 or/and P2X2/3 subtypes, mediate sensory functions in 
the lower urinary tract (Rapp et al., 2005; Ford et al., 2006). The voiding reflex 
involves ATP release from urothelial cells during bladder distension, which initiates 
the micturition reflex by activating P2X3 receptors on suburothelial sensory nerve 
afferents (Calvert et al., 2008). On the other hand, ATP also activates P2X1 
receptors located in the detrusor smooth muscle to initiate bladder contractions 
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during voiding (Burnstock, 1999; Cockayne et al., 2000). Accumulation of 
extracellular ATP has been reported in lower urinary tract disorders (Smith et al., 
2005), such as overactivity (Silva-Ramos et al., 2013) and obstructed (Silva et al., 
2015; Silva-Ramos et al., 2016a) bladders. Overexpression of the P2X3 receptor has 
also been documented in bladder disorders (Brady et al., 2004), including some 
types of neurogenic bladder overactivity. These changes are suggested to be 
responsible for unstable bladder activity (Rapp et al., 2005; Ruggieri, 2006). Due to 
the role of these receptors in the pathophysiology of overactive bladder syndromes, 
several drugs have been tested in models of rat bladder disorders. For instance, the 
selective P2X3 receptor antagonist, A317491, has been proposed for the treatment 
of interstitial cystitis (Ito et al., 2008).  
In this study, we also decided to evaluate the effect of subtype-specifc P2X 
receptor antagonists on evoked [3H]ACh release from the detrusor of control 
individuals and from patients with BOO due to BPH. To this end, we used 
pyridoxaphosphate-6-azophenyl-29.59-disulfonic acid (PPADS, 10 µM, a non-
selective P2 antagonist receptor), A317491 (100 nM, a P2X3 receptor antagonist), 
and TNP-ATP (10 nM, a preferential P2X2/3 receptor antagonist); the latter 
compound has nanomolar affinity for fast desensitizing P2X1, P2X2/3 and P2X3 
receptors (Virginio et al., 1998; Jacobson et al., 2002; Jarvis et al., 2010). Both, 
PPADS and TNP-ATP, inhibited (by about 40%) [3H]ACh release from detrusor strips 
of men with BOO due to BPH, but the two drugs had smaller inhibitory effects in 
control preparations. The selective P2X3 receptor antagonists, A317491 (Jarvis et 
al., 2002), produced the smallest inhibitory effect on evoked [3H]ACh release of the 
three tested antagonists. Taken together these results suggest that endogenous ATP 
facilitates cholinergic hyperactivity in obstructed human detrusor samples through the 
activation of TNP-ATP-sensitive excitatory P2X2/3 receptors. 
Numerous studies demonstrate (1) the existence of functional interactions 
between co-localized ionotropic P2X and metabotropic P2Y receptors, and that (2) 
the crosstalk between P2 purinoceptor subtypes may be affected under pathological 
conditions (James and Butt, 2002; Birder et al., 2004; Tempest et al., 2004). A recent 
study from our group showed that activation of metabotropic P2Y6 and ionotropic 
P2X3 receptors cooperate to increase nonneuronal ATP and [3H]ACh release from 
urothelial strips with the lamina propria attached isolated from control organ donors 
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(Silva et al., 2015). In the urinary bladder ionotropic P2X3 receptors can function as 
homomultimeric P2X3 and heteromultimeric P2X2/3 channels (Cockayne et al., 
2005). Our data show here for the first time that [3H]ACh release from stimulated 
detrusor samples of patients with BOO due to BPH is modulated both positively and 
negatively by P2X2/3 heterodimers and by ADP-sensitive inhibitory P2Y12 receptors, 
respectively. While the ATP-mediated excitation of cholinergic nerve fibers via 
P2X2/3 receptors is already verified in control individuals, the superfluous [3H]ACh 
release observed in obstructed detrusor samples may be (at least partially) 
downmodulated by the enzymatic breakdown of ATP into ADP by NTPDase2 and, 
subsequent, activation of prejunctional inhibitory P2Y12 receptors (see above). 
Although this sequence of events seems to be highly probable, we decided to test 
the functional repercussions of the interplay between these two purinoceptor 
subtypes on cholinergic hyperactivity observed in the detrusor of BPH patients. Data 
show that the inhibitory role of the P2X2/3 antagonist, TNP-ATP, on evoked [3H]ACh 
release was fully prevented by bloking activation of the P2Y12 receptor with AR-
C66096. Thus, results strongly indicate that tonic activation of ADP-sensitive 
inhibitory P2Y12 receptors restrains the P2X2/3-mediated excitation of cholinergic 
nerves in obstructed detrusor samples.  
 
CONCLUSION 
In conclusion, data suggest that drugs that favour ADP accumulation in the 
cholinergic neuromuscular synapse of the human detrusor and/or that promote 
activation of overexpressed inhibitory P2Y12 receptors on cholinergic nerve fibers 
may be useful to counteract OAB symptoms associated with BOO due to BPH. 
Likewise, blockade of fast desensitizing homomultimeric P2X3 and heteromultimeric 
P2X2/3 ionotropic receptors may also be used to cease bladder overactivity by acting 
on both sides (sensory and motor, respectively) of the micturition reflex. 
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ABSTRACT 
The direct detrusor relaxant effect of β3-adrenoceptor agonists as a primary 
mechanism to improve overactive bladder symptoms has been questioned. Among 
other targets, activation of β3-adrenoceptors down-modulate nerve-evoked 
acetylcholine (ACh) release, but there is insufficient evidence for the presence of 
these receptors on bladder cholinergic nerve terminals. Our hypothesis is that 
adenosine formed from the catabolism of cyclic AMP in the detrusor may act as a 
retrograde messenger via prejunctional A1 receptors to explain inhibition of 
cholinergic activity by β3-adrenoceptors. Isoprenaline (1 µM) decreased [3H]ACh 
release from stimulated (10 Hz, 200 pulses) human (-47±5%) and rat (-38±1%) 
detrusor strips. Mirabegron (0.1 µM, -53±8%) and C316,243 (1 µM, -37±7%) 
mimicked isoprenaline (1 µM) inhibition and their effects were prevented by blocking 
β3-adrenoceptors with L748,337 (30 nM) and SR59230A (100 nM), respectively in 
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human and rat detrusor. Mirabegron and isoprenaline increased extracellular 
adenosine in the detrusor. Blockage of A1 receptors with 1,3-dipropyl-8-
cyclopentylxantine (DPCPX, 100 nM) or the equilibrative nucleoside transporters 
(ENT) with dipyridamole (0.5  µM) prevented mirabegron and isoprenaline inhibitory 
effects. Dipyridamole prevented isoprenaline-induced adenosine outflow from the rat 
detrusor and this effect was mimicked by the ENT1 inhibitor, S-(4-nitrobenzyl)-6-
thioinosine (NBTI, 30 µM). Cystometry recordings in anaesthetized rats 
demonstrated that SR59230A, DPCPX, dipyridamole and NBTI reversed the 
decrease in the voiding frequency caused by isoprenaline (0.1 – 1000 nM). Data 
suggest that inhibition of cholinergic neurotransmission by β3-adrenoceptors results 
from adenosine release via equilibrative nucleoside transporters and prejunctional A1 
receptors stimulation in human and rat urinary bladder. 
 
Keywords: Human urinary bladder; Adenosine release; Acetylcholine release; 
Adenosine A1 receptors; β3-adrenoceptor. 
 
INTRODUCTION 
The clinical success of β3-adrenoceptor agonists, like mirabegron, for the 
management of overactive bladder (OAB) syndrome has generated a great interest 
in their mechanisms of action (Andersson, 2016; Thiagamoorthy et al., 2015). 
Stimulation of β3-adrenoceptors reduce basal bladder tension (decreasing 
spontaneous microcontractions in vitro and non-voiding contractions in vivo) and 
relax bladder strips precontracted with carbachol or KCl (Igawa et al., 1999; Takeda 
et al., 1999; Wuest et al., 2009). Whether the direct relaxant effect of β3-adrenoceptor 
agonists on detrusor smooth muscle is the primary underlying mechanism to improve 
OAB symptoms has increasingly been questioned (Gillespie et al., 2015; Igawa and 
Michel, 2013; Persyn et al., 2016). The key argument is that the peak plasma levels 
of mirabegron when administered in therapeutic (50 mg daily) doses (83 – 167 nM) 
are below its potency (EC50 ~1-3 µM) to relax detrusor smooth muscle strips 
(reviewed in Michel and Korstanje, 2016). Supporting the view that mechanisms 
other than direct effects on detrusor muscle might contribute, mirabegron dose-
dependently decreases the activity of Aδ- and C-fibers of primary nerve afferents in 
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response to bladder filling (Aizawa et al., 2015) and activation of β3-adrenoceptors 
inhibits neurogenic contractions of rat and human urinary bladder samples (Rouget et 
al., 2014). 
Recent evidence suggest that activation of β3-adrenoceptors down-modulates 
nerve-evoked acetylcholine (ACh) release in the human bladder (D’Agostino et al., 
2015). The existence of β3-adrenoceptors in the human detrusor has been postulated 
in 1998 and their expression at the mRNA levels was confirmed later on by RT-PCR 
(Igawa et al., 1998; Igawa et al., 1999). Nomiya and Yamaguchi (2003) claimed that 
the β3-adrenoceptor accounts for more than 95% of all β-adrenoceptor mRNA in the 
human bladder (Nomiya and Yamaguchi, 2003; reviewed in Michel and Vryday, 
2006), but such difference has been questioned in a more recent quantitative 
genomic resource describing proteomes and transcriptomes across diverse tissues 
and organs of the human body (Uhlén et al., 2015). Immunolocalization studies 
showed that β3-adrenoceptors were present in the urothelium, interstitial cells and 
smooth muscle fibers of human (Limberg et al., 2010; Otsuka et al., 2013) and rat 
(Kullmann et al., 2009) bladders, but there is contradictory evidence for these 
receptors being expressed on cholinergic nerve terminals (Coelho et al., 2017; 
Otsuka et al., 2008). Therefore, the mechanism by which β3-adrenoceptors operate 
inhibition of evoked ACh release from cholinergic nerve terminals in the urinary 
bladder remains unknown. 
On the molecular level, β3-adrenoceptors couple mainly to stimulatory G 
proteins (Gs), thereby activating adenylyl cyclase to generate intracellular cyclic 
AMP. Besides its multiple downstream intracellular effects, which may involve 
modulation of potassium channels to cause hyperpolarization of the plasma 
membrane (Igawa and Michel, 2013), cyclic AMP may be degraded into AMP and 
adenosine intracellularly or can be actively pumped out from cells contributing to 
extracellular adenosine formation, in a process that depends on the sequential 
activity of ecto-nucleotide pyrophosphatase/phosphodiesterase 1 (ecto-PDE, alias 
ENPP1) and ecto-5’-nucleotidase/CD73 (see e.g. ref. Chiavegatti et al., 2008; Sassi 
et al., 2014). This raises the intriguing question of whether the urinary bladder, like 
many other tissues, provides its own source of extracellular adenosine originated 
from the catabolism of intracellular cyclic AMP and if such a mechanism is 
responsible for the β3-adrenoceptor inhibitory control of cholinergic 
neurotransmission in the human detrusor. 
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Adenosine directly relaxes pre-contracted urinary bladder detrusor strips in 
different species (Acevedo et al., 1992; Brown et al., 1979; Burnstock et al., 1978; 
King et al., 1997; Nicholls et al., 1992), including humans (Rubinstein et al., 1998). 
Notwithstanding this, we recently showed that adenosine-induced relaxation of 
detrusor contractions requires high (millimolar) concentrations of the nucleoside 
compared to those require to decrease nerve-evoked ACh release from human 
detrusor strips (Silva-Ramos et al., 2015). Involvement of the A1 receptor in the 
inhibitory action of adenosine on transmitter release from the stimulated human 
detrusor was confirmed both pharmacologically, using the selective A1 receptor 
antagonist 1,3-dipropyl-8-cyclopentylxanthine (DPCPX), and by confocal microscopy 
showing that the A1 receptor co-localizes with VAChT-immunoreactivity on 
cholinergic nerve terminals of the humans urinary bladder. Taking this into account, 
we hypothesized that adenosine formed from the catabolism of cyclic AMP in the 
detrusor may act as a retrograde messenger via pre-junctional A1 receptors to 
explain the inhibitory control of cholinergic activity by β3-adrenoceptors in the humans 
and rat urinary bladder. We addressed this question by doing in vitro experiments 
using human and rat isolated urinary bladder strips to measure the release of 
[3H]ACh and adenosine, to study the kinetics of the extracellular cyclic AMP 
catabolism by HPLC, and to evaluate the tissue distribution of β3 and A1 receptors in 
the urinary bladder by immunofluorescence confocal microscopy. In addition, we 
tested whether a similar phenomenon occurs to control the sensory bladder drive of 
the micturition cycle by β3-adrenoceptors. To this end, we evaluated the urodynamic 
effects of selective β3- and A1-receptor antagonists on isoprenaline-induced inhibition 
of bladder activity caused by instillation of this drug into the bladder lumen of 
urethane-anaesthetized rats. 
 
MATERIAL AND METHODS 
Animals 
Animal care and experimental procedures were in accordance with the 
guidelines prepared by Committee for the Update of the Guide for the Care and Use 
of Laboratory Animals (National Research Council, USA) and followed the European 
Communities Council Directive (86/609/EEC). All studies involving animals are 
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reported in accordance with the ARRIVE guidelines for reporting experiments 
involving animals. A total of 50 animals were used in the experiments described here. 
Male rats (Wistar, 200-300 g; Charler River, Barcelona, Spain) were kept at a 
constant temperature (21ºC) and a regular light (06:30-19:30 h) – dark (19:30-06:30 
h) cycle, with food and water provided al libitium. 
 
Human bladder samples 
Samples of the human detrusor were collected from the bladder dome of ten 
male organ donors (46±4 years of age) at the time of harvesting organs for 
transplantation. Collected samples were immediately placed at 4-6ºC in mannitol 
transplantation solution at 400 mOsm/kg (M-400) not supplemented with ATP or 
adenosine (230 mM mannitol, 15 mM KH2PO4, 43 mM K2HPO4.3H2O, 15 mM KCl, 
and 10 mM NaHCO3, pH 7.4) and transported to the laboratory. Experiments were 
performed within the first 24 h after collection, which corresponds to the tissue 
viability window. This study and all its procedures were approved by the Ethics 
Committees of CHP and ICBAS-UP and were authorized by the National 
Transplantation Committee. Regarding deceased organ donation, the legal frame 
work allows the “Presumed Consent” stating that residents in Portugal are consenting 
donors for transplantation and research unless the individual previously objected 
during his or her life. The investigation conforms to the principles outlined in The 
Code of ethics of the World Medical Association (Declaration of Helsinki). 
 
Quantification of [3H]ACh release 
The experiments were performed in isolated detrusor muscle strips without the 
mucosa of both human and rat urinary bladders. The mucosa was dissected out 
either by blunt dissection through cleavage at the lamina propria or by gently rubbing 
the urothelium with a cotton wool swab in human and rat bladder samples, 
respectively (Carneiro et al., 2014; Silva-Ramos et al., 2015a). Full thickness isolated 
detrusor muscle strips (3 mm width, 5 mm length; weighting 6.32 ± 0.25 mg (human) 
and 5.91 ± 0.20 mg (rat)) were mounted in 365 µL capacity chambers of a Brandel 
SF-12 automated superfusion system (Valley Internationnal Corp., Austin, TX, USA) 
heated at 37ºC. Then, the preparations were continuously superfused with gassed 
(95% O2 and 5% CO2) Tyrode’s solution (pH 7.4) containing (mM): NaCl 137, KCL 
2.7, CaCl2 1.8, MgCl2 1, NaH2PO4 0.4, NaHCO3 11.9, glucose 11.2 and choline 
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0.001. After a 30 min equilibration period, cholinergic neurons were loaded during 40 
min with 1 µM [3H]choline (specific activity 5 µCi nmol-1) under electrical field 
stimulation (1 Hz frequency, 0.2 ms pulse width, 75 mA) using two platinum-made 
grid electrodes placed above and below the muscle strip (transmural EFS 
stimulation). Following loading, the washout superfusion (1 ml/min) of the 
preparations was performed during 120 min with Tyrode’s solution supplemented 
with the choline uptake inhibitor, hemicholinium-3 (10 µM). Tritium outflow was 
evaluated by liquid scintillation spectrometry (TriCarb2900TR, Perkin Elmer, and 
Boston, USA; % counting efficiency: 56 ± 2%) after appropriate background 
subtraction, using 1 ml bath samples automatically collected every 1 min using the 
SF-12 suprafusion system. [3H]ACh release was evoked by two periods of EFS (S1 
and S2), each consisting of 200 squares wave pulses of 0.2 ms duration delivered at 
10-Hz frequency. Test drugs were added 6 min before S2 and were present up to the 
end of the experiments. The evoked [3H]ACh release was calculated by subtraction 
the basal tritium outflow from the total tritium outflow during the stimulation period 
(see e.g. Carneiro et al., 2014; Silva-Ramos et al., 2015a). In control conditions, 
S2/S1 ratios were 0.99±0.04 (n=6) and 0.96±0.02 (n=4) in human and rat detrusor 
samples, respectively. 
 
Measurement of adenosine release 
The procedures used to measure the release of adenine nucleosides 
(adenosine and inosine) were previously described (see e.g. Correia-de-Sá et al., 
2006; Vieira et al., 2014). Experiments were performed in isolated rat detrusor strips 
without the mucosa using and automated perfusion system for sample collecting for 
given time periods, therefore improving the efficacy of HPLC (with diode array 
detection). After a 30-min equilibration period, the preparations were incubated with 
2.8 mL gassed Tyrode’s solution, which was automatically changed every 15 min by 
emptying and refilling the organ bath with the solution in use. In these experiments, 
samples retained for analysis were collected 15, 30 and 45 min after starting the 
experimental protocol (zero time). Isoprenaline (1 µM) or mirabegron (0.1 µM) were 
added to the incubation solution after the first collection (Basal, 15 min) and were 
kept in contract with the preparations at least for 15 min (Drug, 30 min) before 
starting electrical field stimulation (Drug + EFS, 45 min), which consisted in 3000 
square wave pulses of 1 ms duration delivered at a 10-Hz frequency. Bath aliquots 
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(50-250 µl) were frozen in liquid nitrogen immediately after collection, stored at -20ºC 
(the enzymes are stable for at least 4 weeks) and analyzed within 1 week of 
collection by HPLC with diode array detection (Finnigan Thermo Fisher Scientific 
System LC/DAD, equipped with an Accela Pump coupled to an Accela Autosample, 
a diode array detector and an Accela PDA running the X-Calibur software 
chromatography manager). Chromatographic separation was carried out through a 
Hypersil GOLD C18 column (5 µM, 2.1 mm x 150 mm) equipped with a guard column 
(5 µm, 2.1 mm x 1 mm) using an elution gradient composed of ammonium acetate (5 
mM, with a pH of 6 adjusted with acetic acid) and methanol. During the procedure the 
flow rate was set at 200 µl per min and the column temperature was maintained at 
20ºC. The autosampler was set at 4ºC and 50 µl of standard or sample solution was 
injected, in duplicate, for each HPLC analysis. In order to obtain chromatograms and 
quantitative analysis with maximal sensibility, the diode array detection wavelength 
was set at 259 nm for adenosine and 248 nm for inosine. 
 
Kinetics of cyclic AMP extracellular catabolism by HPLC 
For the kinetic experiments of the extracellular catabolism of cyclic AMP and 
adenosine formation, human and rat detrusor strips without the mucosa were 
mounted in a 2-ml organ bath. All experiments were performed at 37ºC. Preparations 
were superfused with gassed (95% O2 and 5% CO2) Tyrode’s solution. After 
equilibrium, the preparations were incubated with 30 µM of cyclic AMP (zero time). 
Samples of 75 µl were collected from the organ bath at different times up to 45 min 
for HPLC (with UV detection) analysis (LaChrome Elite, Merck, Germany) of the 
variation of substrate disappearance and product formation (Correia-de-Sá et al., 
2006; Duarte-Araújo et al., 2004; Silva-Ramos et al., 2015a; Vieira et al., 2014). The 
stoichiometry of cyclic AMP conversion into their metabolites was kept unaltered (30 
µM). 
 
Immunofluorescence staining and confocal microscopy observation 
Human and rat detrusor strips without the mucosa were stretched in all 
directions and pinned onto a Petri dish coated with Sygard®. The strips were then 
fixed in PLP solution (paraformaldehyde 2%, lysine 0.075 M, sodium phosphate 
0.037 M, sodium periodate 0.01 M) for 16 h at 4ºC. Sixteen-micron sections were 
incubated with selected primary antibodies (table 9) diluted in an incubation buffer 
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(foetal bovine serum 5%, serum albumin 1%, Triton X-100 0.3% in PBS), at 4ºC, for 
16 h. For double immunostaining, antibodies were combined before application to 
tissue samples. After washing away unbound primary antibody, the sections were 
incubated with secondary antibodies (table 9) in the dark for 2 hours, at room 
temperature. Negative controls were carried out by replacing the primary antibodies 
with non-immune serum; cross-reactivity for the secondary antibodies was tested in 
control experiments in which primary antibodies were omitted. Finally, tissue samples 
were mounted on optical-quality glass slides using VectaShield as antifade mounting 
media (VectorLabs) and stored in the dark at 4ºC. Observations were performed and 
analyzed with a laser-scanning confocal microscope (Olympus FluoView, FV1000, 
Tokyo, Japan). 
 
Table 9. Primary and secondary antibodies used to stain human detrusor strips. 
Antigen Code Host Dilution Supplier 
Primary antibodies: 
Anti-VAChT SAB5200240 Mouse 1:50 Sigma 
Anti-A1 receptor Ab75177 Rabbit 1:250 Abcam 
Anti-β3 receptor AAR-017 Rabbit 1:50 Alomone 
Anti-β3 receptor MC-4198 Rabbit 1:50 MBL International 
Anti-β3 receptor SC-1473 Goat 1:200 Santa Cruz 
Anti-ENT1 ANT-051 Rabbit 1:50 Alomone 
Anti-ENT2 ANT-052 Rabbit 1:50 Alomone 
Anti-β-tubulin Ab6046 Rabbit 1:2500 Abcam 
Secondary antibodies:    
Alexa Fluor 488 anti-rabbit A-21206 Donkey 1:1000 Molecular Probes® 
Alexa Fluor 633 anti-ms A-21050 Goat 1:1000 Molecular Probes 
Alexa Fluor 568 anti-gt A11057 Donkey 1:1000 Molecular Probes 
IgG HRP anti-rb Ab98503 Donkey 1:70000 Abcam 
IgG HRP anti-gt Ab97120 Donkey 1:25000 Abcam 
 
 
Western blot analysis 
Human and rat detrusor strips without the mucosa were homogenized in radio-
immunoprecipitation assay buffer (Tris-HCl 25 mM (pH 7.6), NaCl 150 mM, sodium 
deoxycholate 1%, Triton-X-100 1%, sodium dodecyl sulfate (SDS) 0.1%, EDTA 5 
mM) plus a protease inhibitor cocktail. Protein content of the samples was evaluated 
using the BCA protein assay kit according to the manufacturer’s instructions (Pierce, 
Rockford, IL, USA). Samples were solubilized in SDS reducing buffer (Tris-HCl 125 
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mM (pH 6.8), SDS 4%, bromophenol blue 0.005%, glycerol 20%, and 2-
mercaptoethanol 5%) at 70ºC for 10 min, subjected to electrophoresis in 10% SDS-
polyacrylamide gels and electrotransferred onto polyvinylidene difluoride (PVDF) 
membranes (MilliPore, MA, USA). Protein loads were 75 and 150 µg. The 
membranes were, then blocked in Tris-buffered saline (in mM: Tris-HCl 10 (pH 7.6), 
NaCl 150) containing Tween-20 0.05% and bovine serum albumin (BSA) 5% and, 
subsequently, incubated with two distinct anti-β3 adrenoceptor primary antibodies 
either from MBL International Corporation (host species: rabbit; 1:200, MC-4198, also 
known as LS-A4198, Woburn MA, USA) or from Santa Cruz (host species: goat, 
1:200, SC-1473, Dallas TX, USA) in the above blocking buffer overnight at 4ºC. 
Membranes were washed three times for 10 min in TBS/Tween-20 and incubated 
with horseradish peroxidase-conjugated secondary antibody (1:25000; Abcam, 
Cambridge, UK) for 1 h at room temperature. For normalization purpose, membranes 
were incubated with the mouse anti-glyceraldehyde 3-phosphate dehydrogenase 
(GAPDH, EC 1.2.1.12) primary antibody from Santa Cruz (1:200, SC-32233, Dallas, 
TX, USA) following the procedures described above. Membranes were washed three 
times for 10 min and the antigen-antibody complexes were visualized with the 
Immun-Star WesternC Chemiluminescent Kit using the ChemiDoc MP imaging 
system (Bio-Rad Laboratories, Hercules, CA, USA). 
 
In vivo cystometry recordings 
The experiments were carried out in urethane-anaesthetized rats (1.0-1.2 
g/kg), spontaneously breathing. Core body temperature was kept between 36ºC and 
38ºC with the help of a heating pad controlled by a thermosensor connected to a 
rectal probe. A catheter connected to an injection pump was inserted into the left 
jugular vein to permit saline infusion (4 ml/h/kg) and intravenous drugs application. 
After exposing the urinary bladder through a median abdominal incision, a three-
barrel catheter was inserted through its dome. One barrel, was connected to an 
automate perfusion pump for saline and/or drugs infusion; a second barrel, was 
attached to a pressure transducer for continuous monitoring of intravesical pressure; 
the third barrel was used either to drain or to close the bladder circuit in order to 
initiate the micturition reflex. The bladder pressure was continuously monitoring of 
intravesical pressure; a second barrel, was attached to a pressure transducer for 
continuous monitoring of intravesical pressure; the third barrel was used either to 
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drain or to close the bladder circuit in order to initiate the micturition reflex. The 
bladder pressure was continuously monitored on a computer screen with a PowerLab 
data acquisition system (Chart 5, version 4.2 software; AD Instruments, USA), which 
was also used to record hemodynamic and respiratory parameters in the 
anaesthetized rat. After surgical preparation, a 60-min equilibration period was 
undertaken during which saline was infused into the urinary bladder at 0.04 ml/min 
and allowed to freely drain out of the bladder (open circuit). The micturition reflex was 
initiated by closing the draining barrel while keeping intravesical infusion of saline at 
a constant flow rate (0.04 ml/min), which is within the range used in previous studies 
to obtained stable micturition cycles during continuous cystometrograms in 
anaesthetized rat (Carneiro et al., 2014; Honda et al., 2012; Timóteo et al., 2014). 
The flow rate was 2 to 4-fold higher than the normal urinary debit in experimental rats 
(15-30 ml/d) and compared to the conditions used in standard filling cystometry 
(urodynamic test) in humans. Voiding contractions were assumed as large-amplitude 
rhythmic bladder contractions accompanied by urine draining through the urethra 
when bladder pressure reached a certain threshold. The intercontraction interval (ICI, 
min) and the pressure threshold (PTh, cm of H2O) that is required to initiate the 
voiding reflex are normally associated with the sensitive component of the micturition 
reflex (filling phase); conversely, the amplitude (A, cm of H2O) and the duration (∆t, 
sec) of the voiding contractions are mostly associated with the motor component of 
the micturition reflex (emptying phase). For the sake of clarity, the results presented 
in this study will consider the percent variation of ICI values as compared to the 
control situation achieved after six consecutive voiding contractions of similar 
amplitude. Test drugs were applied either into the bladder lumen (by changing the 
syringue connected to the automate perfusion pump, 0.04 ml/min) or intravenously 
through the catheter inserted into the left jugular vein. 
 
Drugs and Solutions 
Adenosine 3’,5’-cyclic monophosphate sodium salt monohydrate (3’,5’cyclic 
AMP), hemicholinium-3, 1.3-dipropyl-8-cyclopentylxanthine (DPCPX), choline 
chloride, paraformaldehyde (prills), lysine, sodium periodate, anhydrous glycerol, 
fetal bovine, fenoterol hydrobromide, (±)-1-[2,3-(dihydro-7-methyl-1H-inden-4-yl]-3-
[(1-methylethyl)amino]-2-butanol hydrochloride (ICI 118,551), 7β-acetoxy-8,13-
epoxy-1α,6β,9α-trihydroxylabd-14-en-11-one (Forskolin, FSK), S-(p-nitrobenzyl)-6-
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thioinosine (NBTI) were obtained from Sigma (St Louis, MO, USA); isoproterenol 
hydrochloride (Isoprenaline), 5-[(2R)-2-[[(2R)-2-(3-chlorophenyl)-2-
hydroxyethyl]amino]propyl]-1,3-benzodioxole-2,2-dicarboxylic acid disodium salt 
(CL316,230A), 1-(2-ethylphenoxy)-3-[[(1S)-1,2,3,4-tetrahydro-1-naphthalenyl]amino]-
(2S)-2-propanol hydrochloride (SR59230A hydrochloride), NG-nitro-L-arginine methyl 
ester (L-NAME) hydrochloride, 4-(3-(cyclopentylox)-4-methoxyphenyl)pyrrolidin-2-one 
(Rolipram) were obtained from Tocris Bioscience (Bristol, UK); N-[[3-[(2S)-2-Hydroxy-
3-[[2-[4-[(phenylsulfonyl)amino]phenyl]ethyl]amino]propoxy]phenyl] methyl]-
acetamine (L-748,337) was obtained from Santa Cruz (Dallas, USA); mirabegron 
was obtained from Selleckchem.com (Houston, USA); dipyridamole was obtained 
from Boehringer Ingelheim (Germany); [methyl-3H] choline chloride (ethanol solution, 
80.6 Ci mmol-1) was obtained from PerkinElmer (Boston, USA); serum albumin, 
Triton X-100 were obtained from Merck (Darmstadt, Germany). DPCPX was 
dissolved in a 5 mM stock solution in 99 % dimethylsulfoxide (DMSO) + 1% NaOH 1 
M (v/v). Mirabegron, FSK and NBTI were dissolved in DMSO, respectively. Other 
drugs were prepared in Tyrode’s solution. All stock solutions were stored as frozen 
aliquots at -20ºC. Dilutions of these stock solutions were made daily and appropriate 
solvent controls were done. No statistical differences between control experiments, 
made in the absence or in the presence of the solvents at the maximal 
concentrations used (0.5% v/v), were observed. 
 
Presentation of data and statistical analysis 
Results are expressed as mean ± SD, with n indicating the number of 
individuals used for a particular set of experiments. Only one experimental procedure 
(e.g. agonist in the absence and in the presence of the antagonist) was performed 
per individual. Statistical analysis of data was carried out using Graph Pad Prism 
6.04 for Windows software (La Jolla, USA). Paired and unpaired Student’s t-test with 
Welch’s correction was used for statistical analysis when parametric data was 
considered. One-way analysis of variance (ANOVA) followed by the Dunnett’s post 
test was used for multiple comparisons. P<0.05 (two-tailed) values were considered 
statistically significant. 
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RESULTS 
Immunolocalization of β3-adrenoceptors and adenosine A1 receptors in 
the human detrusor 
The presence of β3-adrenoceptors in the human detrusor was demonstrated 
by immunofluorescence confocal microscopy using three distinct commercially 
available antibodies (Figure 20A). The antibody from Alomone Labs (AAR-007) is 
directed against a 13 amino acid peptide if the second extracellular loop of the 
mouse β3-adrenoceptor, which is 12/13 and 11/13 identical in the rat and human 
receptors, respectively. The antibody from MBL International Corporation (MC-4198, 
also known as LS-A4198) was raised against a synthetic 20 amino acid peptide from 
the N-terminal domain of the human β3-adrenoceptor, which showed no homology 
with any other human protein as determined by BLAST (Basic Local Alignment 
Search Tool) analysis. The MC-4198 antibody was successfully been used to detect 
β3-adrenoceptors by immunohistochemistry in human (Limberg et al., 2010) and rat 
(Kullmann et al., 2009) bladders. The third antibody from Santa Cruz Biotecnology 
Inc (SC-1472) was raised against a peptide mapping the C-terminus of the human 
β3-adrenoceptor. Concordant staining of human tissues with two or more antibodies 
(e.g. MC-4198 and SC-1472) has been proposed to provide the most convincing 
evidence for β3-adrenoceptor labeling in immunohistochemistry studies (Cernecka et 
al., 2012).  
Our data show that β3-adrenoceptors are expressed on smooth muscle fibers 
of the human (Figure 20A) and rat (Figure 20B) detrusor, although staining was also 
observed in cells located in the urothelium and sub-urothelial layer of the human 
bladder (Figure 20A, bottom micrographs) (cf. Kullmann et al., 2009; Limberg et al., 
2010; Otsuka et al., 2008). In contrast to the predominant diffuse muscular pattern of 
the β3-adrenoceptor immunostaining obtained concordantly with all tested antibodies 
(AAR-017, MC-4198 and SC-1472), the adenosine receptor co-localizes with the 
vesicular ACh transporter (VAChT) on bladder cholinergic nerve terminals (cf. Silva-
Ramos et al., 2015a). 
Using higher magnification images (right hand-side panels) we failed to co-
localize β3-adrenoceptors with VAChT immunostaining, thus suggesting that these 
receptors are not expressed on cholinergic nerve terminals (see also Otsuka et al., 
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2013). The presence of adenosine A1 receptor immunoreactivity was also abundantly 
detected in the urothelium of the human bladder (Figure 20A, bottom micrographs). 
Figure 20. (A) Immunolocalization of β3 and A1 receptors in transverse sections of the human 
detrusor by confocal microscopy. Three distinct β3 antibodies, AAR-017, MC-4198 and SC-1473, were 
used as indicated. A similar staining pattern was obtained for all antibodies showing that β3-
adrenoceptors are diffusely distributed among smooth muscle fibers, but are no present on cholinergic 
nerve fibers stained with the vesicular ACh transporter (VAChT); this aspect is indicated by the open 
arrowheads in the higher magnification image shown on the right hand-side panel. The uppermost 
panel shows that the adenosine A1 receptor is predominantly expressed on VAChT-positive 
cholinergic nerve terminals of the human detrusor; co-localization of A1 (green) and VAChT (red) 
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immunofluorescence is identified by the yellow staining (closed arrowheads) in the high magnification 
image shown in the right hand-side panel. Nuclei are stained with DAPI (blue). Purple staining 
corresponds to collagen autofluorescence emitting in all channels, including the 543 nm laser channel 
(with no secondary antibody, see e.g. Otsuka et al., 2008). Low magnification images to include the 
urothelium and suburothelial layers are shown in the bottom panel. (B) Comparison of the 
immunofluorescence staining pattern of transverse sections of the human and rat detrusor using the 
anti-β3 antibody from Alomone (AAR-017). Images are representative or four different individuals. 
Differential interference contrast (DIC) images are shown for comparison. Scale bar = 50 µm. (C) 
Shown are representative immunoblots of the β3-adrenoceptor in detrusor homogenates of two 
different male human subjects (BH1 and BH2) and one rat (BR1) run in parallel using antibodies 
directed to epitopes localized in the N- (MC-4198) and C- (SC-1473) terminus of the human β3-
adrenoceptor. Please note that  human detrusor homogenates express a prominent band at 56-59 
kDa that is compatible with the predicted size of a glycosylated form of the β3-adrenoceptor; no band 
was detected with the MC-4198 in rat detrusor homogenates, since this antibody was specifically 
raised against the human β3-adrenoceptor. The highly conserved GAPDH enzyme (EC 1.2.1.12, 
MW~37 kDa) was used as a reference protein. Gels were loaded with 150 µg or protein. Host species 
for antibody production were rabbit (rb), mouse (ms) and goat (gt). 
 
 
Moreover, western blot analysis confirmed that the human detrusor expresses 
the β3-adrenoceptor given to the fact that both SC-1472 and MC-4198 antibodies 
detected a major band with an apparent size of 56-59 kDa that is compatible with a 
glycosylated from of the human β3-adrenoceptor (Figure 20C). Weaker bands, 
including one at the theoretical molecular mass (~44kDa) of the β3-adrenoceptor 
based on its amino acid content, were also found in human, but not in rat, detrusor 
homogenates (Figure 20C). The lack of cross reactivity with the rat detrusor was 
anticipated as both, SC-1472 and MC-4198, antibodies were raised specifically 
against the human β3-adrenoceptor. Data agree with previous findings using CHO 
stably transfected to express the human β3-adrenoceptor, where SC-1472 was one 
of the most convincing antibodies to use in immunoblotting tests (Cernecka et al., 
2012). 
 
Stimulation of β3-adrenoceptors in human and rat urinary bladders 
decrease evoked [3H]ACh release depending on the activation of inhibitory 
adenosine A1 receptors 
Figure 21A shows that the β-adrenoceptor agonist, isoprenaline (1 µM), 
decreased by 47 ± 5% (n=6) the release of [3H]ACh evoked by electrical field 
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stimulation (10 Hz, 200 pulses) of the human detrusor; these results are in 
agreement with the study of D’Agostino et al. (D’Agostino et al., 2015). The inhibitory 
effect of isoprenaline (1 µM) was significantly (P<0.01) attenuated by the β3-
adrenoceptor antagonist, SR59230A hydrochloride (100 nM, Figure 21B) (Jedlitschky 
et al., 2000), wich exhibits high affinity (pKi 6.9-8.4) for the human β3 receptor 
subtype although it can also bind to other β-adrenoceptor subtypes. Inhibition of 
isoprenaline relaxation responses by SR59230A in the human bladder has been 
reported before (Takeda et al., 1999). Likewise, mirabegron, used in a concentration 
(0.1 µM) that selectively activates β3-adrenoceptors in the human bladder (Takasu et 
al., 2007), mimicked the inhibitory effect of isoprenaline (1 µM); mirabegron (0.1 µM) 
decreased electrically-evoked [3H]ACh release by 57±6% (n=7, Figure 21C). The 
inhibitory effect of mirabegron (0.1 µM) was significantly (P<0.01) attenuated by 
L748,337 (30 nM), a more selective β3-adrenoceptor antagonist (Ki 4 nM) than 
SR59320A hydrochloride (Candelore et al., 1999). 
Taking into consideration that β3-adrenoceptors are not present on cholinergic 
nerve terminals of the human bladder (see Figure 20), yet both isoprenaline and 
mirabegron were one to two log orders of magnitude more potent in decreasing 
[3H]ACh release than in reducing nerve-evoked contractions of the human detrusor 
(D’Agostino et al., 2015, reviewed in Michel and Korstanje, 2016), we hypothesized 
the involvement of a retrograde messenger like adenosine bolstering inhibition of 
evoked transmitter release via prejunctional A1 receptors (Silva-Ramos et al., 2015a). 
Figure 21 shows that transmitter release inhibition caused by isoprenaline (1 µM, 
Figure 21B) and mirabegron (0.1 µM, Figure 21C) was prevented (P<0.01) by the 
selective adenosine A1 receptor antagonist, 1,3-dipropyl-8-cyclopentylxantine 
(DPCPX, 100 nM).  
Likewise, isoprenaline (1 µM) decreased by 38 ± 1% (n=4) the evoked 
[3H]ACh release in rat urinary bladder strips without the mucosa and its inhibitory 
effect was also prevented by the selective blockade of β3-adrenoceptors and 
adenosine A1 receptors with SR59230A (100 nM, Figure 22A) and DPCPX (100 nM, 
Figure 22C), respectively, whereas the β2-adrenoceptor antagonist, ICI118,551 (50 
nM), was devoid of effect (Figure 22A). Moreover, the isoprenaline (1 µM) inhibitory 
action on evoked [3H]ACh outflow was mimicked by the “rodent selective” β3-
adrenoceptor agonist, CL316,243 (1 µM) (Evans et al., 1999), whereas transmitter 
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release from rat detrusor strips was insensitive to fenoterol (50 nM, a β2-
adrenoceptor agonist) (Figure 22B). 
Figure 21. (A) Inhibitory effect of isoprenaline on electrically-evoked [3H]ACh release from 
urothelium-denuded human detrusor strips. Ordinates represent tritium outflow expressed in 
scintillations per min (cpm). Abscissa indicates the times at which samples were collected. [3H]ACh 
release was elicited by electrical field stimulation (10 Hz, 200 pulses of 0.2 ms duration) twice, starting 
at 4th (S1) and 13th (S2) minutes after the end of washout (zero time). Isoprenaline (1 µM, grey bars) 
was added to the incubation media 6 min before S2 (horizontal bar). Bottom panels show the inhibitory 
effects of isoprenaline (1 µM, B) and mirabegron (0.1 µM, C) on [3H]ACh release from electrically 
stimulated human detrusor strips in the absence and in the presence of selective β3-receptor 
antagonists, SR59230A (100 nM, B) and L748,337 (30 nM, C), and of the A1 receptor antagonist, 
DPCPX (100 nM, B and C); the effect of mirabegron in the presence of dipyridamole (Dipy, 0.5 µM) is 
also shown in panel C. Receptor antagonists and Dipy were present throughout the assay, including 
S1 and S2. The ordinates are changes in S2/S1 ratios compared to the S2/S1 ratio obtained without 
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addition of any drug (dotted horizontal line). The data are means ± SD of three to six individuals; 
duplicates were performed for each individual experiment. #P<0.001 (one-way ANOVA followed by the 
Dunnett’s post test) represent significant differences when compared to the control situation; **P<0.01 
(one-way ANOVA followed by the Dunnett’s post test) represent significant differences when 
compared to the inhibitory effect of isoprenaline. 
 
 
 
Figure 22. Changes in the inhibitory effect of isoprenaline on electrically-evoked [3H]ACh 
release from urothelium-denuded rat detrusor strips in the presence of SR59230A (100 nM, β3-
adrenoceptor antagonist), ICI118,551 (50 nM, β2-adrenoceptor antagonist) (panel A), DPCPX (100 
nM, adenosine A1 receptor antagonist), dipyridamole (Dipy, 0.5 µM, ENT1 and ENT2 inhibitor), NBTI 
(30 µM, selective ENT1 inhibitor), rolipram (ROL, 300 µM, phosphodiesterase IV inhibitor) and L-
NAME (100 µM, NO synthase inhibitor) (panel C). For comparison purposes we also tested the effect 
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of selective β3 (CL316,243, 1 µM), and β2 (fenoterol, 50 nM) adrenoceptor agonists and the adenylyl 
cyclase activator, forskolin (FSK, 3 µM), on evoked [3H]ACh release from rat detrusor strips under 
similar experimental conditions (panel B). [3H]ACh release was elicited by electrical field stimulation 
(10 Hz, 200 pulses of 0.2 ms duration) twice, starting at 4th (S1) and 13th (S2) minutes after the end of 
washout (zero time). Isoprenaline, CL316,243, fenoterol and forskolin were added to the incubation 
media 6 min before S2; SR59230A, ICI118,551, DPCPX, Dipy, NBTI, ROL, and L-NAME were present 
throughout the assay, including S1 and S2. Ordinates are changes in S2/S1 ratios compared to the 
S2/S1 ratio obtained without addition of any drug (dotted horizontal line). The data are means ± SD of 
an n number of individuals; duplicates were performed for each individual experiment. #P<0.001 (one-
way ANOVA followed by the Dunnett's post test) represent significant differences when compared to 
the control situation; **P<0.01 (one-way ANOVA followed by the Dunnett’s post test) represent 
significant differences when compared to the inhibitory effect of isoprenaline or CL316,243. 
 
Based on equipotency of CL316,243 and isoprenaline it has been proposed that rat 
bladder relaxation predominantly occurs via the β3-adrenoceptor subtype (Takeda et 
al., 2000; Woods et al., 2001; Yamazaki et al., 1998). Involvement of β3-
adrenoceptors mediating inhibition of transmitter release caused by CL316,243 (1 
µM) was further confirmed by showing that the effect of the β3-receptor agonist was 
also abolished in the presence of SR59230A (100 nM) (Figure 22B). 
 
 
The inhibitory role of β3-adrenoceptors on evoked [3H]ACh release from 
the urinary bladder requires adenosine release via equilibrative nucleoside 
transporters  
β3-adrenoceptors usually couple to adenylyl cyclase via Gs proteins to 
generate intracellular cyclic AMP. In this context, we show in Figure 22B that the 
inhibitory effects of isoprenaline (1 µM) and CL316,243 (1 µM) were reproduced by 
the adenylyl cyclase activator, forskolin (3 µM), which on its own decreased evoked 
[3H]ACh release by 61±7% (n=5). In many tissues intracellular cyclic AMP 
accumulation translates into increased extracellular adenosine amounts, which 
negatively modulates ACh release from cholinergic bladder nerves (Silva-Ramos et 
al., 2015a). Therefore, we tested whether this mechanism was responsible for the β3-
adrenoreceptor inhibitory control of cholinergic neurotransmission in rat detrusor 
strips. 
Cyclic AMP is effectively and rapidly degraded by phosphodiesterases into 
AMP and adenosine inside the cell, and the nucleoside may be subsequently 
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transported to the extracellular milieu via equilibrative transporters (ENT). The 
influence of this pathway was evaluated by treating rat detrusor strips prior to the 
application of isoprenaline (1 µM) with a phosphodiesterase IV inhibitor, rolipram 
(300 µM), and two equilibrative nucleoside transport (ENT) blockers, dipyridamole 
(0.5 µM) and S-(4-nitrobenzyl)-6-thioinosine (NBTI, 30 µM); in contrast to 
dipyridamole, NBTI is a selective ENT1 inhibitor with no affinity for 
phosphodiestesare enzymes. Results show that in the presence of rolipram (300 
µM), dipyridamole (0.5 µM) or NBTI (30 µM), isoprenaline (1 µM) was decreased 
[3H]ACh release induced by electrical stimulation of rat detrusor strips to a lesser 
extend compared to the control situation (Figure 22C). Likewise, dipyridamole (0.5 
µM) also prevented the inhibitory effect of mirabegron (0.1 µM) on evoked [3H]ACh 
release from isolated human detrusor strips (Figure 22C). Notwithstanding the fact 
that β-adrenoceptor-mediated release of NO has been observed in the rat urothelium 
(Birder et al., 2002) and NO-mediated responses to β3-adrenoceptor agonists have 
been observed in rat aorta and human coronaries, isoprenaline-induced reduction of 
[3H]ACh release from stimulated rat detrusor strips apparently does not involve NO 
because inhibition of NO synthase activity with L-NAME (100 µM) had not effect 
(Figure 22C) (cf. Michel and Korstanje, 2016). Figure 23 shows that incubation of 
human and rat detrusor strips for 15 min with mirabegron (0.1 µM, Figure 23A) and 
isoprenaline (1 µM, Figure 23B), respectively, increased significantly (P<0.05) the 
concentration of adenosine in the incubation fluid, while the amount of inosine 
remained fairly constant compared to basal conditions. Isoprenaline (1 µM)-induced 
adenosine outflow increased further (from 174 ± 21 nM to 241 ± 13 nM, n=4, 
P<0.0001) after electrical stimulation of rat detrusor strips (data not shown) and it 
was largely attenuated following preincubation with SR59230A (100 nM) or 
dipyridamole (0.5 µM) (Figure 23B). The extracellular concentration of adenosine 
measured under these experimental conditions is probably underestimated, because 
it was obtained in a rather large volume of incubation media (2.8 ml) compared with 
the reduced interstitial volume of the bladder in vivo. 
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Figure 23. Mirabegron (0.1 µM, A) and isoprenaline (Isop, 1 µM, B) favour the release of 
adenosine from urothelium-denuned human and rat detrusor strips, respectively. Mirabegron and 
isoprenaline were allowed to contact the preparations for 15 min before sample collection. The 
ordinates represent the concentration of adenosine (ADO, white bars) and inosine (INO, black bars) 
detected by HPLC with diodo array detection in samples collected from the incubation media at 15 min 
intervals (for details, see Materials and Methods). The data are means ± SD of two man and four rats, 
respectively; duplicates were performed for each individual experiment. P<0.05 and ***P<0.001 (one-
way ANOVA followed by the Dunnett’s post test) represent significant differences when compared to 
the control situation (Basal). Please note that the release of adenosine returned to control levels when 
isoprenaline (1 µM) was applied together with SR59230A (0.1 µM) or dipyridamole (Dipy, 0.5 µM). (C) 
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Confocal micrographs showing the immunoreactivity against equilibrative nucleoside transporters, 
ENT1 and ENT2, in transverse sections of human detrusor strips. ENT1 (upper panel) and ENT2 
(bottom panel) immunoreactivity is shown in green; differential interference contrast (DIC) images are 
also shown. Images are representative or four individuals. Scale bars = 100 µm. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 24. Kinetics of the extracellular catabolism of cyclic AMP in urothelium-denuded 
detrusor strips from human and rat bladders. Cyclic AMP (30 µM) was added at zero time to the 
incubation medium. Samples were collected from the incubation fluid at the indicated times on the 
abscissa and analysed by HPLC with UV detection to quantify cyclic AMP (squares), AMP (upward 
triangles), adenosine (ADO, downward triangles), inosine (INO, lozenges) and hypoxanthine (HX, 
circles). Average results obtained from four individuals of each group made in triplicate; the vertical 
bars represent SD and are shown when they exceed the symbols in size. 
 
 
In support for the involvement of equilibrative nucleoside transporters 
mediating adenosine outflow in response to β3-adrenoceptors activation in the urinary 
bladder, we show in Figure 23C that the human detrusor exhibits significant 
immunoreactivity against NBTI-sensitive ENT1 (SLC29A1) and NBTI-insensitive 
ENT2 (SLC29A2) subtypes, which are localized predominantly on the plasma 
membrane of smooth muscle fibers and at interstitial spaces of detrusor muscle 
bundles, respectively. 
Alternatively, cyclic AMP can be actively pumped out from many cell types 
including the rat detrusor (Uchida et al., 2005), thereby contributing to extracellular 
adenosine formation via an enzymatic cascade involving ecto-nucleotide 
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pyrophosphatase/phosphodiesterase 1 (ENPP1) and ecto-5’-nucleotidase/CD73 (see 
e.g. ref. Chiavegatti et al., 2008; Sassi et al., 2014). Figure 24 shows enzymatic 
kinetic experiments where we studied the time course of the extracellular catabolism 
of cyclic AMP and formation of its metabolites, including AMP, adenosine, inosine 
and hypoxanthine, in detrusor strips of both human and rat urinary bladder. The 
activity of ENPP1 calculated 15-min after cyclic AMP (30 µM) application the ratio of 
[AMP+ADO+INO+INO]:[cyclic AMP] per min was 7.5x10-3 (n=4) in the detrusor 
human, whereas under similar experimental conditions dephosphorylation of AMP 
(30 µM) by ecto-5’-nucleotidase/CD73 calculated by the ratio of 
[ADO+INO+INO]:[AMP] per min in a previous report from our group was significantly 
(P<0.05) higher (24.4x10-3, n=4) (Silva-Ramos et al., 2015a). Accordingly, the 
amount of adenosine (plus inosine and hypoxanthine) in the incubation fluid 
originating from the extracellular catabolism of cyclic AMP (30 µM) in the human 
bladder did not surprass 2.62 µM, while this value reached 7.98 µM following 15-min 
incubation with AMP (30 µM). Similar results were obtained in the rat detrusor as can 
be appreciated in Figure 24. 
 
Activation of β3-adrenoceptors decreases non-voiding microcontractions 
and the micturition frequency in anaesthetized rats in vivo with the 
participation of adenosine A1 receptors 
Figure 25 shows that instillation of isoprenaline (0.1-1000 nM) into the lumen 
of the urinary bladder of anaesthetized rats decreased the number and amplitude of 
non-voiding spontaneous microcontractions and the micturition frequency in a 
concentration-dependent manner; the latter was evidenced by prolongation of the 
intercontraction interval (ICI) without significantly (P>0.05) modifying the amplitude 
(A) and the duration (∆t) of voiding bladder contractions (Figure 25A).The calculated 
pEC50 value for isoprenaline under the present experimental conditions (-8.84±0.37; 
Emax 42.03±4.53%; n=5) is consistent with reported values (-8.3 and -9.1) in the 
literature for β3-adrenoceptors activation in the rat isolated detrusor (Yamazaki et al., 
1998). In support of this theory, the selective β3-adrenoceptor agonist, CL316,243 
(pEC50 -8.61±0.43; Emax 36.90±4.60%; n=5), was equipotent to isoprenaline in the 
bladder of anaesthetized rats, whereas β2-adrenoceptor activation with fenoterol was 
less effective (pEC50 -7.90±0.085; Emax 13.87±4.38%; n=5) (Figure 25Bi). The 
inhibitory effect of isoprenaline (0.1-1000 nM) on the micturition reflex seems to be 
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mediated by targets located in the urinary bladder, since instillation of this drug into 
the bladder lumen did not (P>0.05) affect heart rate in the anaesthetized rat which 
would have happened if the drug entered the systemic circulation or was applied via 
i.v. or i.p., i.e. less than 5% increase in heart rate compared to control (405±52 bpm, 
n=5) was observed when isoprenaline was used at the highest concentration. A 
similar result was obtained for the other β-adrenoceptor agonists. 
Pretreatment with the selective β3-receptor antagonist, SR59230A (100 nM), 
prevented the decrease in the voiding frequency caused both by isoprenaline (0.1-
1000 nM) (Figure 25A and 25Bii) and CL316,243 (0.1-1000 nM) (Figure 25Biii), 
whereas blockade of the β2-adrenoceptor with ICI228,552 (50 nM) had only a limited 
effect on the concentration-response curve of isoprenaline (0.1-1000 nM) (Figure 25 
Bii). Inhibition of bladder activity detected with isoprenaline (0.1-1000 nM) was also 
prevented by selectively blocking adenosine A1 receptors with DPCPX (100 nM) 
(Figure 25A and 25Biv) or by inhibiting adenosine outflow to the extracellular milieu 
via equilibrative nucleoside transporters (ENT) with dypiridamole (0.5 µM) or NBTI 
(30 µM) were active either when superfused into the bladder lumen together with 
isoprenaçine (Figure 25) or by continuous i.v. infusion (data not shown). Neither of 
these drugs affected the urodynamic parameters when applied alone, independently 
of the route or administration, even when the concentration of SR59320A was 
increased to 100 µM. These results suggest that the inhibitory effect of β3-
adrenoceptor activation on the distension-induced micturition reflex in the rat in vivo 
is under the tonic control of adenosine A1 receptors activation, but saline bladder 
distension does not generate on its own sufficient amounts of extracellular 
endogenous ligands, such as adenosine and/or noradrenaline, to promote activation 
of A1 and β3 receptors, under the present experimental conditions. 
 
 Interestingly, the adenylyl cyclase activator, forskolin (0.01-10 µM), also 
mimicked the inhibitory effect of β3 adrenoceptor activation in the bladder of 
anaesthetized rats. Forskolin concentration-dependently increased (pEC50 -
6.75±0.30; Emax 39.30±4.38%; n=5) the duration of ICI without any modification in the 
amplitude (A) and the duration (∆t) of voiding bladder contractions. 
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Figure 25. (A) Bladder cystometry recording during normal saline (0.9% w/v of NaCl) and 
isoprenaline (1 µM) infusion into the urinary bladder of urethane-anaesthetized rats verified in the 
absence and in the presence of selective β3- and A1 receptor antagonist, SR59230A (100 nM) and 
DPCPX (100 nM), respectively. Large-amplitude bladder contractions correspond to voiding 
contractions when they were accompanied by urine draining through the urethra. Traces obtained 
during the filling phase of the micturition reflex (dotted rectangles) were enlarged to show non-voiding 
spontaneous microcontractions. Stable urodynamic responses to isoprenaline were reached in 10-15 
min. (B) Show concentration-response curves of isoprenaline (0.1-1000 nM)-induced prolongation of 
the intercontraction interval (ICI) of voiding contractions in the absence and in presence of SR59230A 
(100 nM), ICI118,551 (50 nM), DPCPX (100 nM), dypiridamole (0.5 µM) and NBTI (30 µM); The 
effects of fenoterol (0.1-1000 nM, a β2-adrenoceptor agonist), CL316,243 (0.1-1000 nM, a β3-
adrenoceptor) and forskolin (FSK, 0.01-10 µM, an adenylyl cyclase activator) are also shown for 
comparison. Control values correspond to zero percent variation. The vertical bars represent SD of an 
n number of animals (shown in parenthesis). *P<0.01 (one-way ANOVA followed by the Dunnett’s post 
test) represents significant differences as compared to the effect of isoprenaline or CL316,243 applied 
alone. 
 
DISCUSSION 
There is an increasing interest concerning the role of β3-adrenoceptor agonists 
for the management of the OAB syndrome as an efficacious and more tolerable 
alternative to antimuscarinic drugs (Thiagamoorthy et al., 2015). It was first though 
that improvement of OAB symptoms by β3-adrenoceptor agonists, like mirabegron 
and solabegron, were mostly due to direct relaxation of the detrusor smooth muscle 
(Igawa et al., 1999; Takeda et al., 1999; Wuest et al., 2009). However, newer 
theories suggest that β3-adrenoceptor agonists decrease OAB symptoms also by 
reducing bladder afferent nerve activity (Woods et al., 2001) and/or ACh release from 
parasympathetic postganglionic nerves innervating the detrusor (D’Agostino et al., 
2015). These new paradigms may be clinically relevant because, contrary to the 
initial belief that normally no parasympathetic nerve drive was observed during 
bladder storage, recent evidence demonstrate that there is release of ACh from both 
neuronal and non-neuronal sources, such as the urothelium and lamina propria, 
during the filling phase of the micturition cycle (Yoshida et al., 2004; reviewed in 
Winder et al., 2014). Moreover, this cholinergic trend may be directly or indirectly 
exaggerated in overactive bladder patients via the release of ATP and other “danger” 
molecules (Silva et al., 2015). 
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Notwithstanding the recent therapeutic advances towards the use of β3-
adrenoceptor agonists for lower urinary tract syndromes, research involving β3-
adrenoceptors has been hampered due to unique properties to the β3-adrenoceptor 
which make extrapolation of findings between human and rodent models very difficult 
to reconcile owe to considerable species differences in the selectivity and potency of 
commonly used drugs. Here, we tested an array of the most selective agonists and 
antagonists available for human and rat β3-adrenoceptors in comparison with the 
effect of the non-selective β-adrenoceptor agonist, isoprenaline. Regarding the 
involvement of β3-adrenoceptor on [3H]ACh release from stimulated detrusor strips 
our results show that the inhibitory effect of isoprenaline was mimicked by 
mirabegron and CL316,243, which exhibit some degree of selectivity for β3-
adrenoceptors in human and rat tissues, respectively, when applied in the 
submicromolar concentration range. It is worth noting that mirabegron is about 8-fold 
more potent in the human (Takasu et al., 2007) as compared to the rat bladder 
(Takasu et al., 2007; reviewed in Michel and Korstanje, 2016) and the opposite was 
observed concerning the selectivity of CL316,243 for rodent β3-adrenoceptors (Evans 
et al., 1999). The effects of mirabegron and CL316,243 were prevented by blockage 
of β3-adrenoceptors in human and rat detrusor with L748,337 and SR59230A, 
respectively. While SR59230A is regarded as a potent β3-adrenoceptor antagonist in 
rodents, it can hardly distinguish the human β3-adrenoceptors from other 
adrenoceptors (β1 and β2) expressed in the same tissue (Baker, 2010; Candelore et 
al., 1999). Mirabegron also mimicked the enhancing effect of isoprenaline on 
extracellular adenosine accumulation on human detrusor strips. Overall these results 
proof the involvement of β3-adrenoceptors in the inhibitory control of cholinergic 
neurotransmission and bladder reactivity through the release of adenosine from the 
detrusor. 
In this study, we demonstrated by western blot analysis and 
immunofluorescence confocal microscopy using three distinct commercial antibodies 
(AAR-017, MC-4198 and SC-1473) that β3-adrenoceptors are localized on detrusor 
smooth muscle fibers (cf. Fujimura et al., 1999; Igawa et al., 1998; Igawa et al., 
1999). These receptors seem to be absent from VAChT-positive cholinergic nerves 
of the human urinary bladder cells of intramural nerves (Limberg et al., 2010). 
Contradictory evidence for β3-adrenoceptors being present on ACh-containing nerve 
fibers of the human detrusor exists considering the fact that since submission of the 
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present manuscript new information emerged (Coelho et al., 2017); using 
epifluorescence microscopy, Coelho et al. (2017) showed that β3-adrenoceptors 
stained with the SC-1472 antibody co-localized with VAChT-positive nerve fibers in 
the human detrusor, but the density of nerve varicosities expressing the cholinergic 
marker far exceeded those expressing β3-immunoreactivity. These findings challenge 
the current view about the mechanism and site of action of β3-adrenoceptor agonists 
on cholinergic bladder nerves activity and open the door for novel targets (e.g. 
adenosine) indirectly mediating inhibition of neurogenic bladder contractions. Another 
puzzling finding that has been insufficiently explored so far is the higher effectiveness 
of β3-adrenoceptor agonists in decreasing (D’Agostino et al., 2015; Gillespie et al., 
2015; Rouget et al., 2014). This led several authors to suggest that in vivo 
concentrations of these drugs following clinical application are below the minimum 
required to affect detrusor myogenic contractions as a mechanism underlying relief of 
OAB symptoms (Andersson, 2016). Our results strongly suggest that β3-
adrenoceptors activation (either with isoprenaline or mirabegron) significantly 
increases adenosine release from detrusor smooth muscle fibers, via NBTI-sensitive 
equilibrative nucleoside transporters (ENT1), leading to retrograde activation of A1 
receptors and, thereby, to inhibition of [3H]ACh release from cholinergic nerves of 
human and rat urinary bladders. Reduction of the cholinergic tone responsible for 
non-voiding bladder contractions, acting in coordination with the sensory inhibitory 
drive caused by β3-adrenoceptors agonists and endogenous adenosine (via A1 
receptors), may increase bladder compliance during the filling phase of the 
micturition cycle resulting in improvement of OAB symptoms. This is an interesting 
feature that might put adenosine signaling pathways, consisting of metabolizing 
enzymes, nucleoside transporters, and membrane receptors, in the centre of 
research for novel therapeutic targets to manage OAB syndromes. However, in 
contrast to the relatively well characterized actions of ATP in the urinary bladder both 
in physiological and pathological conditions, limited information is available on the 
role of its breakdown product, adenosine. First reports of the effect of adenosine in 
the lower urinary tract suggested that it reduces the tone and the spontaneous 
activity of the urinary bladder in different species (Acevedo et al., 1992; Brown et al., 
1979; Burnstock et al., 1978; King et al., 1997; Nicholls et al., 1992), including 
humans (Rubinstein et al., 1998). Although information regarding location of 
adenosine receptors on the detrusor is still scant here are reports suggesting that low 
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affinity A2B receptors are abundantly expressed in the rat bladder smooth muscle 
(Stehle et al., 1992; Yu et al., 2006), while our group recently showed that in the 
human detrusor the A2A receptor seems to be the more abundant receptor subtype 
(Silva-Ramos et al., 2015a). Conflicting pharmacological evidence for the presence 
of A1, A2A and A3 receptors in detrusor smooth muscle fibers subsist in the literature 
depending in the animal species and the experimental settings (Gopalakrishnan et 
al., 2002; Vesela et al., 2011; Yang et al., 2000). Despite this, a remarkable 
parallelism seems to exist between the potency of adenosine and β3-adrenoceptor 
agonists to inhibit transmitter release and to promote relaxation of myogenic detrusor 
contraction (see above). Data from our group show that relaxation of human detrusor 
strips pre-contracted with ACh require 30-fold higher concentrations (milimolar range) 
of adenosine than the inhibitory effect of the nucleoside on evoked [3H]ACh release 
operated by prejunctional A1 receptors (Silva-Ramos et al., 2015a). This difference 
was even more significant in the bladder of patients with benign prostatic 
hyperplasia, a pathological condition that may accompanied by OAB-like symptoms. 
It, thus, appears that bladder outlet obstruction (BOO) increases the sensitivity of 
nerve-evoked transmitter release to exogenous adenosine receptor agonists, a 
situation that occurs in parallel to the up-regulation of inhibitory A1 receptors localized 
in VAChT-positive cholinergic nerve fibers. It remains to be investigated whether up-
regulating of the A1 inhibitory control of ACh release also occurs in OAB patients, 
which might contribute to explain the clinical success of β3-adrenoceptor agonists, 
including isoprenaline, was very similar in patients with low bladder compliance, 
hyperreflexic bladders and controls (Igawa et al., 2001), but the relaxing effect of 
clembuterol was significantly greater in neurogenic-contracted bladder strips from 
patients with urodynamically confirmed urge incontinence compared to continent 
patients (Hudman et al., 2001). Amplification of β3-adrenoceptor signaling by 
adenosine A1 receptors may again further relevance considering that no significant 
changes in the mRNA expression of β3-adrenoceptors were observed in humans and 
rats with BOO (Barendrecht et al., 2009; Nomiya et al., 2003), yet β3-adrenoceptors 
agonists decreased more efficiently non-voiding contractions in obstructed bladders 
in vivo (Igawa and Michel, 2013).  
Using western blot analysis and immunofluorescence localization, Yu and col. 
Detected the expression of all four types of adenosine receptors in the bladder 
urothelium of female Sprague-Dawley rats (Yu et al., 2006). The A1 receptors were 
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predominantly localized to the apical membrane of umbrella cells, whereas A2A, A2B 
and A3 receptors were expressed intracellularly or on the basolateral membrane of 
umbrella cells and the plasma membrane of underlying cell layers. Here, we show 
that the A1 receptor is abundantly expressed in the human urothelium (see Figure 
20A). The A1 receptor immunoreactivity was also observed in the underlying 
submucosal connective tissue, yet the staining density was weaker compared to the 
urothelial layer. This findings agrees with the work of Yu and col. showing that 
suburothelial tissue elements (possibly connective cells, myofibroblasts or blood 
vessesls) are more strongly labeled with the A2A antibody (Yu et al., 2006). Based 
upon quantitative PCR experiments, Nomiya and Yamaguchi (2003) claimed that the 
β3-adrenoceptor accounts for more than 95% of all β-adrenoceptor mRNA in the 
human bladder (Nomiya and Yamaguchi, 2003; reviewed in Michel and Vrydag, 
2016), which is consistent with the extensive β3 receptor protein immunoreactivity 
found by us in the human detrusor (Figure 20).  
However, a more recent quantitative analysis under highly standardized 
conditions suggested comparable β1, β2 and β3 adrenoceptors mRNA expression in 
the human bladder (Uhlén et al., 2015). Anyway, the use of selective β3 adrenoceptor 
agonists, such as like mirabegron (Takasu et al., 2007); reviewed in Michel and 
Vrydag, 2006), and antagonists, like L748,337 (Candelore et al., 1999), reduces 
tremendously any lack of discriminative power of less selective compounds (e.g. 
isoprenaline, SR59230A) regarding β-adrenoceptor subtypes in human functional 
studies (Baker, 2010; Hoffamnn et al., 2004). Likewise, neither dobutamine (a β1 
receptor agonist) nor procalterol (a β2 receptor agonist) produced significant 
relaxation in the human detrusor (Igawa et al., 1998), suggesting that the β3-
adrenoceptor is the main responsible for the adrenergic inhibitory tone in human 
bladder. Manipulation of β2-adrenoceptors activity with fenoterol (agonist) and 
ICI118,551 (antagonist) was virtually devoid of effect on [3H]ACh release from the 
stimulated rat detrusor and produced only minor changes in the urodynamic 
parameters evaluated in the anaesthetized rat compared to isoprenaline and 
CL316,243. Thus, our findings suggest that β2-adrenoceptors contribute to a minor 
extend, if any, to control cholinergic neurotransmission and bladder reactivity in the 
rat. 
Besides the presence of β3-adrenoceptors on smooth fibers of the human 
detrusor (see above) these receptors are equally abundant in vimentin-positive 
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interstitial cells of the suburothelium; which may correspond to the immunoreactivity 
we have detected in the suburothelial layer (Figure 20). A minor density of 
expression of β3-adrenoceptors was found in the urothelium. Data from previous 
studies suggest that the majority of these receptors are present in apical umbrella 
cells (Limberg et al., 2010; Otsuka et al., 2008); high magnification micrographs 
obtained by our group showed that β3 and A1 receptors co-localize with CK20, an 
apical urothelial cell marker, in the human bladder (unpublished observations). The 
close proximity of adenosine A1 and β3 receptors in umbrella cells may explain their 
crosstalk to decrease sensitivity in the urinary bladder to isoprenaline-containing 
saline distension in the anaesthetized rat, which resulted in reduction of the voiding 
frequency and in enhancement of the bladder storage capacity. Although 
isoprenaline-induced of the micturition cycle was prevented by co-application with 
selective β3-and A1 receptor antagonists SR59230A and DPCPX, respectively, one 
cannot exclude the participation of suburothelial structures endowed with the two 
receptors, including afferent and efferent nerves (or both) and interstitial cells that 
may influence bladder spontaneous activity and detrusor tonus (Limberg et al., 
2010). In support of this possibility, our results showed that both blockers were 
equally effective when instilled into the bladder lumen or when induced intravenously. 
Moreover, intravenous application of isoprenaline also reduced the intra-vesical 
pressure and increased bladder storage capacity in a model of distension-induced 
bladder activity under isovolumetric conditions in urethane-anaesthetized rats (Lecci 
et al., 1998). 
Interestingly, previous studies demonstrated that β3-adrenoceptors inhibit 
detrusor contractions of the pig urinary via the urothelium (Masunaga et al., 2010), 
most probably through the release of an urothelium-derived factor of unidentified 
nature as it has been proposed in porcine and human bladders (Murakami et al., 
2007; Otsuka et al., 2008). Our best hypothesis is in favor of adenosine, which might 
be released in response to urothelial β3-adrenoceptors activation via equilibrative 
nucleoside transporters existing at the basolateral surface of epithelial cells (Loffler et 
al., 2007), but not evidence still exist to exclude other mechanisms leading to 
urothelial adenosine accumulation, namely the release of ATP and cyclic AMP. 
Differences in the kinetics of the extracellular catabolism of adenine nucleotides by 
ecto-nucleotidases between luminal and abluminal sides of the human urothelium 
indicate that adenosine biosynthesis predominates in the basal layer of the 
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urothelium where ecto-5’-nucleotidases/CD73 is dominantly expressed (Silva-Ramos 
et al., 2015b). This feature strengthens our former hypothesis that adenosine is 
predominantly originated via the nucleoside transport system in the more superficial 
layers of the human urothelium. Once in the extracellular milieu adenosine starts an 
inhibitory signaling cascade at more superficial urothelial layers via the activation of 
neighboring cells endowed with A1 receptors. It has been demonstrated that 
adenosine negatively modulates stretched-induced ATP release over many minutes 
by modulating exocytosis in the apical membrane of umbrella cells (Yu et al., 2006). 
A more acute (within seconds) effect to modulate distension-induced ATP release 
from the urothelium has also been suggested (Dunning-Davies et al., 2013). 
Distension-induced ATP release was decrease by adenosine (1-10 µM) and 
enhanced by adenosine deaminase and DPCPX, but not by blocking A2 receptors 
with 3,7-dimethyl-1-propargyl-xanthine (DMPX). The mechanism by which adenosine 
reduces urothelial ATP release remains unknown, but it might depend on changes in 
the transepithelial potential by interference with mechanosensitive Na+ channels 
(identified as amiloride-sensitive epithelial Na+ channels or ENaC), which may 
ultimately favor Ca2+ outflow via Na+/Ca2+ exchange in urothelial cells (Wu et al., 
2011). These findings support a dominant role of adenosine A1 receptors in 
regulating ATP release from the urothelium and, thus, in the control of the sensory 
filling phase of the micturition cycle. In fact, prolongation of the intercontraction 
interval without affecting the amplitude of voiding contractions was observed when A1 
receptor agonists were applied into the lumen of the urinary bladder in the rat in vivo 
(Kitta et al., 2014). 
Alternatively, the production and release of NO from urothelial cells may follow 
β-adrenoceptors activation leading to increases in intracellular Ca2+ triggered by 
activation of the cyclic AMP pathway (Birder et al., 2002). However, these authors did 
not specifically test the role of any selective β3-adrenoceptor agonist/antagonist. 
Because NO has only minimal relaxing effects on bladder smooth muscle 
(Andersson and Persson, 1995), it was suggested that NO can down-regulate 
bladder activity by suppressing excitability of sensory nerve afferents (Pandita et al., 
2000). Even though we cannot discount the participation of NO in the β3-
adrenoceptor-induced inhibitory pathway controlling bladder activity in the 
anaesthetized rat, blockade of the isoprenaline effect by DPCPX strongly suggest 
that adenosine A1 receptors play a more relevant role. 
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Controversy, still exists in whether the prototypical activation of adenylyl 
cyclase and cyclic AMP generation coupled to β3-adrenoceptors activation is the 
exclusive mechanism triggering the inhibitory effects on urinary bladder tone 
(reviewed in Michel and Vrydar, 2006; Yamaguchi and Chapple, 2007). Other 
possibilities include modulation of membrane potential, ion-channels activity and 
intracellular ion concentrations. Isoprenaline was found to hyperpolarize the cells, 
prevent action potentials and decrease Ca2+ transients. Activation of potassium 
current may cause membrane hyperpolarization and relaxation of the urinary bladder, 
but differences in species and in the stimulation protocol used by distinct research 
groups impair more positive conclusions. Although large conductance calcium-
activated K+ channels (BKCa channels) have been associated with cyclic AMP-
independent relaxation induced by β3-adrenoceptor agonists in pre-contracted rat 
detrusor with high KCl (Uchida et al., 2005), no evidence of such a mechanism exits 
in the human bladder. Notwithstanding this, data from the present study indicate that 
both isoprenaline (via β3-adrenoceptors activation) and the receptor-independent 
adenylyl cyclase activator, forskolin, decreased evoked [3H]ACh release from rat 
bladder strips without urothelium. Furthermore, we showed that the inhibitory effect of 
isoprenaline was prevented in the presence of two equilibrative nucleosides transport 
inhibitors, NBTI and dipyridamole. Likewise, dipyridamole also prevented that the 
inhibitory effect of mirabegron on evoked [3H]ACh release from the human detrusor. 
Distribution of the immunoreactivity against NBTI-sensitive equilibrative nucleoside 
transporter 1 (ENT1) on the plasma membrane of detrusor smooth muscle fibers in 
close proximity to β3-adrenoceptors contrast with the predominance of NBTI-
insensitive (ENT2) immunostaining surrounding smooth muscle bundles. Thus, 
imaging and functional studies suggest that β3-adrenoceptor-induced adenosine 
release from detrusor bladder strips result from translocation of the nucleoside 
across the plasma membrane via the ENT1 subtype. This is possible because 
increased cyclic AMP levels in stimulated cells are effectively degraded into AMP and 
adenosine by highly active phosphodiesterases and 5’-nucleotidase, respectively, to 
control its intracellular effects. Consequently, this raises the transmembrane gradient 
forcing the nucleoside outflow to the extracellular compartment. Alternatively, cyclic 
AMP actively transport outside cells via several members of the group of ATP-
binding cassette (ABC) transporters (Chen et al., 2001; Guo et al., 2003; Jedlitschky 
et al., 2000; Van Aubel et al., 2002). Even though this mechanism has been 
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described at the urinary bladder (Uchida et al., 2005) and cyclic AMP can originate 
adenosine in the extracellular space in many cell types through the sequential 
hydrolysis by two ectoenzymes, ecto-nucleotide pyrophosphatase/ 
phosphodiesterase 1 (ENPP1) and ecto-5’-nucleotidase/CD73 (see e.g. Chiavegatti 
et al., 2008; Sassi et al., 2014), our results demonstrate that the activity of ENPP1 
converting cyclic AMP into AMP is less productive than ecto-5’-nucleotidase/CD73 
that is responsible for AMP dephosphorylation into adenosine in the detrusor of both 
humans and rats. Given that low adenosine amounts resulted from the extracellular 
cyclic AMP-adenosine pathway in human and rat detrusor strips, it might not account 
significantly for the extracellular adenosine accumulation detected following β3-
adrenoceptors activation with isoprenaline or mirabegron. 
 
CONCLUSION 
In conclusion, data from the present study suggest that inhibition of cholinergic 
neurotransmission by β3-adrenoceptors activation results from adenosine release 
from stimulated detrusor smooth muscle fibers, via ENT1, leading to retrograde 
activation of prejunctional A1 receptors in human and rat urinary bladder. β3-
adrenoceptor agonists may also exert a clinically useful effect by fine-tuning 
regulating the sensory bladder drive during urine storage through urothelium-derived 
adenosine release from mechanically-sensitive umbrella cells, which are also 
endowed with ENT1 nucleoside transporters. The molecular mechanism underlying 
adenosine release downstream β3-adrenoceptor-induced adenylyl cyclase activation 
and cyclic AMP generation in smooth muscle fibers and urothelial cells remains to be 
elucidated. Notwithstanding this, we propose here a novel mechanism involving 
endogenous adenosine release and A1 receptor activation which contribute to 
explain, at least partially, the therapeutic success of β3-adrenoceptor agonists on 
OAB symptoms. β3-adrenoceptor agonists with the participation of endogenous 
adenosine may exert inhibitory effects on bladder functions increasing the storage 
capacity and prolonging the micturition interval, without affecting the voiding pressure 
or post-void residual volume. These drugs may act both (a) in the sensory bladder 
drive operated by mechanically-sensitive urothelial cells, sensory nerve afferents and 
interstitial pacemaker cells, and (b) on the efferent motor component resulting in the 
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reduction of non-voiding cholinergic microcontractions and in the increase in bladder 
storage capacity by relaxing the detrusor. Apparently these processes are affectively 
cut-short during the voiding command by yet unknown mechanisms, which may 
involve the unrestrained parasympathetic boost (reviewed in Yamaguchi and 
Chapple, 2007); in fact, β3-adrenoceptor agonists do not affect voiding urodynamics 
paramaters (maximum urinary flow and detrusor pressure at maximal urinary flow) in 
clinical settings (Nitti et al., 2013) and we did not observed any changes in the 
duration an amplitude of voiding urinary contractions in response to isoprenaline and 
CL316,243 in the anaesthetized rat, nor these parameters were affected by blockage 
of adenosine A1 receptors with DPCPX. Thus, we propose that pharmacological 
manipulation of endogenous adenosine levels and/or A1 receptor activation may act 
synergistically with β3-adrenoceptors activation to control bladder overactivity. 
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ABSTRACT 
Previously our group showed that activation of the β3-adrenoceptor with 
therapeutic doses of mirabegron and isoprenaline downregulates cholinergic 
neurotransmission in human and rat bladders, respectively, by indirectly increasing 
adenosine release via equilibrative nucleoside transporters and, subsequent, 
activation of pre-synaptic inhibitory A1 receptors. β3-adrenoceptors, via Gs proteins, 
are usually coupled to the adenylate cyclase / cyclic AMP (AC/cAMP) transduction 
pathway. The cellular effects of cyclic AMP (cAMP) are most often attributed to 
protein kinase A (PKA), but increasing evidence suggests the involvement of EPAC, 
an exchange protein directly activated by cAMP. Our aim in this study was to 
investigate the participation of these two cyclic AMP-dependent signalling pathways 
on β3-adrenoceptor-induced adenosine outflow and inhibition of acetylcholine (ACh) 
release in human and rat urinary bladders. In human urothelium-denuded detrusor 
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samples, mirabegron-induced adenosine outflow was prevented by blocking β3-
adrenoceptors with L748,337 (30 nM) and the equilibrative nucleoside transporter 
(ENT1) with dipyridamole (0.5 µM). The same occurred by inhibiting PKA and EPAC 
with H-89 (10 µM) and ESI-09 (10 µM), respectively. The inhibitory effects of 
mirabegron and isoprenaline on evoked [3H]ACh release from human and rat 
detrusor samples, respectively, were significantly attenuated (P<0.05) by ESI-09 (10 
µM), but not by H-89 (10 µM). Direct activation of adenylyl cyclase with forskolin 
(FSK, 0.03-10 µM) mimicked isoprenaline-induced inhibition of [3H]ACh release from 
the rat detrusor and the same was verified in the voiding frequency of urethane-
anaesthetized rats. The inhibitory action of FSK was prevented by DPCPX (100 nM, 
a selective A1 receptor antagonist), dipyridamole (0.5 µM) and ESI-09 (10 µM), but 
not by H-89 (10 µM), in both models. Data suggest that inhibition of cholinergic 
neurotransmission by β3-adrenoceptors is downstream mediated by the exchange 
protein directly activated by cAMP (EPAC) both in human and rat urinary bladders. 
The link between EPAC activation and adenosine release via equilbrative nucleoside 
transporters remains to be elucidaded.   
 
INTRODUCTION 
β3-adrenoceptor agonists, like as mirabegron, belong to a new class of drugs 
which proved their utility in the treatment of the overactive bladder syndrome 
(Chappel et al., 2014). However, the localization and mechanism of action of these 
receptors in the urinary bladder is still a matter of debate. The localization of β3-
adrenoceptors on bladder cholinergic nerves positive for the vesicular acetylcholine 
transporter (VAChT) has been recently suggested (Coelho et al., 2017). However, 
this finding is not corroborated by other research groups showing a preferential 
localization of β3-adrenoceptors on detrusor smooth muscle fibres of the urinary 
bladder of humans, rats and mice, as determined by immunofluorescence confocal 
microscopy using multiple antibodies targeting different receptor epitopes (Igawa et 
al., 1998; Igawa et al., 1999; Griffin et al., 2017; Silva et al., 2017). Elucidation of the 
mechanism of action of the β3-adrenoceptor agonist, mirabegron, is deemly needed, 
since it has been considered the first of a new class of compounds for the treatment 
of overactive bladder syndromes which molecular mechanism may be different from 
anti-muscarinic drugs (Angulo et al., 2013). The paradoxical localization of β3-
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adrenoceptor on detrusor smooth muscle fibers vs. cholinergic nerves (see above) 
and the fact that peak plasma levels of mirabegron when administrated in therapeutic 
(50 mg daily) doses (83-167 nM) are below its potency (EC50~1-3 µM) to relax 
detrusor smooth muscle strips (Michel and Korstanje, 2016), raise puzzling questions 
about the molecular mechanism of action of mirabegron which are not yet resolved in 
the literature (Andersson, 2017; Okeke et al., 2017). 
D’Agostino et al. (2015) showed that β3-adrenoceptors activation reduced 
[3H]ACh release from stimulated cholinergic bladder nerves. Recently, our group 
added some valuable information demonstrating that activation of β3-adrenoceptors 
in urothelium-denuded detrusor samples of both humans and rats favours the release 
of adenosine, via equilibrative nucleoside transporters (ENT; Silva et al., 2017). 
These findings clearly indicate that cholinergic inhibition by β3-adrenoceptor agonists 
is indirectly mediated by adenosine acting on prejunctional inhibitory A1 receptors 
located on cholinergic bladder nerves (Silva-Ramos et al., 2015a; Silva et al., 2017). 
This was concluded because the ENT inhibitor, dipyridamole, and the selective 
adenosine A1 receptor antagonist, 1,3-dipropyl-8-cyclopentyl xanthine (DPCPX), fully 
prevented [3H]ACh release inhibition by mirabegron, when this compound was 
applied in the low nanomolar concentration range. It remains, however, to be 
determined the exact mechanism underlying adenosine release downstream β3-
adrenoceptors activation in the urinary bladder and whether it is modified under 
pathological conditions. Patients with bladder outflow obstruction (BOO) secondary to 
benign prostatic hyperplasia (BPH) often exhibit bladder overactiviity remaining after 
prostatectomy (reviewed in Komninos and Mitsogiannis, 2014). Our group showed 
that the bladder of these patients exhibit increased amounts of inhibitory A1 receptors 
on cholinergic nerve terminals (Silva-Ramos et al., 2015a), which according to this 
theory make them good candidates for the therapeutic use of β3-adrenoceptor 
agonists, like mirabegron, to control bladder overactivity (Silva et al., 2017).  
Activation of β-adrenoceptors is positively coupled to adenylyl cyclase (AC), 
via Gs-proteins, resulting in the accumulation of intracellular cyclic AMP (cAMP) 
(Wallukat, 2002). Mirabegron increased intracellular cAMP accumulation in CHO 
cells stably transfected with rat and human β3-adrenoceptors (Atanaka et al., 2013). 
In the bladder, both cAMP-dependent and cAMP-independent pathways have been 
reported to be involved in the relaxation of the detrusor smooth muscle (Uchida et al., 
___________________________________________________ORIGINAL RESEARCH ARTICLES 
PhD Thesis: Isabel Sofia Dias da Silva________________________________________147 
 
2005). Moreover, the intracellular cAMP transduction system may be impaired in 
pathological conditions (e.g. hypoxia) (Jóźwiak-Bębenista et al., 2016).  
The cellular effects of cAMP are most often attributed to protein kinase A 
(PKA) and cyclic nucleotide-regulated ion channels (Wang et al., 2017). Activated 
PKA phosphorylates myosin light chain kinase (MLCK), thereby impairing Ca2+-
calmodulin-dependent activation, which reduces myosin light chain (MLC) 
phosphorylation and, hence, the muscle tone (Andersson and Arner, 2004; Hashitani 
et al., 2004). Bladder relaxation caused by β-adrenoceptor agonists may involve 
PKA-mediated phosphorylation of large conductance Ca2+-activated K+ channels 
(BKCa; Petkov, 2014) leading to cell membrane hyperpolarization and to decreases in 
Ca2+ influx via voltage-dependent channels (Wegener et al., 2004). Despite these 
possibilities, detrusor relaxation owing to the AC/PKA pathway downstream 
activation of β-adrenoceptors has been questioned (Frazier et al., 2005), raising the 
hypothesis that PKA-independent effects might also be involved.  
Novel cyclic AMP targets have emerged to explain cell responses that are 
insensitive to PKA inhibition (de Rooij et al., 1998; Kawasaki et al., 1998; reviewed in 
Dekkers et al. 2013). The exchange protein directly activated by cAMP (EPAC) is a 
cyclic AMP-regulated guanine nucleotide exchange factor (GEF) that favors 
GDP/GTP exchange and, thereby, activation of small Ras-like GTPases, such as 
Rho, Rac and Ras. Interestingly, EPAC is known to control distinct cellular 
responses, including calcium handling, cell proliferation, differentiation, migration, 
fibrogenic and inflammatory responses, which might contribute to bladder 
dysfunctions.  
The lack of understanding about the molecular targets of β3-adrenoceptor 
agonists and their putative repercussions in the treatment of lower urinary tract 
symptoms (LUTS) led us to investigate the participation of the two main cyclic AMP-
dependent pathways on β3-adrenoceptor-induced adenosine outflow and inhibition of 
electrically-evoked [3H]ACh release from human and rat urinary bladder samples. To 
test if a similar pathway participates in the inhibition of the sensory bladder drive 
caused by β3-adrenoceptors, we performed in vivo cystometry recordings in 
urethane-anaesthetized male rats. We also evaluated the effect of the β3-
adrenoceptor agonist, mirabegron, on evoked [3H]ACh release from detrusor strips 
isolated from men with BOO due to BPH, in order to test if this mechanism is 
operative in patients with LUTS.   
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MATERIAL AND METHODS 
Animals 
Animal care and experimental procedures were in accordance with the 
guidelines prepared by Commitee for the Update of the Guide for the Care and Use 
of Laboratory Animals (National Research Council, USA) and followed the European 
Communities Council Directive (86/609/EEC). All studies involving animals are 
reported in accordance with the ARRIVE guidelines for reporting experiments 
involving animals. A total of twenty animals were used in the experimental described 
here. Male rats (Wistar, 200-300 g; Charles River, Barcelona, Spain) were kept at a 
constant temperature (21ºC) and a regular light (06:30-19:30 h) – dark (19:30-06:30 
h) cycle, with food and water provided al libitium. 
 
Human bladder samples 
Samples of the human detrusor were collected from the bladder dome of five 
male organ donors (38±4 years of age) at the time of harvesting organs for 
transplantation; detrusor samples were also obtained from six consecutive patients 
(65±1 years of age) with bladder outlet obstruction due to BPH who underwent 
transvesical prostatectomy. Collected samples were immediately placed at 4-6ºC in 
mannitol transplantation solution at 400 mOsm/kg (M-400) not supplemented with 
ATP or adenosine (230 mM mannitol, 15 mM KH2PO4, 43 mM K2HPO4.3H2O, 15 mM 
KCL, and 10 mM NaHCO3, pH 7.4) and transported to the laboratory. Experiments 
were performed within the first 24h after collection, which corresponds to the tissue 
viability window. This study and all its procedures were approved by the Ethics 
Committees of CHP and ICBAS-UP and were authorized by the National 
Transplantation Committee. Regarding decease organ donation, the legal frame work 
allows the “Presumed Consent” stating that residents in Portugal are consenting 
donors for transplantation and research unless the individual previously objected 
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during his or her life. The investigation conforms to the principles outline in The Code 
of Ethics of the World Medical Association (Declaration of Helsinki).  
 
Quantification of [3H]ACh release 
The experiments were performed in isolated detrusor muscle strips without the 
mucosa of both human and rat urinary bladders. The mucosa was dissected out 
either by blunt dissection through cleavage at the lamina propria or by gently rubbing 
the urothelium with a cotton wool swab in human and rat bladder samples, 
respectively (Carneiro et al., 2014; Silva-Ramos et al., 2015a; Silva et al., 2017). Full 
thickness isolated detrusor muscle strips (3 mm width, 5 mm length; weighting 
9.2±0.5 mg (human) and 5.9±0.2 mg (rat)) were mounted in 365 µL capacity 
chambers of a Brandel SF-12 automated superfusion system (Valley International 
Corp., Austin, TX, USA) heated at 37ºC. Then, the preparations were continuously 
superfused with gassed (95% O2 and 5% CO2) Tyrode’s solution (pH 7.4) containing 
(mM): NaCl 137, KCl 2.7, CaCl2 1.8, MgCl2 1, NaH2PO4 0.4, NaHCO3 11.9, glucose 
11.2 and choline 0.001. After a 30 min equilibration period, cholinergic neurons were 
loaded during 40 min with 1 µM [3H]choline (specific activity 5 µCi nmol-1) under 
electrical field stimulation (1 Hz frequency, 0.2 ms pulse width, 75 mA) using two 
platinum-made grid electrodes placed above and below the muscle strip (transmural 
EFS stimulation). Following loading, the washout superfusion (1 ml/min) of the 
preparations was performed during 120 min with Tyrode’s solution supplemented 
with the choline uptake inhibitor, hemicholinium-3 (10 µM). Tritium outflow was 
evaluated by liquid scintillation spectrometry (TriCarb2900TR, Perkin Elmer, and 
Boston, USA; % counting efficiency: 56±2%) after appropriate background 
substraction, using 1 ml bath samples automatically collected every 1 min using the 
SF-12 suprafusion system. [3H]ACh release was evoked by two periods of EFS (S1 
and S2), each consisting of 200 square wave pulses of 0.2 ms duration delivered at 
10-Hz frequency. Test drugs were added 6 min before S2 and were present up to the 
end of the experiments. The evoked [3H]ACh release was calculated by subtracting  
the basal tritium outflow from the total tritium outflow during the stimulation period 
(see e.g. ref. Carneiro et al., 2014 and Silva et al., 2017). In control situations, S2/S1 
ratio were 0.99±0.04 (n=6) and 0.96±0.02 (n=4) in human and rat detrusor samples, 
respectively. 
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Measurement of adenosine release 
The procedures used to measure the release of adenine nucleosides 
(adenosine and inosine) were previously described (see e.g. Correia-de-Sá et al., 
2006; Vieira et al., 2014; Silva et al., 2017). Experiments were performed in isolated 
rat and human detrusor strips without the mucosa using an automated perfusion 
system for sample collecting for given time periods, therefore improving the efficacy 
of HPLC (with diode array detection). After a 30-min equilibration period, the 
preparations were incubated with 2.8 mL gassed Tyrode’s solution, which was 
automatically changed every 15 min by emptying and refilling the organ bath with the 
solution in use. In these experiments, samples retained for analysis were collected 
15, 30 and 45 min after starting the experimental protocol (zero time). Isoprenaline (1 
µM) and mirabegron (0.1 µM) were added to the incubation solution after the first 
collection (Basal, 15 min) and were kept in contact with the preparation at least for 15 
min (Drug 30 min) before starting electrical field stimulation (Drug + EFS, 45 min), 
which consisted in 3000 square wave pulses of 1 ms duration delivered at a 10-Hz 
frequency. Bath aliquots (50-250 µl) were frozen in liquid nitrogen immediately after 
collection, stored at -20ºC (the enzymes are stable for at least 4 weeks) and 
analyzed within 1 week of collection by HPLC with diode array detection (Finnigan 
Thermo Fisher Scientific System LC/DAD, equipped with an Accela Pump coupled to 
an Accela Autosample, a diode array detector and an Accela PDA running the X-
Calibur software chromatograph manager). Chromatographic separation was carried 
out through a Hypersil GOLD C15 column (5 µM, 2.1 mm x 150 mm) equipped with a 
guard column (5 µm, 2.1 mm x 1mm) using an elution gradient composed of 
ammonium acetate (5 mM, with a pH of 6 adjusted with acetic acid) and methanol. 
During the procedure the flow rate was set at 200 µl per min and the column 
temperature was maintained at 20ºC. The autosampler was set at 4ºC and 50 µl of 
standard or sample was injected, in duplicate, for each HPLC analysis. In order to 
obtain chromatograms and quantitative analysis with maximal sensibility, the diode 
array detection wavelength was set at 259 nm for adenosine and 248 nm for inosine. 
 
Western blot analysis 
Human and rat detrusor strips without the mucosa were homogenized in radio-
immunoprecipitation assay buffer (Tris-HCl 25 mM (pH 7.6), NaCl 150 mM, sodium 
deoxycholate 1%, Triton-X-100 1%, sodium dodecyl sulfate (SDS) 0.1%, EDTA 5 
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mM) plus a protease inhibitor cocktail. Protein content of the samples was evaluated 
using the BCA protein assay kit according to the manufacturer’s instructions (Pierce, 
Rockford, IL, USA). Samples were solubilized in SDS reducing buffer (Tris-HCl 125 
mM (pH 6.8), SDS 4% bromophenol blue 0.005%, glycerol 20% and 2-
mercaptoethanol 5%) at 70ºC for 10 min, subjected to electrophoresis in 10% SDS-
polyacrylamide gels and electrotransferred onto polyvinylidene difluoride (PVDF) 
membranes (MilliPore, MA, USA). Protein loads were 75 and 150 µg. The 
membranes were, then, blocked in Tris-buffered saline (in mM: Tris-HCl 10 (pH 7.6), 
NaCl 150) containing Tween 20 0.05% and bovine serum albumin (BSA) 5% and, 
subsequently, incubated with (Table 10) anti-A1 receptor from Abcam (Ab75177), 
anti-β3 receptor from MBL International (MC-4198) and anti-ENT1 from Alomone 
(ANT051) (host species: rabbit (rb)) in the above blocking buffer overnight at 4ºC. 
Membranes were washed three times for 10 min in TBS/Tween-20 an incubated with 
horseradish peroxidase-conjugated secondary antibody (1:25000; Abcam, 
Cambridge, UK) for 1 h at room temperature. For normalization purpose, membranes 
were incubated with the mouse anti-glyceraldehyde 3-phosphate dehydrogenase 
(GAPDH, EC 1.2.1.12) primary antibody from Santa Cruz (1:200, SC-32233, Dallas 
TX, USA) following the procedures described above. Membranes were washed three 
times for 10 min and the antigen-antibody complexes were visualized with the 
Immun-Star WesternC Chemiluminescence Kit using the ChemiDoc MP imaging 
system (Bio-Rad Laboartories, Hercules, CA, USA). 
 
Table 10. Primary and secondary antibodies used in the Western blot experiments. 
Antigen Code Host Dilution Supplier 
Primary antibodies: 
Anti-A1 receptor Ab75177 Rabbit 1:250 Abcam 
Anti-β3 receptor MC-4198 Rabbit 1:50 MBL International 
Anti-ENT1 ANT-051 Rabbit 1:50 Alomone 
Anti-GAPDH Sc-32233 Mouse 1:200 Santa Cruz 
Secondary antibodies:    
IgG HRP anti-rb Ab98503 Donkey 1:70000 Abcam 
 
In vivo cystometry recordings 
The experiments were carried out in urethane-anaesthetized rats (1.0-1.2 
g/kg), spontaneously breathing. Core body temperature was kept between 36ºC and 
38ºC with the help of a heating pad controlled by a thermosensor connected to a 
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rectal probe. A catheter connected to an injection pump was inserted into the left 
jugular vein to permit saline infusion (4 ml/h/kg) and intravenous drugs application. 
After exposing the urinary bladder through a median abdominal incision, a three-
barrel catheter was inserted through its dome. One barrel, was connected to an 
automate perfusion pump for saline and/or drugs infusion; a second barrel, was 
attached to a pressure transducer for continuous monitoring of intravesical pressure; 
the third barrel was used either to drain or to close the bladder circuit in order to 
initiate the micturition reflex. The bladder pressure was continuously monitored on a 
computer screen with a PowerLab data acquisition system (Chart 5, version 4.2 
software; AD Instruments, USA), which was also used to record hemodynamic and 
respiratory parameters in the anaesthetized rat. After surgical preparation, a 60-min 
equilibration period was undertaken during which saline was infused into the urinary 
bladder at 0.04 ml/min and allowed to freely drain out of the bladder (open circuit). 
The micturition reflex was initiated by closing the draining barrel while keeping 
intravesical infusion of saline at a constant flow rate (0.04 ml/min), which is within the 
range used in previous studies to obtained stable micturition cycles during 
continuous cystometrograms in anaesthetized rats (Carneiro et al., 2014; Honda et 
al., 2012; Timóteo et al., 2014; Silva et al., 2017). The flow rate was 2 to 4-fold higher 
than the normal urinary debit in experimental rats (15-30 ml/d) and compare to the 
conditions used in standard filling cystometry (urodynamic test) in humans. Voiding 
contractions were assumed as large-amplitude rhythmic bladder contractions 
accompanied by urine draining through the urethra when bladder pressure reached a 
certain threshold. The intercontraction interval (ICI, min) and the pressure threshold 
(PTh, cm of H2O) that is require to initiate the voiding reflex are normally associated 
with the sensitive component of the micturition reflex (filling phase); conversely, the 
amplitude (A, cm of H2O) and the duration (∆t, sec) of the voiding contractions are 
mostly associated with the motor component of the micturition reflex (empyting 
phase). For the sake of clarity, the results presented in this study will consider the 
percent variation of ICI values as compared to the control situation achieved after six 
consecutive voiding contractions of similar amplitude. Test drugs were applied either 
into the bladder lumen (by changing the syringe connected to the automate perfusion 
pump, 0.04 ml/min) or intravenously through the catheter inserted into the left jugular 
vein.  
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Drugs and Solutions 
Hemicholinium-3, 1,3-dipropyl-8-cyclopentylxanthine (DPCPX), 1,9-
dideoxyforskolin (1,9-ddFSK), choline chloride, 7β-acetoxy-8,13,epoxy-1α,6β,9α-
trihydroxylabd-14-en-11-one (Forskolin, FSK), S-(p-nitrobenzyl)-6-thioinosine (NBTI), 
α-[2-(3-Chlorophenyl)hydrazinylidene]-5-(1,1-dimethylethyl)-b-oxo-3-
isoxazolepropanenitrile (ESI-09) were obtained from Sigma (St Louis, MO, USA); 
isoproterenol hydrochloride (Isoprenaline), N-[2-[[3-(4-Bromophenyl)-2-
propenyl]amino]ethyl]-5-isoquinoline sulfonamide dihydrochloride (H-89) were 
obtained from Tocris Bioscience (Bristol, UK); N-[[3-[(2S)-2-Hydroxy-3-[[2-[4-
[(phenylsulfonyl)amino]phenyl]ethyl]amino] propoxy]phenyl]methyl]-acetamide (L-
749,337) was obtained from Santa Cruz (Dallas, USA); mirabegron was obtained 
from Selleckchem.com (Houston, USA); dipyridamole was obtained from Boehringer 
Ingelheim (Germany); [methyl-3H] choline chloride (ethanol solution, 80.6 Ci nmol-1) 
was obtained from PerkinElmer (Boston, USA). DPCPX was dissolved in a 5 mM 
stock solution in 99% dimethylsulfoxide (DMSO) + 1% NaOH 1 M (v/v). Mirabegron, 
FSK, 1,9-ddFSK, ESI-09 and NBTI were dissolved in DMSO, respectively. Other 
drugs were prepared in Tyrode’s solution. All stock solutions were stored as frozen 
aliquots at -20ºC. Dilutions of these stock solutions were made daily and appropriate 
solvent controls were done. No statistical differences between control experiments, 
made in the absence or in the presence of the solvents at the maximal 
concentrations used (0.5% v/v) were observed. 
 
Presentation of data and statistical analysis 
Results are expressed as mean±SD, with n indicating the number of 
individuals used for a particular set of experiments. Only one experimental procedure 
(e.g. agonist in the absence and in the presence of the antagonist) was performed 
per individual. Statistical analysis of data was carried out using Graph Pad Prism 
6.04 for Windows software (La Jolla, USA). Paired and unpaired Student’s t-test with 
Welch’s correction was used for statistical analysis when parametric data was 
considered. One-way analysis of variance (ANOVA) followed by the Dunnett´s post 
test was used for multiple comparisons. P<0.05 (two-tailed) values were considered 
statistically significant. 
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RESULTS 
β3-Adrenoceptors activation favours adenosine release from human and 
rat urinary bladders through downstream activation of cyclic AMP-dependent 
pathways 
Mirabegron (0.1 µM) and isoprenaline (1 µM) stimulate adenosine (plus 
inosine) outflow from urothelium-denuded human and rat detrusor samples, 
respectively (Silva et al., 2017; see Paper 3 this thesis). Like our previous results 
obtained in the rat detrusor, involvement of β3-adrenoceptors leading to increases in 
the transport of the nucleoside through ENT was confirmed by attenuation of the 
mirabegron (0.1 µM)-induced adenosine outflow from the human detrusor upon 
blocking selectively β3-adrenoceptors with L748,337 (30 nM, Figure 26Aii) and the 
ENT transport system with dipyridamole (Dipy 0.5 µM, Figure 26Aiii). 
In order to test the involvement of cAMP-dependent pathways downstream 
activation of β3-adrenoceptors activation, we used H-89 (10 µM) and ESI-09 (10 µM) 
to selectively inhibit the activation of PKA and EPAC, respectively. Preincubation with 
H-89 (10 µM) and ESI-09 (10 µM) prevented mirabegron (0.1 µM)- and isoprenaline 
(1 µM)-induced increase of adenosine (plus inosine) release from urothelium-
denuded human (Figure 26A) and rat (Figure 26B) detrusor samples, respectively. 
These results suggest that β3-adrenoceptors activation favours adenosine release 
from human and rat urinary bladders through downstream activation of PKA and 
EPAC.  
The ability of the preparations to release adenosine (plus inosine) after 
preincubation with inhibitors of the adenosine transport and cAMP activated enzymes 
was confirmed by testing the amount of adenosine released to the incubation bath 
following electrical stimulation of the preparations (EFS) with 3000 pulses delivered 
at 10 Hz during 5 min. In the absence of test drugs, EFS increased (P<0.05) 
ADO+INO levels in the incubation solution from 26.0±2.4 to 47.0±5.7 pmolmg-1 (n=6) 
of dry weight of preparation in the human detrusor and from 22.8±3.6 to 33.4±4.2 
pmolmg-1 (n=6) of dry weight of preparation in the rat detrusor. EFS-induced 
adenosine (plus inosine) outflow in the presence of test inhibitors applied at least for 
15 min was not significantly (P>0.05) different from control values (data not shown). 
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Figure 26. Effects of mirabegron (0.1 µM, A) and isoprenaline (Isop, 1 µM, B) on adenosine 
(and inosine) outflow from urothelium-denuned human and rat detrusor strips, respectively, in the 
absence and in the presence of inhibitors of PKA (H-89, 10 µM) and EPAC (ESI-09, 10 µM). The 
blocking effects of the β3-adrenoceptor antagonist, L748,337 (30 nM), and the ENT1 transport 
inhibitor, dipyridamole (Dipy 0.5 µM), on mirabegron-induced adenosine release from the human 
detrusor is also shown. Mirabegron and isoprenaline contacted with the preparations for 15 min before 
sample collection. The inhibitors were present throughtout the assay and were applied 15 min before 
mirabegron or isoprenaline. The ordinates represent the concentration of adenosine (ADO, white bars) 
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and inosine (INO, black bars) detected by HPLC with diode array detection in samples collected from 
the incubation media at 15 min intervals (for details, see Materials and Methods). The data are means 
± SD of four to six individuals; duplicates were performed for each individual experiment. *P<0.05 
(one-way ANOVA followed by the Dunnett’s post test) represent significant differences when 
compared to the control situation (basal/inhibitor alone).  
 
β3-Adrenoceptors decrease electrically-evoked ACh release through a 
mechanism depending on EPAC activation in human and rat urinary bladders 
Activation of β3-adrenoceptors with mirabegron (0.1 µM, Figure 27A) and 
isoprenaline (1 µM, Figure 27B) significantly reduced (P<0.001) electrically-evoked 
[3H]ACh release from urothelium-denuded detrusor strips isolated from humans 
(0.44±0.09, n=5, Figure 27A) and rats (0.49±0.06, n=4, Figure 27B), respectively 
(Silva et al., 2017; see Paper 3 this thesis). Inhibition of the EPAC pathway with ESI-
09 (10 µM) attenuated (P<0.01) mirabegron (0.1 µM)- and isoprenaline (1 µM)-
induced inhibition of evoked [3H]ACh release from isolated human (0.94±0.11, n=5, 
Figure 27A) and rat (0.75±0.05, n=6, Figure 27B) detrusor strips, respectively. This 
contrasts with the lack of effect of the PKA inhibitor, H-89 (10 µM), under the same 
experimental conditions (Figure 27A and 27B).  
Likewise, ESI-09 (10 µM, 0.85±0.07, n=6; P<0.01), but not H-89 (10 µM, 
0.59±0.02, n=6; P>0.05), significantly decreased the inhibitory effect of forskolin 
(FSK 3 µM, 0.39±0.04, n=4; P<0.001), a direct activator of the catalytic subunit of 
adenylyl cyclase that mimicked the inhibitory effect of the β3-adrenoceptor activation 
by isoprenaline (1 µM), on evoked [3H]ACh release from isolated rat detrusor strips 
(Figure 27C). These results suggest that β3-adrenoceptors-induced inhibition of 
evoked [3H]ACh release from human and rat detrusor samples depends on 
downstream EPAC activation. 
To confirm the specificity of the inhibitory effect of FSK (3 µM) on cAMP-
dependent pathways, we tested the effect of 1,9-dideoxyforskolin (1,9-ddFSK, 3 µM), 
a FSK analogue that is inactive on adenylyl cyclase (Laurenza et al., 1999). Figure 
27C shows that 1,9-ddFSK (3 µM) did not significantly inhibit the electrically-evoked 
[3H]ACh release from the isolated rat detrusor (0.73±0.06, n=5; P>0.05) under the 
same experimental conditions. The absence of effect of 1,9-ddFSK on evoked 
[3H]ACh release was also observed in longitudinal muscle-myenteric plexus 
preparations of the rat ileum (Duarte-Araújo et al., 2004). 
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Figure 27.  (A) Changes in the inhibitory effects of mirabegron (0.1 µM), (B) isoprenaline (1 
µM), and (C) forskolin (3 µM) on electrically-evoked [3H]ACh release from urothelium-denuded human 
and rat detrusor strips, respectively. [3H]ACh release was elicited by electrical field stimulation (10 Hz, 
200 pulses of 0.2 ms duration) twice, starting at 4th (S1) and 13th (S2) minutes after the end of washout 
(zero time). Mirabegron (0.1 µM), isoprenaline (1 µM), and forskolin (3 µM) were applied 6 min before 
S2 either in the absence or in the presence H-89 (10 µM, a PKA inhibitor) or ESI-09 (10 µM, an EPAC 
inhibitor) throughout the assay, including S1 and S2. For comparison purposes, we also tested the 
effect of the FSK inactive analogue on adenylyl cyclase, 1,9-dideoxyFSK (1,9-ddFSK, 3 µM), on 
[3H]ACh release from rat detrusor strips. Ordinates are changes in S2/S1 ratios compared to the S2/S1 
ratio obtained without addition of any drug (dotted horizontal line). The data are means±SD of an n 
number of individuals. #P<0.001 (one-way ANOVA followed by the Dunnett’s post test) represent 
significant differences when compared to the control situation; **P<0.01 (one-way ANOVA followed by 
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the Dunnett’s post test) represent significant differences when compared to the inhibitory effect of 
mirabegron, isoprenaline or FSK, respectively. 
 
Direct activation of adenylyl cyclase with FSK (3 µM) also decreases 
cholinergic neurotransmission depending on adenosine outflow via 
equilibrative nucleoside transporters and stimulation of A1 receptors 
Data from our previous study demonstrate that inhibition of [3H]ACh release by 
β3-adrenoceptors activation is indirectly mediated by adenosine outflow via 
equilibrative nucleoside transporters (ENT) from stimulated detrusor smooth muscle 
fibers and retrograde activation of prejunctional A1 receptors in both human and rat 
urinary bladders (Silva et al., 2017). Here, we show that direct activation of adenylyl 
cyclase with FSK (3 µM) mimicked the inhibitory effect of isoprenaline (1 µM) on 
evoked [3H]ACh release from urothelium-denuded rat detrusor strips (Figure 27A). 
Like that occurring with isoprenaline (Silva et al., 2017), the inhibitory effect of FSK (3 
µM, 0.39±0.04, n=4; P<0.001) on evoked [3H]ACh from the rat detrusor was reversed 
upon blocking prejunctional prejunctional A1 receptors with 1,3-dipropyl-8-
cyclopentylxanthine (DPCPX, 100 nM; 1.25±0.08, n=7; P<0.01) (Figure 28A). This 
result suggests that FSK-induced decrease of evoked [3H]ACh release in the rat 
detrusor also depends on the activation of inhibitory adenosine A1 receptors.  
In many tissues, including the rat bladder, intracellular cAMP is rapidly 
degraded by phosphodiesterases into AMP and adenosine inside cells, which 
translates into increased amounts of adenosine released to the extracellular milieu 
via ENT (Silva et al., 2017). Synaptic accumulation of adenosine negatively 
modulates ACh release from cholinergic bladder nerves (Silva-Ramos et al., 2015a). 
In view of this, we tested the effects of two ENT inhibitors, dipyridamole (Dipy, 0.5 
µM) and S-(4-nitrobenzyl)-6-thioinosine (NBTI, 30 µM), on evoked transmitter release 
inhibition by FSK (3 µM) in the rat detrusor; in contrast to dipyridamole, NBTI is a 
selective ENT1 inhibitor with no affinity for phosphodiesterase enzymes. Figure 28A 
shows that the inhibitory effect of FSK (3 µM, 0.39±0.07, n=4) on evoked [3H]ACh 
release from rat detrusor strips was reversed in the presence of dipyridamole (0.5 
µM, 1.11±0.15, n=5) or NBTI (30 µM, 0.95±0.11, n=7). A similar result was obtained 
when isoprenaline (1 µM) was used instead of FSK (3 µM) (Silva et al., 2017; see 
Paper 3 this thesis). 
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Figure 28. (A) Changes in the effect of forskolin (FSK, 3 µM) on electrically-evoked [3H]ACh 
release from urothelium-denuded rat detrusor strips in the absence and in the presence of the 
selective adenosine A1 receptor antagonist, DPCPX (100 nM), and two equilibrative nucleoside 
transport inhibitors, dipyridamole (Dipy, 0.5 µM) and NBTI (30 µM). [3H]ACh release was elicited by 
electrical field stimulation (10 Hz, 200 pulses of 0.2 ms duration) twice, starting at 4th (S1) and 13th (S2) 
minutes after the end of washout (zero time). FSK (3 µM) was added to the incubation media 6 min 
before S2; DPCPX, dipyridamole and NBTI were present throughout the assay, including S1 and S2. 
Ordinates are changes in S2/S1 ratios compared to the S2/S1 ratio obtained without addition of any 
drug (dotted horizontal line). The data are means ± SD of an n number of animals. #P<0.001 (one-way 
ANOVA followed by the Dunnett’s post test) represent significant differences when compared to the 
control situation; **P<0.01 (one-way ANOVA followed by the Dunnett’s post test) represent significant 
differences when compared to the inhibitory effect of FSK. (B) Bladder cystometry recordings during 
normal saline (0.9% w/v of NaCl) and forskolin (1 µM) infusion into the urinary bladder of urethane-
anaesthetized rats. Large-amplitude bladder contractions correspond to voiding contractions. Traces 
obtained during the filling phase of the micturition reflex (dotted rectangles) were enlarged to show 
non-voiding spontaneous microcontractions. (C) Shown is the effect of increasing the concentration of 
forskolin (0.03-10 µM) inside the lumen of the urinary bladder on the cystometry parameters recorded: 
Pressure threshold (PTh), intercontraction interval (ICI), contraction duration (∆t) and amplitude (A). 
Control values correspond to zero percent variation. The vertical bars represent ± SD of three to five 
animals. *P<0.01 (two-way ANOVA followed by the Dunnett’s post test) represents significant 
differences as compared to the control situation (zero percent). 
 
Instillation of FSK (0.03-10 µM) into the bladder lumen of anaesthetized rats 
concentration-dependently decreased the number and amplitude of non-voiding 
spontaneous microcontractions and the micturition frequency (Figure 28B); the latter 
was evidenced by prolongation of the intercontraction interval (ICI) without 
significantly (P>0.05) modifying the pressure threshold (PTh), the amplitude (A) and 
the duration (Δt) of voiding bladder contractions (Figure 28C). These results are 
similar to the cystometry recordings obtained when isoprenaline was used instead of 
FSK (see Silva et al., 2017). Instillation of forskolin (0.03-10 µM) into the bladder 
lumen did not (P>0.05) affect the heart rate (464±70 bpm, n=5) of urethane-
anaesthetized rats compared to the saline infusion (445±93 bpm, n=5) under the 
same experimental conditions.  
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Isoprenaline-induced decrease in the voiding frequency in urethane- 
anaesthetized rats depends on EPAC activation 
Figure 29 shows that pretreatment with the selective EPAC inhibitor, ESI-09 
(10 µM), prevented the decrease in the voiding frequency (prolongation of the ICI 
interval) caused by instillation of isoprenaline (0.1-1000 nM) into the bladder lumen, 
whereas inhibition of PKA with H-89 (10 µM) had no effect. Neither of these drugs 
affected the urodynamic parameters when applied alone (data not shown). Instillation 
of H-89 (10 µM) and ESI-09 (10 µM) into the bladder lumen also did not significantly 
(P>0.05) affect the heart rate (429±28 bpm, n=4 and 416±62 bpm, n=5, respectively) 
of urethane-anaesthetized rats when compared to the saline infusion (425±28 bpm, 
n=4 and 392±69 bpm, n=5, respectively). The results suggest that the inhibitory 
effect of isoprenaline (0.1-1000 nM) on the distension-induced micturition reflex in the 
rat in vivo depends on EPAC, but not PKA, activation.  
 
 
 Figure 29. Shown are concentration-response curves of isoprenaline (0.01-1 µM)-induced 
prolongation of the intercontraction interval (ICI) of voiding contractions in the absence and in 
presence of (i) H-89 (10 µM) and (ii) ESI-09 (10 µM). Control values correspond to zero percent 
variation. The vertical bars represent SD of an n number of animals (shown in parenthesis). *P<0.01 
(one-way ANOVA followed by the Dunnett’s post test) represents significant differences as compared 
to the effect of isoprenaline applied alone. 
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β3-Adrenoceptors activation inhibits cholinergic neurotransmission with 
a similar potency in control individuals and in patients with bladder obstruction 
due to benign prostatic hyperplasia (BPH)  
In a previous study, our group showed that electrically-evoked [3H]ACh release 
increases by 1.5-fold (P<0.001) in the detrusor of obstructed patients due to BPH 
compared to control organ donors (Silva-Ramos et al., 2015a). We also showed that 
the A1 receptor is upregulated in VAChT-positive cholinergic nerve terminals of the 
detrusor of obstructed BPH patients, which may contribute to explain the increased 
inhibitory sensitivity to adenosine of nerve-evoked [3H]ACh release in these patients 
compared to control individuals (Silva-Ramos et al., 2015a). These findings, together 
with the results suggesting that inhibition of evoked [3H]ACh release by β3-
adrenoceptors activation is indirectly mediated by adenosine released via ENT1 and 
stimulation of prejunctional inhibitory A1 receptors (Silva et al., 2017), prompted us to 
investigate the effect of mirabegron on evoked [3H]ACh release from detrusor strips 
of obstructed BPH patients in order to prove that this drug has a similar mechanism 
of action in pathological conditions. 
 
Figure 30.  Inhibitory effect of selective β3-adrenoceptors agonist, mirabegron (0.1 µM) on 
electrically evoked [3H]ACh release from mucosal-denuded detrusor strips of organ donors (Control) 
and patients with benign prostatic hyperplasia (BPH); Mirabegron (0.1 µM) was applied 6 min before 
S2; selective A1 receptors antagonist, DPCPX (100 nM) was present throughout all the assay, 
including S1 and S2; [3H]ACh release was elicited by electrical field stimulation (EFS, 10 Hz, 200 
pulses of 0.2 ms duration) twice, starting at 4th (S1) and 13th (S2) minutes after the end of washout 
(zero time). Ordinates are change in S2/S1 ratios compared to the S2/S1 ratio obtained without of any 
drug (dotted horizontal line). The data are means ± SD of a n number of individuals; duplicates were 
performed for each individual experiment. #P<0.001 (one-way ANOVA followed by the Dunnett’s post 
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test) represents significant diferences when compared to the control situation; **P<0.01 (one-way 
ANOVA followed by the Dunnett’s post test) represents significant diferences when compared to the 
inhibitory effect of mirabegron (0.1 µM).  
 
Figure 30 shows that the inhibitory effect of mirabegron (0.1 µM) on evoked 
[3H]ACh release from urothelium-denuded detrusor strips had a similar magnitude in 
control individuals (0.44±0.09, n=5) and in obstructed BPH patients (0.42±0.06, n=5). 
Like that observed in control individuals (Silva et al., 2017; see also Paper 3), 
mirabegron (0.1 µM)-induced decrease of electrically-evoked transmitter release was 
prevented (0.80±0.30, n=5) by the selective β3-adrenoceptor antagonist, L748,337 
(30 nM). The inhibitory effect of mirabegron (0.1 µM) was also dependent on 
activation of adenosine A1 receptors, because its effect was significantly attenuated 
(P<0.05) in the presence of the selective A1 receptor antagonist, DPCPX (100 nM), 
both in control individuals (0.87±0.07, n=5) and obstructed BPH patients (0.71±0.18, 
n=2) (Figure 30).  
 
β3-Adrenoceptors and adenosine A1 receptors are overexpressed while 
ENT1 is downregulated in the detrusor of obstructed BPH patients 
Given that β3-adrenoceptors activation by mirabegron caused a similar 
inhibitory effect on [3H]ACh release from detrusor strips of control individuals and 
obstructed BPH patients, independently of the fact that adenosine A1 receptors are 
overexpressed in cholinergic nerves of BPH patients, we tested the possibility that 
β3-adrenoceptors and/or ENT transporters were downregulated in the detrusor of 
BPH patients.  
The immunoblots depicted in Figure 31 show that β3-adrenoceptors are 1.5 
fold (n=4) enriched (P>0.05) in detrusor lysates of obstructed BPH patients 
compared to control organ donors. The MC-4198 antibody detected a major band 
with an apparent size of 56-59 kDa that is compatible with a glycosylated form of the 
human β3-adrenoceptor. Consistent with increases in function and immunostaining 
detected by confocal microscopy (Silva-Ramos et al., 2015a), we show here that the 
A1 receptor protein is 4.5 fold (n=4) more abundant (P<0.01) in detrusor lysates of 
obstructed BPH patients than in control individuals; the detected band of 45 kDa is 
closer to the predicted band size of 36 kDa.  
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On the contrary, we observed a decrease in the ENT1 protein content in 
detrusor lysates of obstructed BPH patients, which exhibit only 0.35 (n=3) of the total 
amount detected in control individuals; the detected band of 57 kDa was similar to 
the predicted band size of 50-55 kDa.  
 
Western blot analysis
rbβ3 rbA1msGAPDH msGAPDH
C BPH C BPH C BPH C BPH
59-58
45
60-55
rbENT1 msGAPDH
C BPH
 
Figure 31. Shown are representative immunoblots of the β3-adrenoceptor, the A1-receptor and 
the equilibrative nucleoside transporter ENT1 in detrusor homogenates of control individuals (C) and 
obstructed patients due to benign prostatic hyperplasia (BPH), run in parallel. Please note that human 
detrusor homogenates express a prominent bands at 49,9-59,6 kDa to β3-adrenoceptor, 45 kDa to 
receptor of adenosine A1, and 55-60 kDa to ENT1 transporter. The highly conserved GAPDH enzyme 
(EC 1.2.1.12, MW~37kDa) was used a reference protein. Gels were loaded with 150 or 100 µg of 
protein. Host species for antibody production were rabbit (rb) and mouse (ms). 
 
DISCUSSION 
We show here for the first time that adenylyl cyclase (AC) activation, either 
directly by FSK or through stimulation of Gs-protein-coupled β3-adrenoceptors with 
mirabegron and isoprenaline, promotes adenosine outflow into the extracellular 
milieu via ENT1 transport system through preferential downstream stimulation of the 
exchange protein directly activated by cAMP (EPAC) in human and rat detrusor 
samples. Data from this study also strengthens the theory that the inhibitory role of 
β3-adrenoceptor agonists on cholinergic neurotransmission in the urinary bladder is 
indirectly mediated by adenosine release to the synaptic cleft leading to retrograde 
activation of inhibitory A1 receptors located on cholinergic nerve terminals (Silva et 
al., 2017).  
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Selective β3-adrenoceptor agonists, like as mirabegron or solabegron, were 
recently proposed as efficacious and more tolerable alternatives to anti-muscarinic 
drugs for the treatment of overactive bladder (OAB) syndromes (Thiagamoorthy et 
al., 2015). The criteria to introduce β3-adrenoceptor agonists into the clinical setting 
overlooked the dispute on the molecular mechanism of action of these drugs and the 
precise cellular location of β3-adrenoceptors in the human bladder. β3-Adrenoceptors 
were initially found to be predominantly located on detrusor smooth muscle 
membranes (Fujimura et al., 1999; Igawa et al., 1998; Igawa et al., 1999). This 
localization was confirmed later on by immunofluorescence confocal microscopy 
using multiple antibodies directed towards different epitopes of the β3-adrenoceptor 
both in human (Silva et al., 2017) and murine (Griffin et al., 2017). The presence of 
these receptors on cholinergic nerve terminals of the human bladder has recently 
been proposed (Coelho et al., 2017), but in contrast to previous studies these 
authors used different experimental conditions, which include less discriminative 
epifluorescence microscopy, thicker slices, distinct tissue fixation methods and more 
heterogeneous bladder sample donors.  
Improvement of OAB symptoms by β3-adrenoceptor agonists, like mirabegron, 
was initially attributed to direct relaxation of the detrusor smooth muscle (Igawa et al., 
1999; Takeda et al., 1999; Wuest et al., 2009), but this assumption has been 
questioned (Andersson, 2017; Okeke et al., 2017) mostly because the peak plasma 
levels of mirabegron when administrated in therapeutic (50 mg daily) doses (83-167 
nM) are below its potency (EC50~1-3 µM) to relax detrusor smooth muscle strips 
(Michel and Korstanje, 2016). Newer theories suggest that β3-adrenoceptor agonists 
decrease OAB symptoms by reducing afferent nerves activity during bladder filling 
(Woods et al., 2001; Aizawa et al., 2015) and/or by inhibiting ACh release from 
parasympathetic postganglionic nerves innervating the detrusor (D’ Agostino et al., 
2015). Recently, our group added valuable information to these theories by showing 
that β3-adrenoceptors-induced inhibition of bladder overactivity may be indirectly 
mediated by adenosine released from detrusor smooth muscle fibers leading to 
retrograde activation of inhibitory A1 receptors localized on cholinergic nerve 
terminals (Silva et al., 2017). These new paradigms may be clinically relevant 
because, contrary to the initial belief that normally no parasympathetic nerve drive 
was observed during bladder storage, recent evidence demonstrates that there is 
release of ACh from both neuronal and nonneuronal sources, such as the urothelium 
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and lamina propria, during the filling phase of the micturition cycle (Yoshida et al., 
2004; reviewed in Winder et al., 2014). This cholinergic trend may be directly or 
indirectly exaggerated in overactive bladder patients via the balance between 
“regulatory” (e.g. noradrenaline, adenosine, NO) and “danger” (e.g. ATP, substance 
P, prostaglandins) molecules (Birder and de Groat, 2006; Silva et al., 2015; 2017). 
Reduction of the cholinergic tone responsible for nonvoiding bladder contractions, 
acting in coordination with the sensory inhibitory drive caused by β3-adrenoceptor 
agonists and endogenous adenosine (via A1 receptors) shown in anaesthetized rats, 
may increase bladder compliance during the filling phase of the micturition cycle 
resulting in improvement of OAB symptoms (Silva et al., 2017). 
β3-Adrenoceptors usually couple to adenylyl cyclase via Gs proteins leading 
to the intracellular accumulation of cAMP (Tyagi et al., 2009). Despite increases in 
intracellular cAMP have been associated with detrusor relaxation, controversy still 
exists on whether the prototypical activation of adenylyl cyclase and cAMP 
generation by β3-adrenoceptor agonists is the single mechanism responsible for the 
inhibitory effect of these drugs on urinary bladder tone; other possibilities include 
modulation of membrane potential, ion-channels activity, and intracellular ion 
concentrations (Uchida et al., 2005; reviewed in Michel and Vrydag, 2006; 
Yamaguchi and Chapple, 2007). Notwithstanding this, data from the present study 
indicate that both isoprenaline (via β3-adrenoceptors activation) and the receptor-
independent adenylyl cyclase catalytic subunit activator, FSK (Seamon et al., 1981), 
decreased by a similar amount evoked [3H]ACh release from urothelium-denuded 
detrusor strips. Both drugs also diminished the number and amplitude of non-voiding 
spontaneous microcontractions and the micturition frequency in the anaesthetized 
rat, indicating the involvement of the cAMP-dependent pathway downstream β3-
adrenoceptors activation in the urinary bladder.  
Intracellular cAMP can be rapidly metabolized into AMP and adenosine by 
highly effective phosphodiesterases and 5’-nucleotidase, respectively. Consequently, 
this raises the transmembrane gradient forcing the nucleoside outflow to the 
extracellular compartment. Imaging and functional studies from our group suggest 
that β3-adrenoceptors-induced adenosine release from detrusor bladder strips results 
from translocation of the nucleoside across the plasma membrane of smooth muscle 
fibers via the ENT1 transporter subtype (Silva et al., 2017). Here, we show that β3-
adrenoceptors activation with nanomolar concentrations of mirabegron favors the 
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release of adenosine through a dipyridamole-sensitive ENT in urothelium-denuded 
human detrusor strips, thus confirming that the mechanism underlying the nucleoside 
outflow is similar to that observed in the rat bladder (Silva et al., 2017). Cyclic AMP 
may also be actively transported outside cells via several members of the group of 
ATP-binding cassette (ABC) transporters (Chen et al., 2001; Guo et al., 2003; 
Jedlitschky et al., 2000; van Aubel et al., 2002). Even though this mechanism has 
been described at the urinary bladder (Uchida et al., 2005) and cAMP can originate 
adenosine in the extracellular space through the sequential hydrolysis by 
ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1) and ecto-
5’nucleotidase/CD73 (see, e.g., Chiavegatti et al., 2008; Sassi et al., 2014), our 
findings indicate that extracellular cAMP is slowly metabolized into AMP by ENPP1 
which makes this pathway very little efficient in the detrusor of both humans and rats 
(Silva et al., 2017). 
Besides contributing to generate intracellular adenosine leading to 
translocation of the nucleoside to the extracellular milieu, β3-adrenoceptors-induced 
accumulation of intracellular cAMP results in downstream activation of cAMP-
dependent signalling pathways. The best known cellular effects of cAMP are 
attributed to the activation of PKA and cyclic nucleotide-regulated ion channels 
(reviewed in Wang et al., 2017). Activation the cAMP/PKA pathway has been 
involved in urinary bladder neurotransmission (Losavio and Muchnik, 2000), but no 
consensus exist on this matter considering the disparity of the results obtained using 
PKA inhibitors (e.g. H-89) in bladder nerves and detrusor (see, e.g. Frazier et al., 
2008). As a matter of fact, inhibition of PKA with H-89 blocked clenbuterol-induced 
detrusor relaxation while not affecting stimulation-induced muscle tone (Hudman et 
al., 2000). 
Mounting evidence point towards novel cAMP targets to explain cell responses 
that are insensitive to PKA inhibition (reviewed in Dekkers et al., 2013), which include 
the exchange protein directly activated by cAMP (EPAC) pathway (de Rooij et al., 
1998; Kawasaki et al., 1998). While both PKA and EPAC inhibitors, respectively H-89 
and ESI-09, prevented β3-adrenoceptors-induced release of adenosine in urothelium-
denuded detrusor strips from both humans and rats, only the EPAC inhibitor was 
able to remove the inhibitory effect of β3-adrenoceptor agonists on evoked [3H]ACh 
release from human and rat detrusor strips, as well as on the voiding frequency of 
anaesthetized rats. The ability of ESI-09 to selectively and competitively inhibit EPAC 
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activity when applied in concentrations below 20 µM has been demonstrated (Zhu et 
al., 2015) both in vitro (Almahariq et al., 2013) and in vivo (Gong et al., 2013; 
Almahariq et al., 2015). Thus, our findings suggest that stimulation of β3-
adrenoceptors favours adenosine outflow leading to inhibition of urinary bladder 
activity through a mechanism involving preferentially downstream activation of the 
EPAC pathway in human and rat detrusor samples.  
Paradoxical findings (e.g. adenosine outflow vs. ACh release) may result from 
the fact that PKA and EPAC may act independently, converge synergistically, or 
oppose each other in regulation of specific cellular functions depending upon their 
relative abundance, distribution and localization, as well as the specific cellular 
environments (Cheng et al., 2008). It seems that both pathways, PKA and EPAC, are 
equally active in the control of ENT1-mediated adenosine release from human and 
rat detrusor smooth muscle fibers following β3-adrenoceptors activation with 
mirabegron and isoprenaline, respectively. Thus, one should expect inhibition of the 
two cAMP-dependent pathways with H-89 (PKA) and ESI-09 (EPAC) to cause similar 
preventive effects on β3-adrenoceptors-induced inhibition of cholinergic nerves 
activity and of the sensory drive of the micturition reflex, unless PKA exerts a 
counteracting effect on these neural pathways that opposes its effect on adenosine 
release from detrusor smooth muscle fibers. Divergent effects of PKA activation 
within different cell types of the same tissue (e.g. urinary bladder) have been 
reported before using H-89 as PKA inhibitor (Frazier et al., 2008).  
Unlike PKA, EPAC is a cAMP-regulated guanine nucleotide exchange factor 
(GEF) with no kinase activity that favors GDP/GTP exchange and, thereby, activation 
of small Ras-like GTPases, such as Rho, Rac and Ras (de Rooji et al., 1998; 
Kawasaki et al., 1998). Two variants of EPAC protein have been characterized, 
EPAC1 and EPAC2; both forms are ubiquitously expressed. The expression of 
EPAC1- and EPAC2-related proteins has been recently demonstrated in the human 
detrusor smooth muscle (Hayashi et al., 2016). However, their functional role and 
underlying signaling targets are still unresolved. Here, we raise a novel hypothesis 
suggesting that the EPAC signaling pathway is the main responsible for the inhibitory 
effect of β3-adrenoceptor agonists in the urinary bladder by favouring the release of 
adenosine from human detrusor smooth muscle fibers via ENT1 transporters. The 
participation of the EPAC signaling cascade in cAMP-related cell adhesion 
(Ranjarajan et al., 2003; Enserink et al., 2004), cell communication (Cullere et al., 
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2005; Kooistra et al., 2005), cell exocytosis/secretion (Ozaki et al., 2000; Li et al., 
2007; Seino et al., 2005; Maillet et al., 2003), cell proliferation, viability and 
differentiation (Kiermayer et al., 2005; Certal et al., 2015), gene expression and 
phagocytosis (Cheng et al., 2008) brings up the possibility that some of these 
processes affecting the pathophysiology and progression of OAB syndromes might 
also be influenced by therapeutic doses of β3-adrenoceptor agonists.            
Whether differences in the molecular targets of PKA- and EPAC-activated 
pathways reflect their distinct influence on β3-adrenoceptors-mediated inhibition of 
urinary bladder function remains to be elucidated in future studies. Interestingly, the 
link between adenylyl cyclase activation, intracellular cAMP accumulation and 
downstream activation of cAMP-dependent pathways may change according to the 
β-adrenoceptor subtype and probably the pathologic condition. For instance, the β3-
adrenoceptor regulates cystic fibrosis transmembrane conductance regulator chloride 
current (CFTR), but not the mutated DF508-CFTR, through a PKA-independent 
pathway (Leblais et al., 1999). On the other hand, β1- and β2-adrenoceptors, but not 
the β3-adrenoceptor, mediated cAMP-dependent enhancement of vascular 
endothelial growth factor release by differentiated human monocytic cell challenged 
with  lipopolysaccharide (LPS) through downstream PKA activation (El-Zohairy et al., 
2015). Another hypothesis to explain the differential activation of cAMP signalling 
pathways is the observation that cytosolic cAMP unevenly diffuses within the cell and 
concentrates in certain local microdomains (Baillie, 2009). Differences in the 
distribution and activity of intracellular cAMP produced by prostaglandin EP2 and  β2 
receptors was demonstrated in human airway smooth cells (Agarwal et al., 2017). 
Taking into account these complexities, investigation on whether they influence 
bladder sensitivity to β3-adrenoceptor drugs due to changes in receptor coupling to 
distinct downstream cAMP targets, should be undertaken in the context of OAB 
syndromes. This hypothesis is strengthened because it has been demonstrated that 
cAMP-dependent regulation of RhoA/Rho-kinase overexpression attenuates detrusor 
overactivity in an experimental mouse model (Akakpo et al., 2017) and inhibition of 
this EPAC-regulated kinase can also reverse acetic acid-induced bladder overactivity 
in rats (Wrόbel and Rechberger, 2015). 
Interestingly, we show here that β3-adrenoceptors and adenosine A1 receptors 
are overexpressed in detrusor lysates of obstructed BPH patients compared to 
control men, but the opposite was verified regarding the amount of the ENT1 protein.  
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CONCLUSION 
Downregulation of the ENT1 protein expression in obstructed BPH patients 
may contribute to restrain adenosine release and, therefore, the A1 receptor-
mediated inhibition of transmitter release (Silva-Ramos et al., 2015a) to the levels 
one would not expect upon activation of overexpressed β3-adrenoceptors in the 
detrusor of BPH patients. Shortage of adenosine due to deficient outflow via ENT1 
from smooth muscle fibers might contribute to upregulate A1 receptors on cholinergic 
nerves in the detrusor of BPH patients, but limits their full activation capacity resulting 
in an overall identical inhibitory effect of the β3-adrenoceptor agonist, mirabegron, on 
cholinergic neurotransmission among patients and controls. Other authors have 
shown that mirabegron reduced carbachol-induced myographic contractions in 
isolated human detrusor preparations from patients with BOO with and without 
detrusor overactivity and from patients with normal bladder function with a similar 
potency (SvalØ et al., 2013). BOO has been associated with increased detrusor 
smooth muscle hypertrophy and bladder fibrosis (Collado et al., 2016). Thus, one 
may speculate that targeting β3-adrenoceptors, the cAMP-dependent EPAC signaling 
pathway and adenosine A1 receptors may be therapeutically beneficial not only to 
decrease cholinergic bladder hyperactivity (Silva-Ramos et al., 2015a; Silva et al., 
2017), but also to prevent irreversible bladder remodeling secondary to obstruction 
and/or overactivity profiting from the anti-proliferative role of the EPAC pathway on 
activated fibroblasts (Certal et al., 2015).  
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VII. GENERAL DISCUSSION 
It is widely accepted that purines, in particular ATP, are important regulators of 
urinary bladder functions in humans, as well as in other animal species. This 
nucleotide regulates both afferent and efferent signaling pathways. ATP (i) activates 
sensory nerves during bladder filling conveying both normal and abnormal 
sensations, like urgency and pain, (ii) acts as a co-transmitter with acetylcholine 
(ACh) in the parasympathetic control of bladder contraction during voiding, and (iii) 
participates in the central control of bladder reflexes (Fowler et al., 2008; Birder and 
Andersson, 2013). The purinergic tone increases significantly with age and it is 
responsible for up to 40% of nerve-evoked atropine-resistant bladder contractions in 
pathological conditions, including hypertrophic unstable bladder, overactive detrusor, 
neurogenic bladder and interstitial cystitis (Burnstock, 2001; Burnstock, 2006). The 
mechanisms underlying lower urinary tract symptoms (LUTS), as well as overactive 
bladder (OAB), are largely unknown, but these are usually divided into urothelial, 
myogenic and neurogenic. It thus appears that ATP plays a chief role in all of these 
mechanisms. Therefore, one may anticipate benefits in the treatment of LUTS using 
a combination of drugs targeting the purinome, which include ATP release sites, 
ectonucleotide-metabolizing enzymes, P1 and P2 purinoceptors and nucleoside 
transporters, all of these playing relevant roles in regulating urinary bladder function. 
Bladder ATP originates from both neuronal and non-neuronal sources, such 
as urothelial cells, interstitial cells, fibroblast-like cells and smooth muscle fibers. In 
the urinary bladder the primary source of ATP is the urothelium (Kumar et al., 2004). 
Associations between increased ATP levels (purinergic signaling) and lower urinary 
tract disorders have been intensively explored along of the past few years; however, 
the mechanisms causing these relationships are still unclear. In this context, our 
group explored the urinary ATP levels in a group of women with overactive bladder 
(OAB) and men with bladder outlet obstruction (BOO) due to benign prostatic 
hyperplasia (BPH), compared with age-matched controls. Besides determination of 
ATP levels in the urine, we also analyzed the content of nerve growth factor (NGF) in 
the same samples, taking into consideration the reported influence of NGF in the 
patophysiology of OAB syndromes (Liu et al., 2011; Ochodnicky et al., 2012; Cruz, 
2014). Our results show that urinary ATP, but not NGF, normalized by urinary 
creatinine or voided volume was significantly higher in OAB women with detrusor 
overactivity than in healthy controls (Silva-Ramos et al., 2013). We also found a 
____________________________________________________________GENERAL DISCUSSION 
PhD Thesis: Isabel Sofia Dias da Silva________________________________________172 
 
relationship between OAB severity and ATP levels, i.e. patients with OAB wet and 
low mean voided volume had significantly higher urinary ATP levels. Our results 
support a role of ATP in the pathogenesis of detrusor overactivity and suggest that 
urinary ATP may be a highly-sensitive dynamic biomarker of detrusor overactivity in 
women with OAB syndrome (Silva-Ramos et al., 2013). Non-invasive urinary ATP 
measurements may represent an improvement compared to other diagnostic and 
follow-up procedures requiring invasive urodynamic investigations (Silva-Ramos et 
al., 2013). 
LUTS are rather common in adult men over 60 years of age. Although BOO 
due to benign prostatic hyperplasia (BPH) is a common cause of LUTS, intrinsic 
bladder dysfunctions and disorders outside the urinary tract can contribute to these 
symptoms. In Europe, the prevalence of BOO due to BPH in patients with LUTS is 
about 50% (Oelke et al., 2007; Ockrim et al., 2001). Like in OAB women, our results 
showed that urinary ATP levels were also significantly higher in patients with BOO 
due to BPH than in age-matched control men; this was still verified after 
normalization of urinary ATP levels by the voided volume (Silva-Ramos et al., 
2016a). Results suggest that urinary ATP can be a high sensitive non-invasive 
biomarker of BOO, which may have a discriminative value of detrusor competence 
when comparing BPH patients with low urinary flow rates (Silva-Ramos et al., 
2016a). Our findings are clinically relevant because BPH is a very common disorder, 
but the differencial diagnosis of low urinary flow due to BOO or to underactive 
detrusor is difficult in the clinical practice, unless invasive urodynamic tests are 
performed. This is because LUTS are poor predictors of BOO and symptoms scoring 
tests alone are insufficient for accurate decision-making diagnosis (de la Rosette et 
al., 1998). Thus, the possibility of diagnosing detrusor competence in patients with 
BOO due to BPH using a non-invasive biochemical test is appealing, which makes 
urinary ATP a highly-sensitive dynamic biomarker of BOO (Silva-Ramos et al., 
2016a). In a rat model of partial BOO, it was demonstrated that bladder obstruction 
affects both urothelial and sub-urothelial cells leading to increases in ATP release 
from these cells (Shiina et al., 2016). These authors suggested that increased 
extracellular ATP levels may motivate non-voiding bladder tension and cause bladder 
instability. Besides many other signaling molecules released from the urothelium 
(e.g. neurotrophins, acetylcholine, prostaglandins, nitric oxide and cytokines), ATP 
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seems to be the main contributor to the voiding reflex and bladder pain (Merril et al., 
2016).  
The role of ATP as potential biomarker of bladder diseases is corroborated 
animal models of overactive and underactive bladder dysfunctions (Munoz et al., 
2011). ATP was used to follow the benefits of BoNT-A for the treatment of OAB in an 
animal model of chronic spinal cord injury (Smith et al., 2008). It is a common belief 
that investigation of the mechanisms underlying the activity of biomarkers migh 
contribute to a better understanding of the pathophysiology of certain diseases, like 
OAB syndromes (Antunes-Lopes et al., 2014). All evidence demonstrate that ATP 
has a great impact in LUTS, strengthenig our opinion that investigation of the bladder 
“purinome” may be paramount to prompt for novel therapeutic alternatives to 
common medications used in the treatment of OAB syndromes. 
Contrasting to the compelling evidence about the role of ATP and the 
purinergic cascade in bladder function and dysfunction, the role of uracil nucleotides 
in autocrine/paracrine actions controling bladder activity has increasingly been 
reported. Both, uridine triphosphate (UTP) and uridine diphosphate (UDP) were 
detected in human urine samples (Contreras-Sanz et al., 2012). Similarly to ATP, the 
amount of uracil nucleotides was also increased in the urine of OAB patients 
(Contreras-Sanz et al., 2012). Using urethane-anaesthetized rats, our group showed 
that activation of UDP-sensitive urothelial P2Y6 receptors augmented the voiding 
frequency indirectly by increasing the release of ATP from urothelial cells (Carneiro 
et al., 2014). Bladder overactivity produced by urothelial activation of P2Y6 receptors 
depends on the activation of ATP-sensitive P2X3 and P2X1 receptors located on 
sub-urothelial nerve afferents and smooth muscle detrusor fibers, respectively. Fine-
tuning control of this excitatory bladder drive may result from ATP hydrolysis to ADP 
by NTPDase2 located in the lamina propria (probably on interstitial cells) and on 
cholinergic nerve efferents. Formation of ADP at the cholinergic neuromuscular 
synapse decreases ACh release and, subsequent, detrusor contraction through the 
activation of prejunctional inhibitory P2Y1 receptors in rats (Carneiro et al., 2014). 
Deregulation of purinergic bladder signaling may contribute to persistent 
detrusor overactivity in patients with BOO. Work performed in the context of this 
thesis showed that activation of P2Y6 receptors also facilitates non-neuronal ATP and 
ACh release from the urothelium of men with BOO due to BPH. These findings led us 
to propose selective P2Y6 receptor blockade as a novel therapeutic strategy to 
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control persistent bladder storage symptoms in obstructed patients. The positive 
feedback involving the participation of ATP-sensitive P2X3 (and/or P2X2/3) receptors 
in the mechanosensory purinergic drive commanding the micturition reflex found in 
anaesthetized rats (Sun and Chai, 2006; Carneiro et al., 2014) was also observed in 
the urothelium of control men, but not in preparations of BPH patients. The lack of 
effect of fast desensitizing ATP-sensitive receptors might be explained because, in 
contrast to P2Y6, the immunoreactivity against P2X2 and P2X3 receptors decreased 
significantly in the urothelium of BPH patients (see also, Ruggieri, 2006). Urothelial 
ATP release may be a specific modulator in native tissue by purinergic and 
muscarinic neurotransmitters via distinct mechanisms. Released ATP produces 
paracrine effects on underlying tissues (Siu et al., 2014). 
Recently, the pharmacological profiles of spontaneous contractions of the 
mucosa and detrusor layers of the bladder wall were characterized separately. 
Interestingly, the magnitude of spontaneous contractions was higher in the intact 
bladder, followed by the isolated mucosa and the detrusor layer in that ordeer. This is 
paradoxical if one considers the percentage of smooth muscle fibers compared to 
other cell types, which was greater in the detrusor than in the mucosa (Kushida and 
Fry, 2016). Comparing mucosa and detrusor, the pharmacological profiles of the 
spontaneous contractions induced by P2X and P2Y receptor agonists, adenosine 
and capsaicin, were also different. Intact preparations showed tension responses 
which were intermediate to those obtained in the isolated mucosa and detrusor. Low 
extracellular pH generated bigger changes in the detrusor than in the mucosa. 
Mucosal preparations released ATP in an oscillatory manner following variations in 
the spontaneous contractions. The ATP release was greater in the mucosa 
compared to the detrusor and it was augmented by carbachol and reversed by the 
M2-selective antagonist, methoctramine (Kushida and Fry, 2016). Differences in the 
pharmacological profiles between the bladder mucosa and detrusor, implies distinct 
mechanisms underlying contractile activation. Also, the intermediate responses 
obtained from intact preparations imply a dynamic interaction between the two 
bladder layers. The temporal relationship between ATP release oscillations and the 
amplitude of spontaneous contractions is consistent with ATP release controlling the 
bladder spontaneous activity (Kushida and Fry, 2016). 
Despite the differences in the purinergic control of urothelial function, we show 
here that the ATP/ACh release ratio was fivefold higher in the mucosa of obstructed 
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BPH patients than in control individuals. Impairment of the extracellular ATP 
catabolism by NTPDases may account for this difference (Harvey et al., 2002; Silva-
Ramos et al., 2015a), along with a partial loss of choline acetyltransferase (ChAT) 
which together with the mitochondrial enzyme carnitine acetyltransferase are 
responsible for synthesizing ACh in the urothelium (Lips et al., 2007). 
The mechanisms that regulate the release of ATP in the urinary bladder are 
still a matter of debate, but may include vesicle exocytosis (Nakagomi et al., 2016), 
translocation via pannexin-1 containing hemichannels (Shout et al., 2002; Timóteo et 
al., 2014; Negoro et al., 2013), transient receptor potential channels, like TRPV1 
(Charrua et al., 2009) and TRPV4 (Mochizuki et al., 2009), Piezo1 channels 
(Miyamoto et al., 2014), among others. Our findings show that facilitation of ATP 
release from urothelial cells triggered by P2Y6 receptor agonists was prevented by 
pannexin-1 hemichannel inhibitors both in rats (Timóteo et al., 2014) and the same 
was observed in the human samples. Co-localization of pannexin-1 and P2Y6 
receptors in the rat urothelium strengthens the functional data implicating pannexin-1 
as a major releasing pathway of ATP following P2Y6 receptors activation (Timóteo et 
al., 2014).  
Storage of ATP in synaptic vesicles of cholinergic nerves is known for many 
years (reviewed in Mutafova-Yambolieva and Durnin, 2014). Whether this also 
applies to the urothelium is a matter of debate. In 1997, Fergusson and collaborators 
raised three argument levels against the vesicular release of ATP from the 
urothelium: i) rather than inhibiting ATP release, removal of Ca2+ from the 
extracellular medium actually potentiated the release of the nucleotide, ii) 
tetrodotoxin, applied in concentrations that fully blocked nerve-evoked detrusor 
contractions had no significant effect on electrically-evoked ATP from the urothelium, 
and iii) although the suburothelial sensory nerves are packed with secretory 
granules, there are no such granules inside urothelial cells (Fergusson et al., 1997). 
On the other hand, McLatchie and Fry (2014) stimulated urothelial cells in 
suspension by imposing upon them a mild drag force stress and found that urothelial 
ATP release was reduced in low (1.8 mM) calcium medium, but it increased roughly 
by two-fold upon increasing intracellular calcium (McLatchie and Fry, 2014). Under 
these circumstances urothelial ATP release was also reduced by agents blocking 
pannexin and connexin hemichannels. The calcium-dependence of ATP release and 
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its influence by connexin / pannexin channel blockers suggested that a major fraction 
(up to 50%) of the nucleotide release is through these hemichannels (McLatchie and 
Fry, 2014). However, the conspicuous effect of N-ethylmaleimide, which has been 
proposed to reduce vesicular docking to the surface membrane of secretory cells, is 
consistent with a substantial fraction of release by vesicular exocytosis (Andersson, 
2015). Thus, further characterization of the pathways involved in urothelial ATP 
release may help to develop new therapeutic strategies for disorders assumed to be 
characterised by increased ATP release, such as overactive bladder syndromes. 
Further studies are still required to elucidate the complexity of the interplay 
between various P2 purinoceptors to control non-neuronal reflexes in the human 
bladder mucosa, both in health and disease conditions. Extracellular ATP 
accumulation may contribute to the loss of P2X2 and P2X3 receptors 
immunostaining and function in the urothelium of BPH patients. Excess of 
extracellular ATP released from the urothelium in response to stretch and chemical 
irritants may contribute to hyperexcitation of suburothelial nerve afferents via 
homomeric P2X3 and/or heteromeric P2X2/3 receptors. In contrast to that observed 
in the urothelium, increased levels of ATP released by the mucosa of OAB patients is 
associated with an overexpression of P2X3 and/or heteromeric P2X2/3 receptors on 
suburothelial nerves fibers.  
Using immunofluorescence confocal microscopy, we showed that NTPDases1 
and 2 are deficient in obstructed BPH patients, while ecto-5´nucleotidase is fairly 
conserved in both groups. This result is compatible with our findings showing a 
significant reduction of about 1.4 and 1.9 in the kinetics of ATP and ADP catabolism 
in these patients compared to control individuals, which result in deficient adenosine 
formation from the extracellular catabolism of adenine nucleotides despite no 
differences were observed in ecto-5’nucleotidase expression and activity (Silva-
Ramos et al., 2015a). Impairment of NTPDases activity has been described in other 
disorders, including those affecting the central nervous system, such as 
schizophrenia (SZ). Reduction in striatal NTPDase activity may contribute to the 
pathophysiology of SZ, which might explain the deficits in adenosine signaling 
detected in this illness (Aliagas et al., 2013). 
The slower extracellular ADP inactivation compared to ATP in urothelium-
denuded detrusor preparations of BPH patients, combined with the presence of 
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NTPDase2 on VAChT-positive cholinergic nerve terminals (Carneiro et al., 2014), 
might favour transient ADP accumulation at the cholinergic neuromuscular synapse 
and activation of presynaptic ADP-sensitive receptors. To test the activity of these 
receptors we used the enzymatically-stable ADP analogue, ADPβS and selective 
P2Y1, P2Y12 and P2Y13 receptor antagonists. Our results indicate that drugs that 
favour ADP accumulation in the cholinergic neuromuscular synapse of the human 
detrusor and/or that promote activation of overexpressed inhibitory P2Y12 receptors 
may be a suitable therapeutic strategy to counteract cholinergic bladder activity 
associated with obstruction in BPH patients. Data also show that blockade of fast 
desensitizing homomultimeric P2X3 and heteromultimeric P2X2/3 ionotropic 
receptors may additionally be used to cease bladder overacitivity by acting on both 
sides (sensory and motor, respectively) of the micturition reflex (see also, Takezawa 
et al., 2017). 
So far, our data suggest the use of selective P2Y6 receptor antagonists to 
decrease the excessive sensory bladder drive triggered by ATP (and ACh) release 
from injured urothelial cells due to BOO associated with BPH. Whether this theory 
also applies to surplus ATP release from the urothelium of women with OAB, 
requires experimental validation using bladder samples that are much more difficult 
to obtain. Our data also prompted to the beneficial effects of P2Y12 receptor agonists 
and/or P2X2/3 receptor antagonists in order to restrain hyperactivity of cholinergic 
bladder nerves in obstructed patients. Alternatively, blockade of P2X3 receptors on 
suburothelial sensory bladder nerves, with drugs like AF-742, is already are being 
considered for the treatment of OAB and bladder pain (Burnstock, 2011; Sacco et al., 
2015). Interestingly, therapeutic interventions using “purinome-based strategies” 
have also been advanced for interstitial cystitis. In this context it has been 
hypothesized the use of adenosine A1 receptor antagonists, like DPCPX, and P2X7 
receptor antagonists (Aronsson et al., 2012). 
The therapeutic success of β3-adrenoceptor agonists, like mirabegron, for 
managing OAB syndromes has generated a great interest in the discovery of their 
mechanism of action. It has been suggested that stimulation of β3-adrenoceptors 
improve OAB symptoms by directly relaxing detrusor smooth muscle contractions as 
a consequent of intracellular cyclic AMP (cAMP) formation. Increasing evidence 
suggest distinct, eventually more therapeutically relevant, mechanisms of action of 
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β3-adrenoceptors, which includes an inhibitory effect on nerve-evoked ACh release 
(D’Agostino et al., 2007). However, the presence of β3-adrenoceptors on bladder 
cholinergic nerve terminals has been disputed (Coelho et al., 2017). Consensus 
exists more on the predominant localization of β3-adrenoceptors on detrusor smooth 
muscle fibers (Igawa et al., 1998, 1999).  
In this thesis, we tested a newer theory to explain the inhibitory effect of β3-
adrenoceptor agonists on cholinergic bladder transmission, which considered the 
following premises: (i) adenosine A1 receptors present on cholinergic nerves of the 
human detrusor downregulate ACh release (Silva-Ramos et al., 2015a), and (ii) 
adenosine may originate from cAMP catabolism, in a process that depends on the 
sequential activity of ecto-nucleotidase/phosphodiestase 1 (ENPP1) and ecto-
5´nucleotidase/CD73 (Chievegatti et al., 2008; Sassi et al., 2014). Our hypothesis 
was that adenosine formed from the catabolism of cAMP in the detrusor may act as a 
retrograde messenger via prejunctional A1 receptors to explain inhibition of 
cholinergic activity by β3-adrenoceptor agonists. Data show that β3-adrenoceptors 
activation decreases electrically-evoked [3H]ACh release from human and rat 
detrusor strips indirectly by favoring adenosine outflow from smooth muscle fibers via 
equilibrative nucleoside transporters (ENT) and activation of inhibitory A1 receptors 
localized on cholinergic nerve terminals. This mechanism involves adenylyl cyclase 
activation and intracellular cAMP accumulation because it was mimicked by FSK, 
which directly activates the catalytic subunit of adenylyl cyclase without the need for 
receptor couping to Gs proteins. Interestingly, both FSK and β3-adrenoceptor 
agonists also significantly decreased the amplitude and frequency of non-voiding 
contractions, as well as the voiding frequency, in urethane-anaesthetized rats. 
Besides being considered a source of adenosine, intracellular cAMP 
accumulation following β3-adrenoceptors activation triggers a series of downstream 
signaling events which are not fully characterized in the urinary bladder. The 
involvement of cAMP-dependent PKA activation downstream Gs-protein-coupled 
receptors activation, like the β3-adrenoceptor, has been a matter of debate in the 
literature mostly because PKA inhibitors produce divergent effects (see e.g. Frazier 
et al., 2005). Increasing evidence point towards the participation of cAMP-activated 
ion channels and the exchange protein directly activated by cAMP (EPAC) to explain 
cAMP-dependent effects that are resistant to PKA inhibition (de Rooij et al., 1998; 
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Kawasaki et al., 1998). Our results show clearly that β3-adrenoceptors promote 
adenosine release, reduce evoked [3H]ACh release and decrease the voiding 
frequency through a mechanism that is dependent on downstream activation of the 
EPAC, but not PKA, signaling pathway both in human and rat urinary bladders. The 
link between β3-adrenoceptors stimulation and downstream EPAC activation leading 
to increases in adenosine outflow via the ENT1 transporter subtype remains to be 
investigated. 
Thus, β3-adrenoceptor agonists with the participation of endogenous 
adenosine may exert inhibitory effects on bladder function increasing the storage 
capacity and prolonging the micturition interval, without affecting the voiding pressure 
or post-void residual volume. In this context, it remains to be explored the role of β3-
adrenoceptor agonists on urothelium-derived adenosine released from mechanically-
stimulated umbrella cells, which are also endowed with ENT1 nucleoside 
transporters. Our findings led us to propose a novel mechanism involving cAMP-
mediated activation of EPAC, endogenous adenosine release and A1 receptors 
activation in the urinary bladder which contributes to explain, at least partially, the 
therapeutic success of β3-adrenoceptor agonists on OAB symptoms. These drugs 
may act both (1) on the sensory bladder drive operated by mechanically-sensitive 
urothelial cells sensory nerve afferents and interstitial pacemaker cells, and (2) on 
the efferent motor component resulting in the reduction of non-voiding cholinergic 
microcontractions and in the increase in bladder storage capacity by relaxing the 
detrusor. Apparently, these processes are effectively cut-short during the voiding 
command by yet unknown mechanisms, which may involve the unrestrained 
parasympathetic boost. As a matter of fact, β3-adrenoceptor agonists do not affect 
voiding urodynamic parameters (maximum urinary flow and detrusor pressure at 
maximal urinary flow) in clinical settings and we did not observed any changes in the 
duration and amplitude of voiding urinary contraction in response to isoprenaline in 
the anaesthetized rat, nor these were parameters affected by blockage of adenosine 
A1 receptors with DPCPX. Here we clearly demonstrate that selective activation of 
β3-adrenoceptors with mirabegron is equally active to control cholinergic 
neurotransmission in the urinary bladder of obstructed BPH patients. This was 
verified despite β3-adrenoceptors and adenosine A1 receptors are overexpressed in 
the detrusor of BPH patients, which emphasizes the limiting role exerted by 
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downregulated ENT1 nucleoside transporter on adenosine tonus at the bladder 
cholinergic synapse. In view of this, we propose that pharmacological manipulation of 
endogenous adenosine levels and/or A1 receptor activation may act synergistically 
with β3-adrenoreceptors activation to control bladder overactivity in these patients. 
 
 
 
_____________________________________________________________________REFERENCES 
PhD Thesis: Isabel Sofia Dias da Silva________________________________________181 
 
VIII.  REFERENCES 
Abbracchio MP, Burnstock G, Boeynaems J-M, Barnard EA, Boyer JL, 
Kennedy C, Knight G, Fumagalli M, Gachet C, Jacobson K, Weisman GA. 
International Union of Pharmacology LVIII: update on the P2Y G-protein-coupled 
nucleotide receptors: from molecular mechanism and pathophysiology to therapy. 
Pharmacol Rev. 2006. 58(3):281-341. 
Abbracchio MP, Burnstock G, Verkhratsky A, Zimmermann H. Purinergic 
signaling in the nervous system: an overview. Trends Neurosc. 2009. 32: 19-29. 
Abbracchio MP, Burnstock G. Purinergic signaling: pathophysiological roles. J 
Pharmacol. 1998. 78: 113-145. 
Abbracchio MP, Burnstock G. Purinoceptors: are there families of P2X and 
P2Y purinoceptors? Pharmacol Therap. 1994. 64: 445-475. 
Abrams P, Kaplan S, De Koning Gans HJ, Millard R. Safety and tolerability of 
tolterodine for the treatment of overactive bladder in men with bladder outlet 
obstruction. J Urol. 2006a. 175: 999-1004. 
Abrams P, Andersson KE, Buccafusco JJ, Chapple C, de Groat WC, Fryer 
AD, Kay G, Laties A, Nathanson NM, Pasricha PJ, Wein AJ. Muscarinic receptors: 
their distribution and function in body systems, and the implications for treating 
overactive bladder. Br J Pharmacol. 2006b. 148: 565-78. 
Abrams P, Cardozo L, Fall M, Griffiths D, Rosier P, Ulmsten U, van 
Kerrebroeck P, Victor A, Wein A. The standardization of terminology of lower urinary 
tract function: report from the standardisation sub-committee of the International 
Continence Society. Neurourol Urodyn. 2002. 21: 167-78. 
Abrams P. New words for old: lower urinary tract symptoms for “prostatism”: 
BMJ. 1994. 308: 929-30. 
Acevedo CG, Contreras E, Escalona J, Lewin J, Huidobro-Toro JP. 
Pharmacological characterization of adenosine A1 and A2 receptors in the bladder: 
evidence for a modulatory adenosine tone regulating non-adrenergic non-cholinergic 
neurotransmission. Br J Pharmacol. 1992. 107: 120-126. 
Acevedo CG, Contreras E. Possible involvement of adenine nucleotides in the 
neurotransmission of the mouse urinary bladder. Comp Biochem Physiol. 1985. 82: 
357-361. 
Ahlquist RP. A study of the adrenotropic receptors. Am J Physiol. 1948. 153: 
586-600. 
_____________________________________________________________________REFERENCES 
PhD Thesis: Isabel Sofia Dias da Silva________________________________________182 
 
Aizawa N, Homma Y, Igawa Y. Effects of L-arginine, mirabegron, and 
oxybutynin on the primary bladder afferent nerve activities synchronized with reflexic, 
rhythmic bladder contractions in the rat. Neurourol Urodyn. 2015. 34: 368-374. 
Akakpo W, Misicki B, Burnett A. cAMP-Dependent regulation of RhoA/Rho-
kinase attenuates detrusor overactivity in a novel mouse experimental model. BJU 
Int. 2017. 120 (1): 143-151. 
Akino H, Chapple CR, Makay N, Cross RL, Murakami S, Yokayamma O, 
Chess-Williams R, Sellers DJ. Spontaneous contractions of the pig urinary bladder: 
the effect of ATP-sensitive potassium channels and the role of mucosa. BJU Int. 
2008. 102: 1168-1174. 
Ali H, Müller CE, Daly JW, Beaven MA. Methylxanthines block antigen-
induced responses in RBL-2H3 cells independently of adenosine receptors or cyclic 
AMP: evidence for inhibition of antigen binding to IgE. J Pharmacol Exp Ther. 1991. 
258(3): 954-62. 
Almahariq M, Mei FC, Wang H, Cao AT, Yao S, Soong L, Sun J, Cong Y, 
Chen J, Cheng X. Exchange Protein Directly Activated by cAMP (EPAC1) Modulates 
Regulatory T Cell-Mediated Immune Suppression. Biochem J. 2015. 465: 295–303. 
Almahariq M, Tsalkova T, Mei FC, Chen H, Zhou J, Sastry SK, Schwede D, 
Cheng X. A novel EPAC-specific inhibitor suppresses pancreatic cancer cell 
migration and invasion. Mol Pharmacol. 2013. 83: 122–128. 
Amark P, Nergǻrdh A, Kinn AC. The effect of noradrenaline on the contractile 
response of the urinary bladder. An in vitro study in man in cat. Scan J Urol Nephrol. 
1986. 20(3): 203-7. 
Andersson KE, Arner A. Urinary bladder contraction and relaxation: physiology 
and pathophysiology. Physiol Rev. 2004. 84(3): 935-86. 
Andersson KE, Campeau L, Olshansky B. Cardiac effects of muscarinic 
receptor antagonists used for voiding dysfunction. Br J Clin Pharmacol. 2011. 72: 
186-96. 
Andersson KE, Martin N, Nitti V. Selective β3-adrenoceptors agonists for the 
treatment of overactive bladder. J Urol. 2013. 190: 1173-8. 
Andersson KE, Persson K. Nitric oxide synthase and the lower urinary tract: 
Possible implications for physiology and pathophysiology. Scan J urol Nephrol. 1995. 
175:43-55. 
_____________________________________________________________________REFERENCES 
PhD Thesis: Isabel Sofia Dias da Silva________________________________________183 
 
Andersson KE. New developments in the management of overactive bladder: 
focus on mirabegron and onabotulinumtoxin A. Ther Clin Risk Manag. 2013. 9: 161-
70. 
Andersson KE. Pharmacology of lower urinary tract smooth muscles and 
penile erectile tissues. Pharmacol Rev. 1993. 45: 253-308. 
Andersson KE. Pharmacology: On the mode of action of mirabegron. Nat Rev 
Urol. 2016. 13: 131-132. 
Andersson KE. Potential future pharmacological treatment of bladder 
dysfunction. Basic Clin Pharmacol Toxicol. 2016. 119 (Suppl 3): 75-85. 
Angulo JC, Khullar V, Nitti VW, Siddigui E. Evidence available on the use of 
the selective β3-adrenoceptor agonist mirabegron for the treatment of overactive 
bladder. Actas Urol Esp. 2013. 37(10): 640-651. 
Apodaca G. The uroepithelium: Not just a passive barrier. Traffic. 2004. 
5:117–128. 
Applebaum AE, Vance WH, Coggeshall RE. Segmental localization of sensory 
cells that innervate the bladder. J Comp Neurol. 1980. 192: 203-209. 
Aronsson P, Andersson M, Ericsson T, Giglio D. Assessment and 
Characterization of Purinergic Contractions and Relaxations in the rat urinary 
bladder. Basic & Clinic Pharmacol & Toxicology. 2010. 107: 603-613. 
Auli M, Martinez E, Gallego D, Opazo A, Espin F, Marti-Gallostra M, Jiménez 
M, Clavé P. Effect of excitatory and inhibitory neurotransmission on motor patterns of 
human sigmoid colon in vitro. Br J Pharmacol. 2008. 155: 1043-1055. 
Baillie GS. Compartmentalized signaling: spatial regulation of cAMP by the 
action of compartmentalized phosphodiesterases. FEBS J. 2009. 276:1790–99. 
Baker JG. The selectivity of beta-adrenoceptor agonists at human β1-, β2- and 
β3- adrenoceptors. Br J Pharmacol. 2010. 160: 1048-1061. 
Barendrecht MM, Frazier EP, Vrydag W, Alewijnse AE, Peters SL, Michel MC. 
The effect of bladder outlet obstruction on alpha1- and beta-adrenoceptor expression 
and function. Neurourol Urodyn. 2009. 28: 349-355. 
Beckel J, Birder LA. Differential expression and function of nicotinic 
acetylcholine receptors in the urinary bladder epithelium of the rat. J Physiol. 2012. 
590(6): 1485-1480. 
Beckel J, Holstege G. Neurophysiology of the Lower Urinary Tract. Hand Book 
Exp Pharmacol. 2011. 202: 149-69.  
_____________________________________________________________________REFERENCES 
PhD Thesis: Isabel Sofia Dias da Silva________________________________________184 
 
Beckel J, Holstege G. The Rat Nervous System – 4th edition; Chapter 12: The 
Lower Urinary tract”, edited by George Paxinos. 2015. 
Beckel JM, Kanai A, Lee SJ, de Groat WC, Birder LA. Expression of functional 
nicotinic acetylcholine receptors in rat urinary bladder epithelial cells. Am J Physiol 
Renal Physiol. 2006. 290: 103-110. 
Bharucha AE. Pelvic floor: Anatomy and function. Neurogastroenterol Motil. 
2006. 18: 507-519. 
Birder LA, Andersson KE. Urothelial signaling. Physiol Rev. 2013. 93: 653-
680. 
Birder LA, Apodaca G, de Groat WC, Kanai AJ. Adrenergic and capsaicin-
evoked nitric oxide release from urothelium and afferent nerves in urinary bladder. 
Am J Physiol. 1998. 275:F226 – F229. 
Birder LA, Barrick SR, Roppolo JR. Feline interstitial cystitis results in 
mechanical hypersensitivity and altered ATP release from bladder urothelium. Am J 
Physiol Renal Physiol. 2003. 285: F423-F9. 
Birder LA, de Groat WC. Mechanisms of disease: involvement of the 
urothelium in bladder dysfunction. Nat Clin Pract Urol. 2007. 4:46-54. 
Birder LA, Hanna-Mitchell AT, Mayer E, Buffington CA. Cystitis, co-morbid 
disorders and associated epithelial dysfunction. Neurourol Urodyn. 2011. 30(5): 668-
72. 
Birder LA, Kanai AJ, de Groat WC, Kiss S, Nealen ML, Burke NE, Watkins S, 
Reynolds IJ, Caterina MJ. Vanilloid receptor expression suggests a sensory role for 
urinary bladder epithelial cells. Proc Natl Acad Sci USA. 2001. 98:13396–13401. 
Birder LA, Nealen ML, Kiss S, de Groat WC, Caterina MJ, Wang E, Apodaca 
G, Kanai AJ. Beta-adrenoceptor agonists stimulate endothelial nitric oxide synthase 
in rat urinary bladder urothelial cells. J Neurosci 2002, 22: 8063-8070. 
Birder LA, Ruan HZ, Chopra B, Xiang Z, Barrick S, Buffington CA, Roppolo 
JR, Ford AP, de Groat WC, Burnstock G. Alterations in P2X and P2Y purinergic 
receptor expression in urinary bladder from normal cats and cats with interstitial 
cystitis. Am J Physiol Renal Physiol. 2004. 287: F1084-F1091. 
Birder LA. Nervous network for lower urinary tract function. Int J Urol. 2013. 
20:4-12. 
Birder LA. Urinary bladder urothelium: Molecular sensors of chemical/ thermal/ 
mechanical stimuli. Vasc Pharmacol. 2006. 45: 221-226. 
_____________________________________________________________________REFERENCES 
PhD Thesis: Isabel Sofia Dias da Silva________________________________________185 
 
Birder LA. Urothelial signaling. Handb Exp Pharmacol. 2011. 202: 207–231. 
Birder LA; Ruan HZ, Chopra B, Xiang Z, Barrick S, Buffington CA, Roppolo 
JR, Ford AP, de Groat WC, Burnstock G. Alterations in P2X and P2Y purinergic 
receptor expression in urinary bladder from normal cats and cats with interstitial 
cystitis. Am J Physiol Renal Physiol. 2004. 287(5): F1084-91. 
Boeynaems JM, Communi F, Gonzalez NS, Robaye B. Overview of the P2 
receptors. Semin Thromb Hemost. 2005. 31: 139-149. 
Boeynaems JM, Wilkin F, Marteau F, Duhant X, Savi P, Gonzalez NB, Robaye 
B, Communi D. P2Y receptors: new subtypes, new functions. Drug Dev Res. 2003. 
59: 30-35. 
Bollen M, Gijsbers R, Ceulemans H, Stalmans W, Stefan C. Nucleotide 
pyrophosphatase/phosphodiesterases on the more. Crit Rev Biochem Mol Biol. 2000. 
35: 393-432. 
Bolton TB, Zholos AV. Activation of M2 muscarinic receptors in guinea-pig 
ileum opens cationic channels modulated by M3 muscarinic receptors. Life Sci. 1997. 
60: 1121-1128. 
Bonner TI, Buckley NJ, Young AC, Brann MR. Identification of a family of 
muscarinic acetylcholine receptor genes. Science. 1987. 237: 527-532. 
Bonner TI, Young AC, Brann MR, Buckley NJ. Cloning and expression of the 
human and rat M5 muscarinic acetylcholine receptor genes. Neuron. 1988. 1: 403-
410. 
Bonner TI. New subtypes of muscarinic acetylcholine receptors. Trends 
Pharmacol Sci. 1989b. 11-15. 
Bonner TI. The molecular basis of muscarinic receptor diversity. Trends 
Neurosci. 1989a. 12: 148-151. 
Braas KM, May V, Zvara P, Nausch B, Kliment J, Dunleavy JD, Nelson MT, 
Vizzard MA. Role of pituitary adenylate cyclase activating polypeptide in cystitis-
induced plasticity of micturition reflexes. Am J Physiol Regul Integr Comp Physiol. 
2006. 290 (4): R951-R962. 
Brady CM, Apostolidis A, Yiangou Y, Baecker PA, Ford AP, Freeman A, 
Jacques TS, Flower CJ, Anand P. P2X3-immunoreactive nerve fibres in neurogenic 
detrusor overactivity and the effect of intravesical resiniferatoxin. Eur Urol. 2004. 46: 
247-253. 
_____________________________________________________________________REFERENCES 
PhD Thesis: Isabel Sofia Dias da Silva________________________________________186 
 
Brake AJ, Wagenbach MJ, Julius D. New structural motif for ligand-fated ion 
channels defined by an ionotropic ATP receptor. Nature. 1994. 371: 519-523. 
Brederson JD, Jarvis MF. Homomeric and heteromeric P2X3 receptors in 
peripheral sensory neurons. Curr Opin Investig Drugs. 2008. 9: 716-725. 
Bridgeman MB, Friia NJ, Taft C, Shah M. Mirabegron: β3-adrenergic receptor 
agonist for the treatment of overactive bladder. Ann Pharmacother. 2013. 47: 1029-
38. 
Brown C, Burnstock G, Cocks T. Effects of adenosine 5’-triphosphate (ATP) 
and beta-gamma-methylene ATP on the rat urinary bladder. Br J Pharmacol. 1979. 
65: 97-102. 
Bschleipfer T, Schukowski K, Weidner W, Grando SA, Schwantes W, Kummer 
W, Lips KS. Expression and distributions of cholinergic receptors in the human 
urothelium. Life Sciences. 2007. 80: 2303-2307. 
Burnstock G, Cocks T, Crowe R, Kasakov L. Purinergic innervation of the 
guinea-pig urinary bladder. Br J Pharmacol. 1978. 63:125-138. 
Burnstock G, Cocks T, Kasakov L, Wong HK. Direct evidence for ATP release 
from non-adrenergic, non-cholinergic “purinergic” nerves in the guinea-pig taenia coli 
and bladder. Eur J Pharmacol. 1978. 49: 145-149. 
Burnstock G, Dumsday B, Smythe A. Atropine resistant excitation of the 
urinary bladder: the possibility of transmission via nerves releasing a purine 
nucleotide. Br J Pharmacol. 1972. 44: 451-461. 
Burnstock G, Knight GE. Cellular distribution and functions of P2 receptor 
subtypes in different systems. Int Rev Cytol. 2004. 240: 31-304. 
Burnstock G. A basis for distinguishing two types of purinergic receptor. In Cell 
Membrane Receptors for Drugs and Hormones: A Multidisciplinary Approach (Straub 
RW and Bolis L, eds), Raven Press. 1978. 107-118.  
Burnstock G. Historical review: ATP as a neurotransmitter. Trends in 
Pharmacol Sci. 2006. 27 (3).  
Burnstock G. Noradrenaline and ATP: cotransmitters and neuromodulators. J 
Physiol Pharmacol. 1995. 46: 365-384. 
Burnstock G. P2X receptors in sensory neurons. Br J Anaesth. 2000. 84(4): 
476-88. 
Burnstock G. Pathophysiology and therapeutic potential of purinergic 
signaling. Pharmacol Rev. 2006. 58:58-86. 
_____________________________________________________________________REFERENCES 
PhD Thesis: Isabel Sofia Dias da Silva________________________________________187 
 
Burnstock G. Physiology and pathophysiology of purinergic 
neurotransmission. Physiol Rev. 2007. 87(2): 659-797. 
Burnstock G. Purinergic nerves. Pharmacol Rev. 1972. 24: 509-581. 
Burnstock G. Purinergic signaling in lower urinary tract. In Handbook of 
Experimental Pharmacology, Vol 151 (I). Purinergic and Pyrimidinergic Signalling I – 
Molecular, Nervous and Urinogenitary System Function (Abbracchio MP and 
Williams M, eds), Springer-Verlag. 2001: 423-515. 
Burnstock G. Purinergic signaling in the urinary tract in health and disease. 
Purinerg Signal. 2013. 10(1): 103-155. 
Burnstock G. Purinergic signaling. BJ Pharmacol. 2006. 147: S172-S181. 
Burnstock G. Purinergic signaling: Therapeutic developments. Front 
Pharmacol. 2017. 8: 661. 
Burnstock G. Purinoceptors: ontogeny and phylogeny. Drug Dev Res. 1996. 
39: 204-242. 
Burnstock G. Release of vasoactive substances from endothelial cells by 
shear and purinergic mechanosensory transduction. J Anat. 1999. 194: 335-342. 
Bylund DB, Eikenberg DC, Hieble JP (1994) IV. International Union of 
Pharmacology Nomenclature of Adrenoceptors. Pharmacol Rev, 46: 121-36. 
Calvert RC, Thompson CS, Burnstock G. ATP release from the human ureter 
on distension and P2X3 receptor expression on suburothelial sensory nerves. 
Purinergic Sign. 2008. 4: 377-381. 
Candelore MR, Deng L, Tota L, Guan XM, Amend A, Liu Y, Newbold R, 
Cascieri MA, Weber AE. Potente and selective human β3-adrenergic receptor 
antagonists. J Pharmacol Exp Ther. 1999. 290: 649-655. 
Carneiro I, Timóteo MA, Silva I, Vieira C, Baldaia C, Ferreirinha F, Silva-
Ramos M, Correia-de-Sá P. Activation of P2Y6 receptors increases the voiding 
frequency in anaesthetized rats by releasing ATP from the bladder urothelium. Br J 
Pharmacol. 2014. 174(14): 3404-19. 
Carrière I, Fourrier-Reglat A, Dartigues JF, Rouaud O, Pasquier F, Ritchie K, 
Ancelin ML. Drugs with anticholinergic properties, cognitive decline, and dementia in 
an elderly general population. Arch Intern Med. 2009. 169(14): 1317-1324. 
Carter RL, Fricks IP, Barrett MO, Burianek LE, Zhou Y, Ko H, Das A, 
Jacobson KA, Lazarowski ER, Harden TK. Quantification of Gi-mediated inhibition of 
_____________________________________________________________________REFERENCES 
PhD Thesis: Isabel Sofia Dias da Silva________________________________________188 
 
adenylyl cyclase activity reveals that UDP is a potent agonist of the human P2Y14. 
Mol Pharmacol. 2009. 76(6): 1341-8. 
Caudfield MP, Birdsall NJM. International Union of Pharmacology. XVII. 
Classification of muscarinic acetylcholine receptors. Pharmacol Rev. 1998. 50: 279-
290. 
Cernecka H, Ochodnicky P, Lamers WH, Michel MC. Specificity evaluation of 
antibodies against human β3-adrenoceptors. Nauncy Schmiedeberg’s Arch 
Pharmacol. 2012. 385: 875-882. 
Certal M, Vinhas A, Pinheiro AR, Ferreirinha F, Barros-Barbosa AR, Silva I, 
Costa MA, Correia-de-Sá P. Calcium signaling and the novel anti-proliferative effect 
of the UTP-sensitive P2Y11 receptor in rat cardiac myofibroblasts. Cell Calcium. 
2015. 58(5): 518-33. 
Chancellor MB, Fowler CJ, Apostolidis A, de Groat WC, Smith CP, Somogyi 
GT, Aoki KR. Drug Insight: biological effects of botulinum toxin A in the lower urinary 
tract. Nat Clin Pract Urol. 2008. 5(6): 319-28. 
Chancellor MB, Kaplan SA, Blaivas JG. The cholinergic and purinergic 
components of detrusor contractility in a whole rabbit bladder model. J Urol. 1992. 
148: 906-909. 
Chapple C, Khullar V, Gabriel Z, Muston D, Bitoun CE, Weinstein D. The 
effects of antimuscarinic treatments in overactive bladder: an update of a systematic 
review and meta-analysis. Eur Urol. 2008. 54: 543-62. 
Chapple C. Pathophysiology of the lower urinary tract and CNC. Can Urol 
Assoc. 2011. 5(Suppl 2): S126-7. 
Charrua A, Reguenga C, Cordeiro JM, Correia-de-Sá P, Paule C, Nagy I, Cruz 
F, Avelino A. Functional transient receptor potential vanilloid 1 is expressed in human 
urothelial cells. J Urol. 2009. 182(6): 2944-50. 
Chen ZS, Lee K, Kruh GD. Transport of cyclic nucleotides and estradiol 17-β-
D-glucuronide by multidrug resistance protein 4. Resistance to 6-mercaptopuurine 
and 6-thioguanine. J Biol Chem. 2001. 276: 33747-33754. 
Cheng X, Ji Z, Tsalkova T, Mei F. Epac and PKA: a table of two intracellular 
cAMP receptors. Acta Biochem Biophys Sin. 2008. 40(7): 651-662. 
Cheng Y, Mansfield KJ, Allen W, Chess-Williams R, Burcher E, Moore KH. 
ATP during early bladder stretch is important for urgency in detrusor overactivity 
patients. Biomed Res Int. 2014. 2014: 204604. 
_____________________________________________________________________REFERENCES 
PhD Thesis: Isabel Sofia Dias da Silva________________________________________189 
 
Cheng Y, Mansfield KJ, Allen W, Millard RJ, Burcher E, Moore KH. Correlation 
between cystometric volumes, ATP release, and pH in women with overactive 
bladder versus controls. Neurourol Urodyn. 2013. 32(7): 969-73. 
Cheng Y, Mansfield KJ, Allen W, Walsh CA, Burcher E, Moore KH. Does 
adenosine triphosphate released into voided urodynamic fluid contribute to urgency 
signaling in women with bladder dysfunction? J Urol. 2010. 183(3): 1082-6. 
Cheng Y, Mansfield KJ, Sandow SL, Sadananda P, Burcher E, Moore KH. 
Porcine bladder urothelial, myofibroblasts, and detrusor muscle cells: 
characterization and ATP release. Front Pharmacol. 2011. 7: 2-27. 
Chess-Williams R, Chapple CR, Yamanishi T, Sellers DJ. The minor 
population of M3 receptors mediate contraction of human detrusor muscle in vitro. J 
Auton Pharmacol. 2001. 21: 243-248. 
Chiavegetti T, Costa VL Jr, Araújo MS, Godinho RO. Skeletal muscle 
expresses the extracelular cyclic AMP-adenosine pathway. Br J Pharmacol. 2008. 
153:1331-1340. 
Cho KJ, Koh JS, Choi J, Kim JC. Changes in adenosine triphosphate and 
nitric oxide in the urothelium of benign prostate hyperplasia in patients with detrusor 
underactivity. J Urol. 2017. 17: 76743-2. 
Chopra B, Barrick SR, Meyers S, Beckel JM, Zeidel ML, Ford APDW, de Groat 
WC, Birder LA. Expression and function of bradykinin B1 and B2 receptors in normal 
and inflamed rat urinary bladder urothelium. J Physiol. 2005. 562(3): 859-871. 
Chopra B, Gever J, Barrick SR, Hanna-Mitchell AT, Beckel JM, Ford AP, 
Birder LA. Expression and function of rat urothelial P2Y receptors. Am J Physiol 
Renal Physiol. 2008. 294(4): F821-F829. 
Chou EC, Capello SA, Levin RM, Longhurst PA. Excitatory α1-adrenergic 
receptors predominate over inhibitory β-receptors in rabbit dorsal detrusor. J Urol. 
2003. 170: 2503-2507. 
Chua ME, Lapitan MCM, Silangcruz JMA, Jr Luna S, Jr Morales ML. Beta-3 
adrenergic receptor agonist for adult with overactive bladder. Cochrane database 
Syst Rev. 2015. (3): 1-9. 
Cockayne DA, Dunn PM, Zhong Y, Rong W, Hamilton SG, Knight CE, Ruan 
HZ, Ma B, Yip P, Nunn P, McMahon SB, Burnstock G, Ford AP. P2X2 knockout mice 
and P2X2/P2X3 double knockout mice reveal a role for the P2X2 receptor subunit in 
mediating multiple sensory effect of ATP. J Physiol. 2005. 567: 621-639. 
_____________________________________________________________________REFERENCES 
PhD Thesis: Isabel Sofia Dias da Silva________________________________________190 
 
Cockayne DA, Hamilton SG, Zhu QM, Dunn PM, Zhong Y, Novakovic S, 
Malmberg AB, Cain G, Berson A, Kassotakis L, Hedley L, Lachnit WG, Burnstock G, 
McMahon SB, Ford AP. Urinary bladder hyporeflexia and reduced pain-related 
behavior in P2X3-deficient mice. Nature. 2000. 407: 1011-1015. 
Coelho A, Antunes-Lopes T. Gillespie J, Cruz F. Beta-3 adrenergic receptor is 
expressed in acetylcholine- containing nerve fibers of the human urinary bladder: An 
immunohistochemical study. Neurourol Urodyn. 2017. 36(8): 1972-1980.  
Collado A, Batista E, Gelabert-Más A, Corominas JM, Arañó P, Villavicencio 
H. Detrusor quantitative morphometry in obstructed males and controls. J Urol. 2006. 
176: 2722-8. 
Coman OA, Păunescu H, Ghită I, Coman L, Bădărăru A, Fulga I. Beta3-
adrenergic receptors: molecular, histological, functional and pharmacological 
approaches. Rom J Morph Embry. 2009. 50(2):169-179. 
Communi D, Gonzalez NS, Detheux M, Brézillon S, Lamoy V, Parmentier M, 
Boeynaems JM. Identification of a novel human ADP receptor coupled to G(i). J Biol 
Chem. 2001. 276(44): 41479-85. 
Contreras-Sanz A, Schott-Ward TS, Gill HS, Jacoby JC, Birch RE, Malone-
Lee J, Taylor KM, Peppiatt-Wildman CM, Wildman SS. Simultaneous quantification 
of 12 different nucleotides and nucleosides released from renal epithelium and in 
human urine samples using ion-pair reversed-phase HPLC. Purinergic Signal. 2012. 
8(4): 741-51. 
Correia S, Dinis P, Rolo F, Lunet N. Prevalence, treatment and known risk 
factors of urinary incontinence and overactive bladder in the non-institutionalized 
Portuguese population.  Int Urogyn. 2009. 20: 1481-1489. 
Correia-de-Sá P, Adães S, Timóteo MA, Vieira C, Magalhães-Cardoso T, 
Nascimento C, Duarte-Araújo M. Fine-tuning modulation of myenteric motoneurons 
by endogenous adenosine: on the role of secreted adenosine deaminase. Auton 
Neurosci. 2006. 126-127: 211-224. 
Correia-de-Sá P. Pathophysiological significance of nucleotide hydrolyzing 
enzymes in urologic disorder. Purinergic Signal. 2010. 6(Suppl 2), S13.13. 
Cowan WD, Daniel EE. Human female bladder and its noncholinergic 
contractile function. Can J Physiol Pharmacol. 1983. 61(11): 1236-46. 
_____________________________________________________________________REFERENCES 
PhD Thesis: Isabel Sofia Dias da Silva________________________________________191 
 
Cullere X, Shaw SK, Andersson L, Hirahashi J, Luscinskas FW, Mayadas TN. 
Regulation of vascular endothelial barrier function by Epac, a cAMP-activated 
exchange factor for Rap GTPase. Blood. 2005. 105:1950–1955. 
Cunha RA, Sebastião AM, Ribeiro JA. Ecto-5´-nucleotidase is associated with 
cholinergic nerve terminals in the hippocampus but not in the cerebral cortex of the 
rat. J Neurochem. 1992. 59(2): 657-66. 
Cunha RA. Adenosine as a neuromodulator and has a homeostatic regulator 
in the nervous system: different roles, different sources and different receptors. 
Neurochem Int. 2001. 38(2): 107-25. 
Currie CJ, McEwan P, Poole CD, Odeyemi IA, Datta SN, Morgan CL. The 
impact of the overactive bladder on health-related utility and quality of life. BJU Int. 
2006. 97: 1267-72. 
D’Agostino G, Condino AM, Calvi V, Boschi F, Gioglio L, Barbieri A. Purinergic 
P2X3 heteroreceptors enhance parasympathetic motor drive in isolated porcine 
detrusor, a reliable model for development of P2X selective blockers for detrusor 
hyperactivity. Pharmacol Res. 2012. 65: 129-136. 
D’Agostino G, Condino MA, Calvi P. Involvement of β3-adrenoceptors in the 
inhibitory control of cholinergic activity in human bladder: Direct evidence by [3H]-
acetylcholine release experiments in the isolated detrusor. Eur J Pharmacol. 2015. 
758: 115-122. 
D’Mello R, Dickenson AH. Spinal cord mechanisms of pain. Br J Anaesth. 
2008. 101: 8-16. 
Daly DM, Chess-Williams R, Chapple C, Grundy D. The inhibitory role of 
acetylcholine and muscarinic receptors in bladder afferent activity. Eur Urol. 2010. 
58: 22-8. 
De Biasi M, Nigro F, Xu W. Nicotinic acetylcholine receptors in the autonomic 
control of bladder function. Eur J Pharmacol. 2000. 393: 173-140. 
de Groat WC, Booth AM, Yoshimura N. Neurophysiology of micturition and its 
modification in animals models of human disease. In: The Autonomic Nervous 
System. Nervous Control of the Urogenital System, ed. by Maggi CA, Hartwood 
Academic, London. 1993. 3: 227-289. 
de Groat WC, Booth AM. Nervous Control of the Urogenital System 
(Autonomic Nervous System). Ed. Maggi CA. Vol. 3. Harwood Academic Publishers; 
London. 1993. 9:291-347. 
_____________________________________________________________________REFERENCES 
PhD Thesis: Isabel Sofia Dias da Silva________________________________________192 
 
de Groat WC, Booth AM. Physiology of the urinary bladder and urethra. Ann 
Intern Med. 1980. 92: 312-315. 
de Groat WC, Lalley PM. Reflex firing in the lumbar sympathetic outflow to 
activation of vesical afferent fibers. J Physiol. 1972. 226: 289-309. 
de Groat WC, Yoshimura N. Changes in afferent activity after spinal cord 
injury. Neurourol Urodyn. 2010. 29:63–76. 
de Groat WC. Integrative control of the lower urinary tract: preclinical 
perspective. Br J Pharmacol. 2006. 147 (Suppl 2):S25-40. 
de Groat WC. The urothelium in overactive bladder: passive bystander or 
active participant? Urol. 2004. 64: 4-11. 
de la Rosette JJ, Witjes WP, Schafer W, Abrams P, Donovan JL, Peters TJ, 
Millard RJ, Frimodt-Moller C, Kalomiris P. Relationships between lower urinary tract 
symptoms and bladder outlet obstruction: results from the ICS- “BPH” study. 
Neurourol Urody. 1998. 17(2): 99-108. 
de Rooij J, Zwartkruis FJ, Verheijen MH, Coll RH, Nijman SM, Wittinghofer A, 
Bos JL. Epac is a Rap1 guanine-nucleotide-exchange factor directly activated by 
cyclic AMP. Nature. 1998. 396: 474–477. 
Dickenson JM, Blank JL, Hill SJ. Human adenosine A1 receptor and P2Y2-
purinoceptor-mediated activation of the mitogen-activated protein kinase cascade in 
transfected CHO cells. Br J Pharmacol. 1998. 124(7): 1491-9. 
Dixon AK, Gubitz AK, Sirinathsinghji DJ, Richardson PJ, Freeman TC. Tissue 
distribution of adenosine receptor mRNAs in the rat. Br J Pharmacol. 1996. 118: 
1461-1468. 
Donaldson SH, Picher M, Boucher RC. Secreted and cell-associated 
adenylate kinase and nucleoside diphosphokinase contribute to extracellular 
nucleotide metabolism on human airway surfaces. Am J Respir Cell Mol Biol. 2002. 
26: 209-15. 
Dorsam RT, Kunapuli SP. Central role of the P2Y12 receptor in platelet 
activation. J Clin Invest. 2004. 113: 340-5. 
Downie JW, Karmazyn M. Mechanical trauma to bladder epithelium liberates 
prostanoids which modulate neurotransmission in rabbit detrusor muscle. J 
Pharmacol Exp Ther. 1984. 230:445–449. 
_____________________________________________________________________REFERENCES 
PhD Thesis: Isabel Sofia Dias da Silva________________________________________193 
 
Drake MJ, Fowler CJ, Griffiths D, Mayer E, Paton JF, Birder L. Neural control 
of the lower urinary and gastrointestinal tracts: Supraspinal CNS mechanisms. 
Neurousol Urodyn. 2010. 29: 119-127. 
Drake MJ, Nitti VW, Ginsberg DA, Brucker BM, Hepp Z, McCool R, Glanville 
JM, Fleetwood K, James D, Chapple C. Comparative assessment of the efficacy of 
onabotulinumtoxinA and oral therapies (anticholinergics and mirabegron) for 
overactive bladder: a systematic review and network meta-analysis. BJU Int. 2017. 
120: 611-622. 
Drake R, Vogl W, Mitchell AWM, Tibbitts R, Richardson P. Gray’s Atlas of 
Anatomy (4th Edi.) Edinburgh: Churchill Livingstone. 2008. 
Duarte-Araújo M, Nascimento C, Timóteo MA, Magalhães-Cardoso T, Correia-
de-Sá P. Dual effects of adenosine on acetylcholine release from myenteric 
motoneurons are mediated by junctional facilitatory A2A and extrajunctional inhibitory 
A1 receptors. Br J Pharmacol. 2004. 141: 925-934. 
Duarte-Araújo M, Timóteo MA, Correia-de-Sá P. Adenosine activation A2A-
receptors coupled to adenylate cyclase/cyclic AMP pathway downregulates nicotinic 
autoreceptor function at the rat myenteric nerve terminals. Neurochem Int. 2004. 45: 
641-651. 
Dunning-Davies BM, Fry CH, Mansour D, Ferguson DR. The regulation of 
ATP release from the urothelium by adenosine and transepithelial potential. BJU Int. 
2013. 111: 505-513. 
El Hachmane MF, Komai AM, Olofsson CS. Cooling reduces cAMP-stimulated 
exocytosis and adiponectin secretion at a Ca2+ - dependent step in 3T3-L1 
adipocytes. Plos One. 2015. 10:e0119530. 
Elbadawi A. neuromuscular mechanism of micturition. In: Yalla SV, ME 
Elbadawi A. Eds, Neurology and Urodynamics: Principle and Practice. Macmillan, 
New York. 1988: 3-36. 
Elgoyhen AB, Vetter DE, Katz E, Rothlin CV, Heinemann SF, Boulter J. α10: a 
determinant of nicotinic cholinergic receptor function in mammalian vestibular and 
cochlear mechanosensory hair cells. Proc Nat Sci USA. 2001. 98: 3501-3506. 
Elneil S, Skepper JN, Kidd EJ, Williamson JG, Ferguson DR. Distribution of 
P2X(1) and P2X(3) receptors in the rat and humans urinary bladder. Pharmacology. 
2001. 63(2): 120-8. 
_____________________________________________________________________REFERENCES 
PhD Thesis: Isabel Sofia Dias da Silva________________________________________194 
 
El-Zohairy SN, Oriowo MA, Ezeamuzie CI. Cyclic adenosine monophosphate-
mediated enhancement of vascular endothelial growth factor released by 
differentiated human monocytic cells: the role of protein kinase A. Med Princ Pract. 
2015. 24:548-554. 
Enserink JM, Price LS, Methi T, Mahic M, Sonnenberg A, Bos JL, Taskén K. 
The cAMP-Epac-Rap1 pathway regulates cell spreading and cell adhesion to 
laminin-5 through the alpha3beta1 integrin but not the alpha6beta4 integrin. J Biol 
Chem. 2004.  279:44889–44896. 
Evans BA, Papaioannou M, Hamilton S, Summers RJ. Alternative splicing 
generates two isoforms of the beta3-adrenoceptor which are differentially expressed 
in mouse tissues. Br J Pharmacol. 1999. 127: 1525-1531. 
Fasciani I, Temperán A, Pérez-Atencio LF, Escudero A, Martínez-Montero P, 
Molano J, Gómez-Hernández JM, Paino CL, González-Nieto D, Barrio LC. 
Regulation of connexin hemichannel activity by membrane potential and the 
extracellular calcium in health and disease. Neuropharmacology. 2013. 75: 479-90. 
Ferguson DR, Kennedy I, Burton TJ. ATP is released from rabbit urinary 
bladder epithelial cells by hydrostatic pressure changes - A possible sensory 
mechanism? J Physiol. 1997. 505:503–511. 
Floyd K, Hick VE, Morrison JF. Mechanosensitive afferent units in the 
hypogastric nerve of the cat. J Physiol. 1976. 259: 457-471. 
Ford AP, Gever JR, Nunn PA, Zhong Y, Cefalu JS, Dillon MP, Cockayne DA. 
Purinoceptors as therapeutic targets for lower urinary tract dysfunction. Br J 
Pharmacol. 2006. 147 (Suppl 2): S132-43. 
Ford AP, Undem BJ. The therapeutic promise of ATP antagonism at P2X3 
receptors in respiratory and urological disorders. Front Cell Neurosci. 2013. 7: 267. 
Ford AP. In pursuit of P2X3 antagonists: novel therapeutics for chronic pain 
and afferent sensitization. Purin Sign. 2012. 8 (Suppl1): 3-26. 
Fowler CJ, Griffiths D, de Groat WC. The neural control of micturition. Nat Rev 
Neurosci. 2008. 9(6): 453-466. 
Fowler CJ. Integrated control of lower urinary tract – clinical perspective. Br J 
Pharmacol. 2006. 147: S14-S24. 
Frazier EP, Mathy MJ, Peters SL, Michel MC. (2005). Does cyclic AMP 
mediate rat urinary bladder relaxation by isoproterenol? J Pharmacol Exp Ther. 2005. 
313(1), 260–7. 
_____________________________________________________________________REFERENCES 
PhD Thesis: Isabel Sofia Dias da Silva________________________________________195 
 
Frazier EP, Peters SL, Braverman AS, Ruggieri MRSr, Michel M. Signal 
transduction underlying the control of urinary bladder smooth muscle tone by 
muscarinic receptors and beta-adrenoceptors. Nauny Schm Arch Pharmacol. 2008. 
377(4-6): 449-62. 
Fredholm BB, Arslan G, Halldner L, Kull B, Schulte G, Adén U, Svenningsson 
P. Adenosine receptor signaling in vitro and in vivo. Drug Dev Res. 2001. 52: 274-
282. 
Fredholm BB, IJzerman AP, Jacobson KA, Klotz KN, Linden J. International 
Union of Pharmacology. XXV. Nomenclature and classification of adenosine 
receptors. Pharmacol Rev. 2001. 53: 527-552. 
Fredholm BB, IJzerman AP, Jacobson KA; Linden J, Müller CE. International 
Union of Basic and Clinical Pharmacology. LXXXI. Nomenclature and classification of 
adenosine receptors-an update. Pharmacol Rev. 2011. 63(1): 1-34. 
Fredriksson R, Lagerstrom MC, Lundin LG, Schioth HB. The G-protein-
coupled receptors in the human genome form five main families. Phylogenetic 
analysis, paralogon groups, and fingerprints. Mol Pharmacol. 2003. 63: 1256-1272. 
Freire VS, Burkhard FC, Kessler TM, Kuhn A, Draeger A, Monastyrskaya K. 
MicroRNAs may mediate the dwnregulation of neurokinin-1 receptor in chronic 
bladder pain syndrome. Am J Path. 2010. 176 (1): 288-303. 
Frias B, Lopes T, Pinto R, Cruz F, Cruz CD. Neurotrophins in the lower urinary 
tract: becoming of age. Curr Neuropharmacol. 2011. 9(4): 553-8. 
Fry C, Young J. The physiology and pharmacology of the lower urinary tract. 
Surgery (Oxford) Bas Sci. 2010. 28 (7): 317-322. 
Fry C. Physiology of the lower urinary tract. Surgery (Oxford) Renal and 
Urology. 2008. 35 (9) 26:4. 
Fry CH, Kanai AJ, Roosen A, Takeda M, Wood DN. Incontinence. Abrams P, 
Cardozo L, Khoury S, Wein A, editors. Health Publications Ltd; Jersey. 2005: 313-
362. 
Fry CH, Sui GP, Kanai AJ, Wu C. The function of suburothelial myofibroblasts 
in the bladder. Neurourol Urodyn. 2007. 26:914–919. 
Fry CH, Young HS, Jabr RI, McCarthy C, Ikeda Y, Kanai AJ. Modulation of 
spontaneous activity in the overactive bladder: the role of P2Y agonists. Am J Physiol 
Renal Physiol. 2012. 302: F1447. 
_____________________________________________________________________REFERENCES 
PhD Thesis: Isabel Sofia Dias da Silva________________________________________196 
 
Fuhrich DG, Lessey BA, Savaris RF. Comparison of HSCORE assessment of 
endometrial beta 3 integrin subunit expression with digital HSCORE using 
computerized image analysis (ImageJ). Anal Quant Cytopathol Histopathol. 2013. 35: 
210-6. 
Fujimura R, Tamura K, Tsutsumi T, Yamamoto T, Nakamura K, Koibuchi Y, 
Kobayashi M, Yamaguchi O. Expression and possible functional role of the beta3-
adrenoceptor in human and rat detrusor muscle. J Urol. 1999. 161: 680-685. 
Fumagalli M, Trincarelli L. Lecca D, Martini C, Ciana P, Abbracchio MP. 
Cloning, pharmacological characterization and distribution of the rat G-protein-
coupled P2Y13 receptor. Biochem Pharmacol. 2004. 68: 113-124. 
Gachet C, Hechler B. The platelet P2 receptors in thrombosis. Semin Thromb 
Hemost. 2005. 31: 162-167. 
Giglio D, Ryberg AT, To K, Delbro DS, Tobin G. Altered muscarinic receptor 
subtype expression and functional responses in cyclophosphamide induced cystitis in 
rats. Auton Neurosc: Basic and Clin. 2005. 122 (1-2): 9-20. 
Gijsbers R, Aoki J, Arai H, Bollen M. The hydrolysis of lysophospholipids and 
nucleotides by autotaxin (NPP2) involves a single catalytic site. FEBS Lett. 2003. 
538: 60-64. 
Gillespie JI, Rouget C, Palea S, Granato Cm Korstanje C. Beta adrenergic 
modulation of spontaneous microcontractions and electrical field-stimulated 
contractions in isolated strips of rat urinary bladder from normal animals and animals 
with partial bladder outflow obstruction. Naunyn Schmiedeberg’s Arch Pharmacol. 
2015. 388: 719-26. 
Goding JW, Howard MC. Ecto-enzymes of lymphoid cells. Immunol Rev. 
1998. 161: 5-10. 
Gong B, Shelite T, Mei FC, Ha T, Hu Y, Xu G, Chang Q, Wakamiya M, 
Ksiazek TG, Boor PJ, Bouyer DH, Popov VL, Chen J, Walker DH, Chens X. 
Exchange protein directly activated by cAMP plays a critical role in bacterial invasion 
during fatal rickettsioses. Proc Natl Acad Sci USA. 2013. 110: 19615–19620. 
Gonzalez EJ, Heppner TJ, Nelson MT, Vizzard MA. Purinergic signaling 
underlies transforming growth factor-β-mediated bladder afferent nerve 
hyperexcitability. J Physiol. 2016. 594(13): 3575-88. 
Gonzalez EJ, Merrill L, Vizzard MA. Bladder sensory physiology: neuroactive 
compounds and receptors, sensory transducers, and target-derived growth factors as 
_____________________________________________________________________REFERENCES 
PhD Thesis: Isabel Sofia Dias da Silva________________________________________197 
 
targets to improve function. Am J Physiol Regul Integr Comp Physiol. 2014. 306: 
R869-R878. 
Gopalakrishnan SM, Buckner SA, Milicic I, Groebe DR, Whiteaker KL, Burns 
DJ, Warrior U, Gopalakrishnan M. Functional characterization of adenosine receptors 
and coupling to ATP-sensitive K+ channels in Guinea pig urinary bladder smooth 
muscle. J Pharmacol Exp Ther. 2002. 300 (3): 910-7. 
Gosling JA, Dixon JS. Sensory nerves in the mammalian urinary tract. An 
evaluation using light and electron microscopy. J Anat. 1974. 117:133–144. 
Griffin CS, Bradley E, Hollywood MA, McHale NG, Thornbury KD, Sergeant 
GP. β3-adrenoceptor agonists inhibit carbachol-evoked Ca2+ oscillations in murine 
detrusor myocytes. BJU Int. 2017. Dec 6 [Epub ahead of print]. 
Griffiths D, Tadic SD. Bladder control, urgency, and urge incontinence: 
Evidence from functional brain imaging. Neurourol Urodyn. 2008. 27: 466-474. 
Grol S, van Koeveringe GA, de Vente J, van Kerrebroeck PE, Gillespie JI. 
Regional differences in sensory innervation and suburothelial interstitial cells in the 
bladder neck and urethra. BJU Int. 2008. 102:870–877. 
Guan N, Gustafsson LE, Svennersten K.  Inhibitory effects of urothelium-
related factors. Basic Clin Pharmacol Toxicol. 2017. 121 (4): 220-224. 
Guarracino JF, Cinali AR, Fernández V, Roquel LI, Losavio AS. P2Y13 
receptors mediate presynaptic inhibition of acetylcholine release induced by adenine 
nucleotides of the mouse neuromuscular junction. Neurosc. 2016. 326: 31-44. 
Guo Y, Kotova E, Chen ZS, Lee K, Hopper-Borge E, Belinsky MG, Kruh GD. 
MRP8, ATP-binding cassete C11 (ABCC11), is a cyclic nucleotide effluc pump and a 
resistance factor for fluoropyrimidines 2’,3’-dideoxycytidine and 9’-(2’-
phosphonymethoxythyl) adenine. J Biol Chem. 2003. 278: 29509-29514. 
Habler HJ, Janig W, Koltzenburg M. Activation of unmyelinated afferent fibres 
by mechanical stimuli and inflammation of the urinary bladder in the cat. J Physiol. 
1990. 425:545–562. 
Harris S, Rizzolo D. Botulinum toxin as a treatment for refractory overactive 
bladder. JAAPA. 2016. 29(2): 1-4. 
Harvey RA, Skennerton DE, Newgreen D, Fry CH. The contractile potency of 
adenosine triphosphate and ecto-adenosine triphosphatase activity in guinea pig 
detrusor and detrusor from patients with a stable, unstable or obstructed bladder. J 
Urol. 2002. 168: 1235-1239. 
_____________________________________________________________________REFERENCES 
PhD Thesis: Isabel Sofia Dias da Silva________________________________________198 
 
Harvey RD, Belevych AE. Muscarinic regulation of cardiac ion channels. Br J 
Pharmacol. 2003. 139: 1074-84. 
Hashitani H, Brading AF, Suzuki H. Correlation between spontaneous 
electrical, calcium and mechanical activity in detrusor smooth muscle of the guinea-
pig bladder. Br J Pharmacol. 2004. 141(1): 183-93. 
Hatanaka T, Ukai M, Watanabe M, Somega A, Ohtake A, Suzuki M, Ueshima 
K, Sato S, Sasamata M. In vitro and in vivo pharmacology profile of the selective β3-
adrenoceptor agonist mirabegron in rats. N-S Arch Pharmacol. 2013. 386: 247-253. 
Hayashi M, Kajioka S, Itsumi M, Takahashi R, Shahab N, Ishigami T, Takeda 
M, Masuda N, Yamaguchi A, Naito S. Actions of cAMP on calcium sensitization in 
human detrusor smooth muscle contraction. BJU Int. 2016. 117(1): 179-91. 
Hegde SS, Choppin A, Bonhaus D, Briaud S, Loeb M, Moy TM, Loury D, 
Eglen RM. Functional role of M2 and M3 muscarinic receptors in the urinary bladder 
of rats in vitro and in vivo. Br J Pharmacol. 1997. 120: 1409-18. 
Hegde SS, Eglen RM. Muscarinic receptor subtypes modulating smooth 
muscle contractility in the urinary bladder. Life Sci. 1999. 64: 419-428. 
Helfand BT, Evans RM, McVary KT. A comparison of the frequencies of 
medical therapies for overactive bladder in men and women: analysis of more than 
7.2 million aging patients. Eur Urol. 2010. 586-591. 
Herbert JM, Savi P. P2Y12, a new platelet ADP receptor, target of clopidogrel. 
Semin Vasc Med. 2003. 3(2): 113-22. 
Hicks M. The mammalian urinary bladder: an accomodating organ. Biol Rev. 
1975. 50:215–246. 
Hirsh AJ, Stonebraker JR, van Heusden CA, Lazarowski ER, Boucher RC, 
Picher M. Adenosine deaminase 1 and concentrative nucleoside transporters 2 and 3 
regulate adenosine on the apical surface of human airway epithelia: implications for 
inflammatory lung diseases. Biochemistry. 2007. 46: 10373-10383. 
Hoffmann C, Leitz MR, Oberdorf-Maass S, Lohse MJ, Klotz K-N. Comparative 
pharmacology of human β-adrenergic receptor subtypes – characterization of stably 
transfected receptors in CHO cells. Naunyn-Schmiedeberg’s Arch Pharmacol. 2004. 
369: 151-159. 
Holstege G, Mounton LJ. Central nervous system control of micturition. Int Rev 
Neurobiol. 2003. 56: 123-145. 
Holstege G. Micturition and the soul. J Comp Neurol. 2005. 493: 15-20. 
_____________________________________________________________________REFERENCES 
PhD Thesis: Isabel Sofia Dias da Silva________________________________________199 
 
Holstege G. The emotional motor system and micturition control. Neurourol 
Urodyn. 2010. 29: 42-48. 
Holz GG, Kang G, Harbeck M, Roe MW, Chepurny OG. Cell physiology of 
cAMP sensor Epac. J Physiol. 2006. 577: 5-15. 
Honda M, Takenaka A, Inone S, Chancellor MB, Yoshimura N. Sensory 
neurone-specific receptor-mediated regulation of micturition reflex in urethane-
anaesthetized rats. BJU Int. 2012. 109: 628-633. 
Hoyle CH, Chapple C, Burnstock G. Isolated human bladder: evidences for a 
dinucleotide acting on P2X-purinoceptors and for purinergic transmission. Eur J 
Pharmacol. 1989. 174(1): 115-8. 
Hoyle HV, Burnstock G. Postganglionic efferent transmission in the bladder 
and urethra. In Nervous Control of the Urogenital System (Maggi Ca Ed), Harwood, 
Academic Publishers GmbH, Chur, Switzerland. 1993: 349-381. 
Hudman D, Elliott RA, Whitaker P, Terry TR, Sandhu DP, Norman RI. 
Inhibition of the contractile response of isolated human and rat bladders by 
clenbuterol. J Urol. 2001. 166: 1969-1973. 
Husted S, Sjögren C, Andersson KE. Direct effects of adenosine and adenine 
nucleotides on isolated human urinary bladder and their influence on electrically 
induced contractions. J Urol. 1983. 130, 392-398. 
Igawa Y, Michel MC. Pharmacological profile of beta-3-adrenoceptor agonists 
in clinical development for the treatment of overactive bladder syndrome. Naunyn 
Schmiedeberg’s Arch Pharmacol. 2013. 386: 177-183. 
Igawa Y, Yamazaki Y, Takeda H, Akahane M, Ajisawa Y, Yanoyama T, 
Nishizawa O. Possible β3-adrenoceptor-mediated relaxation of the human detrusor. 
Acta Physiol Scand. 1998. 164: 117-118. 
Igawa Y, Yamazaki Y, Takeda H, Hayakawa K, Akahane M, Ajisawa Y, 
Yoneyama T, Nishizawa O, Andersson KE. Functional and molecular biological 
evidence for a possible beta3-adrenoceptor in the human detrusor muscle. Br J 
Pharmacol. 1999. 126: 819-825. 
Igawa Y, Yamazaki Y, Takeda H, Kaidoh K, Akahane M, Ajisawa Y, 
Yoneyama T, Nishizawa O, Andersson KE. Relaxant effects of isoproterenol and 
selective beta3-adrenoceptor agonists on normal, low compliant and hyperreflexic 
human bladders. J Urol. 2001. 165: 240-244. 
_____________________________________________________________________REFERENCES 
PhD Thesis: Isabel Sofia Dias da Silva________________________________________200 
 
Igawa Y, Zhang X, Nishizawa O, Umeda M, Iwata A, Taketo MM, Manabe T, 
Matsui M, Andersson KE. Cystometric findings in mice lacking muscarinic M2 or M3 
receptors. J Urol. 2004. 172: 2460-4. 
Irwin DE, Milsom I, Hunskaar S, Reilly K, Kopp Z, Herschorn S, Coyne K, 
Kelleher C, Hampel C, Artibani W, Abrams P. Population-based survey of urinary 
incontinence, overactive bladder and other lower urinary tract symptoms in five 
countries: results if the EPIC study. Eur Urol. 2006b. 50(6): 1306-1315. 
Irwin DE, Milsom I, Kopp Z, Abrams P, Cardozo L. Impact of overactive 
bladder symptoms on employment, social interactions and emotional wellbeing in six 
European countries. BJU Int. 2006a. 97: 96-100. 
Ito K, Iwami A, Katsura H, Ikeda M. Therapeutic effects of the putative 
P2X3/P2X2/3 antagonist A-317491 on cyclophosphamide-induced cystitis in rats. N-
S Arc Pharmacol. 2008. 372:483-490. 
Jacobson KA, Costanzi S, Joshi BV, Besada P, Shin DH, Ko H, Ivanov AA, 
Mamedova L. Agonists and antagonists for P2 receptors. Novartis Found Symp. 
2006. 276: 58-68. 
Jacobson KA, Jarvis MF, William SM. Purine and pyrimidine (P2) receptors as 
drug targets. J Med Chem. 2002. 45: 4057-4093. 
James G, Butt AM. P2Y and P2X purinoceptors mediated Ca2+ signaling in 
glial cell pathology in the central nervous system. Eur J Pharmacol. 2002. 447(2-3): 
247-60. 
Jarvis MF, Burgard EC, McGaraughty S, Honore P, Lynch K, Brennan TJ, 
Sibieta A, Van Biesen T, Cartmell J, Bianchi B, Niforatos W, Kage K, Yu H, Mikusa J, 
Wismer CT, Zhu Cz, Chu K, Lee CH, Stewart AO, Polakwaski J, Cox BF, Kowaluk E, 
Williams M, Sullivan J, Faltynek C. A-317491, a novel potent and selective non-
nucleotide antagonist of P2X3 and P2X2/3 receptors, reduces chronic inflammatory 
and neuropathic pain in the rat. Proc Natl Acad Sci USA. 2002. 99: 17179-17184. 
Jedlitschky G, Burchell B, Keppler D. The multidrug resistance protein 5 
functions as an ATP dependent export pump for cyclic nucleotides. J Biol Chem. 
2000. 275: 30069-30074. 
Jen PY, Dixon JS, Gosling JA. Immunohistochemical localization of 
neuromarkers and neuropeptides in human fetal and neonatal urinary bladder. B J 
Urol. 1995. 75:230–235. 
_____________________________________________________________________REFERENCES 
PhD Thesis: Isabel Sofia Dias da Silva________________________________________201 
 
Jenes Á, Ruzsnavszky F, Telek A, Szigeti GP, Csernoch L. A possible role of 
the cholinergic and purinergic receptor interaction in the regulation of the rat urinary 
bladder function. J Muscle Res Cell Motil. 2012. 32: 421-431. 
Jhang JF, Kuo HC. Botulinum toxin A and lower urinary tract dysfunction: 
pathophysiology and mechanisms of action. Toxins (Basel). 2016. 8(4): 120. 
Jones SV, Heilman CJ, Brann MR. Functional responses of cloned muscarinic 
receptors expressed in CHO-K1 cells. Mol Pharmacol. 1991. 40: 242-247. 
Jost SP, Gosling JA, Dixon JS. Themorphology of normal human bladder 
urothelium. J Anat. 1989. 167: 103–115. 
Jóźwiak-Bebenista M, Wiktorowska-Owczarek A, Kowalczyk E. Beta-
adrenoceptor mediated cyclic AMP signal in different types of culture nerve cells in 
normoxic and hypoxic conditions. Mol Biol. 2016. 50(5): 838-846. 
Kaan TKY, Yip PK, Grist J, Cefalu JS, Nunn PA, Ford AP, Zhong Y, McMahon 
SB. Endogenous purinergic control of bladder activity via presynaptic P2X3 and 
P2X2/3 receptors in the spinal cord. Neurosc. 2010. 30(12): 4503-4507. 
Kanai A, Andersson KE. Bladder afferent signaling: recent findings. J Urol. 
2010. 183(4): 1288-1295. 
Kang SH, Chess-Williams R, Anoopkumar-Dukie S, McDermott C. Induction of 
inflammatory cytokines and alteration of urothelial ATP, acetylcholine and 
prostaglandin E2 release by doxorubicin. Eur J Pharmacol. 2013. 700: 102-9. 
Kaplan SA, Roehrborn CG, Chancellor M, Carlsson M, Bavendam T, Guan Z. 
Extended-release tolterodine with or without tamsulosin in men with lower urinary 
tract symptoms and overactive bladder: effects on urinary symptoms assessed by the 
International Prostate Symptoms Score. BJU Int. 2008. 102: 1133-9. 
Kasakov L, Burnstock G. The use of the slowly degradable analoge 
alpha,beta-methylene ATP, to produce desensitization of the P2-purinoceptor: effect 
on non-adrenergic, non-cholinergic responses of the guinea-pig urinary bladder. Eur 
J Pharmacol. 1982. 86: 291-294. 
Kavia RB, Dasgupta R, Fowler CJ. Functional imaging and the central control 
of the bladder. J Comp Neurol. 2005. 493: 27-32. 
Kawasaki H, Springett GM, Mochizuki N, Toki S, Nakaya M, Matsuda M, 
Housman DE, Graybiel AM. A family of cAMP-binding proteins that directly activate 
Rap1. Science. 1998. 282: 2275–2279. 
_____________________________________________________________________REFERENCES 
PhD Thesis: Isabel Sofia Dias da Silva________________________________________202 
 
Kelleher CJ, Cardozo LD, Khullar V, Salvatore S. A medium-term analysis of 
the subjective efficacy of treatment for women with detrusor instability and low 
bladder compliance. Br J Obstet Gyneacol. 1997. 104: 988-93. 
Kennedy C, Tasker P, Gallacher G, Westfall TD. Identification of atropine- and 
P2X1 receptor antagonist –resistant, neurogenic contractions of the urinary bladder. 
J Neurosc. 2007. 27(4): 845:851. 
Kessler TM, Bachmann LM, Minder C, Löhrer D, Umbehr M, Schünemann HJ, 
Kessels AGH. Adverse event assessment of antimuscarinics for treating overactive 
bladder: a network meta-analytic approach. Plos One. 2011. 6: e16718. 
Khera M, Somogyi GT, Kiss S, Boone TB, Smith CP. Botulinum toxin A inhibits 
ATP release from bladder urothelium after chronic spinal cord injury. Neurochem Int. 
2004. 45(7): 987-93. 
Kiermayer S, Biondi RM, Imig J, Plotz G, Haupenthal J, Zeuzem S, Piiper A. 
Epac activation converts cAMP from a proliferative into a differentiation signal in 
PC12 cells. Mol Biol Cell. 2005.16:5639–5648.  
Kim JC, Yoo JS, Park EY, Hong SH, Seo SI, Hwang TK. Muscarinic and 
purinergic receptor expression in the urothelium of rats with detrusor overactivity 
induced by bladder outlet obstruction. BJU Int. 2007. 101: 371-375. 
King BF, Knowles ID, Burnstock G, Ramage AG. Investigation of the effects of 
P2 purinoceptor ligands on the micturition reflex in female urethane-anaesthetized 
rats. Br J Pharmacol. 2004. 142(3): 519-30. 
King JA, Huddart H, Staff WG. Purinergic modulation of rat urinary bladder 
detrusor smooth muscle. Gen Pharmacol. 1997. 29: 597-604. 
Kitta T, Chancellor MB, de Groat WC, Kuno S, Nonomura K, Yoshimura N. 
Suppression of bladder overactivity by adenosine A2A receptor antagonist in a rat 
model of Parkinson disease. J Urol. 2012. 187(5): 1890-7. 
Kitta T, Chancellor MB, de Groat WC, Kuno S, Nonomura K, Yoshimura N. 
Roles of adenosine A1 and A2A receptors in the control of micturition in rats. 
Neurourol Urodyn. 2014. 33(8): 1259-65. 
Klinger M, Freissmuth M, Nanoff C. Adenosine receptors: G protein-mediated 
signaling and the role of accessory proteins. Cell Signal. 2002. 14: 99-108. 
Koh SD, Lee H, Ward SM, Sanders KM. The Mystery of the Interstitial cells of 
urinary bladder. Annu Rev Pharmacol Toxicol. 2018. 58: 603-623. 
_____________________________________________________________________REFERENCES 
PhD Thesis: Isabel Sofia Dias da Silva________________________________________203 
 
Komai AM, Brannmark C, Musovic S, Olofsson CS. PKA-independent cAMP 
stimulation of white adipocyte exocytosis and adipokine secretion: modulations by 
Ca2+ and ATP. J Physiol. 2014. 592: 5169-5186. 
Komai AM, Musovic S, Peris E, Alrifaiy A, El Hachmane MF, Johansson M, 
Wernstedt Asterholm I, Olofsson CS. White adipocyte adiponectin exocytosis is 
stimulated via β3-adrenergic signaling and activation of Epac1: Catechol lamine 
resistance in obesity and type 2 diabetes. Diabetes. 2016. 65(11): 3301-3313. 
Kono M, Nakamura Y, Ishiura Y, Komatsu K, Kontani H, Namiki M. Central 
muscarinic receptor subtypes regulating voiding in rats. J Urol. 2006. 175: 353-357. 
Kooistra MR, Corada M, Dejana E, Bos JL. Epac1 regulates integrity of 
endothelial cell junctions through VE-cadherin. FEBS Lett. 2005. 579:4966–4972. 
Kories C, Czyborra C, Fetscher C, Schneider T, Krege S, Michel M. Gender 
comparison of muscarinic receptor expression and function in rat and human urinary 
bladder: differential regulation of M2 and M3 receptor? Naunyn-Schim Arch 
Pharmacol. 2003. 367: 524-531. 
Kruse R, Säve S, Persson K. Adenosine triphosphate induced P2Y2 receptor 
activation induces proinflammatory cytokine release in uroepithelial cells. J Urol. 
2012. 188(6): 2419-25. 
Kubo T, Fukuda K, Mikami A, Maeda A, Takahashi H, Mishina M, Haga T, 
Haga K, Ichiyama A, Kangawa K, Kojima A, Matsuo H, Hirose T, Numa S. Cloning, 
sequencing and expression of complementary DNS encoding the muscarinic 
acetylcholine receptor. Nature. 1986a. 323: 411-416. 
Kukulski F, Lévesque SA, Lavoie EG, Lecka J, Bigonnesse F, Knowles AF, 
Robson SC, Kirley TL, Sévigny J. Comparative hydrolysis of P2 receptor agonist by 
NTPDases1,2,3 and 8. Purinergic Signal. 2005. 1:193-204. 
Kullmann FA, Artim D, Beckel J, Barrick S, de Groat WC, Birder LA. 
Heterogeneity of muscarinic receptor-mediated Ca2+ responses in cultured urothelial 
cells from rat. Am J Physiol Renal Physiol. 2008. 294:F971–F981. 
Kullmann FA, Limberg BJ, Artim DE, Shah M, Downs TR, Contract D, Wost J, 
Rosenbaum JS, de Groat WC. Effects of beta3-adrenergic receptor activation on rat 
urinary bladder hyperactivity induced by ovariectomy. J Pharmacol Exp Ther. 2009. 
330: 704-717. 
_____________________________________________________________________REFERENCES 
PhD Thesis: Isabel Sofia Dias da Silva________________________________________204 
 
Kumar V, Chapple CC, Chess-Williams R. Characteristics of adenosine 
triphosphate release from porcine and human normal bladder. J Urol. 2004. 172: 
744-747. 
Kumar V, Chapple CR, Rosario D, Tophill PR, Chess-Williams. In vitro release 
of adenosine triphosphate from urothelium of human bladders with detrusor 
overactivity, both neurogenic and idiopathic. Eur Urol. 2010. 57: 1087-1092. 
Kumar V, Templeman L, Chapple CR, Chess-Williams R. Recent 
developments in the management of detrusor overactivity. Curr Opin Urol. 2003. 13: 
285-91. 
Kunapuli SP, Dorsam RT, Kim S, Quinton TM. Platelet purinergic receptors. 
Curr Opin Pharmacol. 2003. 3: 175-80. 
Kushida N, Fry CH. On the origin of spontaneous activity in the bladder. BJU 
Int. 2016. 117(6): 982-92. 
Landers ES, Linton LM, Birren B, Nusbaum C, Zody MC, Baldwin J, Devon K, 
Doyle M, FitzHugh W et al. Initial sequencing and analysis of the human genome. 
Nature. 2001. 409: 860-921. 
Lands AM, Arnold A, McAuliff JB, Luduena FP, Brown Jun TG. Differentiation 
of receptor system activated by sympatomimetic amines. Nature. 1967. 214: 597-8. 
Laurenza A, Sutkowski E, Seamon KK. Forskolin: a specific stimulator of 
adenylate cyclase or a diterpene with multiple sites of action. Trends Pharmacol Sci. 
1989. 10: 442-447. 
Lawrence GW, Aoki KR, Dolly JO. Excitatory cholinergic and purinergic 
signaling in bladder are equally susceptible to botulinum neurotoxin a consistent with 
co-release of transmitters from efferent fibers. J Pharmacol Exp Ther. 2010. 334(3): 
1080-6. 
Lazarowski ER, Boucher RC, Harden TK. Mechanisms of release of 
nucleotides and integration of their actions as P2X-and P2Y-receptor activating 
molecules. Mol Pharmacol. 2003. 64: 785-95. 
Le Novére N, Changeus JP. Molecular evolution of the nicotinic acetylcholine 
receptor: an example of multigene family in excitable cells. J Mol Evol. 1995. 40: 155-
172. 
Leblais V, Demolombe S, Vallette G, Langin D, Baró I, Escande D, Gauthier 
C. β3-Adrenoceptor control the cystic fibrosis transmembrane conductance regulator 
_____________________________________________________________________REFERENCES 
PhD Thesis: Isabel Sofia Dias da Silva________________________________________205 
 
through a cAMP/Protein kinase A-independent pathway. J Biol Chem. 1999. 274: 
6107-6113. 
Lecci A, Giuliani S, Tramontana M, Santicioli P, Criscuoli M, Dion S, Maggi 
CA. Bladder distension and activation of the efferent function of sensory fibers: 
similarities with the effect of capsaicin. Br J Pharmacol. 1998. 124: 259-266. 
Lee HY, Bardini M, Burnstock G. Distribution of P2X receptors in the urinary 
bladder and the ureter of the rat. J Urol. 2000. 163: 2002-7. 
Lefkowitz RJ, Shenoy SK. Transduction of receptor signals by beta-arrestins. 
Science. 2005. 308: 512-517.  
Lefkowitz RJ. G protein-coupled receptors. III. New roles for receptor kinases 
and beta-arrestins in receptor signaling and desensitization. J Biol Chem. 1998. 273: 
18677-18680. 
Lepor H. Pathophysiology, epidemiology, and natural history of benign 
prostatic hyperplasia. Rev Urol. 2004. (6):9.  
Lévesque SA, Lavoie ÉG, Lecka J, Bigonness F, Sévigny J. Specificity of the 
ecto-ATPase inhibitor ARL67156 on human and mouse ectonucleotidases. Br J 
Pharmacol. 2007. 152: 141-150. 
Levin RM, Haugaard N, O’Connor L, Buttyan R, Das A, Dixon JS, Gosling JA. 
Obstructive response of human bladder to BPH vs. rabbit bladder response to partial 
outlet obstruction: a direct comparison. Neurourol Urodyn. 2000. 19(5): 609-29. 
Levin RM, Wein AJ. Distribution and function of adrenergic receptors in the 
urinary bladder of the rabbit. Molec Pharmacol. 1979. 16: 441-448. 
Lewis SA, Diamond JM. Active sodium transport by mammalian urinary 
bladder. Nature. 1975. 253:747-8. 
Lewis SA, Hanrahan JW. Apical and basolateral membrane ionic channels in 
rabbit urinary bladder epithelium. Pflugers Arch. 1985. 405 Suppl 1:S83-8. 
Lewis SA, Lewis JR. Kinetics of urothelial ATP release. Am J Physiol Renal 
Physiol. 2006. 291: F332-F340. 
Lewis SA. Everything you wanted to know about the bladder epithelium but 
were afraid to ask. Am J Physiol. 2000. 278, F867–F874. 
Li J, O'Connor KL, Cheng X, Mei FC, Uchida T, Townsend CM Jr, Evers BM. 
Cyclic adenosine 5′-monophosphate-stimulated neurotensin secretion is mediated 
through Rap1 downstream of both Epac and protein kinase A signaling pathways. 
Mol Endocrinol. 2007. 21:159–171.  
_____________________________________________________________________REFERENCES 
PhD Thesis: Isabel Sofia Dias da Silva________________________________________206 
 
Li Y, Xue L. Mao Q, Yao L, Yuan J, Qin W, Zhao Y, Sun H, Liu F, Wang H. 
Expression and electrophysiological characteristics of P2X3 receptors in interstitial 
cells of Cajal in rats with partial bladder outlet obstruction. BJU Int. 2013. 111(5): 
843-51. 
Liang FX, Riedel I, Deng FM, Zhou G, Xu C, Wu XR, Kong XP, Moll R, Sun 
TT. Organization of uroplakin subunits: transmembrane topology, pair formation and 
plaque composition. J Biochem. 2001. 355:13–18. 
Limberg BJ, Andersson KE, Kullmann AF, Burmer G, de Groat WC, 
Rosenbaum JS. β-Adrenergic receptor subtype expression in myocyte and non-
myocyte cells in human female bladder. Cell Tissue Res. 2010. 342(2): 295-306. 
Lips KS, Wunsch J, Zarghooni S, Bschleipfer T, Schukowski K, Weidner W, 
Wessler I, Schwantes U, Koepsell H, Kummer W. Acetylcholine and molecular 
components of its synthesis and release machinery in the urothelium. Eur Urol. 2007. 
51(4): 1042-53. 
Listerud M, Brussaard AB, Devay P, Colman DR, Role LW. Functional 
contribution of neuronal nicotinic subunits revealed by antisense oligonucleotides. 
Science. 1991. 254: 1518-1521. 
Lodish H, Berk A, Lawrence Zipursky S, Matsudaira P, Baltimore D, Darnell J. 
Molecular Cell Biology. 4th edition. New York: WH Freeman. 2000. 
Loffler M, Morote-Garcia JC, Eltzschig SA, Coe IR, Eltzschig HK. Physiological 
roles of vascular nucleoside transporters. Arterioscler Thromb Vasc Biol. 2007. 27: 
1004-1013. 
Losavio A, Muchnik S. Facilitation of spontaneous acetylcholine release 
induced by activation of cAMP in rat neuromuscular junctions. Life Sci. 2000. 66 (26): 
2543-56. 
Lu SH, Groat WC, Lin AT, Chen KK, Chang LS. Evaluation of purinergic 
mechanisms for the treatment of voiding dysfunction: a study in conscious spinal 
cord-injured rats. J Chin Med Assoc. 2007. 70: 439-444. 
Lukas RJ, Changeux JP, Le Novére N, Albuquerque EX, Balfour DJ, Berg DK, 
Bertrand D, Chiappinelli VA, Clarke PB, Collins AC, Dani JA, Grady SR, Kellar KJ, 
Lindstrom JM, Marks MJ, Quik M, Taylor PW, Wonnacott S. International Union of 
Pharmacology XX. Current status of the nomenclature for nicotinic acetylcholine 
receptors and their subunits. Pharmacol Rev. 1999. 51, 397-401. 
_____________________________________________________________________REFERENCES 
PhD Thesis: Isabel Sofia Dias da Silva________________________________________207 
 
Lukas RJ. Diversity and patterns of regulation of nicotinic receptor subtypes. 
Ann N Y Acad Sc. 1995. 757: 153-168. 
Lythgoe C, McVary KT. The use of PDE-5 inhibitors in the treatment of lower 
urinary tract symptoms due to benign prostatic hyperplasia. Curr Urol Rep. 2013. 14: 
585-94. 
Macarak EJ, Howard PS. The role of collagen in bladder filling. Adv Exp Med 
Biol. 1999. 462:215–223.  
Magalhães-Cardoso MT, Pereira MF, Oliveira L, Ribeiro JÁ, Cunha RA, 
Correia-de-Sá P. Ecto-AMP deaminase blunts the ATP-derived adenosine A2A 
receptor facilitation of acetylcholine release at rat motor nerve endings. J Physiol. 
2003. 549: 399-408. 
Maggi CA, Meli A. Modulation by β-adrenoceptors of spontaneous 
contractions of rat urinary bladder. J Auton Pharmacol. 1982. 2: 255-261. 
Maggi CA, Santicioli P, Geppetti P, Frilli S, Spillantini MG, Nediani C, Hunt SP, 
Meli A. Biochemical, anatomical and functional correlates of postnatal development 
of the capsaisin-sensitive innervation of the rat urinary bladder. Brain Res. 1988. 471: 
183-190. 
Maggi CA, Santicioli P, Geppetti P, Furio M, Frilli S, Conte B, Fanciullacci M, 
Giuliani S, Meli A. The contribution of capsaicin-sensitive innervation to activation of 
the spinal vesicovesical reflex in rats: relationship between substance P levels in the 
urinary bladder and the sensory-efferent function of capsaicin-sensitive sensory 
neurons. Brain Res. 1987. 415: 1-13. 
Maggi CA, Santicioli P, Meli A. Pharmacological evidence for the existence of 
two components in the twitch response to field stimulation of detrusor strips from the 
rat urinary bladder. J Auton Pharmacol. 1985. 5: 221-229. 
Mahony DT, Laferte RO, Blais DJ. Integral storage and voiding reflexes. 
Neurophysiologic concept of continence and micturition. Urol. 1977. 9: 95-106. 
Maillet M, Robert SJ, Cacquevel M, Gastineau M, Vivien D, Bertoglio J, 
Zugaza JL, Fischmeister R, Lezoualc’h F. Crosstalk between Rap1 and Rac 
regulates secretion of sAPPalpha. Nat Cell Biol. 2003. 5:633–639. 
Mandelzys A, Pié B, Deneris ES, Cooper E. The developmental increase in 
acetylcholine current densities on rat sympathetic neurons correlates with changes in 
nicotinic ACh receptor alpha-subunit gene expression and occurs independent of 
innervation. J Neurosci. 1994. 14: 2357-2364. 
_____________________________________________________________________REFERENCES 
PhD Thesis: Isabel Sofia Dias da Silva________________________________________208 
 
Mangera A, Apostolidis A, Andersson KE, Dasgupta P, Giannantoni A, 
Roehrborn C, Novara G, Chapple C. An update systematic review and statistical 
comparison of standardized mean outcomes for the use of botulinum toxin in the 
management of lower urinary tract disorders. Eur Urol. 2014. 65: 981-90. 
Mansfield KJ, Liu L, Mitchelson FJ, Moore KH, Millard RJ, Burcher E. 
Muscarinic receptor subtypes in human bladder detrusor and mucosa, studied by 
radioligand binding and quantitative competitive RT-PCR: changes in aging. Br J 
Pharmacol. 2005. 144: 1089-1099. 
Mao D, Yasuda RP, Fan H, Wolfe BB, Kellar KJ. Heterogeneity of nicotinic 
cholinergic receptors in rat superior cervical and nodose ganglia. Mol Pharmacol. 
2006. 70: 1693-1699. 
Marteau F, Le Poul E, Communi D, Communi D, Labouret C, Savi P, 
Boeynaems JM, Gonzalez NS. Pharmacological characterization of the human 
P2Y13 receptor. Mol Pharmacol. 2003. 64(1): 104-12. 
Martin BF. Cell replacement and differentiation in transitional epithelium: a 
histological and autoradiographic study of the guinea-pig bladder and ureter. J Anat. 
1972. 112:433-55. 
Masunaga K, Chapple CR, McKay NG, Yoshida M, Sellers DJ. The β3-
adrenoceptor mediates the inhibitory effects of β-adrenoceptor agonists via the 
urothelium in pig bladder dome. Neurourol Urodyn. 2010. 29: 1320-1325. 
Matos S, Cordeiro JM, Coelho A, Ferreira S, Silva C, Igawa Y, Cruz F, 
Charrua A. Bladder pain induced by prolonged peripheral alpha 1a-adrenoceptor 
stimulation involves the enhancement of transient receptor potential vanilloid 1 
activity and an increase of urothelial adenosine triphosphate release. Acta Physiol. 
2016. 218: 265-275. 
Matsui M, Griffin MT, Shehnaz D, Takedo MM, Ehlert FJ. Increased relaxant 
action of forskolin and isoproterenol against muscarinic agonist-induced contraction 
in smooth muscle from M2 receptor knockout mice. J Pharm. Exp. Therap. 2003. 
305: 106-113. 
Matsui M, Motomura D, Karasawa H, Fujikawa T, Jiang J, Komiya Y, 
Takahashi A, Taketo MM. Multiple functional defects in peripheral autonomic organs 
in mice lacking muscarinic acetylcholine receptor gene for the M3 subtype. Proc Nat 
Acad Sci. 2000. 97: 9579-9584. 
_____________________________________________________________________REFERENCES 
PhD Thesis: Isabel Sofia Dias da Silva________________________________________209 
 
Matsumoto Y, Miyazato M, Furuta A, Torimoto K, Hirao Y, Chancellor MB, 
Yoshimura N. Differential roles of M2 and M3 muscarinic receptor subtypes in 
modulation of bladder afferent activity in rats. Urology. 2010. 75(4): 862-867. 
Matsumoto Y, Miyazato M, Yokoyama H, Kita M, Hirao Y, Chancellor MB, 
Yoshimura N. Role of M2 and M3 muscarinic acetylcholine receptor subtypes in 
activation of bladder afferent pathways in spinal cord injured rats. Urology. 2012. 
79(5): 1184.e15-1184.e20. 
Matsuoka I, Ohkubo S. ATP- and adenosine-mediated signaling in the central 
nervous system: adenosine receptor activation by ATP through rapid and localized 
generation of adenosine by ecto-nucleotidases. J Pharmacol Sci. 2004. 94(2): 95-9. 
McCloskey KD. Bladder interstitial cells: an update review of current 
knowledge. Act Physiol. 2013. 207: 7-15. 
McCloskey KD. Interstitial cells in the urinary bladder – Localization and 
function. Neuroutol Urodyn. 2010. 29: 82-87. 
McHugh EM, McGee R. Direct anesthetic-like effects of forskolin on the 
nicotinic acetylcholine receptors of PC12 cells. J Biol Chem. 1986. 261: 3103-3106. 
McLatchie LM, Fry CH. ATP release from freshly isolated guinea-pig bladder 
urothelial cells: a quantification and study of the mechanisms involved. BJU Int. 2014. 
115 (6): 987-93. 
McLatchie LM, Fry CH. ATP release from freshly isolated guinea-pig bladder 
urothelial cells: a quantification and study of the mechanisms involved. BJU Int. 2015. 
115(6): 987-93. 
Meek PD, Evang SD, Tadrous M, Roux-Lirange D, Triller DM, Gumustop B. 
Overactive bladder drugs and constipation: a meta-analysis of randomized, placebo-
controlled trials. Dig Dis Sci. 2011. 56:7-18. 
Merrill L, Gonzalez EJ, Girard BM, Vizzard MA. Receptors, channels, and 
signaling in the urothelial sensory system in the bladder. Nat Rev Urol. 2016. 13(4): 
193-204. 
Michel MC, Korstanje C. β3-Adrenoceptor agonists for overactive bladder 
syndrome: Role of translational pharmacology in a repositioning clinical drug 
development project. Pharmacol Ther. 2016. 159: 66-82. 
Michel MC, Vrydag W. Alpha1-, alpha2- and beta-adrenoceptors in the urinary 
bladder, urethra and prostate. Br J Pharmacol. 2006. 147(Suppl 2):S88-119. 
_____________________________________________________________________REFERENCES 
PhD Thesis: Isabel Sofia Dias da Silva________________________________________210 
 
Mirone V, Imbimbo C, Longo N, Fusco F. The detrusor muscle: an innocent 
victim of bladder outlet obstruction. Eur Urol. 2007. 51: 57. 
Miyamato T, Mochizuki T, Nakagomi H, Kira S, Watanabe M, Takayama Y, 
Suzuki Y, Koizumi S, Takeda M, Tominaga M. Functional role of Piezo1 in stretch-
evoked Ca2+ influx and ATP release in urothelial cell cultures. J Biol Chem. 2014. 
289(23): 16565-75. 
Mochizuki T, Sokabe T, Araki I, Fujishita K, Shibasaki K, Uchida K, Naruse K, 
Koizumi S, Takeda M, Tominaga M. The TRPV4 cation channel mediates stretch-
evoked Ca2+ influx and ATP release in primary urothelial cell cultures. J Biol Chem. 
2009. 284(32): 21257-64. 
Mochizuki T, Sokabe T, Araki I, Fujishita K, Shibasaki K, Uchida K, Naruse K, 
Koizumi S, Takeda M, Tominaga M. The TRPV4 cation channel mediates stretch-
evoked Ca2+ influx and ATP release in primary urothelial cell cultures. J Biol Chem. 
2009. 284: 21257-64. 
Moore KH, Ray FR, Barden JA. Loss of purinergic P2X3 and P2X5 receptor 
innervation in human detrusor from adults with urge incontinence. J Neurosci. 2001. 
21: 1-6. 
Moro C, Chess-Williams R. Non-adrenergic, non-cholinergic, non-purinergic 
contractions of the urothelium/lamina propria of the pig bladder. Auton Autacoid 
Pharmacol. 2012. 32: 53. 
Morrins JL, Gibbins IL. Co-transmission and neuromodulation. In: Burnstock 
G, Hoyle CHV (eds) Autonomic neuroeffector mechanisms. Harwood Academic 
Publishers. 1992: 33-119. 
Morrison J, Birder L, Craggs M, et al. Incontinence. Abrams P, Cardozo L, 
Khoury S, Wein A, editors. Health Publications Ltd; Jersey: 2005. 363-422. 
Morrison JFB. The activation of bladder wall afferent nerves. Exp Physiol. 
1999. 84: 131-136. 
Mukerji G, Yiangou Y, Grogono K, Underwood J, Agarwal SK, Khullar V, 
Anand P. Localization of M2 and M3 muscarinic receptors in human bladder 
disorders and their clinical correlations. J Urol. 2006. 176(1): 367-73. 
Munoz A, Gangitano DA, Smith CP, Boone TB, Somogyi GT. Removal of 
urothelium affects bladder contractility and release of ATP but not release of NO in 
rat urinary bladder. BMC Urol. 2010. 24;10 :10. 
_____________________________________________________________________REFERENCES 
PhD Thesis: Isabel Sofia Dias da Silva________________________________________211 
 
Munoz A, Smith CP, Boone TB, Somogyi GT. Overactive and underactive 
bladder dysfunction is reflected by alterations in urothelial ATP and NO release. 
Neurochem Int. 2011. 58(3): 295-300. 
Munoz A, Somogyi GT, Boone TB, Ford AP, Smith CP. Modulation of bladder 
afferent signals in normal and spinal cord-injured rats by purinergic P2X3 and P2X2/3 
receptors. BJU Int. 2012. 110(800): E409-E414. 
Murakami S, Chapple CR, Akino H, Sellers DJ, Chess-Williams R. The role of 
the urothelium in mediating bladder responses to isoprenaline. BJU Int. 2007. 
99:669-673. 
Murray JM, Bussiere DE. Targeting the purinome. Methods Mol Biol. 2009. 
575: 47-92. 
Mutafova-Yambolieva VN, Durnin L. The purinergic neurotransmitter revisited: 
a single substance or multiple players? Pharmacol Ther. 2014. 144: 162-91. 
Nakagomi H, Yoshiyama M, Mochizuki T, Miyamoto T, Komatsu R, Imura Y, 
Morizawa Y, Hiasa M, Takaaki M, Kira S, Araki I, Fujishita K, Shibata K, Shigetomi E, 
Shinozaki R, Ichikawa R, Uneyama H, Iwatsuki K, Nomura M, de Groat WC, 
Moriyama Y, Takeda M, Koizumi S. Urothelial ATP exocytosis: regulation of bladder 
compliance in the urine storage phase. Sci Rep. 2016. 6: 29761. 
Namasivayam S, Eardley I, Morrison JFB. Purinergic sensory 
neurotransmission in the urinary bladder: an in vitro study in the rat. BJU Int. 1999. 
84: 854-860. 
Negoro H, Lutz SE, Liou LS, Kanematsu A, Ogawa O, Scemes E, Suadicani 
SO. Pannexin 1 involvement in bladder dysfunction in a multiple sclerosis model. 
Scient Reports. 2013. 3: 2152. 
Negoro H, Urban-Maldonado M, Liou LS, Spray DC, Thi MM, Suadicani SO. 
Pannexin 1 channels play essential roles in urothelial mechanotransduction and 
intercellular signaling. Plos One. 2014. 9(8): e106269. 
Nicholls J, Hourani SM, Kitchen I. Characterization of P1-purinoceptors on rat 
duodenum and urinary bladder. Br J Pharmacol. 1992. 105: 639-642. 
Nitti VW, Rosenberg S, Mitcheson DH, He W, Fakhoury A, Martin NE. 
Urodynamics and safety of the β3- adrenoceptor agonist mirabegron in males with 
lower urinary tract symptoms and bladder outlet obstruction. J Urol. 2013. 190: 1320-
1327. 
_____________________________________________________________________REFERENCES 
PhD Thesis: Isabel Sofia Dias da Silva________________________________________212 
 
Nomiya M, Yamaguchi O. A quantitative analysis of mRNA expression of α1 
and β-adrenoceptor subtypes and their functional roles in human normal and 
obstructed bladders. J Urol. 2003. 170: 649-653. 
North RA. Molecular physiology of P2X receptors. Physiol Rev. 2002. 82: 
1013-1067. 
Novak I. ATP as a signaling molecule: the exocrine focus. News in Physiol Sci. 
2003. 18(1): 12-17. 
Novara G, Galfano A, Secco S, D’Elia C, Cavalleri S, Ficarra V, Artibani W. A 
systematic review and meta-analysis of randomized controlled trials with 
antimuscarinic drugs for overactive bladder. Eur Urol. 2008. 54: 740-63. 
O´Reilly BA, Kosaka AH, Knight GF, Chang TK, Ford AP, Rymer JM, Popert 
R, Burnstock G, McMahon SB. P2X receptors and their role in female idiophatic 
detrusor instability. J Urol. 2002. 167: 157-164. 
O’Reilly BA, Kosaka AH, Chang TK, Ford AP, Popert R, McMahon SB. A 
quantitative analysis of purinoceptor expression in the bladders of patients with 
symptomatic outlet obstruction. BJU Int. 2001a. 87: 617-622. 
O’Reilly BA, Kosaka AH, Chang TK, Ford AP, Popert R, Rymer JM, McMahon 
SB. A quantitative analysis of purinoceptors expression in human fetal and adult 
bladders. J Urol. 2001b. 165(5): 1730-4. 
Obrara K, Lepor H, Walden PD. Localization of P2Y1 purinoceptors transcripts 
in the rat penis and urinary bladder. J Urol. 1998. 160: 587-591. 
Ochodnicky P, Uvelius B, Anderson KE, Michel MC. Autonomic nervous 
control of the urinary bladder. Acta Physiol. 2013. 207-16. 
Ockrim JL, Laniado ME, Patel A, Tubaro A, S St Clair Carter. A probability 
based system for combining simple office parameters as a predictor of bladder 
outflow obstruction. J Urol. 2001. 166(6): 2221-2225. 
Oelke M, Höfner K, Jonas U, de la Rosette JJ, Ubbink DT, Wijkstra H. 
Diagnostic Accuracy of Noninvasive Tests to Evaluate Bladder Outlet Obstruction in 
Men: Detrusor Wall Thickness, Uroflowmetry, Postvoid Residual Urine, and Prostate 
Volume. Eur Urol. 2007. 52 (3): 827-835.  
Ogoda M, Ito Y, Fuchihata Y, Onoue S, Yamada S. Characterization of 
muscarinic and P2X receptors in the urothelium and detrusor muscle of the rat 
bladder. J Pharmacol Sci. 2016. 131(1): 58-63.  
_____________________________________________________________________REFERENCES 
PhD Thesis: Isabel Sofia Dias da Silva________________________________________213 
 
Oike, M, Creed KE, Onoue H, Tanaka H, Ito Y. Increase in calcium in smooth 
muscle cells of the rabbit bladder induced by acetylcholine and ATP. J Auton Nerv 
Syst. 1998. 69:141-147. 
Otsuka A, Kawasaki H, Matsumoto R, Shinbo H, Kurita Y, Iwashita T, Ozono 
S. Expression of β-adrenoceptor in the human urinary bladder urothelium. Naunyn 
Scmiedeberg’s Arch Pharmacol. 2008. 377: 473-81. 
Owen SJ, Massa HH, Rose’Meyer BB. Loss of adenosine A2B receptor 
mediated relaxant responses in the aged female rat bladder; effects of dietary 
phytoestrogens. Naunyn Schmiedebergs Arch Pharmacol. 2012. 385: 539-549. 
Ozaki N, Shibasaki T, Kashima Y, Miki T, Takahashi K, Ueno H, Sunaga Y, 
Yano H, Matsuura Y, Iwanaga T, Takai Y, Seino S. cAMP-GEFII is a direct target of 
cAMP in regulated exocytosis. Nat Cell Biol. 2000. 2:805–811.  
Ozawa H, Chancellor MB, Jung SY, Yokoyama T, Fraser MO, Yu Y, de Groat 
WC, Yoshimura N. Effect of intravesical nitric oxide therapy on cyclophosphamide-
induced cystitis. 1999. J Urol, 162(6): 2211-2216. 
Package insert. Myrbetriq (mirabegron). Norman, OK: Astellas Pharma 
Tecnhologies, Inc., June 2012. 
Paes-De-Carvalho R. Adenosine as a signaling molecule in the retina: 
biochemical and developmental aspects. An Acad Bras Cienc. 2002. 74(3): 437-51. 
Pakzad M, Ikeda Y, McCarthy C, Kitney DG, Jabr RI, Fry CH. Contractile 
effects and receptor analysis of adenosine-receptors in human detrusor muscle from 
stable and neuropathic bladders. Naunyn Schmiedebergs Arch Pharmacol. 2016. 
389(8): 921-9. 
Palea S, Artibani W, Ostardo E, Trist DG, Pietra C. Evidence for purinergic 
neurotransmission in human urinary bladder affected by interstitial cystitis. J Urol. 
1993. 150(6): 2007-12. 
Palea S, Corsi M, Pietra W, Artibani W, Calpista A, Gaviraghi G, Trist DG. 
ADP beta S induces contraction of the human isolated urinary bladder through a 
purinoceptor subtype different from P2X and P2Y. J Pharmacol Exp Ther. 1994. 269: 
193-197. 
Palmer RK, Boyer JL, Schacter JB, Nicolas RA, Harden TK. Agonist action of 
adenosine triphosphate at the human P2Y1 receptor. Mol Pharmacol. 1998. 54: 1118-
1123. 
_____________________________________________________________________REFERENCES 
PhD Thesis: Isabel Sofia Dias da Silva________________________________________214 
 
Pandita RK, Mizusawa H, Andersson KE. Intravesical oxyhemoflobin initiates 
bladder overactivity in conscious, normal rats. J Urol. 2000. 164: 545-550. 
Parija SC, Raviprakash V, Mishra SK. Adenosine- and α,β.methylene ATP-
induced differential inhibition of cholinergic and non-cholinergic responses in rat 
urinary bladder. Br J Pharmacol. 1991. 102: 396-400. 
Park JM, Bloom DA, McGuire EJ. The guarding reflex revisited. Br J Urol. 
1997. 80: 940-945. 
Paukert M, Osteroth R, Geisler HS, Brändle U, Glowatzki E, Ruppersberg JP, 
Gründer S. Inflammatory mediator potentiat ATP-gated channels through the P2X(3) 
subunit. J Biol Chem. 2001. 276: 21077-21082. 
Peralta EG, Ashkenazi A, Winslow JW, Ramachandran J, Capon DJ. 
Differential regulation of PI hydrolysis and adenylyl cyclase by muscarinic receptor 
subtypes. Nature. 1988. 334: 434-437. 
Peralta EG, Ashkenazi A, Winslow JW, Smith DH, Ramachandran J, Capon 
DJ. Distinct primary structures, ligand-binding properties and tissue-specific 
expression or four human muscarinic acetylcholine. EMBO. 1987. 6: 3923-3929. 
Persyn S, De Wachter S, Wyndaele JJ, Eastham J, Gillespie J. The actions of 
isoprenaline and mirabegron in the isolated whole rat and guinea pig bladder. Auton 
Neurosci. 2016a. 198: 19-27. 
Persyn S, Eastham J, De Wachter S, Gillespie J. Adrenergic signaling 
elements in the bladder wall of the adult rat. Auton Neurosci. 2016b. 201: 40-48. 
Petkov GV. Central role of the BK channel in urinary bladder smooth muscle 
physiology and pathophysiology. Am J Physiol Regul Integr Comp Physiol. 2014. 
307(6): 571-84. 
Picher M, Boucher RC. Human airway ecto-adenylate kinase. A mechanism to 
propagate ATP signaling on airway surfaces. J Biol Chem. 2003. 278: 11256-64. 
Poth K, Nutter TJ, Cuevas J, Parker MJ, Adams DJ, Luetje CW. Heterogeneity 
of nicotinic receptors class and subunit mRNA expression among individual 
parasympathetic neurons from rat intracardiac ganglia. J Neurosci. 1997. 17: 586-
596. 
Prakasam HS, Herrington H, Roppolo JR, Jackson EK, Apodaca G. 
Modulation of bladder function by luminal adenosine turnover and A1 receptor 
activation. Am J Physiol Renal Physiol. 2012. 303: F279-F292. 
_____________________________________________________________________REFERENCES 
PhD Thesis: Isabel Sofia Dias da Silva________________________________________215 
 
Provophys et al., Human Physiology; Wikibooks contributors. 2006-2007. 
chapter 10. 
Pullen AH, Tucker D, Martin JE. Morphological and morphometric 
characterization of Onuf’s nucleus in the spinal cord in man. J Anat. 1997. 191: 201-
213. 
Qu HC, Zhang W, Liu YL, Wang PI. Association between polymorphism of β3-
adrenoceptor gene and overactive bladder: a meta-analysis. Genet Mol Res. 2015. 
14: 2495-501. 
Ralevic V, Burnstock G. Receptors for purines and pyrimidines. Pharmacol 
Rev. 1998. 50: 413-492. 
Ramer MS, Bradbury EJ, McMahon SB. Nerve growth factor induces P2X(3) 
Expression in sensory neurons. J Neurochem. 2001. 77: 864-875. 
Rangarajan S, Enserink JM, Kuiperij HB, de Rooij J, Price LS, Schwede F, 
Bos JL. Cyclic AMP induces integrin-mediated cell adhesion through Epac and Rap1 
upon stimulation of the beta 2-adrenergic receptor. J Cell Biol. 2003. 160:487–493. 
Rapp DE, Lyon MB, Bales GT, Cook SP. A role for the P2X receptor in urinary 
tract physiology and the pathophysiology of urinary dysfunction. Eur Urol. 2005. 48: 
303-308. 
Ray FR, Moore KH, Hansen MA, Barden JA. Loss of purinergic P2X receptor 
innervation in human detrusor and subepithelium from adults with sensory urgency. 
Cell Tissue Res. 2003. 314: 351-359. 
Reiter E, Lefkowitz RJ. GRKs and beta-arrestins: roles in receptor silencing, 
trafficking and signaling. Thends Endrocrinol Metab. 2006. 17: 159-165. 
Reshkin SJ, Guerra L, Bagorda A, Debellis L, Cardone R, Li AH, Jacobson 
KA, Casavola V. Activation of A(3) adenosine receptor induces calcium entry and 
chloride secretion in A(6) cell. J Membr Biol. 2000. 178: 103-113. 
Resta R, Yamashita Y, Thompson LF. Ecto-enzyme and signaling functions of 
lymphocyte CD73. Immunol Rev. 1998. 161: 95-109. 
Roberts JA, Vial HR, Digby KC, Agboh KC, Wen H, Atterbury-Thomas A, 
Evans RJ. Molecular properties of P2X receptors. Pflugers Arch. 2006. 452: 486-500. 
Robson SC, Sévigny J, Zimmermann H. The E-NTPDase family of 
ectonucleotidases: Structure function relationships and pathophysiological 
significance. Purinergic Signal. 2006. 2: 409-430. 
_____________________________________________________________________REFERENCES 
PhD Thesis: Isabel Sofia Dias da Silva________________________________________216 
 
Rockenbach L, Braganhol E, Dietrich F, Figueiró F, Pugliese M, Edelweiss MI, 
Morrone FB, Sévigny J, Battastini AM. NTPDase3 and ecto-5’-nucleotidase/CD73 
are differentially expressed during mouse bladder cancer progression. Purinergic 
Signal. 2014. 10(3): 421-30. 
Roehrborn CG, Abrams P, Royner ES, Kaplan Sam Herschom S, Guan Z. 
Efficacy and tolerability of tolterodine extended-release in men with overactive 
bladder and urgency urinary incontinence. BJU Int. 2006. 97: 1003-6. 
Rong W, Spyer M, Burnstock G. Activation and sensitization of low and high 
threshold afferent fibers mediated by P2X receptors in the mouse urinary bladder. J 
Physiol. 2002. 541: 591-600. 
RØtterud R, Nesland JM, Berner A, Fosså SD. Expression of the epidermal 
growth factor receptor family in normal and malignant urothelium. BJU Int. 2005. 95 
(9): 1344-1350. 
Rouget C, Rekik M, Camparo P, Botto H, Rischmann P, Lluel P, Palea S, 
Westfall TD. Modulation of nerve-evoked contractions by β3-adrenoceptor agonism 
in human and rat isolated urinary bladder. Pharmacol Res. 2014. 80: 14-20. 
Rubinstein R, Shalev M, Nissenkorn I, Cohen S. Effect of exogenous 
adenosine and its monophosphate on the contractile response to acetylcholine in the 
human isolated detrusor muscle strips. J Auton Pharmacol. 1998. 18: 99-104. 
Ruggieri MR Sr, Braverman AS, Pontari MA. Combined use of alpha-
adrenergic and muscarinic antagonists for the treatment of voiding dysfunction. J 
Urol. 2005. 174: 1743-8. 
Ruggieri MR. Mechanisms of disease: role of purinergic signaling in the 
pathophysiology of bladder dysfunction. Nature Clin Pract Urol. 2006. 3: 206-215. 
Sadananda P, Shang F, Liu L, Mansfield KJ, Burcher E. Release of ATP from 
rat urinary bladder mucosa: role of acid, vanilloids and stretch. Br J Pharmacol. 2009. 
158: 1655-1662. 
Sakagami H, Aoki J, Natori Y, Nishikawa K, Kakehi Y, Natori Y, Arai H. 
Biochemical and molecular characterization of a novel choline-specific 
glycerophosphodiester phosphodiesterase belonging to the nucleotide 
pyrophosphatase/phosphodiesterase family. J Biol Chem. 2005. 280: 23084-23093. 
Santoso AG, Sonarno IA, Arsad NA, Liang W. The role of the urothelium and 
ATP in mediating detrusor smooth muscle contractility. Urology. 2010. 76: 1267 (e7-
e12). 
_____________________________________________________________________REFERENCES 
PhD Thesis: Isabel Sofia Dias da Silva________________________________________217 
 
Sargent PB. The diversity of neuronal nicotinic acetylcholine receptors. Ann 
Rev Neurosci. 1993.16:403-443. 
Sassi Y, Ahles A, Truong DJ, Baqi Y, Lee SY, Husse B, Hulot JS, Foinquinos 
A, Thum T, Müller CE, Dendorfer A, Laggerbauer B, Engelhardt S. Cardiac myocyte-
secreted cAMP exerts paracrine action via adenosine receptor activation. J Clin 
Invest. 2014. 124: 5385-5397. 
Säve A, Persson K. Extracellular ATP and P2Y receptor activation induce a 
proinflammatory host response in the human urinary tract. Infec Immun. 2010. 78(8): 
3609-3615. 
Schachter JB, Harden TK. An examination of deoxyadenosine 5´(alpha-
thio)triphosphate as a ligand to define P2Y receptors and its selectivity as a low 
potency partial agonist of the P2Y1 receptor. Br J Pharmacol. 1997. 121(2): 338-44. 
Schmidt M, Bienek C, van Koppen CJ, Michel MC, Jacobs KH. Differential 
calcium signaling by M2 and M3 muscarinic acetylcholine receptors in a single cell 
type. Naunyn-Schm Arch Pharmacol. 1995. 352: 469-476. 
Schulte G, Fredholm BB. Human adenosine A(1), A(2A), A(2B), and A(3) 
receptors expressed in Chinese hamster ovary cells all mediate the phosphorylation 
of extracellular-regulated kinase ½. Mol Pharmacol. 2000. 58(3): 477-82. 
Schulte G, Fredholm BB. Signalling from adenosine receptors to mitogen-
activated protein kinases. Cell Signal. 2003. 15: 813-827. 
Schwiebert EM, Zsembery A. Extracellular ATP as a signaling molecule for 
epithelial cells. Bioch Biophysica Acta. 2003. 1615: 7-32. Review. 
Seamon KB, Padgett W, Daty JW. Forskolin: unique diterpene activator of 
adenylate cyclase in membranes and in intact cells. Proc Natl Acad Sci. 1981. 78: 
3363-3367. 
Searl TJ, Dynda DI, Alanee SR, El-Zawahry AM, McVary KT, Silinsky EM. A1 
adenosine receptor-mediated inhibition of parasympathetic neuromuscular 
transmission in human and murine urinary bladder. J Pharmacol Exp Ther. 2016. 
356(1): 116-22. 
Seguchi H, Nishimura J, Zhou Y, Niiro N, Kumazawa J, Kanaide H. 
Expression of β3-adrenoceptors in rat detrusor smooth muscle. Journal of Urology. 
1998. 159: 2197-2201. 
Seino S, Shibasaki T. PKA-dependent and PKA-independent pathways for 
cAMP-regulated exocytosis. Physiol Rev. 2005. 85:1303–1342.  
_____________________________________________________________________REFERENCES 
PhD Thesis: Isabel Sofia Dias da Silva________________________________________218 
 
Sellers DJ, Chess-Williams R. Muscarinic agonists and antagonists: effect on 
the urinary bladder. Hands Exp Pharmacol. 2012. 208: 375. 
Sellers DJ, Yamanishi T, Chapple CR, Couldwell C, Yasuda K, Chess-
Williams R. M3 muscarinic receptors but not M2 mediate contraction of the porcine 
detrusor muscle in vitro. J Auton Pharmacol. 2000. 20: 171-176. 
Sengupta JN, Gebhart GF. Mechanosensitive properties of pelvic nerve 
afferent fibers innervating the urinary bladder of the rat. J Neurophysiol. 1994. 72: 
2420-2430. 
Shachter JB, Harden TK. An examination of deoxyadenosine 5’(α-
thio)triphosphate as a ligand to define P2Y receptors and its selectivity as a low 
potency partial agonist of the P2Y1 receptor. Br J Pharmacol, 1997. 121: 338-344. 
Shafik A. Neuronal innervation of urethral and anal sphincters: surgical 
anatomy and clinical implications. Curr Opin Obstet Gynecol. 2000. 12: 387-398. 
Shah AP, Mevcha A, Wilby D, Alatsatianos A, Hardman JC, Jacques S, Wilton 
JC. Continence and Micturition: An Anatomical Basis. Clinical Anatomy. 2014. 27: 
1275-1283. 
Shaikh G, Cronstein B. Signaling pathways involving adenosine A2A and A2B 
receptors in wound healing and fibrosis. Purinergic Signal. 2016. 12(2): 191-7. 
Shaver SR. P2Y receptors: biological advances and therapeutic opportunities. 
Curr Opin Drug Discov Develp. 2001. 4(5): 665-670. 
Silva-Ramos I, Silva I, Duarte-Araújo M, Lafuente-de-Carvalho J, Correia-de-
Sá P. Loss of balance between excitatory P2X3 and inhibitory A2 receptors 
contribute to cholinergic hyperactivity in obstructed human bladder. Clin Pharmacol 
Toxicol. 2010. 107 (Suppl 1), 112-161. 
Silva-Ramos M, Silva I, Faria M, Magalhães-Cardoso MT, Correia J, 
Ferreirinha F, Correia-de-Sá P. Impairment of ATP hydrolysis decreases adenosine 
A1 receptor tonus favoring cholinergic nerve hyperactivity in the obstructed human 
urinary bladder. Purinergic Signal. 2015a. 11:595-606. 
Silva-Ramos M, Silva I, Faria M, Magalhães-Cardoso MT, Correia-de-Sá P. 
Urinary Bladder Disorders: Is adenosine friend or foe? In Adenosine Receptors: 
Pharmacology, Functions and Therapeutic Aspects. Ed. K. Warrick, nova Science 
Publishers, Inc (USA). 2015b. 
_____________________________________________________________________REFERENCES 
PhD Thesis: Isabel Sofia Dias da Silva________________________________________219 
 
Silva-Ramos M, Silva I, Oliveira JC, Correia-de-Sá P. Increased urinary 
adenosine triphosphate in patients with bladder outlet obstruction due to benign 
prostate hyperplasia. Prostate. 2016a. 76: 1353-1363. 
Silva-Ramos M, Silva I, Ferreirinha F, Faria M, Correia-de-Sá P. Overactive 
bladder (OAB): is there a place for drugs targeting the purinergic cascade? In 
Overactive Bladder (OAB): Prevalence, Risk Factors and Management. Ed. Elvira 
Larson, Nova Science Publishers, Inc (USA). 2016b. Chapter 6, pp. 127-156. ISBN: 
978-1-63485-033-9. 
Silva-Ramos M, Silva I, Oliveira O, Ferreira S, Reis MJ, Oliveira JC, Correia-
de-Sá P. Urinary ATP may be a dynamic biomarker of detrusor overactivity in women 
with overactive bladder syndrome. Plos One. 2013. 8(5): e64696. 
Sjögren C, Andersson KE, Husted S, Mattiasson A, Moller-Madsen B. Atropine 
resistance of transmurally stimulated isolated human bladder muscle. J Urol. 1982. 
128: 1368. 
Smith CP, Vemulakonda VM, Kiss S, Boone TB, Somogyi GT. Enhanced ATP 
release from rat bladder urothelium during chronic bladder inflammation: Effect of 
botulinum toxin A. Neurochem Int. 2005. 47(4): 291-7. 
Smith PP. Purinoceptors and bladder dysfunction. Curr Bladder Dysfunct Rep. 
2011. 6: 85-92. 
Socodato R, Brito R, Calaza KC, Paes-de-Carvalho R. Developmental 
regulation survival by adenosine in the in vitro and in vivo avian retina depends on a 
shift of signaling pathways leading to CREB phosphorylation or dephosphorylation. J 
Neurochem. 2011. 116(2): 227-39.  
Sout CE, Costantin JL, Naus CC, Charles AC. Intercellular calcium signaling in 
astrocytes via ATP release through connexin hemichannels. J Biol Chem. 2002. 
277(12): 10482-10488. 
Speakman MJ, Brading AF, Gilpin CJ, Dixon JS, Gilpin SA, Gosling JA. 
Bladder outflow obstruction – a cause of denervation supersensitivity. J Urol. 1987. 
138: 1461-1466. 
Spector DA, Wade JB, Dillow R, Steplock DA, Weinman EJ. Expression, 
localization, and regulation of aquaporin-1 to -3 in rat urothelia. Am J Physiol Renal 
Physiol. 2002. 282:F1034-42. 
Staskin DR, Chawla RK, Oefelein MG. Pharmacodynamics of overactive 
bladder drugs: shifting the curve. Curr Bladder Dysfunct Rep. 2011. 6: 51-63. 
_____________________________________________________________________REFERENCES 
PhD Thesis: Isabel Sofia Dias da Silva________________________________________220 
 
Stefan C, Jansen S, Bollen M. Modulation of purinergic signaling by NPP-type 
ectophosphodiesterases. Purnergic Signa. 2006. 2: 361-370. 
Stefan C, Jansen S, Bollen M. NPP-type ectophosphodiesterases: unity in 
diversity. Trends Biochem Sci. 2005. 30: 542-550. 
Stehle JH, Rivkees SA, Lee JJ, Weaver DR, Deeds JD, Reppert SM. 
Molecular cloning and expression of the cDNA for a novel A2-adenosine receptor 
subtype. Mol Endocrinol. 1992. 6: 384-393. 
Stella J, Bavaresco L, Braganhol E, Rockenbach L, Farias PF, Wink MR, 
Azambuja AA, Barrios CH, Morrone FB. Differential ectonucleotidase expression in 
human bladder cancer cell lines. Urol Oncol. 2010. 28(3): 260-7. 
Stewart WF, Van Rooyen JB, Cundiff GW, Abrams P, Herzog AR, Corey R, 
Hunt TL, Wein AJ. Prevalence and burden of overactive bladder in the United States. 
World J Urol. 2003. 20: 327-36. 
Strosberg AD. Structure, function, and regulation of adrenergic receptors. 
Protein Sci. 1993. 2(8): 1198-209. 
Sugaya K, Mori S, Tsuchida S. Efferent and primary afferent neural pathways 
innervating  the lower urinary tract of the cat. Part I. Efferent neural pathways. Nippon 
Hinyokika Gakkai Zasshi (Jpn J. Urol). 1988a. 79: 868-879. 
Sugaya K, Nishijima S, Miyazato M, Ogawa Y. Central nervous control of 
micturition and urine storage. J Smooth Muscle Res. 2005. 41 (3): 117-132. 
Suh YS, Ko KJ, Kim TH, Lee HS, Sung HH, Cho WJ, Lee M, Lee KS. Potential 
biomarkers for diagnosis of overactive bladder patients: urinary nerve growth factor, 
prostaglandin E2, and adenosine triphosphate. Int Neurourol J. 2017. 21(3): 171-177. 
Sui G, Fry B, Montgomery M, Roberts M, Wu R, Wu C. Purinergic and 
muscarinic modulation of ATP release from the urothelium and its paracrine actions. 
Am J Physiol Renal Physiol. 2014. (306): F286-F298. 
Sui GP, Rothery S, Dupont E, Fry CH, Severs NJ. Gap junctions and connexin 
expression in human suburothelial interstitial cells. BJU Int. 2002. 90: 118-129. 
Sui GP, Wu C, Fry CH. Characterization of the purinergic receptor subtype on 
guinea-pig suburothelial myofibroblasts. BJU Int. 2006. 97(6): 1327-31. 
Sun TT. Altered phenotype of cultured urothelial and other stratified epithelial 
cells: implications for wound healing. Am J Physiol Renal Physiol. 2006. 291:F9–F21. 
Sun Y, Chai TC. Augmented extracellular ATP signaling in bladder urothelial 
cells from patients with interstitial cystitis. Am J Physiol Cell Physiol. 2006. 290: C27. 
_____________________________________________________________________REFERENCES 
PhD Thesis: Isabel Sofia Dias da Silva________________________________________221 
 
Sun Y, MaLossi J, Jacobs SC, Chai TC. Effect of doxazosin on stretch-
activated adenosine triphosphate release in bladder urothelial cells from patients with 
benign prostatic hyperplasia. Urology. 2002. 60(2): 351-6. 
Surprenant A, North RA. Signaling at purinergic P2X receptors. Annu Rev 
Physiol. 2009. 71: 333-359. 
SvalØ J, Nordling J, Bouchelouche K, Andersson KE, Korstanje C, 
Bouchelouche P. The novel β3-adrenoceptor agonist mirabegron reduces carbachol-
induced contractile activity in detrusor tissue from patients with bladder outflow 
obstruction with or without detrusor overactivity. Eur J Pharmacol. 2013. 699 (1-
3):101-105. 
Svennersten K, Hallén-Grufman K, de Verdier PJ, Wiklund NP, Poljakovic M. 
Localization of P2X receptor subtypes 2, 3 and 7 in human urinary bladder. BMC 
Urol. 2015. 8: 15-81. 
Takasu T, Ukai M, Sato S, Matsui T, Nagase I, Maruyama T, Sasamata M, 
Miyata K, Uchida H, Yamaguchi O. Effect of (R)-2-(2-aminothiazol-4-yl)-4’-{2-[(2-
hydroxy-2-phenylethyl)amino]ethyl} acetanilide (YM178), a novel selective β3-
adrenoceptor agonist, on bladder function. J Pharmacol Exp Ther. 2007. 321: 642-
647. 
Takeda H, Yamazaki Y, Akahane M, Igawa Y, Ajisawa Y, Nishizawa O. Role 
of β3-adrenoceptor in urine storage in the rat: comparison between the selective β3-
adrenoceptor agonist, CL316,243, and various smooth muscle relaxants. J 
Pharmacol Exp Ther. 2000. 293: 939-345. 
Takeda M, Obara K, Mizusawa T, Tomita Y, Arai K, Tsutsui T, Hatano A, 
Takahashi K, Nomura S. Evidence for β3-adrenoceptor subtypes in relaxation of the 
human urinary bladder detrusor: analysis by molecular biological and 
pharmacological methods. J Pharmacol Exp Ther. 1999. 288: 1367-1373. 
Takezawa K, Kondo M, Kiuchi H, Ueda N, Soda T, Fukuhara S, Takao T, 
Miyagawa Y, Tsujimura A, Matsumoto-Miyai K, Ishida Y, Negoro H, Ogawa O, 
Nonomura N, Shimada S. Authentic role of ATP signaling in micturition reflex. Sci 
Repor. 2016. 6: 19585. 
Tempest HV, Dixon AK, Turner WH, Elneil S, Sellers LA, Ferguson DR. P2X 
and P2X receptor expression in human bladder urothelium and changes in interstitial 
cystitis. BJU Int. 2004. 93(9): 1344-8. 
_____________________________________________________________________REFERENCES 
PhD Thesis: Isabel Sofia Dias da Silva________________________________________222 
 
Thiagamoorthy G, Giarenis I, Cardozo L. Early investigational β3 adrenoceptor 
agonists for the management of the overactive bladder syndrome. Expert Opin 
Investig Drugs. 2015. 24: 1299-1306. 
Timóteo MA, Carneiro I, Silva I, Noronha-Matos JB, Ferreirinha F, Silva-
Ramos M, Correia-de-Sá P. ATP released via pannexin-1 hemichannels mediates 
bladder overactivity triggered by urothelial P2Y6 receptors. Biochem Pharmacol. 
2014. 87(2): 372-379. 
Togashi H, Emala CW, Hall IP, Hirshman CA. Carbachol induced actin 
reorganization involves Gi activation of Rho in human airway smooth muscle. Am J 
Physiol. 1998. 274: L803-L809. 
Tyagi P, Thomas CA, Yoshimura N, Chancellor MB. Investigations into the 
presence of functional β1, β2 and β3-adrenoceptors in urothelium and detrusor of 
human bladder. Int Braz J Urol. 2009. 35(1): 76-83. 
Tyagi S, Tyagi P, Van-le S, Yoshimura N, Chancellor MB, de Miguel F. 
Qualitative and quantitative expression profile of muscarinic receptors in human 
urothelium and detrusor. J Urol. 2006. 176(4 Pt 1): 1673-8. 
Uchida H, Shishido K, Nomiya M, Yamaguchi O. Involvement of cyclic AMP-
dependent and –independent mechanisms in the relaxation of rat detrusor muscle via 
β-adrenoceptors. Eur J Pharmacol. 2005. 518: 195-202. 
Uchiyama T, Chess-Williams R. Muscarinic receptor subtypes of the bladder 
and gastrointestinal tract. J Smooth Muscle Res. 2004. 40 (6): 237-247. 
Uhlén M, Fagerberg L, Hallström BM, Lindskog C, Oksvold P, Mardinoglu A, 
Sivertsson Å, Kampf C, Sjöstedt E, Asplund A, Olsson I, Edlund K, Lundberg E, 
Navani S, Szigyarto CA, Odeberg J, Djureinovic D, Takanen JO, Hober S, Alm T, 
Edqvist PH, Berling H, Tegel H, Mulder J, Rockberg J, Nilsson P, Schwenk JM, 
Hamsten M, von Feilitzen K, Forsberg M, Persson L, Johansson F, Zwahlen M, von 
Heijne G, Nielsen J, Pontén F. Proteomics. Tissue-based map of the human 
proteome. Science. 2015. 347: 126419. 
Valera S, Hussy N, Evans RJ, Adami N, North RA, Surprenant A, Buell G. A 
new class of ligand-gated ion channel defined by P2X receptor for extracellular ATP. 
Nature. 1994. 371: 516-519. 
Van Aubel RA, Smeets PH, Peters JG, Bindels RJ, Russel FG. The 
MRP4/ABCC4 gene encodes a novel apical organic anion transporter in human 
_____________________________________________________________________REFERENCES 
PhD Thesis: Isabel Sofia Dias da Silva________________________________________223 
 
kidney proximal tubules: putative efflux pump for urinary cAMP and cGMP. J Am Soc 
Nephrol. 2002. 13: 595-603. 
Van de Graaff, Ward Rhees. Human anatomy and Physiology, Editor by 
Wilhelm PB, McGraw-Hill companies. 2001. 
Vander et al.: Human Physiology: The Mechanism of Body Function, Eighth 
Edition; The McGraw−Hill Companies, 2001. Chapter 16. 
Vesela R, Aronsson P, Tobin G. Functional and morphological examination of 
P1A1 purinoceptors in the normal and inflamed urinary bladder of the rat. Auton 
Neurosci. 2011. 159: 26-31. 
Vial C, Evans RJ. P2X receptor expression in mouse urinary bladder and the 
requirement of P2X(1) receptors for functional P2X receptor responses in the mouse 
urinary bladder smooth muscle. Br J Pharmacol. 2000. 131: 1489-1495. 
Vieira C, Magalhães-Cardoso MT, Ferreirinha F, Silva I, Dias AS, Pelletier J, 
Sévigny J, Correia-de-Sá P. Feed-forward inhibition of CD73 and upregulation of 
adenosine deaminase contribute to the loss of adenosine neuromodulation in 
postinflammatory ileitis. Mediators Inflamm. 2014. 2014:254640. 
Virgino C, Robertson G, Surprenant A, North RA. Trinitrophenyl-substituted 
nucleotides are potent antagonists selective for P2X1, P2X3 and heteromeric 
P2X2/3. Mol Pharmacol. 1998. 53: 969-973. 
Vlaskovska M, Kasakov L, Rong W, Bodin P, Bardini M, Cockayne DA, Ford 
AP, Burnstock G.  P2X3 knockout mice reveal a major sensory role for urothelially 
released ATP. J Neurosc. 2001. 21: 5670-5677. 
Vollmayer P, Clair T, Goding JW, Sano K, Servos J, Zimmermann H. 
Hydrolysis of diadenosine polyphosphates by nucleotide pyrophosphatases/ 
phosphodiesterases. Eur J Biochem. 2003. 270: 297-8. 
Volonté C, D’Ambrosi N. Membrane compartments and purinergic signaling: 
the purinome, a complex interplay among ligand, degrading enzymes, receptors and 
transporters. J FEBS. 2009. 276: 318-329. 
Vorhoff T, Zimmermann H, Pelletier J, Sévigny J, Braun N. Cloning and 
characterization of the ecto-nucleotidase NTPDase3 from rat brain: Predicted 
secondary structure and relation to other members of the E-NTPDase family and 
actin. Purinergic Signal. 2005. 1: 259-270. 
_____________________________________________________________________REFERENCES 
PhD Thesis: Isabel Sofia Dias da Silva________________________________________224 
 
Waldo GL, Corbitt J, Boyer JL, Ravi G, Kim HS, Ji XD, Lacy J, Jacobson KA, 
Harden TK. Quantitation of the P2Y(1) receptor with a high affinity radiolabeled 
antagonist. Mol Pharmacol. 2002. 62(5): 1249-57. 
Waldo GL, Harden TK. Agonist binding and Gq-stimulating activities of the 
purified human P2Y1 receptor. Mol Pharmacol. 2004. 65: 426-436. 
Walker B. Renewal of cell populations in the female mouse. Am J Anat. 1960. 
107, 95–105. 
Wall MJ, Wigmore G, Lopatář J, Frenguelli BG, Dale N. The novel NTPDase 
inhibitor sodium polyoxotungstate (POM-1) inhibits ATP breakdown but also blocks 
central synaptic transmission, an action independent of NTPDase inhibition. 
Neuropharm. 2008. 55: 1251-1258. 
Wallukat G. The β-adrenergic receptors. Herz. 2002. 27(7): 683-690. 
Wang EC, Lee J, Ruiz WG, Balestreire EM, von Bodungen M, Barrick S, 
Cockayne DA, Birder LA, Apodaca G. ATP and purinergic receptor-dependent 
membrane traffic in bladder umbrella cells. J Clin Invest. 2005. 115(9): 2412-2422. 
Wang EC, Lee JM, Johnson JP, Kleyman TR, Bridges R, Apodaca G. 
Hydrostatic pressure regulated ion transport in bladder uroepithelium. Am J Physiol 
Renal Physiol. 2003. 285:F651-63. 
Wang EC, Lee JM, Ruiz WG, Balestreire EM, von Bodungen M, Barrick S, 
Cockayne DA, Birder LA, Apodaca G. ATP and purinergic receptor dependent 
membrane traffic in bladder umbrella cells. J Clin Invest. 2005. 115(9): 2412-2422. 
Wang L, Jacobson SE, Bengtsson A, Erlinge D. P2 receptor mRNA 
expression profiles in human lymphocytes, monocytes and CD34+ stem and 
progenitor cells. BMC Immunol. 2004. 5:16. 
Wang P, Liu Z, Chen H, Ye N, Cheng X, Zhou J. Exchange proteins directly 
activated by cAMP (EPACs): Emerging therapeutic targets. Bioorg Med Chem Lett. 
2017. 27(8): 1633-39. 
Wang P, Luthin GR, Ruggieri MR. Muscarinic acetylcholine receptor subtypes 
mediating urinary bladder contractility and coupling to GTP binding proteins. J 
Pharmavol Exp Ther. 1995. 273: 959-966. 
Wegener JW, Schulla V, Lee TS, Koller A, Feil S, Feil R, Kleppisch T, 
Klugbauer N, Moosmang S, Welling A, Hofmann F. An essential role of Cav1.2 L-
type calcium channel for urinary bladder function. FASEB J. 2004. 18(10): 1159-61. 
_____________________________________________________________________REFERENCES 
PhD Thesis: Isabel Sofia Dias da Silva________________________________________225 
 
Wessler I, Kilbinger A, Bittinger F, Unger R, Kirkpatrick CJ. The non-neuronal 
cholinergic system in humans: Expression, function and pathophysiology. Life Sci. 
2003. 72 (18-19): 2055-2061. 
Wettstein MS, Buser L, Hermanns T, Roudnicky F, Eberli D, Baumeister P, 
Sulser T, Wild P, Poyet C. CD73 predicts favorable prognosis in patients with 
nonmuscle-invasive urothelial bladder cancer. Dis Markers. 2015. 785461. 
Winder M, Tobin G, Zupanĉiĉ D, Romih R. Signaling molecules in the 
urothelium. Biomed Rest Int. 2014. 297295. 
Wiseman OJ, Brady CM, Hussain IF, Dasgupta P, Watt H, Fowler CJ, Landon 
DN. The ultrastructure of bladder lamina propria nerves in healthy subjects and 
patients with detrusor hyperreflexia. J Urol. 2002. 168:2040–2045. 
Wood MW, Breitschwerdt EB, Nordone SK, Linder KE, Gookin JL. 
Uropathogenic E. coli promote a paracellular urothelial barrier defect characterized 
by altered tight junction integrity, epithelial cell sloughing and cytokine release. J 
Comp Pathol. 2012. 147:11–19. 
Woods M, Carson N, Norton NW, Sheldon JH, Argentieri TM. Efficacy of the 
beta3-adrenergic receptor agonist CL316243 on experimental bladder hyperreflexia 
and detrusor instability in the rat. J Urol. 2001. 166(3): 1142-7. 
Wrόbel A, Rechberger T. The influence of Rho-kinase inhibition on acetic acid-
induced detrusor overactivity. Neurourol Urodyn. 2015. 36(2): 263-270. 
Wu C, Gui GP, Fry CH. Intracellular Ca2+ regulation and electrophysiological 
properties of bladder urothelium subjected to stretch and exogenous agonists. Cell 
Calc. 2011. 49: 395-399. 
Wu X, Kong X, Pellicer A, Kreibich G, Sun T-T. Uroplakins in urothelial 
biology, function, and disease. Kidney International.  2009. 75(11):1153–1165. 
Wu Y, Shi C, Deng J, Zhang X, Song B, Li L.  Expression and function of 
muscarinic subtype receptors in bladder interstitial cells of cajal in rats. Cellular and 
Molecular Urol. 2014. 11(03): 1642-1647. 
Wuest M, Eichhorn B, Grimm MO, Wirth MP, Ravens U, Kaumann AJ. 
Catecholamines relax detrusor through beta 2-adrenoceptors in mouse and beta 3-
adrenoceptors in man. J Pharmacol Exp Ther. 2009. 328: 213-222. 
Xin W, Li N, Fernandes VS, Petkov GV. Constitutively active PKA regulates 
neuronal acetylcholine release and contractility of guinea pig urinary bladder smooth 
muscle. Am J Physiol Renal Physiol. 2016. 310(11): 1377-84. 
_____________________________________________________________________REFERENCES 
PhD Thesis: Isabel Sofia Dias da Silva________________________________________226 
 
Xu L, Gebhart GF. Characterization of mouse lumbar splanchnic nerve and 
pelvic urinary bladder mechanosensory afferents. J Neurophysio. 2008. 99: 244-253. 
Xu W, Gelber S, Orr-Urtreger A, Armstrong D, Lewis RA, Ou C-N, Patrick J, 
Role L, De Biasi M, Beaudet A. Megacystis, mydriasis, and ion channel defect in 
mice lacking the α3 neuronal nicotinic acetylcholine receptor. Proc Natl Acad Sci. 
1999a. 96: 5746-5751. 
Xu W, Orr-Urtreger A, Nigro F, Gelber S, Sutcliffe CB, Armstrong D, Patrick 
JW, Role LW, Beaudet AL, De Biasi M. Multiorgan autonomic dysfunction in mice 
lacking the β2 and the β4 subunits of neuronal nicotinic acetylcholine receptors. J 
Neurosc. 1999b. 19: 9298-9305. 
Yamaguchi O, Chapple CR. Beta3-adrenoceptors in urinary bladder. 
Neurourol Urodyn. 2007. 26: 752-756. 
Yamaguchi O. Beta3-adrenoceptors in human detrusor muscle. Urology. 2002. 
59: S25-9. 
Yamaguchi O. Latest treatment for lower urinary tract dysfunction: therapeutic 
agents and mechanism of action. Int J Urol. 2013. 20: 28-39. 
Yamamichi F, Shigemura K, Behnsawy HM, Yamashita M, Shirakawa T, 
Fujisawa M. Beta-3 adrenergic receptors could be significant factor for overactive 
bladder-related symptoms. Int J Clin Pathol. 2015. 8(9): 11863-11870. 
Yamanishi T, Chapple CR, Yasuda K, Chess-Williams R. The role of M2-
muscarinic receptors in mediating contraction of the pig urinary bladder in vitro. Br J 
Pharmacol. 2000. 131: 1482-1488.7 
Yamanishi T, Kaga K, Fuse M, Shibata C, Kamai T, Uchiyama T. The role of 
muscarinic receptor subtypes on carbachol-induced contraction of normal human 
detrusor and overactive detrusor associated with benign prostatic hyperplasia. J 
Pharmacol Sci. 2015. 128: 65-70. 
Yamazaki Y, Takeda H, Akahane M, Igawa Y, Nishizawa O, Ajisawa Y. 
Species differences in the distribution of β-adrenoceptor subtypes in bladder smooth 
muscle. Br J Pharmacol. 1998. 124: 593-599. 
Yang SJ, An JY, Shim JO, Park CH, Huh IH, Sohn UD. The mechanism of 
contraction by 2-chliriadenosine in cat detrusor muscle cells. J Urol. 2000. 163: 652-
658. 
_____________________________________________________________________REFERENCES 
PhD Thesis: Isabel Sofia Dias da Silva________________________________________227 
 
Yegutkin GG, Henttinen T, Jalkanen S. Extracellular ATP formation on 
vascular endothelial cells is mediated by ecto-nucleotide kinase activities via 
phosphotransfer reactions. FASEB. 2001. 15: 251-60. 
Yokokawa R, Akino H, Ito H, Zha X, Yokoyama O. Nerve growth factor release 
from the urothelium increases via activation of bladder C-fibers in rats with cerebral 
infarction. Neurourol Urodyn. 2017. 36(6): 1448-1455. 
Yoshida M, Homm Y, Inadome A, Yono M, Seshita H, Miyamoto Y, Murakami 
S, Kawabe K, Ueda S. Age-related changes in cholinergic and purinergic 
neurotransmission in human isolated bladder smooth muscles. Exp Gerontol. 2001. 
36(1):99-109. 
Yoshida M, Masunaga K, Nagata T, Yono M, Homma Y. The forefront for 
novel therapeutic agent based on the pathophysiology of lower urinary tract 
dysfunction: pathophysiology and pharmacotherapy of overactive bladder. J 
Pharmacol Sci. 2010. 112(2): 128-134. 
Yoshida M, Miyamae K, Iwashita H, Otani M, Inadome A. Management of 
detrusor dysfunction in the elderly: changes in acetylcholine and adenosine 
triphosphate release during aging. Urology. 2004. 63 (3 Suppl 1): 17-23. 
Yoshimura N, Chancellor MB. Neurophysiology of lower urinary. Rev Urol. 
2003. 5(8): 3-10. 
Yoshimura N, de Groat WC. Neural control of the lower urinary tract. Int J Urol. 
1997. 4: 111-125. 
Yoshimura N, Seki S, de Groat WC. Nitric oxide modulates Ca2+ channels in 
dorsal root ganglion neurons innervating rat urinary bladder. J Neurophysiol. 2001. 
86(1): 304-311. 
Yu W, Robson SC, Hill WG. Expression and distribution of ectonucleotidases 
in mouse urinary bladder. Plos One. 2011. 6(4):e18704. 
Yu W, Sun X, Robson SC, Hill WG. ADP-induced bladder contractility is 
mediated by P2Y12 receptor and temporally regulated by ectonucleotidases and 
adenosine signaling. FASEB. 2014. 28(12): 5288-98. 
Yu W, Sun X, Robson SC, Hill WG. Extracellular UDP enhances P2X-
mediated bladder smooth muscle contractility via P2Y6 activation of the 
phospholipase C / inositol triphosphate pathway. FASEB. 2013. 27(5): 1895-903. 
_____________________________________________________________________REFERENCES 
PhD Thesis: Isabel Sofia Dias da Silva________________________________________228 
 
Yu W, Zacharia LC, Jackson EK, Apodaca G. Adenosine receptor expression 
and function in bladder uroepithelium. Am J Physiol Cell Physiol. 2006. 291(2): C254-
C265.  
Yu Y, Daugherty SL, de Groat WC. Effects of nicotinic receptor agonists on 
bladder afferent nerve activity in an in vitro bladder-pelvic nerve preparation. Brain 
Res. 2016. 1637: 91-101. 
Zarghooni S, Wunsch J, Bodenbenner M, Brüggmann D, Grando SA, 
Schwantes U, Wess J, Kummer W, Lips KS. Expression of muscarinic and nicotinic 
acetylcholine receptors in the mouse urothelium. Life Sciences. 2007. 80: 2308-2313. 
Zhang FL, Luo L, Gustafson E, Palmer K, Qiao X, Fan X, Yang S, Laz TM, 
Bayne M, Monsma F JR. P2Y13: identification and characterization of a novel Gαi-
coupled ADP receptor from human and mouse. J Pharmacol Exp Ther. 2002. 301: 
705-713. 
Zhang YJ, Bai Q. Urinary prostaglandins E2 correlates to overactive bladder 
symptoms in patients with benign prostatic hyperplasia. Zhonghua Nan Ke Xue. 
2014. 20(3): 244-8. 
Zhu Y, Chen H, Boulton S, Mei F, Ye N, Melacini G, Zhou J, Cheng X. 
Biochemical and Pharmacological Characterization of ESI-09 Based EPAC inhibitors: 
Defining the ESI-09 “Therapeutic Window”. Scientific Report. 2015. 5: 9344. 
Zimmermann H, Braun N, Kegel B, Heine P. New insights into molecular 
structure and function of ectonucleotidases in the nervous system. Neurochem Int. 
1998. 32: 421-5. 
Zimmermann H. 5’-nucleotidase-molecular structure and functional aspects. 
Biochem J. 1992. 285: 385-365. 
Zimmermann H. Ectonucleotidases: some recent developments and a note on 
nomenclature. Drug Dev Res. 2001. 52: 44-56. 
Zimmermann H. Extracellular metabolism of ATP and other nucleotides. 
Nauyn-Schm Arch Pharmacol. 2000. 362: 299-309. 
 
